0001437749-24-03397010-Q NATIONAL HEALTHCARE CORP 20241107202411071659081659081659081

gaap:USStatesAndPoliticalSubdivisionsMember2024-09-30 0001047335us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-30 0001047335us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-30 0001047335us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-30 0001047335us-gaap:FairValueInputsLevel1Member2024-09-30 0001047335us-gaap:FairValueInputsLevel2Member2024-09-30 0001047335us-gaap:FairValueInputsLevel3Member2024-09-30 0001047335us-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001047335us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001047335us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001047335us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001047335us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-31 0001047335us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-31 0001047335us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-31 0001047335us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0001047335us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0001047335us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-31 0001047335us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-31 0001047335us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-31 0001047335us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-31 0001047335nhc:InpatientServicesSegmentMember2023-12-31 0001047335nhc:HomecareAndHospiceSegmentMember2023-12-31 0001047335nhc:HomecareAndHospiceSegmentMember2024-01-012024-09-30 0001047335nhc:InpatientServicesSegmentMember2024-09-30 0001047335nhc:HomecareAndHospiceSegmentMember2024-09-30 0001047335us-gaap:TradeNamesMember2024-09-30 0001047335us-gaap:TradeNamesMember2023-12-31 0001047335nhc:CertificatesOfNeedMember2024-09-30 0001047335nhc:CertificatesOfNeedMember2023-12-31 0001047335us-gaap:LicensingAgreementsMember2024-09-30 0001047335us-gaap:LicensingAgreementsMember2023-12-31 0001047335us-gaap:CommonStockMember2024-01-012024-09-30 0001047335us-gaap:CommonStockMember2023-01-012023-09-30 0001047335nhc:SalariesWagesAndBenefitsMember2024-07-012024-09-30 0001047335nhc:SalariesWagesAndBenefitsMember2023-07-012023-09-30 0001047335nhc:SalariesWagesAndBenefitsMember2024-01-012024-09-30 0001047335nhc:SalariesWagesAndBenefitsMember2023-01-012023-09-30 00010473352023-01-012023-12-31 0001047335nhc:ExercisePriceRange1Member2024-09-30 0001047335nhc:ExercisePriceRange1Member2024-01-012024-09-30 0001047335nhc:ExercisePriceRange2Member2024-09-30 0001047335nhc:ExercisePriceRange2Member2024-01-012024-09-30 0001047335nhc:CreditFacilityMember2024-09-30 0001047335nhc:CreditFacilityMember2024-08-01 0001047335nhc:CreditFacilityMember2024-08-012024-08-01 0001047335nhc:TermFacilityMembernhc:CreditFacilityMember2024-08-01 0001047335us-gaap:RevolvingCreditFacilityMembernhc:CreditFacilityMember2024-08-01 0001047335nhc:CreditFacilityMembersrt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-08-012024-08-01 0001047335nhc:CreditFacilityMembersrt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-08-012024-08-01 0001047335nhc:CreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2024-08-012024-08-01 0001047335nhc:CreditFacilityMembersrt:MaximumMemberus-gaap:BaseRateMember2024-08-012024-08-01

Â Â Table of Contents Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â â˜‘QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedÂ September 30, 2024 OR â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromÂ toÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Stockholdersâ€™ Equity Â Â Â

over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered.Â Â Contract liabilities are recorded forÂ payments the Company receives in whichÂ performance obligations have not been completed. Â The Company determines the transaction price based on established billing rates reduced by explicit price concessionsÂ provided to third party payors. Explicit price concessionsÂ are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,574,000Â and $7,098,000 for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $1,668,000 and $5,331,000, respectively.Â As of September 30, 2024Â and December 31, 2023, the Company has recorded allowance for doubtful accounts of $10,859,000 and $8,054,000, respectively, as our best estimate of expectedÂ losses inherent in the accounts receivable balance. Â Other Revenues Â Other revenues include revenues from the provision of insurance services to other healthcare providers, management and accounting services to other healthcareÂ providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements. Â We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned. Â Government Grants Â We account for government grants in accordance with International Accounting Standards ("IAS") 20,Â Accounting for Government Grants and Disclosure of Government Assistance,Â and as such, we recognize grant income on a systematic basis in line with the recognition of specific expenses and lost revenues for which the grants are intended to compensate. Â For the nine months ended September 30, 2024, all conditions related to the Employee Retention Credit ("ERC") were met and the credit was recognized as government stimulus income. The ERC was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The qualified wages and health insurance benefits paid by the Company were related to the second, third and fourth quarters of 2020. Â Segment Reporting Â In accordance with the provisions of Accounting Standards Codification ("ASC") 280, Segment Reporting, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an â€œall otherâ€ category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 7 for further disclosure of the Companyâ€™s operating segments. Â Other Operating Expenses Â Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance. Â General and Administrative Costs Â With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation and incentive compensation, which were $6,288,000 and $19,678,000 for the three and nine months ended September 30, 2024, respectively. General and administrative costs were $5,661,000 and $16,309,000 for the three and nine months ended September 30, 2023, respectively. The increased general and administrative costs incurred during 2024 are due to acquisition-related expenses for the White Oak Senior Living portfolio. See Note 3 - Acquisition of White Oak Senior Living for additional detail regarding the acquisition. Â 11 Table of Contents Â Long-Term Leases Â The Companyâ€™s lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, regional offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain. Â The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recordedÂ and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases. Â Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuateÂ with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred. Â Property and Equipment Â Property and equipment are recorded at cost or fair value, if acquired. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method. Â Business Combinations Â We account for transactions that represent business combinations usingÂ the acquisition method of accounting in accordance with FASB ASC Topic 805, Business Combinations (Topic 805). Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts during the measurement period. The measurement period isÂ defined as theÂ date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date. Â Goodwill generated from business combinationsÂ is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates Â Goodwill and Other Intangible Assets Â Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter.Â Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. Â The Companyâ€™s indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the fair value of the intangible asset is below its carrying amount. Â Accrued Risk ReservesÂ Â Â We are selfâ€“insured for risks related to workersâ€™ compensation and general and professional liability insurance. We have two whollyâ€“owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis. Â Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period. Â 12 Table of Contents Â We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverage includes both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us. Â Continuing Care Contracts Â We have continuing care retirement centers (â€œCCRCâ€) within our operations. Residents at these retirement centers may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original residentâ€™s entry fee. Â Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarily determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrentÂ liabilities inÂ our consolidated balance sheets.Â Â We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recordedÂ with a corresponding charge to income. As of September 30, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.Â Â Other Noncurrent Liabilities Â Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation (â€œNationalâ€) andÂ the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents. Â Noncontrolling Interest Â The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Companyâ€™s earnings per share is calculated based on net income attributable to NHCâ€™s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions. Â Variable Interest Entities Â We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity (â€œVIEâ€) and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. Â The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as â€œinvestments in unconsolidated companiesâ€ in the interim condensed consolidated balance sheets. Â Recently Issued Accounting Guidance Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) No. 2023-07, â€œSegment Reporting (Topic 280): Improvement to Reportable Segment Disclosures.â€ The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024,Â and interim periods within fiscal years beginning after December 15, 2024.Â We are currently evaluating the impact this standard will have on our disclosures. Â 13 Table of Contents Â Â Note 3 â€“ Acquisition of White Oak Senior Living Â On August 1, 2024, the Company purchased certain assets and assumed certain liabilities of the White Oak Senior Living (â€œWhite Oakâ€) portfolioÂ for a purchase price ofÂ $221,400,000. The White OakÂ portfolio consists of 22Â healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities,Â four independent living facilities, andÂ a long-term care pharmacy.Â The operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina (2,278 total beds/units).Â The acquisition represents both an expansion of NHCâ€™s operations into a new state (North Carolina) and a strategic advancement

of its growth in its existing operational footprint.Â Â The Company utilized widely accepted income-based, market-based, and cost-based valuation approaches to perform the preliminary purchase price allocation. Â The Company has performed a preliminary valuation analysis of the fair market value of White Oakâ€™s assets acquired and liabilities assumed. The final valuation of the assets acquiredÂ and liabilities assumed was not complete as of September 30, 2024, but will be finalized within the allowable measurement period. The following table summarizes the allocation of the preliminary purchase price as of the transactionâ€™s closing date (in thousands): Â Â Â Amount Â Cash and cash equivalents Â $9Â Inventories Â Â 1,054Â Prepaid expenses and other assets Â Â 137Â Property and equipment Â Â 203,695Â Deferred tax asset Â Â 2,499Â Operating lease right-of-use assetsÂ Â 11,380Â Intangible assets Â Â 12,765Â Total assets acquired Â Â 231,539Â Â Â Â Â Â Operating lease liabilities, current portionÂ Â 424Â Accrued payroll Â Â 3,559Â Other current liabilities Â Â 1,085Â Operating lease liabilities, less current portionÂ Â 10,956Â Other noncurrent liabilities Â Â 1,005Â Total liabilities assumed Â Â 17,029Â Â Â Â Â Â Net identifiable assets acquired Â Â 214,510Â Goodwill Â Â 1,395Â Total estimated fair value of the acquisition Â $215,905Â Â The indefinite-lived intangible assets acquired include the trade name of White Oak and the skilled nursing certificates of need and licenses. The goodwill is recorded in the inpatient services segment and is attributed to the workforce acquired and reputation of the business as part of the transaction. We expect the goodwill to be deductible for income tax purposes. Â For the three and nine months ended September 30, 2024, White Oak contributed net operating revenuesÂ of $37,305,000 and income before income taxes of $1,557,000 that are included in the Companyâ€™s interim condensed consolidated statements of operations.Â The Company recognized $637,000 and $2,831,000 in acquisition-related expenses for the three and nine months ended September 30, 2024, respectively, in connection with the White Oak acquisition. These costs related to legal and other professional fees, which wereÂ included as a component of other operating expenses in the interim condensed consolidated statements of operations. Â The following table contains unaudited pro forma interim condensed consolidated statements of operations information for the three months and nine months ended September 30, 2024 and 2023, assuming that the White Oak acquisition closed on January 1, 2023. The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed (in thousands). Â Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30 Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net operating revenues and grant income Â $358,334Â Â $337,817Â Â $1,065,418Â Â $987,186Â Income before income taxes Â Â 58,881Â Â Â 14,087Â Â Â 134,777Â Â Â 49,113Â Net income attributable to NHC Â $43,413Â Â $10,431Â Â $99,121Â Â $34,064Â Â 14 Table of Contents Â Â Â Note 4 â€“ Net Patient Revenues Â The Company disaggregates revenue from contracts with customers by service type and by payor. Â Revenue by Service Type Â The Companyâ€™s net patient services can generally be classified into the following two categories: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services (in thousands). Â Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30 Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net patient revenues: Â Â Â Â Â

operations by business segment (in thousands): Â Â Â Three Months Ended September 30, 2024 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 293,026 Â Â $ 35,648 Â Â $ - Â Â $ 328,674 Â Other revenues Â Â 370 Â Â Â - Â Â Â 11,154 Â Â Â 11,524 Â Net operating revenues Â Â 293,396 Â Â Â 35,648 Â Â Â 11,154 Â Â Â 340,198 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 175,241 Â Â Â 21,456 Â Â Â 16,698 Â Â Â 213,395 Â Other operating Â Â 72,384 Â Â Â 6,612 Â Â Â 3,513 Â Â Â 82,509 Â Rent Â Â 8,422 Â Â Â 602 Â Â Â 1,862 Â Â Â 10,886 Â Depreciation and amortization Â Â 9,632 Â Â Â 172 Â Â Â 815 Â Â Â 10,619 Â Interest Â Â 1,742 Â Â Â - Â Â Â - Â Â Â 1,742 Â Total costs and expenses Â Â 267,421 Â Â Â 28,842 Â Â Â 22,888 Â Â Â 319,151 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income/(loss) from operations Â Â 25,975 Â Â Â 6,806 Â Â Â (11,734) Â Â 21,047 Â Non-operating income Â Â - Â Â Â - Â Â Â 4,224 Â Â Â 4,224 Â Unrealized gains on marketable equity securities Â Â - Â Â Â - Â Â Â 32,767 Â Â Â 32,767 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income before income taxes Â $ 25,975 Â Â $ 6,806 Â Â $ 25,257 Â Â $ 58,038 Â Â Â Â Three Months Ended September 30, 2023 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 243,865 Â Â $ 33,140 Â Â $ - Â Â $ 277,005 Â Other revenues Â Â 297 Â Â Â - Â Â Â 11,183 Â Â Â 11,480 Â Net operating revenues Â Â 244,162 Â Â Â 33,140 Â Â Â 11,183 Â Â Â 288,485 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 151,912 Â Â Â 20,066 Â Â Â 10,686 Â Â Â 182,664 Â Other operating Â Â 64,228 Â Â Â 5,868 Â Â Â 2,394 Â Â Â 72,490 Â Rent Â Â 8,186 Â Â Â 538 Â Â Â 1,370 Â Â Â 10,094 Â Depreciation and amortization Â Â 9,203 Â Â Â 185 Â Â Â 747 Â Â Â 10,135 Â Interest Â Â 77 Â Â Â - Â Â Â - Â Â Â 77 Â Total costs and expenses Â Â 233,606 Â Â Â 26,657 Â Â Â 15,197 Â Â Â 275,460 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income/(loss) from operations Â Â 10,556 Â Â Â 6,483 Â Â Â (4,014) Â Â 13,025 Â Non-operating income Â Â - Â Â Â - Â Â Â 4,097 Â Â Â 4,097 Â Unrealized losses on marketable equity securities Â Â - Â Â Â - Â Â Â (3,093) Â Â (3,093) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income/(loss) before income taxes Â $ 10,556 Â Â $ 6,483 Â Â $ (3,010) Â $ 14,029 Â Â 18 Table of Contents Â Â Â Nine Months Ended September 30, 2024 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 790,664 Â Â $ 103,751 Â Â $ - Â Â $ 894,415 Â Other revenues Â Â 710 Â Â Â - Â Â Â 33,462 Â Â Â 34,172 Â Government stimulus income Â Â - Â Â Â - Â Â Â 9,445 Â Â Â 9,445 Â Net operating revenues and grant income Â Â 791,374 Â Â Â 103,751 Â Â Â 42,907 Â Â Â 938,032 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 474,190 Â Â Â 63,761 Â Â Â 38,658 Â Â Â 576,609 Â Other operating Â Â 207,883 Â Â Â 18,977 Â Â Â 11,232 Â Â Â 238,092 Â Rent Â Â 24,795 Â Â Â 1,736 Â Â Â 5,273 Â Â Â 31,804 Â Depreciation and amortization Â Â 27,646 Â Â Â 545 Â Â Â 2,352 Â Â Â 30,543 Â Interest Â Â 1,788 Â Â Â - Â Â Â - Â Â Â 1,788 Â Total costs and expenses Â Â 736,302 Â Â Â 85,019 Â Â Â 57,515 Â Â Â 878,836 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income/(loss) from operations Â Â 55,072 Â Â Â 18,732 Â Â Â (14,608) Â Â 59,196 Â Non-operating income Â Â - Â Â Â - Â Â Â 14,865 Â Â Â 14,865 Â Unrealized gains on marketable equity securities Â Â - Â Â Â - Â Â Â 56,290 Â Â Â 56,290 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income before income taxes Â $ 55,072 Â Â $ 18,732 Â Â $ 56,547 Â Â $ 130,351 Â Â Â Â Nine Months Ended September 30, 2023 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 706,795 Â Â $ 97,822 Â Â $ - Â Â $ 804,617 Â Other revenues Â Â 894 Â Â Â - Â Â Â 35,119 Â Â Â 36,013 Â Net operating revenues Â Â 707,689 Â Â Â 97,822 Â Â Â 35,119 Â Â Â 840,630 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 435,517 Â Â Â 60,804 Â Â Â 29,461 Â Â Â 525,782 Â Other operating Â Â 192,473 Â Â Â 17,356 Â Â Â 7,384 Â Â Â 217,213 Â Rent Â Â 24,520 Â Â Â 1,639 Â Â Â 3,928 Â Â Â 30,087 Â Depreciation and amortization Â Â 27,474 Â Â Â 555 Â Â Â 2,237 Â Â Â 30,266 Â Interest Â Â 268 Â Â Â - Â Â Â - Â Â Â 268 Â Total costs and expenses Â Â 680,252 Â Â Â 80,354 Â Â Â 43,010 Â Â Â 803,616 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income/(loss) from operations Â Â 27,437 Â Â Â 17,468 Â Â Â (7,891) Â Â 37,014 Â Non-operating income Â Â - Â Â Â - Â Â Â 12,116 Â Â Â 12,116 Â Unrealized gains on marketable equity securities Â Â - Â Â Â - Â Â Â 2,943 Â Â Â 2,943 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income before income taxes Â $ 27,437 Â Â $ 17,468 Â Â $ 7,168 Â Â $ 52,073 Â Â Â Note 8 â€“ Long-Term Leases Â Operating Leases Â At September 30, 2024, we lease from NHI the real property of 28 skilled nursing facilities, five assisted living centers and three independent living centers under one lease agreement. As part of the lease agreement, we sublease four Florida skilled nursing facilities to a third-party operator. The lease includes base rent plus a percentage rent. The annual base rent is $32,625,000 in 2024, $32,225,000 in 2025, and $31,975,000 in 2026 with the lease term expiring in December 2026. The percentage rent is based on a quarterly calculation of revenue increases and is payable on a quarterly basis. Total facility rent expense to NHI was $10,085,000 and $9,300,000 for the three months ended September 30, 2024 and 2023, respectively. Total facility rent expense to NHI was $29,371,000 and $27,719,000 for the nine months ended September 30, 2024 and 2023, respectively. Â 19 Table of Contents Â Minimum Lease Payments Â The following table summarizes the maturity of our operating lease liabilities as of September 30, 2024 (in thousands): Â Â Â Operating Leases Â 2025 Â $ 35,858 Â 2026 Â Â 35,183 Â 2027 Â Â 10,471 Â 2028 Â Â 1,702 Â 2029 Â Â 1,424 Â Thereafter Â Â 11,768 Â Total minimum lease payments Â Â 96,406 Â Less: amounts representing interest Â Â (11,961) Present value of future minimum lease payments Â Â 84,445 Â Less: current portion Â Â (31,366) Noncurrent lease liabilities Â $ 53,079 Â Â 20 Table of Contents Â Â Â Note 9 â€“ Earnings per Share Â Basic net income per share is computed based on the weighted average number of common shares outstanding for each period presented. Diluted net income per share reflects the potential dilution that would have occurred if securities to issue common stock were exercised, converted, or resulted in the issuance of common stock that would have then shared in our earnings. Â The following table summarizes the earnings and the weighted average number of common shares used in the calculation of basic and diluted earnings per share (in thousands, except for share and per share amounts): Â Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30 Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding
Â Â 15,411,680Â Â Â 15,299,913Â Â Â 15,384,758Â Â Â 15,311,453Â Net income attributable to National HealthCare Corporation
Â $42,789Â Â $10,388Â Â $95,846Â Â $38,392Â Earnings per common share, basic Â $2.78Â Â $0.68Â Â $6.23Â Â $2.51Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Diluted: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding Â Â 15,411,680Â Â Â 15,299,913Â Â Â 15,384,758Â Â Â 15,311,453Â Effects of dilutive instruments Â Â 255,641Â Â Â 24,598Â Â Â 191,536Â Â Â 22,816Â Weighted average common shares outstanding
Â Â 15,667,321Â Â Â 15,324,511Â Â Â 15,576,294Â Â Â 15,334,269Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income attributable to National HealthCare Corporation
Â $42,789Â Â $10,388Â Â $95,846Â Â $38,392Â Earnings per common share, diluted Â $2.73Â Â $0.68Â Â $6.15Â Â $2.50Â Â For the three and nineÂ months ending September 30, 2024, we did not exclude any stock options from the calculation of diluted weighted average shares of common stock outstanding. For the three and nine months ending September 30, 2023, 637,409 of stock optionsÂ have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect.Â Â Â Note 10 â€“ Investments in Marketable Securities Â Our investments in marketable equity securities are carried at fair value with the changes in unrealized gains and losses recognized in our results of operations at each measurement date. Our investments in marketable debt securities are classified as available for sale securities and carried at fair value with the unrealized gains and losses recognized through accumulated other comprehensive income at each measurement date. Any credit-related decline in fair market values below the amortized cost of our available for sale debt securities are recorded in our results of operations through an allowance for credit losses. Realized gains and losses from securities sales are recognized in results of operations upon disposition of the securities using the specific identification method on a trade date basis. Refer to Note 11Â for a description of the Company's methodology for determining the fair value of marketable securities.Â Â Marketable securities consist of the following (in thousands): Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Amortized Cost Â Â Fair Value Â Â Amortized Cost Â Â Fair Value Â Investments available for sale: Â Marketable equity securities Â $ 30,176 Â Â $ 164,754 Â Â $ 30,176 Â Â $ 111,117 Â Corporate debt securities Â Â â€“ Â Â Â â€“ Â Â Â 2,497 Â Â Â 2,441 Â U.S. Treasury securities Â Â â€“ Â Â Â â€“ Â Â Â 2,990 Â Â Â 2,986 Â Restricted investments available for sale: Â Marketable equity securities Â Â 17,702 Â Â Â 23,001 Â Â Â 24,134 Â Â Â 26,779 Â Corporate debt securities Â Â 59,267 Â Â Â 58,812 Â Â Â 59,586 Â Â Â 57,731 Â Asset-based securities Â Â 17,756 Â Â Â 16,646 Â Â Â 19,388 Â Â Â 17,659 Â U.S. Treasury securities Â Â 46,224 Â Â Â 44,671 Â Â Â 46,771 Â Â Â 42,863 Â State and municipal securities Â Â 3,813 Â Â Â 3,782 Â Â Â 4,106 Â Â Â 4,047 Â Â Â $ 174,938 Â Â $ 311,666 Â Â $ 189,648 Â Â Â 265,623 Â Â 21 Table of Contents Â Included in the marketable equity securities are the following (in thousands, except share amounts): Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Shares Â Â Cost Â Â Fair Value Â Â Shares Â Â Cost Â Â Fair Value Â NHI Common Stock Â Â 1,630,642 Â Â $ 24,734 Â Â $ 137,072 Â Â Â 1,630,642 Â Â $ 24,734 Â Â $ 91,071 Â Â The amortized cost and estimated fair value of debt securities classified as available for sale, by contractual maturity, are as follows (in thousands): Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Cost Â Â Fair Value Â Â Cost Â Â Fair Value Â Maturities: Â Within 1 year Â $ 24,509 Â Â $ 24,023 Â Â $ 19,664 Â Â $ 19,328 Â 1 to 5 years Â Â 71,047 Â Â Â 69,082 Â Â Â 81,517 Â Â Â 77,118 Â 6 to 10 years Â Â 31,197 Â Â Â 30,499 Â Â Â 33,515 Â Â Â 30,802 Â Over 10 years Â Â 307 Â Â Â 307 Â Â Â 642 Â Â Â 479 Â Â Â $ 127,060 Â Â $ 123,911 Â Â $ 135,338 Â Â $ 127,727 Â Â Gross unrealized gains related to marketable equity securities are $140,177,000 and $84,514,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to marketable equity securities are $300,000 and $928,000 as of September 30, 2024 and December 31, 2023, respectively. For the three months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $32,767,000 and net unrealized losses of $3,093,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations. For the nine months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $56,290,000 and 2,943,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations. Â Gross unrealized gains related to available for sale marketable debt securities are $1,104,000 and $326,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to available for sale marketable debt securities are $4,253,000 and $7,937,000 as of September 30, 2024 and December 31, 2023, respectively. Â The Companyâ€™s unrealized losses in our available for sale marketable debt securities were determined to be non-credit related. The Company has not recognized any credit related impairments for the nine months endedÂ September 30, 2024 and 2023. Â For the marketable debt securities in gross unrealized loss positions, (a) it is more likely than not that the Company will not be required to sell the investment securities before recovery of the unrealized losses, and (b) the Company expects that the contractual principal and interest will be received on the investment securities. Â Proceeds from the sale of available for sale marketable securities during the nine months ended September 30, 2024 and 2023 were $39,776,000 and $36,578,000, respectively. Investment gains of $331,000 and investment losses of $603,000 were realized on these sales during the nine months ended September 30, 2024 and 2023, respectively.Â Â Â Note 11 â€“ Fair Value Measurements Â The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs that may be used to measure fair value: Â LevelÂ 1Â Â â€“Â The valuation is based on quoted prices in active markets for identical instruments. LevelÂ 2Â â€“Â The valuation is based on observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and modelâ€“based valuation techniques for which all significant assumptions are observable in the market. LevelÂ 3Â â€“Â The valuation is based on unobservable inputs that are supported by minimal or no market activity and that are significant to the fair value of the instrument. Level 3 valuations are typically performed using pricing models, discounted cash flow methodologies, or similar techniques that incorporate managementâ€™s own estimates of assumptions that market participants would use in pricing the instrument, or valuations that require significant management judgment or estimation. Â 22 Table of Contents Â A financial instrumentâ€™s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Â The following table summarizes fair value measurements by level at September 30, 2024 and December 31, 2023 for assets and liabilities measured at fair value on a recurring basis (in thousands): Â Â Â Fair Value Measurements Using Â September 30, 2024 Â Fair Value Â Â Quoted Prices in Active Markets For Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Cash and cash equivalents Â $ 84,807 Â Â $ 84,807 Â Â $ â€“ Â Â $ â€“ Â Restricted cash and cash equivalents Â Â

30,267 Â Â Â 30,267 Â Â Â â€“ Â Â Â â€“ Â Marketable equity securities Â Â 187,755 Â Â Â 187,755 Â Â Â â€“ Â Â Â â€“ Â Corporate debt securities Â Â 58,812 Â Â Â 39,475 Â Â Â 19,337 Â Â Â â€“ Â Assetâ€“backed securities Â Â 16,646 Â Â Â â€“ Â Â Â 16,186 Â Â Â 460 Â U.S. Treasury securities Â Â 44,671 Â Â Â 44,671 Â Â Â â€“ Â Â Â â€“ Â State and municipal securities Â Â 3,782 Â Â Â â€“ Â Â Â 3,782 Â Â Â â€“ Â Total financial assets Â $ 426,740 Â Â $ 386,975 Â Â $ 39,305 Â Â $ 460 Â Â Â Â Fair Value Measurements Using Â December 31, 2023 Â Fair Value Â Â Quoted Prices in Active Markets For Identical Assets (Level 1) Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3) Â Cash and cash equivalents Â $ 107,076 Â Â $ 107,076 Â Â $ â€“ Â Â $ â€“ Â Restricted cash and cash equivalents Â Â 18,892 Â Â Â 18,892 Â Â Â â€“ Â Â Â â€“ Â Marketable equity securities Â Â 137,896 Â Â Â 137,896 Â Â Â â€“ Â Â Â â€“ Â Corporate debt securities Â Â 60,171 Â Â Â 42,860 Â Â Â 17,311 Â Â Â â€“ Â Assetâ€“backed securities Â Â 17,659 Â Â Â â€“ Â Â Â 17,210 Â Â Â 449 Â U.S. Treasury securities Â Â 45,850 Â Â Â 45,850 Â Â Â â€“ Â Â Â â€“ Â State and municipal securities Â Â 4,047 Â Â Â â€“ Â Â Â 4,047 Â Â Â â€“ Â Total financial assets Â $ 391,591 Â Â $ 352,574 Â Â $ 38,568 Â Â $ 449 Â Â Â Note 12 â€“ Goodwill and Other Intangible Assets Â At September 30, 2024, the Company reviewed the carrying value of goodwill for impairment indicators. As a result of the review, there were no impairment indicators regarding the Companyâ€™s goodwill that required a quantitative test to be performed. However, our accounting estimates could materially change from period to period due to changing market factors. We will continue to monitor future events, changes in circumstances, and the potential impact thereof. If actual results are not consistent with our assumptions and estimates, we may be exposed to future goodwill impairment losses Â 23 Table of Contents Â See Note 3 â€“ Acquisition of White Oak Senior Living for further detail describing the goodwill and indefinite-lived intangible asset additions in 2024. At September 30, 2024, the following table represents the activity related to our goodwill by segment (in thousands): Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â January 1, 2024 Â $ 3,741 Â Â $ 164,554 Â Â $ â€“ Â Â $ 168,295 Â Additions Â Â 1,395 Â Â Â â€“ Â Â Â â€“ Â Â Â 1,395 Â September 30, 2024 Â $ 5,136 Â Â $ 164,554 Â Â $ â€“ Â Â $ 169,690 Â Â Indefinite-lived intangible assets consist of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Trade names $15,836Â Â $4,340 Certificates of need Â 1,757Â Â Â 532 LicensesÂ 2,212Â Â Â 2,166 Total $19,805Â Â $7,038 Â As part of the White Oak Senior Living acquisition, we recorded indefinite-lived intangible assets that consisted of the trade name ($11,496,000) and certificates of need and licenses ($1,271,000). Â Â Note 13 - Stock Repurchase Program Â During the nine months ended September 30, 2024, the Company repurchased 133,151 shares of its common stock for a total cost of $13,502,000. During the nine months ended September 30, 2023, the Company repurchased 44,349 shares of its common stock for a total cost of $2,482,000. The shares were funded from cash on hand and were cancelled and returned to the status of authorized but unissued.Â Â Â Note 14 â€“ Stockâ€“Based Compensation Â NHC recognizes stockâ€“based compensation expense for all stock options granted over the requisite service period using the fair value at the date of grant using the Blackâ€“Scholes pricing model. Stockâ€“based compensation totaled $1,093,000 and $708,000 for the three months ended September 30, 2024 and 2023, respectively. Stock-based compensation totaled $3,062,000 and $2,119,000 for the nine months ended September 30, 2024 and 2023, respectively. Stockâ€“based compensation is included in â€œSalaries, wages and benefitsâ€ in the interim condensed consolidated statements of operations. Â At September 30, 2024, the Company had $5,752,000 of unrecognized compensation cost related to unvested stockâ€“based compensation awards. This unrecognized compensation cost will be amortized over an approximate two-year period. Â Stock Options Â The following table summarizes the significant assumptions used to value the options granted for the nine months ended September 30, 2024 and for the year ended December 31, 2023. Â Â Â September 30, 2024 Â Â December 31, 2023 Â Riskâ€“free interest rate Â Â 4.40% Â Â Â 4.52% Â Expected volatility Â Â 24.1% Â Â Â 29.3% Â Expected life, in years Â Â 2.9 Â Â Â 2.9 Â Expected dividend yield Â Â 2.63% Â Â Â 4.41% Â Â The following table summarizes our outstanding stock options for the nine months ended September 30, 2024 and for the year ended December 31, 2023. Â Â Â Number of Shares Â Â Weighted Average Exercise Price Â Â Aggregate Intrinsic Value Â Options outstanding at January 1, 2023 Â Â 445,144Â Â $66.62Â Â $â€“Â Options granted Â Â 299,278Â Â Â 54.44Â Â Â â€“Â Options exercised Â Â (103,481)Â Â 64.72Â Â Â Â â€“Â Options cancelled Â Â (52,407)Â Â 60.58Â Â Â Â â€“Â Options outstanding at December 31, 2023 Â Â 588,534Â Â Â 61.30Â Â Â Â â€“Â Options granted Â Â 298,097Â Â Â 94.42Â Â Â Â â€“Â Options exercised Â Â (211,040)Â Â 63.75Â Â Â Â â€“Â Options cancelled Â Â (33,202)Â Â 79.34Â Â Â Â â€“Â Options outstanding at September 30, 2024 Â Â 642,389Â Â Â 74.93Â Â $32,658,000Â Â Â Â Â Â Â Â Â Â Â Â Â Â Options exercisable at September 30, 2024 Â Â 153,439Â Â Â 63.87Â Â $9,498,000Â Â 24 Table of Contents Â Options Outstanding September 30, 2024 Â Â Exercise Prices Â Â Weighted Average Exercise Price Â Â Weighted Average Remaining Contractual Life in Years Â 331,037Â Â Â 53.94-69.19Â Â Â 58.88Â Â Â 3.0Â 311,352Â Â Â 71.64-96.03Â Â Â 92.00Â Â Â 4.1Â 642,389Â Â Â Â Â Â Â Â 74.93Â Â Â 3.5Â Â Â Note 15 â€“ Long-Term Debt Â Longâ€“term debt consists of the following (dollars in thousands): Â Â Â Interest rate at September 30, 2024 Â Â Maturity Â Â September 30, 2024 Â Â December 31, 2023 Â Credit facility, interest payable monthly Â Â Variable, 6.8% Â Â Â 2029 Â Â $ 147,000 Â Â $ â€“ Â Less current portion Â Â Â Â Â Â Â Â Â Â Â Â (7,500) Â Â â€“ Â Total long-term debt Â Â Â Â Â Â Â Â Â Â $ 139,500 Â Â $ â€“ Â On August 1, 2024, the Company entered into a $200,000,000 senior credit facility with a five-year term consisting of a $150,000,000 term facility and a $50,000,000 revolving line of credit (the â€œCredit Facilityâ€).Â The Credit Facility is for general corporate purposes, including working capital and acquisitions.Â The loans bear interest at either (i) Term Secured Overnight Financing Rate (â€œSOFRâ€) for interest periods of one, three or six months, plus the applicable margin or, at NHCâ€™s option, (ii) the Base Rate plus the applicable margin.Â The applicable margin is an interest rate per annum between 1.30% and 1.65% for Term SOFR loans and between .30% and .65% for Base Rate loans, depending upon the CompanyÂ meeting certain conditions. The revolving line of creditÂ contains a commitment fee equal to 0.25% of the unused borrowing capacity. There are no amounts outstanding on the revolving line of credit at September 30, 2024. Â NHCâ€™s obligations under the Credit Facility are unsecured. The Credit Facility contains customary representations and warranties, financial covenants, and other customary affirmative and negative covenants. The Credit Facility also contains customary events of default. As of September 30, 2024, the Company is compliant with all financial covenants.Â Based on level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt based upon the interest rates that the Company believes it can currently obtain for similar debt. Â The aggregate maturities of longâ€“term debt for the five years subsequent to September 30, 2024 are as follows (in thousands): Â Â Â Longâ€“Term Debt Â 2025 Â $ 7,500 Â 2026 Â Â 7,500 Â 2027 Â Â 7,500 Â 2028 Â Â 7,500 Â 2029 Â Â 117,000 Â Total Â $ 147,000 Â Â Â Note 16 â€“ Income Taxes Â The Company's income tax provision as a percentage of our income before income taxes was 26.4% and 27.9% for the three months ended September 30, 2024 and 2023, respectively. Â The Company's income tax provision as a percentage of our income before income taxes was 26.3% and 28.3% for the nine months ended September 30, 2024 and 2023, respectively.Â Â Typically, these percentages vary from the U.S. federal statutory income tax rate of 21% primarily due toÂ state income taxes, excess tax benefits from stock-based compensation, benefits resulting from the lapsing of statute of limitations of items in our tax contingency reserve, and non-deductible expenses. For the three months and nine months ended September 30, 2024, the accrual of state income tax was the mostÂ significant reconciling item. For the three and nine months ended September 30, 2023, the accrual of state income tax was the only significant reconciling items. Â 25 Table of Contents Â Our quarterly income tax provision, and our estimate of our annual effective income tax rate, is subject to variation due to several factors, including volatility based on the amount of pre-tax income or loss.Â Â Â The Company is no longer subject to U.S. federal and state examinations by tax authorities for years before 2020 (with certain state exceptions).Â Â Â Note 17 â€“ Contingencies and Commitments Â Accrued Risk Reserves Â We have whollyâ€“owned limited purpose insurance companies that insure risks related to workersâ€™ compensation and general and professional liability insurance claims both for our owned andÂ leased entities and certain of the entities to which we provide management or accounting services. The liability we have recognized for reported claims and estimates for incurred but unreported claims totals $110,204,000 and $103,259,000 at September 30, 2024 and December 31, 2023, respectively. The liability is included in accrued risk reserves in the interim condensed consolidated balance sheets and is subject to adjustment for actual claims incurred. It is possible that these claims plus unasserted claims could exceed our insurance coverages and our reserves, which could have a material adverse effect on our consolidated financial position, results of operations and cash flows. Â As a result of the terms of our insurance policies and our use of wholly owned limited purpose insurance companies, we have retained significant insurance risk with respect to workersâ€™ compensation and general and professional liability. We consider the professional services of independent actuaries to assist us in estimating our exposures for claims obligations (for both asserted and unasserted claims) related to deductibles and exposures in excess of coverage limits, and we maintain reserves for these obligations. Such estimates are based on many variables including historical and statistical information and other factors. Â Workersâ€™ Compensation Â For workersâ€™ compensation, we utilize a whollyâ€“owned Tennessee domiciled property/casualty insurance company to write coverage for NHC affiliates and for thirdâ€“party customers. Policies are written for a duration of twelve months and cover only risks related to workersâ€™ compensation losses. All customers are companies which operate in the senior care industry. Business is written on a direct basis.Â Â General and Professional Liability Insurance and Lawsuits Â The senior care industry has experienced significant increases in both the number of personal injury/wrongful death claims and in the severity of awards based upon alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. Additional insurance is purchased through third party providers that serve to supplement the coverage provided through our wholly owned captive insurance company. Â There is certain additional litigation incidental to our business, none of which, based upon information available to date, would be material to our financial position, results of operations, or cash flows. In addition, the longâ€“term care industry is continuously subject to scrutiny by governmental regulators, which could result in litigation or claims related to regulatory compliance matters. Â Qui Tam Litigation Â United States of America, ex rel. Jennifer Cook and Sally Gaither v. Integrated Behavioral Health, Inc., NHC HealthCare/Moulton, LLC, et al., Case No. 2:20-CV-00877-AMM (N.D. Ala.)Â This is a qui tam case originally filed under seal on June 22, 2020. The United States declined intervention on March 1, 2021. Thereafter, the Plaintiffs filed an amended Complaint against Dr. Sanja Malhotra, Integrated Behavioral Health, Inc. and other entities that Dr. Malhotra was alleged to own or in which he allegedly had a financial interest. The Complaint also named multiple skilled nursing facilities as Defendants, including NHC Healthcare/Moulton, LLC, an affiliate of National HealthCare Corporation. The Complaint alleged that nurse practitioners affiliated with Dr. Malhotra provided free services to the facilities in exchange for referrals to entities owned by or in which Dr. Malhotra had a financial interest in violation of the False Claims Act and Anti-Kickback Statute. NHC Healthcare/Moulton, LLC denied the allegations and filed a motion to dismiss on November 4, 2021. On January 28, 2022, the district court stayed this matter and administratively terminated the motion to dismiss pending the U.S. Supreme Court's review of a petition for certiorari filed in an unrelated matter but involving one of the legal arguments raised in the motion to dismiss. Thereafter, the U.S. Supreme Court denied the petition for certiorari in the unrelated matter. As a result, NHC Healthcare/Moulton, LLC renewed its motion to dismiss. The District Court granted NHC Healthcare/Moultonâ€™s Motion to Dismiss, along with other pending Motions to Dismiss, and entered an Order of Dismissal on March 23, 2023 and an Amended Order of Dismissal on April 4, 2023, which dismissed the case in its entirety with prejudice with respect to the claims asserted by the Plaintiffs. The Plaintiffs filed a Notice of Appeal on April 20, 2023 to appeal the dismissal to the United States Court of Appeals for the Eleventh Circuit. On December 21, 2023, the Eleventh Circuit entered an Order affirming the District Courtâ€™s dismissal of the claims.Â The time period for the Plaintiffs to file a Petition for a Writ of Certiorari with the United States Supreme Court has expired making the Order affirming dismissal issued by the Eleventh Circuit final.Â Â 26 Table of Contents Â Civil Investigative Demand Â On or about May 21, 2024, Caris Healthcare, L.P. (â€œCarisâ€) received a Civil Investigative Demand (â€œCIDâ€) from the U.S. Attorneyâ€™s Office for the Eastern District of Tennessee. The CID requests the production of certain medical records for patients at Carisâ€™ Nashville office and other documents related to the billing for hospice services for the period of January 1, 2019, through the date of the CID. The Company is cooperating with respect to the requests and remains in the process of responding to the CID. Â Governmental Regulations Â Laws and regulations governing Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid and other federal healthcare programs. Â Â Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Â Forwardâ€“Looking Statements Â References throughout this document to the Company include National HealthCare Corporation and its wholly owned subsidiaries. In accordance with the Securities and Exchange Commissions â€œPlain Englishâ€ guidelines, this Quarterly Report on Form 10â€“Q has been written in the first person. In this document, the words â€œweâ€, â€œourâ€, â€œoursâ€ and â€œusâ€ refer only to National HealthCare Corporation and its whollyâ€“owned subsidiaries and not any other person. Â This Quarterly Report on Form 10â€“Q

and other information we provide from time to time, contains certain â€œforwardâ€“lookingâ€ statements as that term is defined by the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations or cash flows, continued performance improvements, ability to service and refinance our debt obligations, ability to finance growth opportunities, ability to control our patient care liability costs, ability to respond to changes in government regulations, ability to execute our threeâ€“year strategic plan, and similar statements including, without limitations, those containing words such as â€œbelievesâ€, â€œanticipatesâ€, â€œexpectsâ€, â€œintendsâ€, â€œestimatesâ€, â€œplansâ€, and other similar expressions are forwardâ€“looking statements. Â Forwardâ€“looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forwardâ€“looking statements as a result of, but not limited to, the following factors: Â â— national and local economic conditions, including their effect on the availability and cost of labor, utilities and materials; Â â— the effect of government regulations and changes in regulations governing the healthcare industry, including our compliance with such regulations; Â â— changes in Medicare and Medicaid payment levels and methodologies and the application of such methodologies by the government and its fiscal intermediaries; Â â— liabilities and other claims asserted against us, including patient care liabilities, as well as the resolution of current litigation (see Note 17: Contingencies and Commitments); Â â— the ability to attract and retain qualified personnel; Â â— the availability and terms of capital to fund acquisitions and capital improvements; Â 27 Table of Contents Â â— the competitive environment in which we operate; Â â— our need to make investments continually in our processes and information systems to protect the privacy of patients, partnersÂ and other persons and reduce the risk of successful cybersecurity attacks; Â â— damage to our reputation, regulatory penalties, legal claims and liability under state and federal laws that we could suffer upon any cybersecurity or privacy breaches; Â â— the ability to maintain and increase census levels; and Â â— demographic changes. Â See the notes to the quarterly financial statements, and â€œItem 1. Businessâ€ in our 2023 Annual Report on Form 10â€“K for a discussion of various governmental regulations and other operating factors relating to the healthcare industry and the risk factors inherent in them. This may be found on our web site at www.nhccare.com. You should carefully consider these risks before making any investment in the Company. These risks and uncertainties are not the only ones facing us. There may be additional risks that we do not presently know of or that we currently deem immaterial. If any of the risks occur, our business, financial condition or results of operations could be materially adversely affected. In that case, the trading price of our shares of stock could decline, and you may lose all or part of your investment. Given these risks and uncertainties, we can give no assurances that these forwardâ€“looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. Â Overview Â National HealthCare Corporation (â€œNHCâ€ or the â€œCompanyâ€) is a leading provider of senior health care services. As of September 30, 2024, we operate or manage, through certain affiliates, 80 skilled nursing facilities with a total of 10,349 licensed beds, 26 assisted living facilities with 1,413 units, nine independent living facilities, three behavioral health hospitals, 34 homecare agencies, and 32 hospice agencies. We operate specialized care units within certain of our healthcare centers such as Alzheimer's disease care units and sub-acute nursing units. In addition, we provide insurance services, management and accounting services, and we lease properties to operators of skilled nursing and assisted living facilities. We operate in 9 states and are located primarily in the southeastern United States. Â Centers for Medicare and Medicaid Services Minimum Staffing Standards Â On April 22, 2024, the Centers for Medicare and Medicaid Services (â€œCMSâ€) issued the Minimum Staffing Standards for Long-Term Care (â€œLTCâ€) Facilities and Medicaid Institutional Payment Transparency Reporting final rule. Included in this final rule are new comprehensive minimum nurse staffing requirements, which aim to significantly reduce the risk of residents receiving unsafe and low-quality care within LTC facilities. CMS is finalizing a total nurse staffing standard of 3.48 hours per resident day (â€œHPRDâ€), which must include at least 0.55 HPRD of direct registered nurse (â€œRNâ€) care and 2.45 HPRD of direct nurse aide care. Facilities may use any combination of nurse staff (RN, licensed practical nurse and licensed vocational nurse, or nurse aide) to account for the additional 0.48 HPRD needed to comply with the total nurse staffing standard. Â CMS is also finalizing enhanced facility assessment requirements and a requirement to have an RN onsite 24 hours a day, seven days a week (â€œ24/7â€), to provide skilled nursing care. The 24/7 RN onsite can be the Director of Nursing; however, they must be available to provide direct resident care. Â This final rule provides a staggered implementation timeframe of the minimum nurse staffing standards and a 24/7 RN requirement based on geographic location, as well as possible exemptions for qualifying facilities for some parts of these requirements based on workforce unavailability and other factors. Â Summary of Goals and Areas of Focus Â Occupancy Â A primary area of management focus continues to be the rates of occupancy within our skilled nursing facilities. The overall census in owned and leased skilled nursing facilities for the three months ending September 30, 2024 was 88.3% compared to 88.1% for the same period a year ago.Â Â For the nine months ended September 30, 2024, overall census in our owned and leased skilled nursing facilities was 88.6% compared to 87.8% for the same period a year ago. Â 28 Table of Contents Â Due to Americaâ€™s healthcare labor shortage, the challenge of maintaining desirable patient census levels has been amplified. Management has undertaken a number of steps in order to best position our current and future health care facilities. This includes working internally to examine and improve systems to be most responsive to referral sources and payors, as well as find creative initiatives to retain and attract qualified healthcare professionals. Additionally, NHC is in various stages of partnerships with hospital systems, payors, and other postâ€“acute alliances to better position ourselves so we are an active participant in the delivery of post-acute healthcare services. Â Quality of Patient Care Â CMS introduced the Five-Star Quality Rating System to help consumers, their families and caregivers compare skilled nursing facilities more easily. The Five-Star Quality Rating System gives each skilled nursing operation a rating rangingÂ between one and five stars in various categories (five stars being the best). The Company has always strived for patient-centered care and quality outcomes as precursors to outstanding financial performance. Â The tables below summarizeÂ NHC'sÂ overall performance in these Five-StarÂ ratings versus the skilled nursing industry as of September 30, 2024: Â Â Â NHC Ratings Â Â Industry Ratings Â Total number of skilled nursing facilities, end of period Â Â 80 Â Â Â Â Â Number of 4 and 5-star rated skilled nursing facilities Â Â 45 Â Â Â Â Â Percentage of 4 and 5-star rated skilled nursing facilities Â Â 56% Â Â Â 36% Â Average rating for all skilled nursing facilities, end of period Â Â 3.5 Â Â Â 2.9 Â Â Development and Growth Â We are undertaking to expand our senior care operations while protecting our existing operations and markets. The following table lists our recent development activities. Â Type of Operation Â Description Â Size Â Location Â Placed in Service Hospice Â New Agency Â 1 agency Â Cedar Bluff, VA Â March 2023 Skilled Nursing Â Acquisition Â 66 beds Â Nashville, TN Â May 2023 Homecare Â New Agency Â 1 agency Â Tallahassee, FL Â May 2023 Assisted Living Facility Â New Operations Â 135 units Â Vero Beach, FL Â July 2023 Assisted Living Facility Â New Operations Â 95 units Â Merritt Island, FL Â July 2023 Assisted Living Facility Â New Operations Â 100 units Â Stuart, FL Â July 2023 Hospice Â New Agency Â 1 agency Â Morristown, TN Â April 2024 Hospice Â New Agency Â 1 agency Â Lawrenceburg, TN Â July 2024 Hospice Â New Agency Â 1 agency Â Wytheville, VA Â August 2024 Â On August 1, 2024, the Company purchased the White OakÂ portfolio, including its long-term care pharmacy. The White OakÂ portfolio consists ofÂ 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities.Â The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina. Â Accrued Risk Reserves Â Our accrued professional liability and workersâ€™ compensation reserves totaled $110,204,000 at September 30, 2024 and are a primary area of management focus. We have set aside restricted cash and cash equivalents and marketable securities to fund our estimated professional liability and workersâ€™ compensation liabilities. Â As to exposure for professional liability claims, we have developed performance certification criteria to measure and bring focus to the patient care issues most likely to produce professional liability exposure, including inâ€“house acquired pressure ulcers, significant weight loss and numbers of falls. These programs for certification, which we regularly modify and improve, have produced measurable improvements in reducing these incidents. Our experience is that achieving goals in these patient care areas improves both patient and employee satisfaction. Â 29 Table of Contents Â Government Reimbursement Programs Â Medicare â€“ Skilled Nursing Facilities Â In July 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates and policy changes for skilled nursing facilities, which began on October 1, 2023. The fiscal year 2024 rule equates to a net increase of 4.0%, or approximately $1.4 billion, in Medicare Part A payments to SNFs in fiscal year 2024 compared to 2023 levels. The rule includes a 3.0% market basket rate increase, a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment, as well as a negative 2.3%, or approximately $789 million, decrease in 2024 SNF Payment Prospective Systems rates as a result of the second phase of the Patient Driven Payment Model parity adjustment recalibration. Â In JulyÂ 2024, CMS released its final rule outlining fiscal year 2025 Medicare payment rates and policy changes for skilled nursing facilities, which began on October 1, 2024. The fiscal year 2025 ruleÂ equates to a net 4.2% increase in Medicare Part A payments to SNFs in fiscal year 2025 compared to 2024 levels. The rule includes a market basket increase of 3.0%, an increase of 1.7% to the market basket forecast error adjustment, and a negative 0.5% productivity adjustment. This final rule also changes CMSâ€™ enforcement policies to impose more equitable and consistent civil monetary penalties ("CMPs") for health and safety violations as part of the agencyâ€™s ongoing work to increase the safety and care provided in Americaâ€™s nursing homes. CMS revised the regulation to expand the type of CMPs that can be imposed to allow for more per instance and per day CMPs to be imposed, as appropriate. In the final rule it also finalized updates to the SNF Quality Reporting Program ("QRP") to better account for adverse social conditions that negatively impact individualsâ€™ health or healthcare. CMS also finalized its proposal to adopt a data validation process for the SNF QRP beginning the same year. Â For the first nine months of 2024, our average Medicare per diem rate for skilled nursing facilities increased 4.9% as compared to the same period in 2023.Â Â Medicaid â€“ Skilled Nursing Facilities Â Effective July 1, 2024 and for the fiscal year 2025, the state of Tennessee implemented specific individual nursing facility increases. We estimate the resulting increase in revenue for the 2025 fiscal year will be approximately $11,000,000 annually, or $2,750,000 per quarter. Additionally, the state of Tennessee implemented non-recurring rate increases for fiscal year 2025 for continued stabilization payments and Medicaid rate rebasing. These non-recurring rate increases will result in an additional increase in revenue for the 2025 fiscal year of approximately $8,200,000 annually, or $2,050,000 per quarter. Â Effective October 1, 2024 and for the fiscal year 2025, the state of South Carolina implemented specific individual nursing facility increases. We estimate the resulting increase in revenue for the 2025 fiscal year will be approximately $500,000 annually, or $125,000 per quarter. Â Effective July 1, 2024 and for the fiscal year 2025, the state of Missouri has proposedÂ specific individual nursing facility increases, subject to approval from Centers for Medicare and Medicaid Services ("CMS"). Upon CMS' approval, we estimate the resulting increase in revenue for the 2025 fiscal year will be approximately $6,600,000 annually, or $1,650,000 per quarter. Â We have also received from many of the states in which we operate a supplemental Medicaid payment to help mitigate the inflationary labor and medical supplies costs resulting from the pandemic. We haveÂ recorded $5,267,000 and $4,232,000 in net patient revenues for these supplemental Medicaid payments for the three months ended September 30, 2024 and 2023, respectively. We haveÂ recorded $11,314,000 and $15,3620,000 in net patient revenues for these supplemental Medicaid payments for the nine months ended September 30, 2024 and 2023, respectively. Â For the first nine months of 2024, our average Medicaid per diem increased 10.2% compared to the same period in 2023. Â State Medicaid plans subject to budget constraints are of particular concern to us. Changes in federal funding coupled with state budget problems and Medicaid expansion under the Affordable Care Act have produced an uncertain environment. Some states will not keep pace with post-acute healthcare inflation. States are currently under pressure to pursue other alternatives to skilled nursing care such as community and homeâ€“based services. Medicaid programs are funded jointly by the federal government and the states and are administered by states under approved plans.Â Most state Medicaid payments are made under a prospective payment system or under programs which negotiate payment levels with individual providers.Â Some states use, or have applied to use, waivers granted by CMS to implement expansion, impose different eligibility or enrollment restrictions, or otherwise implement programs that vary from federal standards. Â Medicare â€“ Homecare Programs Â In November 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates. CMS projects payments to home health agencies in fiscal year 2024 will increase in aggregate by 0.8%, or $140 million. The increase is the result of a 3.3% market basket update, reduced by a 0.3% productivity adjustment. The increase is offset by a behavioral adjustment that will cut payments by a net 2.6%. The behavioral adjustment was designed to achieve budget-neutral implementation of the PDPM. Finally, CMS also adjusted the fixed-dollar loss ratio for outlier payments, which will increase payments by 0.4%. Â In June 2024, CMS released its proposed rule outlining fiscal year 2025 Medicare payment rates. CMS projects payments to home health agencies in fiscal year 2025 will decrease by 1.7% or $280 million, relative to the prior year. This decrease reflects a 2.5% home health payment update, reduced by a 3.6% decrease related to the Patient-Driven Groupings Model (â€œPDGMâ€) rebalancing and an estimated 0.6% decrease that reflects a proposed fixed dollar loss for outlier payments. As required by the Bipartisan Budget Act of 2018, this rule proposes a permanent prospective adjustment to the CY2025 home health payment rate to account for the impact of implementing the PDGM. This adjustment accounts for differences between assumed behavior changes and actual behavior changes on estimated aggregate expenditures due to the CY2020 implementation of PDGM and the change to a 30-day unit of payment. Â 30 Table of Contents Â Medicare â€“ Hospice Â In July 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates. CMS issued a rate increase of 3.1%, or $780 million, effective October 1, 2023.

This increase is the result of a 3.3% market basket increase reduced by a 0.2% productivity adjustment. The FY2024 hospice payment update also includes an update to the statutory aggregate cap amount, which limits the overall payments per patient that are made annually. The cap amount for FY2024 is $33,494.Â Â In JulyÂ 2024, CMS released its finalÂ rule outlining fiscal year 2025 Medicare payment rates. CMS issued a rate increase of 2.9%, or $790Â million, effective October 1, 2024. This increase is the result of a 3.4% market basket increase reduced by a 0.5% productivity adjustment. The FY2025 hospice payment update also includes an update to the statutory aggregate cap amount, which limits the overall payments per patient that are made annually. The cap amount for FY2025 is $34,465.Â Â Segment Reporting Â The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals; and (2) homecare and hospice services. These reportable operating segments are consistent with information used by the Companyâ€™s Chief Executive Officer, as chief operating decision maker (â€œCODMâ€), to assess performance and allocate resources. The Company also reports an â€œall otherâ€ category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. Â The Companyâ€™s CODM evaluates performance and allocates capital resources to each segment based on an operating model that is designed to improve the quality of patient care and profitability of the Company while enhancing long-term shareholder value. The CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below. Â The following table sets forth the Companyâ€™s unaudited interim condensed consolidated statements of operations by business segment (in thousands):Â Â Â Â Three Months Ended September 30, 2024 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 293,026 Â Â $ 35,648 Â Â $ - Â Â $ 328,674 Â Other revenues Â Â 370 Â Â Â - Â Â Â 11,154 Â Â Â 11,524 Â Net operating revenues Â Â 293,396 Â Â Â 35,648 Â Â Â 11,154 Â Â Â 340,198 Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 175,241 Â Â Â 21,456 Â Â Â 16,698 Â Â Â 213,395 Â Other operating Â Â 72,384 Â Â Â 6,612 Â Â Â 3,513 Â Â Â 82,509 Â Rent Â Â 8,422 Â Â Â 602 Â Â Â 1,862 Â Â Â 10,886 Â Depreciation and amortization Â Â 9,632 Â Â Â 172 Â Â Â 815 Â Â Â 10,619 Â Interest Â Â 1,742 Â Â Â - Â Â Â - Â Â Â 1,742 Â Total costs and expenses Â Â 267,421 Â Â Â 28,842 Â Â Â 22,888 Â Â Â 319,151 Â Income/(loss) from operations Â Â 25,975 Â Â Â 6,806 Â Â Â (11,734) Â Â 21,047 Â Non-operating income Â Â - Â Â Â - Â Â Â 4,224 Â Â Â 4,224 Â Unrealized gains on marketable equity securities Â Â - Â Â Â - Â Â Â 32,767 Â Â 32,767 Â Income before income taxes Â $ 25,975 Â Â $ 6,806 Â Â $ 25,257 Â Â $ 58,038 Â Â 31 Table of Contents Â Â Â Three Months Ended September 30, 2023 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 243,865 Â Â $ 33,140 Â Â $ - Â Â $ 277,005 Â Other revenues Â Â 297 Â Â Â - Â Â Â 11,183 Â Â Â 11,480 Â Net operating revenues Â Â 244,162 Â Â Â 33,140 Â Â Â 11,183 Â Â Â 288,485 Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 151,912 Â Â Â 20,066 Â Â Â 10,686 Â Â Â 182,664 Â Other operating Â Â 64,228 Â Â Â 5,868 Â Â Â 2,394 Â Â Â 72,490 Â Rent Â Â 8,186 Â Â Â 538 Â Â Â 1,370 Â Â Â 10,094 Â Depreciation and amortization Â Â 9,203 Â Â Â 185 Â Â Â 747 Â Â Â 10,135 Â Interest Â Â 77 Â Â Â - Â Â Â - Â Â Â 77 Â Total costs and expenses Â Â 233,606 Â Â Â 26,657 Â Â Â 15,197 Â Â Â 275,460 Â Income/(loss) from operations Â Â 10,556 Â Â 6,483 Â Â Â (4,014) Â Â 13,025 Â Non-operating income Â Â - Â Â Â - Â Â Â 4,097 Â Â Â 4,097 Â Unrealized losses on marketable equity securities Â Â - Â Â Â - Â Â Â (3,093) Â Â (3,093) Â Income/(loss) before income taxes Â $ 10,556 Â Â $ 6,483 Â Â $ (3,010) Â $ 14,029 Â Â Â Â Â Nine Months Ended September 30, 2024 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 790,664 Â Â $ 103,751 Â Â $ - Â Â $ 894,415 Â Other revenues Â Â 710 Â Â Â - Â Â Â 33,462 Â Â Â 34,172 Â Government stimulus income Â Â - Â Â Â - Â Â Â 9,445 Â Â Â 9,445 Â Net operating revenues and grant income Â Â 791,374 Â Â Â 103,751 Â Â Â 42,907 Â Â Â 938,032 Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 474,190 Â Â Â 63,761 Â Â Â 38,658 Â Â Â 576,609 Â Other operating Â Â 207,883 Â Â Â 18,977 Â Â Â 11,232 Â Â Â 238,092 Â Rent Â Â 24,795 Â Â Â 1,736 Â Â Â 5,273 Â Â Â 31,804 Â Depreciation and amortization Â Â 27,646 Â Â Â 545 Â Â Â 2,352 Â Â Â 30,543 Â Interest Â Â 1,788 Â Â Â - Â Â Â 1,788 Â Total costs and expenses Â Â 736,302 Â Â Â 85,019 Â Â Â 57,515 Â Â Â 878,836 Â Income/(loss) from operations Â Â 55,072 Â Â Â 18,732 Â Â Â (14,608) Â Â 59,196 Â Non-operating income Â Â - Â Â Â - Â Â Â 14,865 Â Â Â 14,865 Â Unrealized gains on marketable equity securities Â Â - Â Â Â - Â Â Â 56,290 Â Â Â 56,290 Â Income before income taxes Â $ 55,072 Â Â $ 18,732 Â Â $ 56,547 Â Â $ 130,351 Â Â 32 Table of Contents Â Â Â Nine Months Ended September 30, 2023 Â Â Â Inpatient Services Â Â Homecare and Hospice Â Â All Other Â Â Total Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net patient revenues Â $ 706,795 Â Â $ 97,822 Â Â $ - Â Â $ 804,617 Â Other revenues Â Â 894 Â Â Â - Â Â Â 35,119 Â Â Â 36,013 Â Net operating revenues Â Â 707,689 Â Â Â 97,822 Â Â Â 35,119 Â Â Â 840,630 Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 435,517 Â Â Â 60,804 Â Â Â 29,461 Â Â Â 525,782 Â Other operating Â Â 192,473 Â Â Â 17,356 Â Â Â 7,384 Â Â Â 217,213 Â Rent Â Â 24,520 Â Â Â 1,639 Â Â Â 3,928 Â Â Â 30,087 Â Depreciation and amortization Â Â 27,474 Â Â Â 555 Â Â Â 2,237 Â Â Â 30,266 Â Interest Â Â 268 Â Â Â - Â Â Â - Â Â Â 268 Â Total costs and expenses Â Â 680,252 Â Â Â 80,354 Â Â Â 43,010 Â Â Â 803,616 Â Income/(loss) from operations Â Â 27,437 Â Â Â 17,468 Â Â Â (7,891) Â Â 37,014 Â Non-operating income Â Â - Â Â Â - Â Â Â 12,116 Â Â Â 12,116 Â Unrealized gains on marketable equity securities Â Â - Â Â Â - Â Â Â 2,943 Â Â Â 2,943 Â Income before income taxes Â $ 27,437 Â Â $ 17,468 Â Â $ 7,168 Â Â $ 52,073 Â Â 33 Table of Contents Â Non-GAAP Financial Presentation Â The Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Companyâ€™s operations and measure the Companyâ€™s performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Â Specifically, the Company believes the presentation of non-GAAP financial information that excludes the unrealized gains or losses on our marketable equity securities, operating results for newly opened facilities or agencies not at full capacity, gains on sale of unconsolidated companies, share-based compensation expense, acquisition-related expenses, and the recognition of the employee retention creditÂ is helpful in allowing investors to assess the Companyâ€™s operations more accurately. Â The operating results for newly opened facilities or agencies not at full capacityÂ include newly constructed healthcare facilities or agencies that are still considered in the start-up phase, which areÂ two hospice agencies for the three and nine months ended September 30, 3024. For the three and nine months ended September 30, 2023, included are two behavioral health hospitals, two homecare agencies, and two hospice agencies. The acquisition-related expenses represent expenses incurred to acquire the White Oak portfolio.Â Â Â The tables below provide reconciliations of GAAP to non-GAAP items (dollars in thousands, except per share data): Â Â Â Three Months Ended September 30 Â Â Nine Months Ended September 30 Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income attributable to National Healthcare Corporation Â $ 42,789 Â Â $ 10,388 Â Â $ 95,846 Â Â $ 38,392 Â Non-GAAP adjustments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unrealized (gains)/losses on marketable equity securities Â Â (32,767) Â Â 3,093 Â Â Â (56,290) Â Â (2,943) Operating results for newly opened facilities or agencies not at full capacity Â Â 120 Â Â Â 66 Â Â Â 140 Â Â Â 1,616 Â Share-based compensation expense Â Â 1,093 Â Â Â 708 Â Â Â 3,062 Â Â Â 2,119 Â Gain on sale of unconsolidated company Â Â - Â Â Â - Â Â Â (1,024) Â Â - Â Acquisition-related expenses Â Â 637 Â Â Â - Â Â Â 2,831 Â Â Â - Â Employee retention credit Â Â - Â Â Â - Â Â Â (9,445) Â Â - Â Income tax expense/(benefit) on non-GAAP adjustments Â Â 8,038 Â Â Â (1,005) Â Â 15,789 Â Â Â (206) Non-GAAP Net income Â $ 19,910 Â Â $ 13,250 Â Â $ 50,909 Â Â $ 38,978 Â GAAP diluted earnings per share Â $ 2.73 Â Â $ 0.68 Â Â $ 6.15 Â Â $ 2.51 Â Non-GAAP adjustments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unrealized (gains)/losses on marketable equity securities Â Â (1.55) Â Â 0.15 Â Â Â (2.67) Â Â (0.14) Operating results for newly opened facilities or agencies not at full capacity Â Â 0.01 Â Â Â - Â Â Â 0.01 Â Â Â 0.07 Â Share-based compensation expense Â Â 0.05 Â Â Â 0.03 Â Â Â 0.15 Â Â Â 0.10 Â Gain on sale of unconsolidated company Â Â - Â Â Â - Â Â Â (0.05) Â Â - Â Acquisition-related expenses Â Â 0.03 Â Â Â - Â Â Â 0.13 Â Â Â - Â Employee retention credit Â Â - Â Â Â - Â Â Â (0.45) Â Â - Â Non-GAAP diluted earnings per share Â $ 1.27 Â Â $ 0.86 Â Â $ 3.27 Â Â $ 2.54 Â Â 34 Table of Contents Â Results of Operations Â The following table and discussion set forth items from the interim condensed consolidated statements of operationsÂ as a percentage of net operating revenues and grant income for the three and nine months ended September 30, 2024 and 2023. Â Percentage of Net Operating Revenues Â Â Â Three Months Ended September 30 Â Â Nine Months Ended June 30 Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net operating revenues and grant income Â Â 100.0 % Â Â 100.0 % Â Â 100 % Â Â 100 % Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages, and benefits Â Â 62.7 Â Â Â 63.3 Â Â Â 61.5 Â Â Â 62.5 Â Other operating Â Â 24.3 Â Â Â 25.1 Â Â Â 25.4 Â Â Â 25.8 Â Facility rent Â Â 3.2 Â Â Â 3.5 Â Â Â 3.4 Â Â Â 3.6 Â Depreciation and amortization Â Â 3.1 Â Â Â 3.5 Â Â Â 3.3 Â Â Â 3.6 Â Interest Â Â 0.5 Â Â Â 0.1 Â Â Â 0.1 Â Â Â 0.1 Â Total costs and expenses Â Â 93.8 Â Â Â 95.5 Â Â Â 93.7 Â Â Â 95.6 Â Income from operations Â Â 6.2 Â Â Â 4.5 Â Â Â 6.3 Â Â Â 4.4 Â Nonâ€“operating income Â Â 1.3 Â Â Â 1.4 Â Â Â 1.5 Â Â Â 1.4 Â Unrealized gains/(losses) on marketable equity securities Â Â 9.6 Â Â Â (1.0) Â Â 6.1 Â Â Â 0.4 Â Income before income taxes Â Â 17.1 Â Â Â 4.9 Â Â Â 13.9 Â Â Â 6.2 Â Income tax provision Â Â (4.5) Â Â (1.4) Â Â (3.7) Â Â (1.8) Net income Â Â 12.6 Â Â Â 3.5 Â Â Â 10.2 Â Â Â 4.4 Â Net income attributable to noncontrolling interest Â Â 0.0 Â Â Â 0.1 Â Â Â 0.0 Â Â Â 0.2 Â Net income attributable to stockholders of NHC Â Â 12.6 Â Â Â 3.6 Â Â Â 10.2 Â Â Â 4.6 Â Â Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023 Â Results for the quarter ended September 30, 2024 compared to the third quarter of 2023 include a 17.9% increase in net operating revenues. For the quarter ended September 30, 2024, GAAP net income attributable to NHC was $42,789,000 compared to $10,388,000 for the same period in 2023. Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended September 30, 2024 was $19,910,000 compared to $13,250,000 for the same period in 2023.Â The increase in adjusted net income for the threeÂ months ended September 30, 2024 compared to the same period of 2023 was primarily due to theÂ per diemÂ increases in our skilled nursingÂ facilitiesÂ andÂ the continued reduction of nurse agency staffing expense within our operations. Â On August 1, 2024, the Company purchased the White OakÂ portfolio, including its long-term care pharmacy. The White OakÂ portfolio consists ofÂ 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities.Â The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina.Â Â Â Net operating revenues Â Net patient revenues increased $51,669,000, or 18.7%, compared to the same period last year. Â The total census at owned and leased skilled nursing facilities for the quarter averaged 88.3%, compared to an average of 88.1% for the same quarter a year ago. Overall, the composite skilled nursing facility per diem increased 7.8% compared to the same quarter a year ago. Our Medicare per diem rates increased 4.8% and managed care per diem rates decreased 6.0% compared to the same quarter a year ago. Medicaid and private pay per diem rates increased 13.1% and 14.1%, respectively, compared to the same quarter a year ago. For the three months endedÂ September 30, 2024 and 2023, respectively, $5,267,000 and $4,232,000 have been included in our net patient revenues for supplemental Medicaid payments that are in addition to our Medicaid skilled nursing per diems. Â White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $37,299,000 in net patient revenues for the quarter ended September 30, 2024 compared to the same quarter in the prior year. Â On March 1, 2024, the Company exited aÂ lease and transferred the operations of two skilled nursing facilities (included assisted living units) andÂ one memory care facilityÂ located in Missouri.Â The exiting of these operationsÂ resulted in net patient revenues decreasing $7,861,000 for the quarter ended September 30, 2024 compared to the same quarter in the prior year.Â Â Other revenues decreased $44,000, or 0.4%, compared to the same quarter last year, as further detailed in Note 5 to our interim condensed consolidated financial statements. Â 35 Table of Contents Â Total costs and expenses Â Total costs and expenses for the three months ended September 30, 2024 compared to the same period of 2023 increased $43,691,000, or 15.9%, to $319,151,000 from $275,460,000. Â Salaries, wages, and benefits as a percentage of net operating revenues was 62.7% compared to 63.3% for the three months ended September 30, 2024 and 2023, respectively. We continue to work diligently to find solutions to reduce and eliminate the agency nurse staffing within our healthcare operations. Our agency staffing expense decreased approximately 60% for the three months ended September 30, 2024 compared to the same period of 2023. Â White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $24,511,000 in salaries, wages, and benefits for the quarter ended September 30, 2024 compared to the same quarter

in the prior year. Â On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in salaries, wages, and benefits decreasing $6,148,000 for the quarter ended September 30, 2024 compared to the same quarter in the prior year. Â Other operating expenses as a percentage of net operating revenues was 24.3% and 25.1% for the three months ended September 30, 2024 and 2023, respectively. White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $8,238,000 in other operating expenses for the quarter ended September 30, 2024 compared to the same quarter in the prior year. Â On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in other operating expenses decreasing $2,316,000 for the quarter ended September 30, 2024 compared to the same quarter in the prior year. Â Other income Â Nonâ€“operating income increased by $127,000 compared to the same period last year, as further detailed in Note 6Â to our interim condensed consolidated financial statements. Â Income taxes Â The income tax provision for the three months ended September 30, 2024 is $15,338,000 (an effective income tax rate of 26.4%).Â Â Noncontrolling interest Â The noncontrolling interest inÂ subsidiariesÂ is presented within total equity of the Companyâ€™s consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its consolidated statements of operations. The Companyâ€™s earnings per share is calculated based on net income attributable to NHCâ€™s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. Â Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023 Â Results for the nine months ended September 30, 2024 compared to the same period of 2023 include an 11.6% increase in net operating revenues and grant income. For the nine months ended September 30, 2024, GAAP net income attributable to NHC was $95,846,000 compared to $38,392,000 for the same period in 2023. Excluding the unrealized gains in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the nine months ended September 30, 2024 was $50,909,000 compared to $38,978,000 for the same period in 2023.Â The increase in adjusted net income for the nine months ended September 30, 2024 compared to the same period of 2023 was primarily due to theÂ per diemÂ increases in our skilled nursing facilitiesÂ andÂ the continued reduction of nurse agency staffing expense within our operations. Â On August 1, 2024, the Company purchased the White OakÂ portfolio, including its long-term care pharmacy. The White OakÂ portfolio consists ofÂ 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities.Â The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina.Â Â Â Â 36 Table of Contents Â Net operating revenues and grant income Â Net patient revenues increased $89,798,000, or 11.2%, compared to the same period last year. Â The total census at owned and leased skilled nursing facilities for the nine months ended September 30, 2024 averaged 88.6%, compared to an average of 87.8% for the same period a year ago. Overall, the composite skilled nursing facility per diem increased 7.7% compared to the same period a year ago. Our Medicare per diem rates increased 4.9% and managed care per diem rates decreased 0.1% compared to the same period a year ago. Medicaid and private pay per diem rates increased 10.2% and 12.9%, respectively, compared to the same period a year ago. For the nine months endedÂ September 30, 2024 and 2023, respectively, $11,314,000 and $15,362,000 have been included in our net patient revenues for supplemental Medicaid payments that are in addition to our Medicaid skilled nursing per diems. Â White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $37,299,000 in net patient revenues for the nine months ended September 30, 2024 compared to the same period in the prior year. Â On March 1, 2024, the Company exited aÂ lease and transferred the operations of two skilled nursing facilities (included assisted living units) andÂ one memory care facilityÂ located in Missouri.Â The exiting of these operationsÂ resulted in net patient revenues decreasing $18,799,000 for the nine months ended September 30, 2024 compared to the same period in the prior year.Â Â Other revenues decreased $1,841,000, or 5.1%, compared to the same period last year, as further detailed in Note 5 to our interim condensed consolidated financial statements. Â During the nineÂ months ended September 30, 2024, the Company recognized $9,445,000 related to the Employee Retention Credit (â€œERCâ€)Â that was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. During the second quarter of 2024, all conditions related to the assistance were met and the credit was recognized as government stimulus income. Â Total costs and expenses Â Total costs and expenses for the nine months ended September 30, 2024 compared to the same period of 2023 increased $75,220,000, or 9.4%, to $878,836,000 from $803,616,000. Â Salaries, wages, and benefits as a percentage of net operating revenues was 61.5% compared to 62.5% for the nine months ended September 30, 2024 and 2023, respectively.Â We continue to work diligently to find solutions to reduce and eliminate the agency nurse staffing within our healthcare operations. Our agency staffing expense decreased approximately 55% for the nine months ended September 30, 2024 compared to the same period of 2023. Â White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $24,511,000 in salaries, wages, and benefits for the nine months ended September 30, 2024 compared to the same period in the prior year. Â On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in salaries, wages, and benefits decreasing $14,097,000 for the nine months ended September 30, 2024 compared to the same period in the prior year. Â Other operating expenses as a percentage of net operating revenues was 25.4% and 25.8% for the nine months ended September 30, 2024 and 2023, respectively. White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $8,238,000 in other operating expenses for the nine months ended September 30, 2024 compared to the same period in the prior year. Â On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in other operating expenses decreasing $4,452,000 for the nine months ended September 30, 2024 compared to the same quarter in the prior year. Â Other income Â Nonâ€“operating income increased by $2,749,000 compared to the same period last year, as further detailed in Note 6Â to our interim condensed consolidated financial statements. Â Income taxes Â The income tax provision for the nine months ended September 30, 2024 is $34,294,000 (an effective income tax rate of 26.3%).Â Â 37 Table of Contents Â Liquidity, Capital Resources, and Financial Condition Â Our primary sources of cash include revenues from the operations of our healthcare and senior living facilities, management and accounting services, rental income, and investment income. Our primary uses of cash include salaries, wages and other operating costs of our healthcare and senior living facilities, the cost of additions to and acquisitions of real property, facility rent expenses, and dividend distributions. These sources and uses of cash are reflected in our interim condensed consolidated statements of cash flows and are discussed in further detail below. Â The following is a summary of our sources and uses of cash flows (dollars in thousands): Â Â Â Nine Months Ended September 30 Â Â Six Month Change Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Cash, cash equivalents, restricted cash, and restricted cash equivalents, at beginning of period Â $ 125,968 Â Â $ 74,865 Â Â $ 51,103 Â Â 68.3 % Â Cash provided by operating activities Â Â 94,514 Â Â Â 85,483 Â Â Â 9,031 Â Â Â 10.6 Â Cash used in investing activities Â Â (225,048) Â Â (7,382) Â Â (217,666) Â Â (2,948.6) Â Cash provided by/(used in) financing activities Â Â 119,640 Â Â Â (32,711) Â Â 152,351 Â Â Â 465.7 Â Cash, cash equivalents, restricted cash, and restricted cash equivalents, at end of period Â $ 115,074 Â Â $ 120,255 Â Â $ (5,181) Â Â (4.3)% Â Operating Activities Â Net cash provided by operating activities for the nine months ended September 30, 2024 was $94,514,000 as compared to $85,483,000 in the same period last year. Cash provided by operating activities consisted of net income of $96,057,000 and adjustments for nonâ€“cash items of $9,070,000. There was cash provided by working capital in the amount of $7,015,000 for the nine months ended September 30, 2024 compared to $20,645,000 for the same period a year ago. Â Included in the adjustments for non-cash items are depreciation and amortization expense, equity in earnings of unconsolidated investments, unrealized gains on our marketable equity securities, gains on sales of investments, deferred taxes, and stock compensation.Â Â Investing Activities Â Net cash used in investing activities totaled $225,048,000 for the nine months ended September 30, 2024, compared to $7,382,000 for the nine months ended September 30, 2023. Cash used for property and equipment additions was $19,944,000 and $19,300,000 for the nine months ended September 30, 2024, and 2023, respectively. On August 1, 2024, the acquisition of White Oak Senior Living resulted in cash used of $215,896,000. Proceeds from the sale of marketable securities, net of purchases, resulted in cash provided by investing activityÂ of $15,040,000 and $14,815,000 for the nine months ended September 30, 2024 and 2023, respectively. In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency resulting in proceeds from the sale of $2,100,000.Â For the nine months ended September 30, 2024, we contributed capital of $8,370,000 to a joint venture, multi-family development that is under construction in Franklin, Tennessee.Â Â Â Financing ActivitiesÂ Â Net cash provided by financing activities totaled $119,640,000 for the nine months ended September 30, 2024 compared toÂ net cash used of $32,711,000 for the nine months ended September 30, 2023. The funding for the White Oak acquisitionÂ was provided by the Companyâ€™s cash on hand and borrowings under the credit facility of approximately $150,000,000. During the third quarter of 2024, cash of $3,000,000 was used to pay down the outstanding principal balance on our credit facility. We made principal payments under our finance lease obligations in the amount of $860,000 and $3,711,000 for the nine months ended September 30, 2024 and 2023, respectively. Cash used for dividend payments to common stockholders totaled $27,545,000 in the current year period compared to $26,520,000 for the same period a year ago. Cash provided byÂ the issuance of common stock totaled $13,471,000 for the nine months ended September 30, 2024 compared to $260,000 for the same period a year ago. We repurchased common shares outstanding in the amount of $13,502,000 and $2,482,000 for the nine months ended September 30, 2024 and 2023, respectively. Â Â Â 38 Table of Contents Â Shortâ€“term liquidity Â We expect to meet our short-term liquidity requirements primarily from our cash flows from operating activities. In addition to cash flows from operations, our current cash on hand of $84,807,000, our marketable equity securities of $164,754,000, and our borrowing capacity on the $50 million available line of creditÂ are expected to be adequate to meet our contractual obligations, operating liquidity, and our growth and development plans in the next twelve months.Â We also have substantial value in our unencumbered real estate assets, which could potentially be used as collateral in future borrowing opportunities. Â Longâ€“term liquidity Â We expect to meet our long-term liquidity requirements primarily from our cash flows from operating activities, our current cash on hand of $84,807,000, our marketable equity securities of $164,754,000, and our borrowing capacity on the $50 million available line of credit.Â We also have substantial value in our unencumbered real estate assets, which could potentially be used as collateral in future borrowing opportunities. Â Our ability to meet our longâ€“term contractual obligations, and to finance our operating requirements and growth plans will depend upon our future performance. Our future performance will be affected by business, economic, financial and other factors, including potential changes in state and federal government payment rates for healthcare, customer demand, success of our marketing efforts, pressures from competitors, and the state of the economy, including the state of financial and credit markets, as well as many unforeseen factors. Â Â Commitment and Contingencies Â Governmental Regulations Â Laws and regulations governing Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid, and other federal healthcare programs. Â Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. Â Market risk represents the potential economic loss arising from adverse changes in the fair value of financial instruments. Currently, our exposure to market risk relates primarily to our fixedâ€“income and equity portfolios. These investment portfolios are exposed primarily to, but not limited to, interest rate risk, credit risk, equity price risk, and concentration risk. We also have exposure to market risk that includes our cash and cash equivalents. The Company's senior management has established comprehensive risk management policies and procedures to manage these market risks. Â Interest Rate Risk Â The fair values of our fixedâ€“income investments fluctuate in response to changes in market interest rates. Increases and decreases in prevailing interest rates generally translate into decreases and increases, respectively, in the fair values of those instruments. Additionally, the fair values of interest rate sensitive instruments may be affected by the creditworthiness of the issuer, prepayment options, the liquidity of the instrument and other general market conditions. At September 30, 2024, we have available for sale marketable debt securities in the amount of $123,911,000. The fixed maturity portfolio is comprised of investments with primarily shortâ€“term and intermediateâ€“term maturities. The fixed maturity portfolio allows our insurance company subsidiaries to achieve an adequate riskâ€“adjusted return while maintaining sufficient liquidity to meet obligations. Â As of September 30, 2024, our credit facilityÂ bears interest at variable interest rates. Currently, we have an outstanding balance on our credit facility of $147.0 million.Â Based on our outstanding balance on the credit facility, a 1% change in interest rates would change interest cost by approximately $1,470,000. Â Our cash and cash equivalents consist of highly liquid investments with a maturity of less than three months when purchased. As a result of the shortâ€“term nature of our cash instruments, a hypothetical 1% change in interest rates would have minimal impact on our future earnings and cash flows related to these instruments. Â We do not currently use any

derivative instruments to hedge our interest rate exposure. We have not used derivative instruments for trading purposes and the use of such instruments in the future would be subject to approvals by the Investment Committee of the Board of Directors. Â Credit Risk Â Credit risk is managed by diversifying the fixed maturity portfolio to avoid concentrations in any single industry group or issuer and by limiting investments in securities with lower credit ratings. Â 39 Table of Contents Â Equity Price and Concentration Risk Â Our marketable equity securities are recorded at their fair market value based on quoted market prices. Thus, there is exposure to equity price risk, which is the potential change in fair value due to a change in quoted market prices. At September 30, 2024, the fair value of our marketable equity securities is approximately $187,755,000. Of the $187.8 million equity securities portfolio, our investment in NHI comprises approximately $137.1Â million, or 73.0%, of the total fair value. We manage our exposure to NHI by closely monitoring the financial condition, performance, and outlook of the company. Hypothetically, a 10% change in quoted market prices would result in a related increase or decrease in the fair value of our equity investments of approximately $18.8 million. At September 30, 2024, our equity securities had net unrealized gains of $139.9 million. Of the $139.9 million of unrealized gains, $112.3 million is related to our investment in NHI. Â Item 4. Controls and Procedures. Â As of September 30, 2024, an evaluation was performed under the supervision and with the participation of the Companyâ€™s management, including the Chief Executive Officer (â€œCEOâ€) and Chief Financial Officer (â€œCFOâ€), of the effectiveness of the design and operation of the Companyâ€™s disclosure controls and procedures. Based on that evaluation, the Companyâ€™s management, including the CEO and CFO, concluded that the Companyâ€™s disclosure controls and procedures were effective as of September 30, 2024. Â As permitted by guidance issued by the SEC that an assessment of internal control over financial reporting of a recently acquired business may be omitted from management's evaluation of disclosure controls and procedures, management excluded an assessment of the internal controls of White Oak Senior Living, which we acquired on August 1, 2024, from its evaluation of the effectiveness of our disclosure controls and procedures. White Oak Senior Living represented 15% of our consolidated total assets and 4% of our consolidated total net operating revenues and grant income as of and for the nine months ended September 30, 2024. We are in the process of integrating White Oak Senior Living into our system of internal control over financial reporting. Â Other than with respect to the integration of White Oak Senior Living into our system of internal control over financial reporting, there have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â Â PART II. OTHER INFORMATION Â Item 1. Legal Proceedings. Â For a discussion of prior, current, and pending litigation of material significance to NHC, please see Note 17Â of this Form 10â€“Q. Â Item 1A. Risk Factors. Â During the nineÂ months ended September 30, 2024, there were no material changes to the risk factors that were disclosed in Item 1A of National HealthCare Corporationâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Â Not applicable Â Item 3. Defaults Upon Senior Securities. Â None Â Item 4. Mine Safety Disclosures. Â Not applicable Â Item 5. Other Information. Â None Â 40 Table of Contents Â Â Item 6. Exhibits.Â Â Â (a) List of exhibits Â EXHIBIT INDEX Â Exhibit No. Â Description Â Â Â 3.1.1 Â Certificate of Incorporation of National HealthCare Corporation (Incorporated by reference to Exhibit 3.1 to the Registrantâ€™s registration statement on Form S-4 (File No. 333-37185) dated October 3, 1997.) Â Â Â 3.1.2 Â Certificate of Amendment to the Certificate of Incorporation of National HealthCare CorporationÂ (Incorporated by reference to Exhibit 3.5 to the quarterly report on Form 10-Q filed on August 3, 2017.) Â Â Â 3.4 Â Restated Bylaws as amended February 14, 2013 (Incorporated by reference to Exhibit 3.5 to the quarterly report on Form 10-Q filed on May 8, 2013.) Â Â Â 4.1 Â Form of Common Stock (Incorporated by reference to Exhibit 4.1 to the quarterly report on Form 10-Q filed on August 3, 2017.) Â Â Â 10.1 Â Purchase and Sale Agreement dated May 31, 2024 between NHC/OP, L.P., a wholly owned subsidiary of NHC, and Douglas M. Cecil, Oliver K. Cecil, Jr., Dorothy Dean Cecil, Jeni Cecil Feeser, Beth Creech Cecil, John Barber And Teresa J. Cecil, As Trustee Of The Teresa J. Cecil Revocable Trust U/A Dated July 20, 2006, As Amended And Restated On February 15, 2023 (Incorporated by reference to Exhibit 10.1 to the quarterly report on Form 10-Q filed on August 8, 2024.) Â Â Â 31.1 Â Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Â Â Â 31.2 Â Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Â Â Â 32 Â Certification pursuant to 18 U.S.C. Section 1350 by Chief Executive Officer and Chief Financial Officer Â Â Â 101.INS Â Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema Document Â Â Â 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document Â Â Â 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document Â Â Â 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â 104 Â Cover Page Interactive File (embedded within the Inline XBRL document and include in Exhibit 101) Â 41 Table of Contents Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â NATIONAL HEALTHCARE CORPORATION Â (Registrant) Â Â Â Â Date: November 7, 2024 /s/ Stephen F. Flatt Â Â Stephen F. Flatt Â Â Chief Executive Officer Â Â Â Â Â Â Â Â Date: November 7, 2024 /s/ Brian F. Kidd Â Â Brian F. Kidd Â Â Senior Vice President and Chief Financial Officer Â Â 42 EX-31.1 2 ex_739864.htm EXHIBIT 31.1 ex_739864.htm EXHIBIT 31.1 Â CERTIFICATION Â I, Stephen F. Flatt, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of National HealthCare Corporation; Â 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and Â 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function); Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Â Date: November 7, 2024 Â Â Â /s/ Stephen F. Flatt Â Â Stephen F. Flatt Â Â Chief Executive Officer Â Â Â EX-31.2 3 ex_739865.htm EXHIBIT 31.2 ex_739865.htm EXHIBIT 31.2 Â CERTIFICATION Â I, Brian F. Kidd, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of National HealthCare Corporation; Â 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and Â 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function): Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Â Date: November 7, 2024 Â Â /s/ Brian F. Kidd Â Â Brian F. Kidd Â Â Senior Vice President and Chief Financial Officer Â Â EX-32 4 ex_739866.htm EXHIBIT 32 ex_739866.htm Exhibit 32 Â Certification of Quarterly Report on Form 10-Q of National HealthCare Corporation For the Quarter Ended September 30, 2024 Â Â The undersigned hereby certify, pursuant to 18 U.S.C. Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned's best knowledge and belief, the Quarterly Report on Form 10-Q for National HealthCare Corporation ("Issuer") for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"): Â (a) fully complies with the requirements of section 13(a) or 15(d) of the Securities Â Exchange Act of 1934; and Â (b) the information contained in the Report fairly presents, in all material respects, Â the financial condition and results of operations of the Issuer. Â Â This Certification accompanies the Quarterly Report on Form 10-Q of the Issuer for the quarterly period ended September 30, 2024. Â This Certification is executed as of November 7, 2024. Â Â Â Â /s/Stephen F. Flatt Â Â Stephen F. Flatt Â Â Chief Executive Officer Â Â Â Â Â Â /s/ Brian F. Kidd Â Â Brian F. Kidd Â Â Senior Vice President and Chief Financial Officer Â Â Â A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Â Â EX-101.SCH 5 nhc-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Interim Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Description of Business link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Acquisition of White Oak Senior Living link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Net Patient Revenues link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Other Revenues link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Non-operating Income link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Business Segments link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Long-term Leases link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Earnings Per Share link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Investments in Marketable

Securities link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 12 - Goodwill and Other Intangible Assets link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 13 - Stock Repurchase Program link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 14 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 15 - Long-term Debt link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 16 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 17 - Contingencies and Commitments link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 3 - Acquisition of White Oak Senior Living (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 4 - Net Patient Revenues (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 5 - Other Revenues (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 6 - Non-operating Income (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 7 - Business Segments (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 8 - Long-term Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 9 - Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 10 - Investments in Marketable Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 11 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 12 - Goodwill and Other Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 14 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 15 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 1 - Description of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 3 - Acquisition of White Oak Senior Living (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 4 - Net Patient Revenues (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 4 - Net Patient Revenues - Revenue Disaggregation (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 5 - Other Revenues (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 5 - Other Revenues - Summary of Other Revenues (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 6 - Non-operating Income (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 6 - Non-operating Income - Summary of Non-operating Income (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 7 - Business Segments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 8 - Long-term Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 9 - Earnings Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 10 - Investments in Marketable Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 10 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 12 - Goodwill and Other Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 13 - Stock Repurchase Program (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 14 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 15 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 15 - Long-term Debt - Summary of Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 15 - Long-term Debt - Maturities of Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 16 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995518 - Disclosure - Note 17 - Contingencies and Commitments (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 nhc-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 nhc-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nhc-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Expected dividend yield us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue Over 10 years, fair value Note To Financial Statement Details Textual Intangible assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Significant Accounting Policies Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Note 3 - Acquisition of White Oak Senior Living us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Within 1 year, cost Note 4 - Net Patient Revenues Riskâ€“free interest rate Note 5 - Other Revenues us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Within 1 year, fair value Note 6 - Non-operating Income us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue 1 to 5 years, fair value Note 7 - Business Segments us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue 6 to 10 years, fair value Note 8 - Long-term Leases Note 9 - Earnings Per Share Prepaid expenses and other assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Note 10 - Investments in Marketable Securities Income Tax Disclosure [Text Block] Note 11 - Fair Value Measurements Note 12 - Goodwill and Other Intangible Assets Note 14 - Stock-based Compensation Cash and cash equivalents us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Accrued risk reserves, current portion Note 15 - Long-term Debt Inventories us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Expected volatility Restricted investments available for sale, debt, fair value Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details) us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details) Schedule of Debt [Table Text Block] Note 4 - Net Patient Revenues - Revenue Disaggregation (Details) Balance Sheet Classifications: Note 5 - Other Revenues - Summary of Other Revenues (Details) Expected life (Year) Note 6 - Non-operating Income - Summary of Non-operating Income (Details) Asset-Backed Securities [Member] Other current liabilities Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details) Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details) Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details) Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details) US States and Political Subdivisions Debt Securities [Member] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 10 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details) Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details) Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details) Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details) Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details) Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details) Note 15 - Long-term Debt - Summary of Long-term Debt (Details) Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Note 15 - Long-term Debt - Maturities of Long-term Debt (Details) Notes To Financial Statements US Treasury Securities [Member] Notes To Financial Statements [Abstract] nhc_NumberOfSkilledNursingFacilitiesSubleased Number of Skilled Nursing Facilities Subleased Represents the number of skilled nursing facilities that the company subleases. us-gaap_GoodwillAndIntangibleAssetImpairment Goodwill and Intangible Asset Impairment, Total US Government Corporations and Agencies Securities [Member] Corporate Debt Securities [Member] Long-term debt due within one year Less current portion us-gaap_OtherComprehensiveIncomeLossTax Income tax (expense)/benefit related to items of other comprehensive income Other comprehensive income (loss) Other comprehensive income/(loss), net of tax Options exercisable, weighted average exercise price (in dollars per share) Equity Securities [Member] Lessee, Operating and Finance Leases [Text Block] Disclosure for operating and finance leases of lessee. Net income attributable to NHC us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Options exercisable, aggregate intrinsic value Other comprehensive income/(loss): Business Acquisition, Pro Forma Information [Table Text Block] Options exercisable, shares (in shares) us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total equity Balance Balance Options outstanding, aggregate intrinsic value Marketable equity securities us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent us-gaap_PaymentsToAcquireMarketableSecurities Purchases of marketable securities Financial Instruments [Domain] nhc_NumberOfSkilledNursingCentersLeasedFromNHI Number of Skilled Nursing Centers Leased from NHI Number of Skilled Nursing Centers under lease agreements with NHI us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average exercise price (in dollars per share) nhc_NumberOfAssistedLivingCentersLeasedFromNHI Number of Assisted Living Centers Leased from NHI Number of Assisted Living Centers under lease agreements with NHI Options cancelled, weighted average exercise price (in dollars per share) Financial Instrument [Axis] Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Options granted, weighted average exercise price (in dollars per share) Options exercised, weighted average exercise price (in dollars per share) nhc_NumberOfIndependentLivingCentersLeasedFromNHI Number of Independent Living Centers Leased from NHI Number of Independent Living Centers under lease agreements with NHI Credit Facility [Member] Represents credit facility. Dividends payable nhc_PaymentsForProceedsFromNotesReceivableTotal Investments in notes receivable Represents the cash paid or received by the reporting entity associated with notes receivable. Revolving Credit Facility [Member] Options outstanding (in shares) Options outstanding, shares (in shares) Options outstanding, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Options cancelled, shares (in shares) Credit Facility [Axis] Credit Facility [Domain] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Accrued payroll us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] Licensing Agreements [Member] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Effects of dilutive instruments (in shares) Amounts due to third party payors Weighted average common shares outstanding: Unrealized gains on marketable equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Unrealized gains on marketable equity securities Trade accounts payable Current Liabilities: Treasury Stock [Text Block]

Operating lease obligations us-gaap_Assets Total assets nhc_NumberOfBeds Number of Beds Number of licensed skilled nursing beds that are operated or managed as of the balance sheet date. National [Member] Represents the name of the credit facility, National. Property and Equipment: Facility rent Rent Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Other Revenues [Text Block] Disclosure of other revenues. Rental income us-gaap_OperatingLeaseLeaseIncome Share-Based Payment Arrangement [Text Block] Schedule of Other Revenues [Table Text Block] Tabular disclosure of the detailed components of other operating revenues. Restricted cash and cash equivalents us-gaap_RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents Net income attributable to National HealthCare Corporation Net income attributable to National HealthCare Corporation Intangible assets us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Net (income)/loss attributable to noncontrolling interest Share-Based Payment Arrangement, Option [Member] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Goodwill, additions Indefinite-lived intangible assets us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Net (income)/loss attributable to noncontrolling interest Business Combination Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization us-gaap_PropertyPlantAndEquipmentNet Net property and equipment Goodwill Goodwill Goodwill, balance Goodwill, balance Property and equipment, at cost us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage us-gaap_ProfitLoss Net income Net income Marketable Securities Cash Flows From Investing Activities: Available-for-sale securities (USD) Unrestricted investments available for sale, debt, fair value Fair Value NHI Common Stock [Member] NHI common stock [member Earnings per share attributable to National HealthCare Corporation stockholders: Earnings Per Share [Text Block] Marketable equity securities NHI Common Stock, fair value Investments in unconsolidated companies Equity in earnings of unconsolidated investments Equity in earnings of unconsolidated investments Other Operating Expenses Policy [Policy Text Block] Disclosure of accounting policy for other operating expenses. us-gaap_IncomeTaxExpenseBenefit Income tax provision Consolidation, Variable Interest Entity, Policy [Policy Text Block] Government stimulus income Accrued payroll us-gaap_IncreaseDecreaseInAccruedSalaries us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) Trade accounts payable us-gaap_IncreaseDecreaseInAccountsPayableTrade Restricted cash and cash equivalents, less current portion us-gaap_GeneralAndAdministrativeExpense General and Administrative Expense Restricted cash and cash equivalents, current portion Cash and cash equivalents Cash and cash equivalents Inpatient Services [Member] The amount of revenue derived from inpatient services. Other current liabilities us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other noncurrent liabilities us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Salaries, wages, and benefits Medicaid [Member] Related to the program Medicaid. Managed Care [Member] Related to managed care provided by the company. us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense Accrued risk reserves us-gaap_IncreaseDecreaseInSelfInsuranceReserve Medicare [Member] Related to the Medicare program. Workers Compensation Revenue [Member] Related to revenue derived from workers compensation agreements. Private Pay and Other [Member] Related to private pay received and other revenue sources. Homecare Services Segment [Member] Information pertaining to the Homecare Services Segment. Inpatient Services Segment [Member] Information pertaining to the Inpatient Services Segment, which includes the operation of skilled nursing facilities and assisted and independent living facilities Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income attributable to National HealthCare Corporation City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) nhc_NumberOfBehavioralHealthHospitals Number of Behavioral Health Hospitals The number of behavioral health hospitals. Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Entrance fee refunds The cash inflow (outflow) associated with entrance fee deposits (refunds). Interest rate us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other assets us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Realized (gains)/losses on sale of marketable securities Document Fiscal Period Focus us-gaap_DebtSecuritiesRealizedGainLoss Debt Securities, Realized Gain (Loss) Document Fiscal Year Focus Deferred income taxes us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Document Period End Date Entity File Number Entity Emerging Growth Company Document Type us-gaap_NumberOfStatesInWhichEntityOperates Number of States in which Entity Operates Entity Small Business Entity Shell Company us-gaap_PropertyManagementFeeRevenue Property Management Fee Revenue Document Information [Line Items] Document Information [Table] Entity Filer Category Debt Instrument [Axis] NHI Common Stock, Shares (in shares) Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs us-gaap_DividendsCommonStock Dividends declared to common stockholders Exercise Price Range 1 [Member] Exercise price range 1 [member Variable Rate [Domain] Exercise Price Range 2 [Member] Exercise price range two [member Variable Rate [Axis] us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Stockâ€"based compensation Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key Depreciation and amortization Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] Professional Liability Insurance [Member] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss Material Terms of Trading Arrangement [Text Block] Restricted marketable equity securities us-gaap_StockRepurchasedDuringPeriodShares Repurchase of common shares (in shares) Entity Common Stock, Shares Outstanding us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Stock Repurchased and Retired During Period, Shares (in shares) Marketable Securities [Table Text Block] us-gaap_StockRepurchasedDuringPeriodValue Repurchase of common shares Long-Term Debt [Text Block] Investments [Domain] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Investment Type [Axis] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_LineOfCreditFacilityCommitmentFeePercentage Line of Credit Facility, Commitment Fee Percentage Shares sold â€" options exercised (in shares) Options exercised, shares (in shares) us-gaap_TableTextBlock Notes Tables us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Shares sold â€" options exercised Other revenues nhc_OtherRevenues Total other revenues The revenues not separately disclosed. Management and accounting services fees nhc_ManagementAndAccountingServicesFeesRevenue The amount of management and accounting services fees revenue. Revenue, concentration percentage The percentage of total revenue from contracts with customers, including the assessed tax. us-gaap_ProvisionForDoubtfulAccounts Accounts Receivable, Credit Loss Expense (Reversal) nhc_EquitySecuritiesFvNiGrossUnrealizedGain Equity Securities Fv Ni Gross Unrealized Gain The amount of gross unrealized gains from equity securities measured at fair value with gains losses reported on the income statement. Secured Overnight Financing Rate (SOFR) [Member] Options granted, shares (in shares) Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block] Other nhc_MiscellaneousRevenue The amount of miscellaneous revenue. nhc_EquitySecuritiesFvNiGrossUnrealizedLoss Equity Securities Fv Ni Gross Unrealized Loss The gross unrealized loss on equity securities measured at fair value with gains and losses recognized on the income statement. us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and equity Other operating Retained earnings Accumulated other comprehensive loss nhc_NumberOfSkilledNursingCenters Number of Skilled Nursing Ficilitiess Number of skilled nursing centers operated or managed as of the balance sheet date. Liability Reserve Estimate, Policy [Policy Text Block] nhc_NumberOfIndependentLivingFacilities Number of Independent Living Facilities Number of independent living facilities in which the company operates as of the Balance Sheet date. nhc_NumberOfAssistedLivingFacilities Number of Assisted Living Facilities Number of assisted living facilities in which company operates as of the Balance Sheet date. nhc_NumberOfHomecarePrograms Number of Homecare Programs Number of homecare Programs in which the company operates as of the Balance Sheet date. Interest Equipment and Furniture [Member] Information pertaining to equipment and furniture. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Operating lease liabilities, less current portion Noncurrent lease liabilities Two Leases with NHI [Member] Represents information about two leases with National Health Investors, Inc. ("NHI"). Present value of future minimum lease payments Dividends and net realized gains and losses on sales of securities The amount of dividends and other net realized gains and losses resulting from the sale of securities. Operating lease liabilities, current portion Less: current portion Lease One With NHI [Member] Represents information about the first lease with National Health Investors, Inc. ("NHI"). Finance lease obligations, current portion Deposits and other assets Distributions from unconsolidated investments Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total minimum lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: amounts representing interest us-gaap_FinanceLeasePrincipalPayments Principal payments under finance lease obligations us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2028 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2029 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Thereafter us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two Segment Reporting, Policy [Policy Text Block] us-gaap_ShareBasedCompensation Stockâ€"based compensation us-gaap_OtherAssetsNoncurrent Total other assets Lessee, Leases [Policy Text Block] Business Combinations Policy [Policy Text Block] Net operating revenues us-gaap_Revenues Net operating revenues and grant income Total financial assets us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract (Year) Unrestricted investments available for sale, equity, amortized cost NHI Common Stock, Cost Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Depreciation and amortization us-gaap_DepreciationDepletionAndAmortization us-gaap_AssetsCurrent Total current assets us-gaap_CashAndCashEquivalentsFairValueDisclosure Cash and cash equivalents Selling, General and Administrative Expenses, Policy [Policy Text Block] Interest income Common stock, $.01 par value; 45,000,000 shares authorized; 15,440,970 and 15,350,661 shares, respectively, issued and outstanding Adjustments to reconcile net income to net cash provided by operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Contributions attributable to noncontrolling interest Amount of increase in noncontrolling interest from capital contribution from noncontrolling interest holders. Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Gain on sale of unconsolidated company Gain (Loss) on Sale of Unconsolidated Company Gain on sale of unconsolidated company Represents the amount of gain (loss) from sale of an unconsolidated company. Proceeds from the sale of unconsolidated company Proceeds from Sale of Unconsolidated Company The cash inflow associated with the sale of an unconsolidated company during the period. Statistical Measurement [Domain] Restricted investments available for sale, debt, amortized cost Amortized cost of restricted investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Maximum [Member] Minimum [Member] Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Investment, Name [Domain] Restricted investments available for sale, equity, amortized cost Cost of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value. Investment, Name [Axis] Investments available for sale, amortized cost Amortized cost of investment in marketable securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Geographical [Axis] nhc_PaymentsForProceedsFromUnconsolidatedInvestments Investments in unconsolidated companies The net cash outflow or inflow associated with unconsolidated investments during the period. Geographical [Domain] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Inventories Net patient revenues Revenue from Contract with Customer, Including Assessed Tax FLORIDA Other Business Acquisitions [Member] Represents other business acquisitions. Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] White Oak Senior Living [Member] Represents White Oak Senior Living. Fair Value Hierarchy and NAV [Axis] Lessee, Lease, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's operating and finance lease liability. nhc_NumberOfSkilledNursingFacilities Number of Skilled Nursing Facilities Number of skilled nursing facilities operated or managed as of the balance sheet date. us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Noncontrolling

interest Cash Flows From Operating Activities: Schedule of Segment Reporting Information, by Segment [Table Text Block] SOUTH CAROLINA Notes receivable Revenue [Policy Text Block] Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable us-gaap_NumberOfReportableSegments Number of Reportable Segments Capital in excess of par value Building and Building Improvements [Member] Revenues: Marketable debt securities AOCI Attributable to Parent [Member] Equity: Property, Plant and Equipment, Policy [Policy Text Block] Nonâ€“operating income Non-operating income (loss) Total non-operating income Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Current Assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Restricted marketable debt securities, current portion Represents current restricted marketable debt securities. Restricted marketable debt securities, less current portion Represents noncurrent restricted marketable debt securities. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, End of Period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net Increase/(Decrease) in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by/(used in) financing activities Other Assets: us-gaap_Liabilities Total liabilities Income/(loss) from operations Income from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other income: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Prepaid expenses and other assets Base Rate [Member] Schedule of Other Nonoperating Income, by Component [Table Text Block] Deferred income taxes Other Nonoperating Income and Expense [Text Block] us-gaap_SelfInsuranceReserve Self Insurance Reserve Salaries, Wages, and Benefits [Member] Financial statement caption encompassing salaries, wages, and benefits. us-gaap_PaymentsOfDividendsCommonStock Dividends paid to common stockholders Total costs and expenses Total costs and expenses Both NHI Lease Agreements [Member] Represents information about the both leases with National Health Investors, Inc. ("NHI"). Noncontrolling Interest [Member] us-gaap_PaymentsForRepurchaseOfCommonStock Repurchase of common shares Costs and expenses: NHI Lease Agreement [Member] Represents NHI agreement. Retained Earnings [Member] Issuance of common shares Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] nhc_NumberOfHospiceAgencies Number of Hospice Agencies Represents the number of hospice agencies operated or managed by the reporting entity as of the specified date. Credit facility, interest payable monthly Total Noncontrolling interest contributions us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes Accrued payroll nhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll Amount of accrued payroll assumed at the acquisition date. Income before income taxes us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Homecare and Hospice [Member] Represents information regarding revenue derived from homecare and hospice. Homecare and Hospice Segment [Member] Represents information regarding the Homecare and Hospice segment. us-gaap_LineOfCredit Long-Term Line of Credit Insurance services us-gaap_InsuranceServicesRevenue Insurance Services Revenue Disaggregation of Revenue [Table Text Block] Homecare Agency in Nashville, Tennessee [Member] Represents homecare agency in Nashville, Tennessee. Revenue from Contract with Customer [Text Block] Health Care Organization, Revenue Sources [Axis] Document Quarterly Report Health Care Organization, Revenue Sources [Domain] Entity Incorporation, State or Country Code Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Basis of Accounting, Policy [Policy Text Block] us-gaap_RepaymentsOfLongTermLinesOfCredit Repayments under credit facility Entity Interactive Data Current Dividends declared to common stockholders, per share (in dollars per share) Dividends declared per common share (in dollars per share) 2028 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour 2029 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive Security Exchange Name 2025 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths 2026 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo Title of 12(b) Security 2027 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree Receivable Type [Axis] Receivable [Domain] Borrowings under credit facility Government Assistance [Policy Text Block] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] us-gaap_ContinuingCareRetirementCommunitiesAdvanceFeesObligationForFutureServicesAmount Continuing Care Retirement Communities, Refund Obligation Segments [Axis] Segments [Domain] Other Operating Segment [Member] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Weighted average common shares outstanding (in shares) Net operating revenues and grant income nhc_BusinessAcquisitionsProformaNetOperatingRevenuesAndGrantIncome Total pro forma net operating revenue and grant income for a period as if the business combination or combinations had been completed at the beginning of the period. Statement [Table] Statement of Financial Position [Abstract] Earnings per common share, diluted (in dollars per share) Diluted (in dollars per share) Weighted average common shares outstanding (in shares) Basic (in shares) Diluted: us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent Medicare and Medicaid [Member] Medicare and medicaid [member Business Acquisition [Axis] Earnings per common share, basic (in dollars per share) Basic (in dollars per share) nhc_NonrefundableResidentEntryFeePercentage Nonrefundable Resident Entry Fee Percentage The percentage of the resident entry fee that becomes nonrefundable upon occupancy. Business Acquisition, Acquiree [Domain] Amounts due to third party payors nhc_IncreaseDecreaseInDueToThirdPartyPayors The increase (decrease) during the reporting period in other obligations due to third party payors that are payable within one year (or one business cycle). Refundable Advance Fees [Member] Refundable advance fees [member nhc_RefundableResidentEntryFeePercentage Refundable Resident Entry Fee Percentage Remaining refundable portion of the resident's entry fee. Basic: Original Entry Fee [Member] Original entry fee [member Statement of Cash Flows [Abstract] nhc_AppreciationOfApartmentOverOriginalResidentsEntryFeePercentage Appreciation of Apartment Over Original Residents Entry Fee Percentage Percentage of appreciation added to refundable part of resident's original entry fee if apartment exceeds the original resident's entry fee. Appreciation [Member] Appreciation [member Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Domain] Lease Contractual Term [Axis] Income Statement [Abstract] Refundable entrance fees Income before income taxes nhc_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeTax Amount before tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period. Investments Classified by Contractual Maturity Date [Table Text Block] Other Noncurrent Liabilities [Policy Text Block] Accounting policy disclosure of other noncurrent liabilities. Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax Reclassification adjustment for realized losses on sales of marketable debt securities Unrealized gains/(losses) on investments in marketable debt securities Cash Flows From Financing Activities: Accrued risk reserves, less current portion us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other noncurrent liabilities Continuing Care Contracts and Refundable Entrance Fees, Policy [Policy Text Block] Disclosure of accounting policy for continuing care contracts and refundable entrance fees. nhc_NumberOfLongtermCarePharmacies Number of Long-term Care Pharmacies The number of long-term care pharmacies. nhc_NumberOfHealthcareOperations Number of Healthcare Operations The number of healthcare operations. nhc_NumberOfAssistedLivingUnits Number of Assisted Living Units The number of assisted living units. nhc_NumberOfLicensedSkilledNursingBeds Number of Licensed Skilled Nursing Beds The number of licensed skilled nursing beds. Certificates of Need [Member] Related to certificates of need. Changes in operating assets and liabilities: Operating lease right-of-use assets nhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAsset The amount of right-of-use asset recognized as of the acquisition date. nhc_NumberOfIndependentLivingUnits Number of Independent Living Units The number of independent living units. Operating lease liabilities, less current portion nhc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent Amount of noncurrent lease obligation assumed in business combination. Operating lease liabilities, current portion nhc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent Amount of current lease obligation assumed in business combination. us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Net identifiable assets acquired nhc_NumberOfAssistedLivingAndIndependentLivingUnits Number of Assisted Living and Independent Living Units The number of assisted living and independent living units. us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Total estimated fair value of the acquisition White Oak Senior Living Portfolio [Member] Represents the White Oak Senior Living portfolio. nhc_NumberOfContinuingCareRetirementCenters Number of Continuing Care Retirement Centers The number of continuing care retirement centers. us-gaap_StockholdersEquity Total National HealthCare Corporation stockholdersâ€™ equity Term Facility [Member] Represents term facility. us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Total liabilities assumed Other noncurrent liabilities us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Acquisition of other businesses, net of cash acquired Class of Stock [Axis] Total long-term debt Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_PaymentsToAcquireBusinessesGross Acquisition of White Oak Senior Living, net of cash acquired Other current liabilities us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Options outstanding, weighted average exercise price (in dollars per share) us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Total assets acquired us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Options outstanding, weighted average remaining contractual life (Year) Options outstanding, exercise price, upper range (in dollars per share) Deferred tax asset us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets Unrestricted investments available for sale, debt, amortized cost Cost Exercise Price Range [Axis] us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost 1 to 5 years, cost Exercise Price Range [Domain] us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost 6 to 10 years, cost Property and equipment us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost Over 10 years, cost Options outstanding, exercise price, lower range (in dollars per share) EX-101.PRE 9 nhc-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 10 nhc01.jpg begin 644 nhc01.jpg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|[\!_(5^V?_!S;_R:3X%_ M['"+_P!(KROQ,?[WX#^0K;.O]X1CX4Z9$G_>D)1117D61^EA1111RH04444>C MJ ****.5 %%%%'*@"BBBCE0!1111RH=PHHHHY4(****.5 %%%%'*@"BBBCE0 M[A1111RH04444.B M88_S]*]K_;NM[>__ &UO$4-S=+9V]P;!)IRA?[,A@3YV ZC\>U82?!OX;R>6 M%^,%BRR L&32)-IY(X^?GI7].X.LHT(\W8_SPQU/_:)^K/,GE4Q?+\W/84U9 M_,<*JL9,;8U !:1VR%7DC@GOVKTI?A%\-UD^;XP6L:8RHR_";P%-<"-OC;-)&XRT3Z5.Q([=3@\YX[#%1/\'OA MS)$VWXNVZS1J6*C1Y?GY)!!&[@]?;%7CKPM\2OL+2;]AY;ZI;NH =&/(<88,N6SMSQNP.5_ MX-Q?#D-GKGQ/\1:MJ^DZ+8ZEX?71++>>^NTA:XN&#?. Q!(PRK_P$U\:_*?^ M'=GT^,/DE8W2'9I,\<@7_:(;D/T/:H8_A+X!53&GQL6*-@DRP0Z7-&JD=AE^ M@Z_4FO+J94O92Y-KG9]?"Y/&O[=GPICC:VMK;3O$$-]=W%S<++#%!"ER2I4PJEA526Z1Q^UM6]H^I]'?\ !>70X/"7_!0!_'.@WVGW M%%GKEI;W>F7UC="X07<).W<5)V$<_ABNA^/OQB*_\%E/@5X39=9TGPM^T1\. M;1K866L2BWM?$T0"@>3*Q 9_O'!'?K7R@/@_\/<[S\9"\<>0B2:5.W!!'!W$ M9]O0]^(?^%0?#E2ZM\8+4-;HK!6T=\;L8Y)<.IXR"O:2'1XI8Y&/4J^\ Y/'; ZUZ1K_P"Q]X7_M &>/V;?$6M?$[Q5I/]H;7O)C_Y8"RN"V,="P8]/;MBL2?X,?#N^G:ZG^,4,TTGS&>?1IY),?7=MG]:[N6HY+F9Q5733T6IYDCR;?WAQ)@;QG=\V!GG%&X \8KTZ/X.?#QMVWXO6 M[8Y .C3\9Z=^YS3O^%-_#UH]R_%RT*]03H_X]_7(KT55C%WP[3YU-'W%^@HK^:,5_%EZG^C^3/_9(-=D%%%%<]CT$] HHHI!D_N^+HFSD?\^5Y7XG,,C=E!P.KCTK^BC_@K9^PA MK7[?GP=\/^&="UBWT6ZT?6$U1Y;B'S(Y%6&:+;[']LG.?X<8YR/SZF_X-K?B M#NVCX@:.<8Y2R./YUZ&:82I5J\T#\\X!XRP6798\+7>MV_O/S;*X_BC_.^Q M2;?]J/\ [^"OTD/_;6?$(C_D?I)_\ /\ ^O36_P"#:[XA*?\ D?M)_P# M+_Z]C^S:H?\1$RK^8_-[;_ +4?_?P4;?\ :C_[M^"OTA_XAL?B%_P!#]I7_(!?_7H_XAL?B%_T/VE?^ 7_->C^S:H?\1$RK^8 M_-[;_M1_]_!1M_VH_P#OX*_2'_B&Q^(7_0_:5_X!?_7H_P"(;'XA?]#]I7_@ M%_\ 7H_LVJ'_ !$3*OYC\WMO^U'_-_!1M_VH_\ OX*_2'_B&Q^(7_0_:5_X M!?\ UZ/^(;'XA?\ 0_:5_P" 7_UZ/[-JA_Q$3*OYC\WMO^U'_P! !3ECR/O1 M_P#?8K]'_P#B&O\ B&>GC[2?_/_.O2C_@VQ^(:_P#,_:/^-H:/[-JB_P"(MB93_#GYOLF#]Z/_+[%"QY'WH_^^Q7Z0-_P;8_$,G_DH&B_^AH7_@VR^(:MC_DH&B_^ IH_LVJ'_$1,I_G/S?9,'[T?_?8INW_:C_[^"OTB;_@VQ^(9/_)0 M-%_\!#2?\0U_Q#_Z*!HO_@(:/[-JA_Q$3*?YS\X%CR/O1_\ ?8H9,'[T?_?8 MK](%_P"#;+XAJ/\ DH&B_P#@*:&_X-L?B&3_,E T7_P$-']FU0_XB)E/\Y^ M;ZQY'WH_^^Q0R8/WH_\ OL5^D"_\&V7Q#4?\E T7_P !30W_;8_$,G_DH&B_^AH7_@VR^(:C_DH&B_\ @*:/[-JA_P 1$RG^<_-W;_M1_P#?P4Y8\C[T?_?8K]'_ /B&O^(?_10-_M%_\ 0TJ_P#!ME\0U'_)0-%_\!31_9M4/^(B93_.?F^R8/WH_P#OL4+'D?>C M_P"Q7Z0-_P;8_$,G_DH&B_^AH7_@VR^(:C_DH&B_\ @*:/[-JA_P 1$RG^M<_-]DVG[T?\ WV*F?XD_!A7Z1#_(-K_B$__-0M)7V%J?\"FO_,&V/Q"0M_$32?QM34_V=5*_XB-E/\Y^;^SYL97_+Z'^-5=4XCLMQP/[0MAQS_RT%?I M4G_!MOX^3[WQ$TK/M:&O+?VRO^")'BS]D?X%W?C[4_&6G:I9Z/?6F^W6'R]^ M90 .OZXKULGPIY!J6_8^L?$UQ:Q^'=3AD*^(-6F;1M7?#264 M>T?N9QD;7#J_?D,#Q7/_ +>VJ76B?MJ>(KNR:2QNX;:SE1XAC:QMTYJ^*\AA M\8:UI&G_&*WU;4K?3VG-U):QS;8Y)CUD(]3Q^5?T11P[G2AZ'\38BM>O-O: MYZWX2_9QTCQ<=/T:237+?7KY;A?F(:*.2!V!)Z?>7!'U[U#X#_9GTGXA^"M0 MU33=3OM,U*TNOL!L2]H3+(%,:EL;1M(8<'DGK7E[_1)U_P];A=8U)9++ M= %=)<2\MG[W\^.13=9^(6O:S+,]YJU]=2>:+@9.U3*#E'(']WC'(Y&<]JZ) M85QZG/[:/8]D_P"&*K>X@^V7%U>1V5G)>)=VQC3[1#Y,3,'QC.&90O0<'OCG ME?A-X#\/:S\%;O5-7:VTVXL_$UK90SM:*V8F)#QGIMS^//:N5M_C!XFCUNXU M1->UC^TM0*+=7+3;I)D"D,AXQR3G..!QSUK'C\37T>GK9F\DCM6N4O9HS]RX MG7/[QACDG(^F*GZNWK^:X67X0>'=$\5:QINK?V]OT?3(KMRBB-=FV[,!?7OZ<]^. M/U3XP>*-;*K>:]?W,.LIY?D[?N\X[&H-3^)_B+6[J6XO-7O+BZDC$7G'&Y@# MD;S_!>G:J]B^7EZ%.M'L>XZ1^R9IMG\,/&7BNSNKC6[[PJR?V=I2,&5]R(Y M:5.K8#'(']VN8^&7P0D_:)\R>)I+>'0X;>Y@MFL+&$Q_P!KQ,Q\R>-2<_(" M.,'IU&*\'TT7XG^(/#ER)K/5]0M9#,;EWCDVEY3P6/!&"F%P<]*MW/QF\4S:S M;ZE'KE]'>V:NML\.$2W#9R HXZ<4HTY*]@E5C)6:/4?BE^RSX:\#^!O[:74M M8NHYM5ZE\3?$&N:*=*O\ 6KVYTZ1S,+69MT0FX^=1 MV.,]^]7#\;/%L>F6UO#X@U!8K.(Q1'AI$CZ>67QEE '0^IHIX=O63!5(K9'I M&@_LUZ!J_P /-.UZWO-;F75U,D-OY2-):1@A2F#RSMY$C0K87$?^L63CMQQQ7E,?Q)UV"YAGM]3O+=H\E-K?=! MQQZ8RN>G>F6/Q$US2VG%OJE\D_I@=J=2@Y2O(8[.VC_MG5/+@G^U0 MIYO^JE'1O?W'>K$/Q6\2V4CS1ZUJ2R2,3(=W^NSG(G;W MKUS]EG1IO$WP?^+UA&RI<:I_9-I&\K8P9+EN<^WZYKS\UP]\%--ZGKY-5C]; MI-:6:9S2'?&C+\RLBL"#UR >^/6EZ>WU8?XU^CNF?\&W'CZ^TNTEC^(&DLKV M\3#?;'*Y13CJ?6IC_P &U_Q"' -0-'_"V-?SABLOJ^UEZG]NY;X@992P*4I M[)'YNJFX?>C'U<4OE?[4?_?8K](A_P &VGQ#4?\ (_Z/^-J:#_P;:?$,_P#, M_P"B_P#@*:R_LVJ>HO$3*;?&?FZR8/WH_P#OL4W;_M1_]_!7Z1-_P;8_$,G_M)*!HO\ X"&D_P"(:_XA_P#10-%_\!#1_9M4/^(B93_.?F]M_P!J/_OX* M1]Z/_OL5^C__ !#7_$/_**!HO\ X"&E7_@VR^(:C_DH&B_^ IH_LVJ'_$1, MI_G/S?9,'[T?_?8INW_:C_[^"OTB;_@VQ^(9/_)0-%_\!#2?\0U_Q#_Z*!HO M_@(:/[-JA_Q$3*?YS\WMO^U'_P! !1M_VH_^_@K](?\ B&O^(?\ T4#1?_ 0 MT?\ $-?\0\ HH&B_P#@(:/[-JA_Q$3*?YS\X%CR/O1_]]BADP?O1_\ ?8K] M(%_X-LOB&H_Y*!HO_@*:&_X-L?B&3_R4#1?_$-']FU0_XB)E/\Y^;NW_:C M_P"_@HV_[4?_'\%?I#_ ,0U_P 0_P#HH&B_^AH_P"(:_XA_P#10-%_\!#1 M_9M4/^(B93_.?F]M_P!J/_OX*-O^U'_W\%?I#_Q#7?$3_H?M'/TM*7_B&O\ MB$.OC[2?_/_.O1_9M4/^(B93_.?F[M_P!J/_OX*-O^U'_W\%?I#_Q#8_$+ M_H?M*_\ +_Z]*_P"9B/_@GYXL\;7FN>(+/78_%%I:PQ M^1#*Y?D&%W/KSGS#V&,#KGCLP.!J0K*[/(Q8YY8_I5AD#]:4(!7T=D?SWYD/D+_M?]]&FO%@\?S-6-@I-Q@ M5F5E/3]328;T_4U:,2G_/71Y*_Y-_"KAO3]3AO3]35KR5_PFCR5_R:!Z M%%7#>GZFC#>GZFK7DK_DT>2O^30&A5PWI^IHPWI^IJUY*_P"31Y*_Y-:%7#> MGZFC#>GZFK7DK_DT>2O^30&A5PWI^IHPWI^IJUY*_P"31Y*_Y-:%7#>GZFC M#>GZFK7DK_DT>2O^30&A5PW^2:,-ZM^!-6O)7_)H\E?\F@6A5PW]Y_\ OHT8 M;^__?1JUY*_Y-'DK_DT!H5<-_>?_+Z-&&_O/_WT:M>2O^31Y*_Y-:%7#?WG_.^C1AO[S_P#?1JUY*_Y M-'DK_DT!H5<-_>?_+Z-&&_O/_WT:M>2O^31Y*_Y-:%7#?WG_[Z-&&_O/_ M]]&K7DK_)-'DK_DT!H5<-_>?_OHTH$GJW_?1JSY*_Y-C5:T*XC9S@LP_&MOC?_(+O1X_X)Q^+&;#*M[I^[/9?M"@G\,YK[0\M)O#NFZ7K.CZG8V;P7$6JP*"!BX(9@0>.GOUKS";]A+XJR M+\OANS'TU:U_^+K]_P"/_@WZ_9)B3:OPMO-NT)@^,=>._@_X_:4?\&_W](M&/\ A5EU_P"%AKO_,FU^A4^,,)&*2C+3R7_,D?+RX>Q#;:?#MJ/8:M:_^/T-^P5\51M_XI^WSG)/]K6O/_C]?T#_@@%^R6!_P D MMNO_K]=_\ DV@_\$/V2C_,TMNO\ PL-=_P#DVG+C+"O>,ON7^9G_*MU MN\?O?^1^*?L'?%1&)_X1ZWY/3^UNFR_L&?%1EX/V^/^PM:_P#Q=?T M#_@@#^R4/^:6W7_A7ZY_\F4O_#@/]DL#_DEMU_X5^N?_"92_P!<,+_++[E_MF#X:K]X>_\(_G_%_8)^*Q7_D7[4_75;7_.+I&_8*^*H/_(NVWX:M:_\MQ=?T G_@@'^R6?\FEMU_P"%?KG_,F4A_X(?LE_FEMU_X6&N__)M;1XVP MJ5N67W+_##_%;K]X_>_P#(_%?V"_BL8]O_"/P+SVU>U_^+J.7]@SXK1_\ MR[;M]=7M?_BZ_H"'_!'_]DL?\TMNO_"PUW_Y-H/_0_9*;_FEMU_X5^N__M ";1_KMA?Y9?/WO_(_G\/[!GQ6)"_\M([;?*,?\A>U_^+I$_8.^*P/_"+MO_X-[7_XNOZ!!_P0_9*!_Y)9=?^%?KO M_P FTG_$/]^R3G_DEEU_X6&N_P#R;2_UPPO\LON7^8?ZMU^\?O?^1^_# O MQ6EV@>';;@_Y_"]K_P#%T2?$?%=GQ_PCML/^XO:_P#Q=?T!)_P0&_9,3[OP MMNO_K]<_\ DR@_\5!?V2RV?^%6W6?^QOUS_P"3*/\ 7#"_RR^Y?YA_JW7[MQ^]_Y_9_8-^*C/@^&;1CM*Y.K6QZ_\#KU+]G_X^+/@/\ #?Q?<>*K"QTV M'5M1T:&WQ>Q3/(ZW)R $9C_$*_;)?^" O[):'CX6W7_A7ZY_\F5+I'_!!+]E M'0O$%EJEK\+[I+S3YX[F!F\7:XZ))&VY&*->%&PW/S @]ZX\9Q1AZU)PBI:^ M2_S-,-P[6I5E4;7WO_(^H/!%KY7A'35WL=MK"#@X_P"6:UJK#DGF3@X^^:FM MM/AM$VQIM7CC)[?H!4@C4#_P"O7PTK-W/KJ<(Q5BJ49.AD_P"^C1AO[S_]M&K1B4__*Z/)7_I%Z%7#?WG_[Z-&&_O/\ ]]&K7DK_)-'DK_DT!H5<-_>M?_ODHT8;^_WT:M>2O^31Y*_P"30&A5PWJY_P#OHT8;^__'T:M>2O^31Y M*_Y-:%7#?WG_P"^C1AO[S_]]&K7DK_DT>2O^30&A5PWJY_^^C1AO[S_/?1 MJUY*_P"31Y*_Y-:%7#?WG_[Z-&&_O/_-]&K7DK_DT>2O\ DT!H5<-_M?B3 M1AO3]35KR5_R:/)7_)H'H5<-Z?J:_-Z?J:M>2O\ DT>2O^30&A5PWI^IHPWI M^IJUY*_Y-'DK_DT!H5<-Z?J:_-Z?J:M>2O\ DT>2O^30&A5PWI^IHPWI^IJU MY*_Y-'DK_DT!H5<-Z?J:_-Z?J:M>2O\ DT>2O^30&A5PWI^IHPWI^IJUY*_Y M-'DK_DT!H5<-Z?J:_-Z?J:M>2O\ DT>2O^30&A5Y_N_J:7RM_8_F:L^2O^30 G(E'_.N@G0KB+ ZLOXFI+= XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended	
	Sep. 30, 2024	Nov. 04, 2024
Document Information [Line Items]		
Entity Central Index Key	0001047335	
Entity Registrant Name	NATIONAL HEALTHCARE CORP	
Amendment Flag	false	
Current Fiscal Year End Date	--12-31	
Document Fiscal Period Focus	Q3	
Document Fiscal Year Focus	2024	

Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-13489
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-2057472
Entity Address, Address Line One	100 E. Vine Street
Entity Address, City or Town	Murfreesboro
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37130
City Area Code	615
Local Phone Number	890–2020
Title of 12(b) Security	Common, $0.01 par value
Trading Symbol	NHC
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	15,441,070

XML 13 R2.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:				
Net patient revenues	$ 328,674,000	$ 277,005,000	$ 894,415,000	$ 804,617,000
Other revenues	11,524,000	11,480,000	34,172,000	36,013,000
Government stimulus income	0	0	9,445,000	0
Net operating revenues and grant income	340,198,000	288,485,000	938,032,000	840,630,000
Costs and expenses:				
Salaries, wages, and benefits	213,395,000	182,664,000	576,609,000	525,782,000
Other operating	82,509,000	72,490,000	238,092,000	217,213,000
Facility rent	10,886,000	10,094,000	31,804,000	30,087,000
Depreciation and amortization	10,619,000	10,135,000	30,543,000	30,266,000
Interest	1,742,000	77,000	1,788,000	268,000
Total costs and expenses	319,151,000	275,460,000	878,836,000	803,616,000
Income from operations	21,047,000	13,025,000	59,196,000	37,014,000
Other income:				
Non–operating income	4,224,000	4,097,000	14,865,000	12,116,000
Unrealized gains on marketable equity securities	32,767,000	(3,093,000)	56,290,000	2,943,000
Income before income taxes	58,038,000	14,029,000	130,351,000	52,073,000
Income tax provision	(15,338,000)	(3,908,000)	(34,294,000)	(14,750,000)
Net income	42,700,000	10,121,000	96,057,000	37,323,000
Net (income)/loss attributable to noncontrolling interest	89,000	267,000	(211,000)	1,069,000
Net income attributable to National HealthCare Corporation	$ 42,789,000	$ 10,388,000	$ 95,846,000	$ 38,392,000
Earnings per share attributable to National HealthCare Corporation stockholders:				
Basic (in dollars per share)	$ 2.78	$ 0.68	$ 6.23	$ 2.51
Diluted (in dollars per share)	$ 2.73	$ 0.68	$ 6.15	$ 2.5
Weighted average common shares outstanding:				
Basic (in shares)	15,411,680	15,299,913	15,384,758	15,311,453
Diluted (in shares)	15,667,321	15,324,511	15,576,294	15,334,269
Dividends declared per common share (in dollars per share)	$ 0.61	$ 0.59	$ 1.81	$ 1.75

XML 14 R3.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net income	$ 42,700	$ 10,121	$ 96,057	$ 37,323
Other comprehensive income/(loss):				
Unrealized gains/(losses) on investments in marketable debt securities	3,516	(1,185)	3,074	(605)
Reclassification adjustment for realized losses on sales of marketable debt securities	0	0	1,388	20
Income tax (expense)/benefit related to items of other comprehensive income	(460)	124	(711)	3
Other comprehensive income/(loss), net of tax	3,056	(1,061)	3,751	(582)
Net (income)/loss attributable to noncontrolling interest	89	267	(211)	1,069
Comprehensive income attributable to National HealthCare Corporation	$ 45,845	$ 9,327	$ 99,597	$ 37,810

XML 15 R4.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current Assets:		
Cash and cash equivalents	$ 84,807	$ 107,076
Restricted cash and cash equivalents, current portion	29,032	17,725
Marketable equity securities	164,754	111,117
Marketable debt securities	0	5,427
Restricted marketable equity securities	23,001	26,779
Restricted marketable debt securities, current portion	2,045	12,822
Accounts receivable	128,782	108,545

Inventories	7,840	7,386
Prepaid expenses and other assets	4,887	8,855
Notes receivable	578	503
Total current assets	445,726	406,235
Property and Equipment:		
Property and equipment, at cost	1,283,184	1,101,681
Accumulated depreciation and amortization	(596,759)	(608,352)
Net property and equipment	686,425	493,329
Other Assets:		
Restricted cash and cash equivalents, less current portion	1,235	1,167
Restricted marketable debt securities, less current portion	121,866	109,478
Deposits and other assets	10,084	14,786
Operating lease right-of-use assets	85,926	94,201
Goodwill	169,690	168,295
Intangible assets	19,805	7,038
Investments in unconsolidated companies	21,950	16,267
Total other assets	430,556	411,232
Total assets	1,562,707	1,310,796
Current Liabilities:		
Trade accounts payable	22,724	19,194
Finance lease obligations, current portion	0	860
Operating lease liabilities, current portion	31,366	29,352
Accrued payroll	89,757	84,110
Amounts due to third party payors	18,815	18,369
Accrued risk reserves, current portion	31,076	30,549
Other current liabilities	37,289	22,991
Dividends payable	9,419	9,051
Long-term debt due within one year	7,500	0
Total current liabilities	247,946	214,476
Total long-term debt	139,500	0
Operating lease liabilities, less current portion	53,079	63,175
Accrued risk reserves, less current portion	79,128	72,710
Refundable entrance fees	6,063	6,376
Deferred income taxes	30,842	17,200
Other noncurrent liabilities	19,353	26,379
Total liabilities	575,911	400,316
Equity:		
Common stock, $.01 par value; 45,000,000 shares authorized; 15,440,970 and 15,350,661 shares, respectively, issued and outstanding	154	153
Capital in excess of par value	230,635	227,604
Retained earnings	755,532	687,599
Accumulated other comprehensive loss	(2,853)	(6,604)
Total National HealthCare Corporation stockholders' equity	983,468	908,752
Noncontrolling interest	3,328	1,728
Total equity	986,796	910,480
Total liabilities and equity	$ 1,562,707	$ 1,310,796

XML 16 R5.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	**Sep. 30, 2024**	**Dec. 31, 2023**
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	45,000,000	45,000,000
Common stock, shares issued (in shares)	15,440,970	15,350,661
Common stock, shares outstanding (in shares)	15,440,970	15,350,661

XML 17 R6.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Cash Flows From Operating Activities:		
Net income	$ 96,057,000	$ 37,323,000
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	30,543,000	30,266,000
Equity in earnings of unconsolidated investments	(589,000)	(1,941,000)
Distributions from unconsolidated investments	512,000	470,000
Unrealized gains on marketable equity securities	(56,290,000)	(2,943,000)
Realized (gains)/losses on sale of marketable securities	(331,000)	603,000
Gain on sale of unconsolidated company	(1,024,000)	0
Deferred income taxes	(15,559,000)	1,059,000
Stock–based compensation	3,062,000	2,119,000
Changes in operating assets and liabilities:		
Accounts receivable	(19,898,000)	(2,617,000)
Inventories	598,000	(285,000)
Prepaid expenses and other assets	8,809,000	2,444,000
Operating lease obligations	193,000	(936,000)
Trade accounts payable	3,530,000	(487,000)
Accrued payroll	1,989,000	(2,791,000)
Amounts due to third party payors	446,000	(1,043,000)
Accrued risk reserves	6,945,000	5,656,000
Other current liabilities	12,434,000	14,035,000
Other noncurrent liabilities	(8,031,000)	6,669,000
Net cash provided by operating activities	94,514,000	85,483,000
Cash Flows From Investing Activities:		
Purchases of property and equipment	(19,444,000)	(19,300,000)
Proceeds from the sale of unconsolidated company	2,100,000	0

Investments in notes receivable	(75,000)	(197,000)
Investments in unconsolidated companies	(8,370,000)	0
Purchases of marketable securities	(24,736,000)	(21,763,000)
Proceeds from sale of marketable securities	39,776,000	36,578,000
Net cash used in investing activities	(225,048,000)	(7,382,000)
Cash Flows From Financing Activities:		
Borrowings under credit facility	150,000,000	0
Repayments under credit facility	(3,000,000)	0
Principal payments under finance lease obligations	(860,000)	(3,711,000)
Dividends paid to common stockholders	(27,545,000)	(26,520,000)
Noncontrolling interest contributions	1,389,000	0
Issuance of common shares	13,471,000	260,000
Repurchase of common shares	(13,502,000)	(2,482,000)
Entrance fee refunds	(313,000)	(258,000)
Net cash provided by/(used in) financing activities	119,640,000	(32,711,000)
Net Increase/(Decrease) in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	(10,894,000)	45,390,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning of Period	125,968,000	74,865,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, End of Period	115,074,000	120,255,000
Balance Sheet Classifications:		
Cash and cash equivalents	84,807,000	100,308,000
Restricted Cash and Cash Equivalents	30,267,000	19,947,000
Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	115,074,000	120,255,000
White Oak Senior Living [Member]		
Cash Flows From Investing Activities:		
Acquisition of White Oak Senior Living, net of cash acquired	(215,896,000)	0
Other Business Acquisitions [Member]		
Cash Flows From Investing Activities:		
Acquisition of other businesses, net of cash acquired	$ 2,097,000	$ (2,700,000)

XML 18 R7.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2022	15,357,746					
Balance at Dec. 31, 2022	$ 153	$ 226,991	$ 656,664	$ (9,532)	$ 3,238	$ 877,514
Net income	0	0	11,723	0	(438)	11,285
Other comprehensive income (loss)	0	0	0	1,679	0	1,679
Stock–based compensation	$ 0	639	0	0	0	639
Shares sold – options exercised (in shares)	7,046					
Shares sold – options exercised	$ 0	0	0	0	0	0
Repurchase of common shares (in shares)	(44,349)					
Repurchase of common shares	$ 0	(2,482)	0	0	0	(2,482)
Dividends declared to common stockholders	$ 0	0	(8,733)	0	0	(8,733)
Balance (in shares) at Mar. 31, 2023	15,320,443					
Balance at Mar. 31, 2023	$ 153	225,148	659,654	(7,853)	2,800	879,902
Balance (in shares) at Dec. 31, 2022	15,357,746					
Balance at Dec. 31, 2022	$ 153	226,991	656,664	(9,532)	3,238	877,514
Net income						37,323
Other comprehensive income (loss)						(582)
Balance (in shares) at Sep. 30, 2023	15,324,560					
Balance at Sep. 30, 2023	$ 153	226,888	668,244	(10,114)	2,169	887,340
Balance (in shares) at Dec. 31, 2022	15,357,746					
Balance at Dec. 31, 2022	$ 153	226,991	656,664	(9,532)	3,238	$ 877,514
Shares sold – options exercised (in shares)						103,481
Balance (in shares) at Dec. 31, 2023	15,350,661					
Balance at Dec. 31, 2023	$ 153	227,604	687,599	(6,604)	1,728	$ 910,480
Balance (in shares) at Mar. 31, 2023	15,320,443					
Balance at Mar. 31, 2023	$ 153	225,148	659,654	(7,853)	2,800	879,902
Net income	0	0	16,281	0	(364)	15,917
Other comprehensive income (loss)	0	0	0	(1,200)	0	(1,200)
Stock–based compensation	$ 0	772	0	0	0	772
Shares sold – options exercised (in shares)	100					
Shares sold – options exercised	$ 0	6	0	0	0	6
Dividends declared to common stockholders	$ 0	0	(9,039)	0	0	(9,039)
Balance (in shares) at Jun. 30, 2023	15,320,543					
Balance at Jun. 30, 2023	$ 153	225,926	666,896	(9,053)	2,436	886,358
Net income	0	0	10,388	0	(267)	10,121
Other comprehensive income (loss)	0	0	0	(1,061)	0	(1,061)
Stock–based compensation	$ 0	708	0	0	0	708
Shares sold – options exercised (in shares)	4,017					

Shares sold – options exercised	$ 0	254	0	0	0	254
Dividends declared to common stockholders	$ 0	0	(9,040)	0	0	(9,040)
Balance (in shares) at Sep. 30, 2023	15,324,560					
Balance at Sep. 30, 2023	$ 153	226,888	668,244	(10,114)	2,169	887,340
Balance (in shares) at Dec. 31, 2023	15,350,661					
Balance at Dec. 31, 2023	$ 153	227,604	687,599	(6,604)	1,728	910,480
Net income	0	0	26,213	0	38	26,251
Other comprehensive income (loss)	0	0	0	(437)	0	(437)
Stock–based compensation	$ 0	793	0	0	0	793
Shares sold – options exercised (in shares)	150,194					
Shares sold – options exercised	$ 1	8,412	0	0	0	8,413
Repurchase of common shares (in shares)	(101,131)					
Repurchase of common shares	$ 0	(9,900)	0	0	0	(9,900)
Dividends declared to common stockholders	$ 0	0	(9,086)	0	0	(9,086)
Balance (in shares) at Mar. 31, 2024	15,399,724					
Balance at Mar. 31, 2024	$ 154	226,909	704,726	(7,041)	1,766	926,514
Balance (in shares) at Dec. 31, 2023	15,350,661					
Balance at Dec. 31, 2023	$ 153	227,604	687,599	(6,604)	1,728	910,480
Net income						96,057
Other comprehensive income (loss)						$ 3,751
Shares sold – options exercised (in shares)						211,040
Balance (in shares) at Sep. 30, 2024	15,440,970					
Balance at Sep. 30, 2024	$ 154	230,635	755,532	(2,853)	3,328	$ 986,796
Balance (in shares) at Mar. 31, 2024	15,399,724					
Balance at Mar. 31, 2024	$ 154	226,909	704,726	(7,041)	1,766	926,514
Net income	0	0	26,844	0	262	27,106
Other comprehensive income (loss)	0	0	0	1,132	0	1,132
Stock–based compensation	$ 0	1,176	0	0	0	1,176
Shares sold – options exercised (in shares)	38,849					
Shares sold – options exercised	$ 0	2,827	0	0	0	2,827
Repurchase of common shares (in shares)	(15,636)					
Repurchase of common shares	$ 0	(1,502)	0	0	0	(1,502)
Dividends declared to common stockholders	$ 0	0	(9,408)	0	0	(9,408)
Balance (in shares) at Jun. 30, 2024	15,422,937					
Balance at Jun. 30, 2024	$ 154	229,410	722,162	(5,909)	2,028	947,845
Net income	0	0	42,789	0	(89)	42,700
Other comprehensive income (loss)	0	0	0	3,056	0	3,056
Stock–based compensation	$ 0	1,093	0	0	0	1,093
Shares sold – options exercised (in shares)	34,417					
Shares sold – options exercised		2,232	0	0	0	2,232
Repurchase of common shares (in shares)	(16,384)					
Repurchase of common shares	$ 0	(2,100)	0	0	0	(2,100)
Dividends declared to common stockholders	0	0	(9,419)	0	0	(9,419)
Contributions attributable to noncontrolling interest					1,389	1,389
Balance (in shares) at Sep. 30, 2024	15,440,970					
Balance at Sep. 30, 2024	$ 154	$ 230,635	$ 755,532	$ (2,853)	$ 3,328	$ 986,796

XML 19 R8.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Dividends declared to common stockholders, per share (in dollars per share)	$ 0.61	$ 0.61	$ 0.59	$ 0.59	$ 0.59	$ 0.57	$ 1.81	$ 1.75

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business	9 Months Ended Sep. 30, 2024

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Description of Business

National HealthCare Corporation (“NHC” or the “Company”) is a leading provider of senior health care services. As of September 30, 2024, we operate or manage, through certain affiliates, 80 skilled nursing facilities with a total of 10,349 licensed beds, 26 assisted living facilities with 1,413 units, nine independent living facilities, three behavioral health hospitals, 34 homecare agencies, and 32 hospice agencies. We operate specialized care units within certain of our healthcare centers such as Alzheimer's disease care units and sub-acute nursing units. In addition, we provide insurance services, management and accounting services, and we lease properties to operators of skilled nursing and assisted living facilities. We operate in 9 states and are located primarily in the southeastern United States.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies	9 Months Ended Sep. 30, 2024

Note 2 – Summary of Significant Accounting Policies

The listing below is not intended to be a comprehensive list of all our significant accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by U.S. generally accepted accounting principles ("GAAP"), with limited need for management's judgment in their application. There are also areas in which management's judgment in selecting any available alternative would not produce a materially different result. See our audited December 31, 2023 consolidated financial statements and notes thereto which contain accounting policies and other disclosures required by U.S. GAAP. Our audited December 31, 2023 consolidated financial statements are available at our web site: www.nhccare.com.

Basis of Presentation

The unaudited interim condensed consolidated financial statements to which these notes are attached include all normal, recurring adjustments which are necessary to fairly present the financial position, results of operations and cash flows of NHC. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by NHC. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to NHC and the noncontrolling interest in its consolidated statements of operations.

We assume that users of these interim financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate the disclosure contained in our most recent annual report to stockholders have been omitted. This interim financial information is not necessarily indicative of the results that may be expected for a full year for a variety of reasons.

Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.

Net Patient Revenues and Accounts Receivable

Net patient revenues are derived from services rendered to patients for skilled and intermediate nursing, rehabilitation therapy, assisted living and independent living, home health care services, hospice services, and behavioral health services. Net patient revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient services. These amounts are due from patients, governmental programs, and other third-party payors, and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations.

The Company recognizes revenue as its performance obligations are completed. Routine services are treated as a single performance obligation satisfied over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered. Contract liabilities are recorded for payments the Company receives in which performance obligations have not been completed.

The Company determines the transaction price based on established billing rates reduced by explicit price concessions provided to third party payors. Explicit price concessions are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,574,000 and $7,098,000 for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $1,668,000 and $5,331,000, respectively. As of September 30, 2024 and December 31, 2023, the Company has recorded allowance for doubtful accounts of $10,859,000 and $8,054,000, respectively, as our best estimate of expected losses inherent in the accounts receivable balance.

Other Revenues

Other revenues include revenues from the provision of insurance services to other healthcare providers, management and accounting services to other healthcare providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements.

We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned.

Government Grants

We account for government grants in accordance with International Accounting Standards ("IAS") 20, *Accounting for Government Grants and Disclosure of Government Assistance*, and as such, we recognize grant income on a systematic basis in line with the recognition of specific expenses and lost revenues for which the grants are intended to compensate.

For the nine months ended September 30, 2024, all conditions related to the Employee Retention Credit ("ERC") were met and the credit was recognized as government stimulus income. The ERC was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The qualified wages and health insurance benefits paid by the Company were related to the second, third and fourth quarters of 2020.

Segment Reporting

In accordance with the provisions of Accounting Standards Codification ("ASC") 280, *Segment Reporting*, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an "all other" category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 7 for further disclosure of the Company's operating segments.

Other Operating Expenses

Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance.

General and Administrative Costs

With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation and incentive compensation, which were $6,288,000 and $19,678,000 for the three and nine months ended September 30, 2024, respectively. General and administrative costs were $5,661,000 and $16,309,000 for the three and nine months ended September 30, 2023, respectively. The increased general and administrative costs incurred during 2024 are due to acquisition-related expenses for the White Oak Senior Living portfolio. See *Note 3 - Acquisition of White Oak Senior Living* for additional detail regarding the acquisition.

Long-Term Leases

The Company's lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, regional offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain.

The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recorded and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases.

Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuate with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred.

Property and Equipment

Property and equipment are recorded at cost or fair value, if acquired. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method.

Business Combinations

We account for transactions that represent business combinations using the acquisition method of accounting in accordance with FASB ASC Topic 805, *Business Combinations* (Topic 805). Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets

acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts during the measurement period. The measurement period is defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date.

Goodwill generated from business combinations is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter. Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.

The Company's indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the fair value of the intangible asset is below its carrying amount.

Accrued Risk Reserves

We are self–insured for risks related to workers' compensation and general and professional liability insurance. We have two wholly–owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis.

Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period.

We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverage includes both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us.

Continuing Care Contracts

We have continuing care retirement centers ("CCRC") within our operations. Residents at these retirement centers may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original resident's entry fee.

Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarily determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrent liabilities in our consolidated balance sheets.

We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recorded with a corresponding charge to income. As of September 30, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.

Other Noncurrent Liabilities

Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation ("National") and the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents.

Noncontrolling Interest

The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Company's earnings per share is calculated based on net income attributable to NHC's stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions.

Variable Interest Entities

We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity ("VIE") and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.

The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as "investments in unconsolidated companies" in the interim condensed consolidated balance sheets.

Recently Issued Accounting Guidance

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, "Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures." The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact this standard will have on our disclosures.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of White Oak Senior Living

Notes to Financial Statements

Business Combination Disclosure [Text Block]

9 Months Ended

Sep. 30, 2024

Note 3 – Acquisition of White Oak Senior Living

On August 1, 2024, the Company purchased certain assets and assumed certain liabilities of the White Oak Senior Living ("White Oak") portfolio for a purchase price of $221,400,000. The White Oak portfolio consists of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four independent living facilities, and a long-term care pharmacy. The operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina (2,278 total beds/units). The acquisition represents both an expansion of NHC's operations into a new state (North Carolina) and a strategic advancement of its growth in its existing operational footprint.

The Company utilized widely accepted income-based, market-based, and cost-based valuation approaches to perform the preliminary purchase price allocation.

The Company has performed a preliminary valuation analysis of the fair market value of White Oak's assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was not complete as of September 30, 2024, but will be finalized within the allowable measurement period. The following table summarizes the allocation of the preliminary purchase price as of the transaction's closing date (*in thousands*):

	Amount
Cash and cash equivalents	$ 9
Inventories	1,054
Prepaid expenses and other assets	137
Property and equipment	203,695
Deferred tax asset	2,499
Operating lease right-of-use assets	11,380
Intangible assets	12,765
Total assets acquired	231,539
Operating lease liabilities, current portion	424

Accrued payroll	3,559
Other current liabilities	1,085
Operating lease liabilities, less current portion	10,956
Other noncurrent liabilities	1,005
Total liabilities assumed	17,029
Net identifiable assets acquired	214,510
Goodwill	1,395
Total estimated fair value of the acquisition	$ 215,905

The indefinite-lived intangible assets acquired include the trade name of White Oak and the skilled nursing certificates of need and licenses. The goodwill is recorded in the inpatient services segment and is attributed to the workforce acquired and reputation of the business as part of the transaction. We expect the goodwill to be deductible for income tax purposes.

For the three and nine months ended September 30, 2024, White Oak contributed net operating revenues of $37,305,000 and income before income taxes of $1,557,000 that are included in the Company's interim condensed consolidated statements of operations. The Company recognized $637,000 and $2,831,000 in acquisition-related expenses for the three and nine months ended September 30, 2024, respectively, in connection with the White Oak acquisition. These costs related to legal and other professional fees, which were included as a component of other operating expenses in the interim condensed consolidated statements of operations.

The following table contains unaudited pro forma interim condensed consolidated statements of operations information for the three months and nine months ended September 30, 2024 and 2023, assuming that the White Oak acquisition closed on January 1, 2023. The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed *(in thousands)*.

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Net operating revenues and grant income	$ 358,334	$ 337,817	$ 1,065,418	$ 987,186
Income before income taxes	58,881	14,087	134,777	49,113
Net income attributable to NHC	$ 43,413	$ 10,431	$ 99,121	$ 34,064

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 4 - Net Patient Revenues

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

9 Months Ended
Sep. 30, 2024

Note 4 – Net Patient Revenues

The Company disaggregates revenue from contracts with customers by service type and by payor.

Revenue by Service Type

The Company's net patient services can generally be classified into the following two categories: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services *(in thousands)*.

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Net patient revenues:				
Inpatient services	$ 293,026	$ 243,865	$ 790,664	$ 706,795
Homecare and hospice	35,648	33,140	103,751	97,822
Total net patient revenue	$ 328,674	$ 277,005	$ 894,415	$ 804,617

For inpatient and hospice services, revenue is recognized on a daily basis as each day represents a separate contract and performance obligation. For homecare, revenue is recognized when services are provided based on the number of days of service rendered in the period of care or on a per-visit basis. Typically, patients and third-party payors are billed monthly after services are performed or the patient is discharged, and payments are due based on contract terms.

As our performance obligations relate to contracts with a duration of one year or less, the Company is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients are typically under no obligation to remain admitted in our facilities or under our care. As the period between the time of service and time of payment is typically one year or less, the Company did not adjust for the effects of a significant financing component.

Revenue by Payor

Certain groups of patients receive funds to pay the cost of their care from a common source. The following table sets forth sources of net patient revenues for the periods indicated:

	Three Months Ended September 30		Nine Months Ended September 30	
Source	2024	2023	2024	2023
Medicare	30%	33%	32%	35%
Managed Care	9%	10%	10%	10%
Medicaid	33%	32%	30%	30%
Private Pay and Other	28%	25%	28%	25%
Total	100%	100%	100%	100%

Medicare covers skilled nursing services for beneficiaries who require nursing care and/or rehabilitation services following a hospitalization of at least three consecutive days. For each eligible day a Medicare beneficiary is in a skilled nursing facility, Medicare pays the facility a daily payment, subject to adjustment for certain factors such as a wage index in the geographic area. The payment covers all services provided by the skilled nursing facility for the beneficiary that day, including room and board, nursing, therapy and drugs, as well as an estimate of capital–related costs to deliver those services.

For homecare services, Medicare pays based on the acuity level of the patient and based on periods of care. A period of care is defined as a length of care up to 30 days with multiple continuous periods allowed. The services covered by the payment include all disciplines of care, in addition to medical supplies, within the scope of the home health benefit.

For hospice services, Medicare pays a daily rate to cover the hospice's costs for providing services included in the patient care plan. Medicare makes daily payments based on 1 of 4 levels of hospice care. All hospice care and services offered to patients and their families must follow an individualized written plan of care that meets the patient's needs.

Our hospice service revenue is subject to certain limitations on payments from Medicare. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded. If applicable, we record these cap adjustments as a reduction to revenue.

Medicaid is operated by individual states with the financial participation of the federal government. The states in which we operate currently use prospective cost–based reimbursement systems. Under cost–based reimbursement systems, the skilled nursing facility is reimbursed for the reasonable direct and indirect allowable costs it incurred in a base year in providing routine resident care services as defined by the program.

Private pay, managed care, and other payment sources include commercial insurance, individual patient funds, managed care plans and the Veterans Administration. Private paying patients, private insurance carriers and the Veterans Administration generally pay based on the healthcare center's charges or specifically negotiated contracts. For private pay patients in skilled nursing, assisted living and independent living facilities, the Company bills for room and board charges, with the remittance being due on receipt of the statement and generally by the 10th day of the month the services are performed.

Certain managed care payors for homecare services pay on a per-visit basis. This revenue is recorded on an accrual basis based upon the date of services at amounts equal to its established or estimated per-visit rates.

State Relief Supplemental Funding

The Company received supplemental Medicaid payments from various states, including healthcare relief funding under the American Rescue Plan Act ("ARPA") and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses or various patient care related expenses. We have recorded $5,267,000 and $4,232,000 in net patient revenues for these supplemental Medicaid payments for the three months ended September 30, 2024 and 2023, respectively. We have recorded $11,314,000 and $15,362,000 in net patient revenues for these supplemental Medicaid payments for the nine months ended September 30, 2024 and 2023, respectively.

Third Party Payors

Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Noncompliance with such laws and regulations can be subject to regulatory actions including fines, penalties, and exclusion from the Medicare and Medicaid programs. We believe that we are following all applicable laws and regulations.

Medicare and Medicaid program revenues, as well as certain Managed Care program revenues, are subject to audit and retroactive adjustment by government representatives or their agents. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. We believe that any differences between the net revenues recorded, and final determination will not materially affect the consolidated financial statements. We have made provisions of approximately $18,815,000 and $18,369,000 as of September 30, 2024 and December 31, 2023, respectively, for various Medicare, Medicaid, and Managed Care claims reviews and current and prior year cost reports.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 5 - Other Revenues

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Other Revenues [Text Block]

Note 5 – Other Revenues

Other revenues are outlined in the table below. Revenues from rental income include health care real estate properties owned by us and leased to third party operators. Revenues from management and accounting services include fees provided to manage and provide accounting services to other healthcare operators. Revenues from insurance services include premiums for workers' compensation and professional liability insurance policies that our wholly owned insurance subsidiaries have written for certain healthcare operators to which we provide management or accounting services. "Other" revenues include miscellaneous health care related earnings *(in thousands)*.

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Rental income	$ 6,028	$ 5,958	$ 18,015	$ 17,966
Management and accounting services fees	4,226	4,185	12,744	14,045
Insurance services	818	989	2,506	2,920
Other	452	348	907	1,082
Total other revenues	$ 11,524	$ 11,480	$ 34,172	$ 36,013

Rental Income

The Company leases real estate assets consisting of skilled nursing facilities and assisted living facilities to third party operators. Additionally, we sublease four Florida skilled nursing facilities included in our lease from National Health Investors ("NHI") as noted in Note 8 – Long Term Leases.

Management Fees from National Health Corporation

We manage five skilled nursing facilities owned by National Health Corporation ("National"). We recognized management fees and interest on management fees from these facilities of $1,348,000 and $1,243,000 for the three months ended September 30, 2024 and 2023, respectively. We recognized management fees and interest on management fees of $4,014,000 and $3,968,000 from these facilities for the nine months ended September 30, 2024 and 2023, respectively.

Insurance Services

For workers' compensation insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended September 30, 2024 and 2023 were $529,000 and $678,000, respectively. The premium revenues reflected in the interim condensed consolidated statements of operations for the nine months ended September 30, 2024 and 2023 were $1,638,000 and $1,985,000, respectively. Associated losses and expenses including those for self-insurance are included in the interim condensed consolidated statements of operations as "Salaries, wages and benefits."

For professional liability insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended September 30, 2024 and 2023 were $289,000 and $312,000, respectively. The premium revenues reflected in the interim condensed consolidated statements of operations for the nine months ended September 30, 2024 and 2023 were $868,000 and $935,000, respectively. Associated losses and expenses including those for self–insurance are included in the interim condensed consolidated statements of operations as "Other operating costs and expenses".

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 6 - Non-operating Income

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Other Nonoperating Income and Expense [Text Block]

Note 6 – Non–Operating Income

Non–operating income is comprised of the following *(in thousands)*:

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Dividends and net realized gains and losses on sales of securities	$ 1,683	$ 1,690	$ 5,462	$ 4,604
Interest income	2,603	2,222	7,790	5,571
Equity in earnings of unconsolidated investments	(62)	185	589	1,941
Gain on sale of unconsolidated company	-	-	1,024	-
Total non-operating income	$ 4,224	$ 4,097	$ 14,865	$ 12,116

Gain on sale of unconsolidated company

In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency located in Nashville, Tennessee. The total consideration paid to the Company was $2,100,000, which resulted in a gain of $1,024,000.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 7 - Business Segments

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 7 – Business Segments

The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals; and (2) homecare and hospice services. These reportable operating segments are consistent with information used by the Company's Chief Executive Officer, as chief operating decision maker ("CODM"), to assess performance and allocate resources. The Company also reports an "all other" category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office.

The Company's CODM evaluates performance and allocates capital resources to each segment based on an operating model that is designed to improve the quality of patient care and profitability of the Company while enhancing long-term shareholder value. The CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below.

The following table sets forth the Company's unaudited interim condensed consolidated statements of operations by business segment *(in thousands)*:

	Three Months Ended September 30, 2024			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 293,026	$ 35,648	$ -	$ 328,674
Other revenues	370	-	11,154	11,524
Net operating revenues	293,396	35,648	11,154	340,198
Costs and expenses:				
Salaries, wages, and benefits	175,241	21,456	16,698	213,395
Other operating	72,384	6,612	3,513	82,509
Rent	8,422	602	1,862	10,886
Depreciation and amortization	9,632	172	815	10,619
Interest	1,742	-	-	1,742

Total costs and expenses	267,421	28,842	22,888	319,151
Income/(loss) from operations	25,975	6,806	(11,734)	21,047
Non-operating income	-	-	4,224	4,224
Unrealized gains on marketable equity securities	-	-	32,767	32,767
Income before income taxes	$ 25,975	$ 6,806	$ 25,257	$ 58,038

	Three Months Ended September 30, 2023			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 243,865	$ 33,140	$ -	$ 277,005
Other revenues	297	-	11,183	11,480
Net operating revenues	244,162	33,140	11,183	288,485
Costs and expenses:				
Salaries, wages, and benefits	151,912	20,066	10,686	182,664
Other operating	64,228	5,868	2,394	72,490
Rent	8,186	538	1,370	10,094
Depreciation and amortization	9,203	185	747	10,135
Interest	77	-	-	77
Total costs and expenses	233,606	26,657	15,197	275,460
Income/(loss) from operations	10,556	6,483	(4,014)	13,025
Non-operating income	-	-	4,097	4,097
Unrealized losses on marketable equity securities	-	-	(3,093)	(3,093)
Income/(loss) before income taxes	$ 10,556	$ 6,483	$ (3,010)	$ 14,029

	Nine Months Ended September 30, 2024			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 790,664	$ 103,751	$ -	$ 894,415
Other revenues	710	-	33,462	34,172
Government stimulus income	-	-	9,445	9,445
Net operating revenues and grant income	791,374	103,751	42,907	938,032
Costs and expenses:				
Salaries, wages, and benefits	474,190	63,761	38,658	576,609
Other operating	207,883	18,977	11,232	238,092
Rent	24,795	1,736	5,273	31,804
Depreciation and amortization	27,646	545	2,352	30,543
Interest	1,788	-	-	1,788
Total costs and expenses	736,302	85,019	57,515	878,836
Income/(loss) from operations	55,072	18,732	(14,608)	59,196
Non-operating income	-	-	14,865	14,865
Unrealized gains on marketable equity securities	-	-	56,290	56,290
Income before income taxes	$ 55,072	$ 18,732	$ 56,547	$ 130,351

	Nine Months Ended September 30, 2023			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 706,795	$ 97,822	$ -	$ 804,617
Other revenues	894	-	35,119	36,013
Net operating revenues	707,689	97,822	35,119	840,630
Costs and expenses:				
Salaries, wages, and benefits	435,517	60,804	29,461	525,782
Other operating	192,473	17,356	7,384	217,213
Rent	24,520	1,639	3,928	30,087
Depreciation and amortization	27,474	555	2,237	30,266
Interest	268	-	-	268
Total costs and expenses	680,252	80,354	43,010	803,616
Income/(loss) from operations	27,437	17,468	(7,891)	37,014
Non-operating income	-	-	12,116	12,116
Unrealized gains on marketable equity securities	-	-	2,943	2,943
Income before income taxes	$ 27,437	$ 17,468	$ 7,168	$ 52,073

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 8 - Long-term Leases

9 Months Ended Sep. 30, 2024

Notes to Financial Statements

Lessee, Operating and Finance Leases [Text Block]

Note 8 – Long-Term Leases

Operating Leases

At September 30, 2024, we lease from NHI the real property of 28 skilled nursing facilities, five assisted living centers and three independent living centers under one lease agreement. As part of the lease agreement, we sublease four Florida skilled nursing facilities to a third-party operator. The lease includes base rent plus a percentage rent. The annual base rent is $32,625,000 in 2024, $32,225,000 in 2025, and $31,975,000 in 2026 with the lease term expiring in December 2026. The percentage rent is based on a quarterly calculation of revenue increases and is payable on a quarterly basis. Total facility rent expense to NHI was $10,085,000 and $9,300,000 for the three months ended September 30, 2024 and 2023, respectively. Total facility rent expense to NHI was $29,371,000 and $27,719,000 for the nine months ended September 30, 2024 and 2023, respectively.

Minimum Lease Payments

The following table summarizes the maturity of our operating lease liabilities as of September 30, 2024 (*in thousands*):

	Operating Leases
2025	$ 35,858
2026	35,183
2027	10,471
2028	1,702
2029	1,424
Thereafter	11,768
Total minimum lease payments	96,406
Less: amounts representing interest	(11,961)
Present value of future minimum lease payments	84,445
Less: current portion	(31,366)
Noncurrent lease liabilities	$ 53,079

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 9 - Earnings Per

9 Months Ended

Share

Sep. 30, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 9 – Earnings per Share

Basic net income per share is computed based on the weighted average number of common shares outstanding for each period presented. Diluted net income per share reflects the potential dilution that would have occurred if securities to issue common stock were exercised, converted, or resulted in the issuance of common stock that would have then shared in our earnings.

The following table summarizes the earnings and the weighted average number of common shares used in the calculation of basic and diluted earnings per share (in thousands, except for share and per share amounts):

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Basic:				
Weighted average common shares outstanding	15,411,680	15,299,913	15,384,758	15,311,453
Net income attributable to National HealthCare Corporation	$ 42,789	$ 10,388	$ 95,846	$ 38,392
Earnings per common share, basic	$ 2.78	$ 0.68	$ 6.23	$ 2.51
Diluted:				
Weighted average common shares outstanding	15,411,680	15,299,913	15,384,758	15,311,453
Effects of dilutive instruments	255,641	24,598	191,536	22,816
Weighted average common shares outstanding	15,667,321	15,324,511	15,576,294	15,334,269
Net income attributable to National HealthCare Corporation	$ 42,789	$ 10,388	$ 95,846	$ 38,392
Earnings per common share, diluted	$ 2.73	$ 0.68	$ 6.15	$ 2.50

For the three and nine months ending September 30, 2024, we did not exclude any stock options from the calculation of diluted weighted average shares of common stock outstanding. For the three and nine months ending September 30, 2023, 637,409 of stock options have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 10 - Investments in Marketable Securities

9 Months Ended

Sep. 30, 2024

Notes to Financial Statements

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Note 10 – Investments in Marketable Securities

Our investments in marketable equity securities are carried at fair value with the changes in unrealized gains and losses recognized in our results of operations at each measurement date. Our investments in marketable debt securities are classified as available for sale securities and carried at fair value with the unrealized gains and losses recognized through accumulated other comprehensive income at each measurement date. Any credit-related decline in fair market values below the amortized cost of our available for sale debt securities are recorded in our results of operations through an allowance for credit losses. Realized gains and losses from securities sales are recognized in results of operations upon disposition of the securities using the specific identification method on a trade date basis. Refer to Note 11 for a description of the Company's methodology for determining the fair value of marketable securities.

Marketable securities consist of the following *(in thousands)*:

	September 30, 2024		December 31, 2023	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Investments available for sale:				
Marketable equity securities	$ 30,176	$ 164,754	$ 30,176	$ 111,117
Corporate debt securities	–	–	2,497	2,441
U.S. Treasury securities	–	–	2,990	2,986
Restricted investments available for sale:				
Marketable equity securities	17,702	23,001	24,134	26,779
Corporate debt securities	59,267	58,812	59,586	57,731
Asset-based securities	17,756	16,646	19,388	17,659
U.S. Treasury securities	46,224	44,671	46,771	42,863
State and municipal securities	3,813	3,782	4,106	4,047
	$ 174,938	$ 311,666	$ 189,648	265,623

Included in the marketable equity securities are the following *(in thousands, except share amounts)*:

	September 30, 2024			December 31, 2023		
	Shares	Cost	Fair Value	Shares	Cost	Fair Value
NHI Common Stock	1,630,642	$ 24,734	$ 137,072	1,630,642	$ 24,734	$ 91,071

The amortized cost and estimated fair value of debt securities classified as available for sale, by contractual maturity, are as follows *(in thousands)*:

	September 30, 2024		December 31, 2023	
	Cost	Fair Value	Cost	Fair Value
Maturities:				
Within 1 year	$ 24,509	$ 24,023	$ 19,664	$ 19,328
1 to 5 years	71,047	69,082	81,517	77,118
6 to 10 years	31,197	30,499	33,515	30,802
Over 10 years	307	307	642	479
	$ 127,060	$ 123,911	$ 135,338	$ 127,727

Gross unrealized gains related to marketable equity securities are $140,177,000 and $84,514,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to marketable equity securities are $300,000 and $928,000 as of September 30, 2024 and December 31, 2023, respectively. For the three months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $32,767,000 and net unrealized losses of $3,093,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations. For the nine months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $56,290,000 and 2,943,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations.

Gross unrealized gains related to available for sale marketable debt securities are $1,104,000 and $326,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to available for sale marketable debt securities are $4,253,000 and $7,937,000 as of September 30, 2024 and December 31, 2023, respectively.

The Company’s unrealized losses in our available for sale marketable debt securities were determined to be non-credit related. The Company has not recognized any credit related impairments for the nine months ended September 30, 2024 and 2023.

For the marketable debt securities in gross unrealized loss positions, (a) it is more likely than not that the Company will not be required to sell the investment securities before recovery of the unrealized losses, and (b) the Company expects that the contractual principal and interest will be received on the investment securities.

Proceeds from the sale of available for sale marketable securities during the nine months ended September 30, 2024 and 2023 were $39,776,000 and $36,578,000, respectively. Investment gains of $331,000 and investment losses of $603,000 were realized on these sales during the nine months ended September 30, 2024 and 2023, respectively.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 11 - Fair Value Measurements

9 Months Ended

Sep. 30, 2024

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note 11 – Fair Value Measurements

The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value

measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs that may be used to measure fair value:

Level 1 – The valuation is based on quoted prices in active markets for identical instruments.
Level 2 – The valuation is based on observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model–based valuation techniques for which all significant assumptions are observable in the market.
Level 3 – The valuation is based on unobservable inputs that are supported by minimal or no market activity and that are significant to the fair value of the instrument. Level 3 valuations are typically performed using pricing models, discounted cash flow methodologies, or similar techniques that incorporate management's own estimates of assumptions that market participants would use in pricing the instrument, or valuations that require significant management judgment or estimation.

A financial instrument's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.

The following table summarizes fair value measurements by level at September 30, 2024 and December 31, 2023 for assets and liabilities measured at fair value on a recurring basis *(in thousands)*:

		Fair Value Measurements Using		
September 30, 2024	Fair Value	Quoted Prices in Active Markets For Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$ 84,807	$ 84,807	$ –	$ –
Restricted cash and cash equivalents	30,267	30,267	–	–
Marketable equity securities	187,755	187,755	–	–
Corporate debt securities	58,812	39,475	19,337	–
Asset–backed securities	16,646	–	16,186	460
U.S. Treasury securities	44,671	44,671	–	–
State and municipal securities	3,782	–	3,782	–
Total financial assets	$ 426,740	$ 386,975	$ 39,305	$ 460

		Fair Value Measurements Using		
December 31, 2023	Fair Value	Quoted Prices in Active Markets For Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$ 107,076	$ 107,076	$ –	$ –
Restricted cash and cash equivalents	18,892	18,892	–	–
Marketable equity securities	137,896	137,896	–	–
Corporate debt securities	60,171	42,860	17,311	–
Asset–backed securities	17,659	–	17,210	449
U.S. Treasury securities	45,850	45,850	–	–
State and municipal securities	4,047	–	4,047	–
Total financial assets	$ 391,591	$ 352,574	$ 38,568	$ 449

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 12 - Goodwill and Other Intangible Assets

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

Note 12 – Goodwill and Other Intangible Assets

At September 30, 2024, the Company reviewed the carrying value of goodwill for impairment indicators. As a result of the review, there were no impairment indicators regarding the Company's goodwill that required a quantitative test to be performed. However, our accounting estimates could materially change from period to period due to changing market factors. We will continue to monitor future events, changes in circumstances, and the potential impact thereof. If actual results are not consistent with our assumptions and estimates, we may be exposed to future goodwill impairment losses

See Note 3 – *Acquisition of White Oak Senior Living* for further detail describing the goodwill and indefinite-lived intangible asset additions in 2024. At September 30, 2024, the following table represents the activity related to our goodwill by segment (*in thousands*):

	Inpatient Services	Homecare and Hospice	All Other	Total
January 1, 2024	$ 3,741	$ 164,554	$ –	$ 168,295
Additions	1,395	–	–	1,395
September 30, 2024	$ 5,136	$ 164,554	$ –	$ 169,690

Indefinite-lived intangible assets consist of the following *(in thousands)*:

	September 30, 2024	December 31, 2023
Trade names	$ 15,836	$ 4,340
Certificates of need	1,757	532
Licenses	2,212	2,166
Total	$ 19,805	$ 7,038

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 13 - Stock Repurchase Program

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Treasury Stock [Text Block]

Note 13 - Stock Repurchase Program

During the nine months ended September 30, 2024, the Company repurchased 133,151 shares of its common stock for a total cost of $13,502,000. During the nine months ended September 30, 2023, the Company repurchased 44,349 shares of its common stock for a total cost of $2,482,000. The shares were funded from cash on hand and were cancelled and returned to the status of authorized but unissued.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 14 - Stock-based Compensation

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

Note 14 – Stock–Based Compensation

NHC recognizes stock–based compensation expense for all stock options granted over the requisite service period using the fair value at the date of grant using the Black–Scholes pricing model. Stock–based compensation totaled $1,093,000 and $708,000 for the three months ended September 30, 2024 and 2023, respectively. Stock-based compensation totaled $3,062,000 and $2,119,000 for the nine months ended September 30, 2024 and 2023, respectively. Stock–based compensation is included in "Salaries, wages and benefits" in the interim condensed consolidated statements of operations.

At September 30, 2024, the Company had $5,752,000 of unrecognized compensation cost related to unvested stock–based compensation awards. This unrecognized compensation cost will be amortized over an approximate two-year period.

Stock Options

The following table summarizes the significant assumptions used to value the options granted for the nine months ended September 30, 2024 and for the year ended December 31, 2023.

	September 30,	December 31,

	2024	2023
Risk–free interest rate	4.40%	4.52%
Expected volatility	24.1%	29.3%
Expected life, in years	2.9	2.9
Expected dividend yield	2.63%	4.41%

The following table summarizes our outstanding stock options for the nine months ended September 30, 2024 and for the year ended December 31, 2023.

	Number of Shares	Weighted Average Exercise Price	Aggregate Intrinsic Value
Options outstanding at January 1, 2023	445,144	$ 66.62	$ –
Options granted	299,278	54.44	–
Options exercised	(103,481)	64.72	–
Options cancelled	(52,407)	60.58	–
Options outstanding at December 31, 2023	588,534	61.30	–
Options granted	298,097	94.42	–
Options exercised	(211,040)	63.75	–
Options cancelled	(33,202)	79.34	–
Options outstanding at September 30, 2024	642,389	74.93	$ 32,658,000
Options exercisable at September 30, 2024	153,439	63.87	$ 9,498,000

Options Outstanding September 30, 2024	Exercise Prices	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life in Years
331,037	53.94 - 69.19	58.88	3.0
311,352	71.64 - 96.03	92.00	4.1
642,389		74.93	3.5

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 15 - Long-term Debt

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Long-Term Debt [Text Block]

Note 15 – Long-Term Debt

Long–term debt consists of the following (*dollars in thousands*):

	Interest rate at September 30, 2024	Maturity	September 30, 2024	December 31, 2023
Credit facility, interest payable monthly	Variable, 6.8%	2029	$ 147,000	$ –
Less current portion			(7,500)	–
Total long-term debt			$ 139,500	$ –

On August 1, 2024, the Company entered into a $200,000,000 senior credit facility with a five-year term consisting of a $150,000,000 term facility and a $50,000,000 revolving line of credit (the "Credit Facility"). The Credit Facility is for general corporate purposes, including working capital and acquisitions. The loans bear interest at either (i) Term Secured Overnight Financing Rate ("SOFR") for interest periods of one, three or six months, plus the applicable margin or, at NHC's option, (ii) the Base Rate plus the applicable margin. The applicable margin is an interest rate per annum between 1.30% and 1.65% for Term SOFR loans and between .30% and .65% for Base Rate loans, depending upon the Company meeting certain conditions. The revolving line of credit contains a commitment fee equal to 0.25% of the unused borrowing capacity. There are no amounts outstanding on the revolving line of credit at September 30, 2024.

NHC's obligations under the Credit Facility are unsecured. The Credit Facility contains customary representations and warranties, financial covenants, and other customary affirmative and negative covenants. The Credit Facility also contains customary events of default. As of September 30, 2024, the Company is compliant with all financial covenants. Based on level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt based upon the interest rates that the Company believes it can currently obtain for similar debt.

The aggregate maturities of long–term debt for the five years subsequent to September 30, 2024 are as follows *(in thousands)*:

	Long–Term Debt
2025	$ 7,500
2026	7,500
2027	7,500
2028	7,500
2029	117,000
Total	$ 147,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 16 - Income Taxes

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Note 16 – Income Taxes

The Company's income tax provision as a percentage of our income before income taxes was 26.4% and 27.9% for the three months ended September 30, 2024 and 2023, respectively.

The Company's income tax provision as a percentage of our income before income taxes was 26.3% and 28.3% for the nine months ended September 30, 2024 and 2023, respectively.

Typically, these percentages vary from the U.S. federal statutory income tax rate of 21% primarily due to state income taxes, excess tax benefits from stock-based compensation, benefits resulting from the lapsing of statute of limitations of items in our tax contingency reserve, and non-deductible expenses. For the three months and nine months ended September 30, 2024, the accrual of state income tax was the most significant reconciling item. For the three and nine months ended September 30, 2023, the accrual of state income tax was the only significant reconciling items.

Our quarterly income tax provision, and our estimate of our annual effective income tax rate, is subject to variation due to several factors, including volatility based on the amount of pre-tax income or loss.

The Company is no longer subject to U.S. federal and state examinations by tax authorities for years before 2020 (with certain state exceptions).

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 17 - Contingencies and Commitments

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Note 17 – Contingencies and Commitments

Accrued Risk Reserves

We have wholly–owned limited purpose insurance companies that insure risks related to workers' compensation and general and professional liability insurance claims both for our owned and leased entities and certain of the entities to which we provide management or accounting services. The liability we have recognized for reported claims and estimates for incurred but unreported claims totals $110,204,000 and $103,259,000 at September 30, 2024 and December 31, 2023, respectively. The liability is included in accrued risk reserves in the interim condensed consolidated balance sheets and is subject to adjustment for actual claims incurred. It is possible that these claims plus unasserted claims could exceed our insurance coverages and our reserves, which could have a material adverse effect on our consolidated financial position, results of operations and cash flows.

As a result of the terms of our insurance policies and our use of wholly owned limited purpose insurance companies, we have retained significant insurance risk with respect to workers' compensation and general and professional liability. We consider the professional services of independent actuaries to assist us in estimating our exposures

for claims obligations (for both asserted and unasserted claims) related to deductibles and exposures in excess of coverage limits, and we maintain reserves for these obligations. Such estimates are based on many variables including historical and statistical information and other factors.

Workers' Compensation

For workers' compensation, we utilize a wholly–owned Tennessee domiciled property/casualty insurance company to write coverage for NHC affiliates and for third–party customers. Policies are written for a duration of twelve months and cover only risks related to workers' compensation losses. All customers are companies which operate in the senior care industry. Business is written on a direct basis.

General and Professional Liability Insurance and Lawsuits

The senior care industry has experienced significant increases in both the number of personal injury/wrongful death claims and in the severity of awards based upon alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. Additional insurance is purchased through third party providers that serve to supplement the coverage provided through our wholly owned captive insurance company.

There is certain additional litigation incidental to our business, none of which, based upon information available to date, would be material to our financial position, results of operations, or cash flows. In addition, the long–term care industry is continuously subject to scrutiny by governmental regulators, which could result in litigation or claims related to regulatory compliance matters.

Qui Tam Litigation

United States of America, ex rel. Jennifer Cook and Sally Gaither v. Integrated Behavioral Health, Inc., NHC HealthCare/Moulton, LLC, et al., Case No. 2:20-CV-00877-AMM (N.D. Ala.) This is a qui tam case originally filed under seal on June 22, 2020. The United States declined intervention on March 1, 2021. Thereafter, the Plaintiffs filed an amended Complaint against Dr. Sanja Malhotra, Integrated Behavioral Health, Inc. and other entities that Dr. Malhotra was alleged to own or in which he allegedly had a financial interest. The Complaint also named multiple skilled nursing facilities as Defendants, including NHC Healthcare/Moulton, LLC, an affiliate of National HealthCare Corporation. The Complaint alleged that nurse practitioners affiliated with Dr. Malhotra provided free services to the facilities in exchange for referrals to entities owned by or in which Dr. Malhotra had a financial interest in violation of the False Claims Act and Anti-Kickback Statute. NHC Healthcare/Moulton, LLC denied the allegations and filed a motion to dismiss on November 4, 2021. On January 28, 2022, the district court stayed this matter and administratively terminated the motion to dismiss pending the U.S. Supreme Court's review of a petition for certiorari filed in an unrelated matter but involving one of the legal arguments raised in the motion to dismiss. Thereafter, the U.S. Supreme Court denied the petition for certiorari in the unrelated matter. As a result, NHC Healthcare/Moulton, LLC renewed its motion to dismiss. The District Court granted NHC Healthcare/Moulton's Motion to Dismiss, along with other pending Motions to Dismiss, and entered an Order of Dismissal on March 23, 2023 and an Amended Order of Dismissal on April 4, 2023, which dismissed the case in its entirety with prejudice with respect to the claims asserted by the Plaintiffs. The Plaintiffs filed a Notice of Appeal on April 20, 2023 to appeal the dismissal to the United States Court of Appeals for the Eleventh Circuit. On December 21, 2023, the Eleventh Circuit entered an Order affirming the District Court's dismissal of the claims. The time period for the Plaintiffs to file a Petition for a Writ of Certiorari with the United States Supreme Court has expired making the Order affirming dismissal issued by the Eleventh Circuit final.

Civil Investigative Demand

On or about May 21, 2024, Caris Healthcare, L.P. ("Caris") received a Civil Investigative Demand ("CID") from the U.S. Attorney's Office for the Eastern District of Tennessee. The CID requests the production of certain medical records for patients at Caris' Nashville office and other documents related to the billing for hospice services for the period of January 1, 2019, through the date of the CID. The Company is cooperating with respect to the requests and remains in the process of responding to the CID.

Governmental Regulations

Laws and regulations governing Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid and other federal healthcare programs.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	**3 Months Ended Sep. 30, 2024**
Insider Trading Arr Line Items	
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

XML 38 R27.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	**9 Months Ended Sep. 30, 2024**
Accounting Policies [Abstract]	
Basis of Accounting, Policy [Policy Text Block]	*Basis of Presentation* The unaudited interim condensed consolidated financial statements to which these notes are attached include all normal, recurring adjustments which are necessary to fairly present the financial position, results of operations and cash flows of NHC. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by NHC. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to NHC and the noncontrolling interest in its consolidated statements of operations. We assume that users of these interim financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate the disclosure contained in our most recent annual report to stockholders have been omitted. This interim financial information is not necessarily indicative of the results that may be expected for a full year for a variety of reasons.
Use of Estimates, Policy [Policy Text Block]	*Estimates and Assumptions* The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.
Revenue [Policy Text Block]	*Net Patient Revenues and Accounts Receivable* Net patient revenues are derived from services rendered to patients for skilled and intermediate nursing, rehabilitation therapy, assisted living and independent living, home health care services, hospice services, and behavioral health services. Net patient revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient services. These amounts are due from patients, governmental programs, and other third-party payors, and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. The Company recognizes revenue as its performance obligations are completed. Routine services are treated as a single performance obligation satisfied over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered. Contract liabilities are recorded for payments the Company receives in which performance obligations have not been completed. The Company determines the transaction price based on established billing rates reduced by explicit price concessions provided to third party payors. Explicit price concessions are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,574,000 and $7,098,000 for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $1,668,000 and $5,331,000, respectively. As of September 30, 2024 and December 31, 2023, the Company has recorded allowance for doubtful accounts of $10,859,000 and $8,054,000, respectively, as our best estimate of expected losses inherent in the accounts receivable balance.
Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block]	*Other Revenues* Other revenues include revenues from the provision of insurance services to other healthcare providers, management and accounting services to other healthcare providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements. We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned.

Government Assistance [Policy Text Block]

Government Grants

We account for government grants in accordance with International Accounting Standards ("IAS") 20, *Accounting for Government Grants and Disclosure of Government Assistance,* and as such, we recognize grant income on a systematic basis in line with the recognition of specific expenses and lost revenues for which the grants are intended to compensate.

For the nine months ended September 30, 2024, all conditions related to the Employee Retention Credit ("ERC") were met and the credit was recognized as government stimulus income. The ERC was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The qualified wages and health insurance benefits paid by the Company were related to the second, third and fourth quarters of 2020.

Segment Reporting, Policy [Policy Text Block]

Segment Reporting

In accordance with the provisions of Accounting Standards Codification ("ASC") 280, *Segment Reporting*, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 7 for further disclosure of the Company’s operating segments.

Other Operating Expenses Policy [Policy Text Block]

Other Operating Expenses

Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance.

Selling, General and Administrative Expenses, Policy [Policy Text Block]

General and Administrative Costs

With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation and incentive compensation, which were $6,288,000 and $19,678,000 for the three and nine months ended September 30, 2024, respectively. General and administrative costs were $5,661,000 and $16,309,000 for the three and nine months ended September 30, 2023, respectively. The increased general and administrative costs incurred during 2024 are due to acquisition-related expenses for the White Oak Senior Living portfolio. See *Note 3 - Acquisition of White Oak Senior Living* for additional detail regarding the acquisition.

Lessee, Leases [Policy Text Block]

Long-Term Leases

The Company’s lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, regional offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain.

The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recorded and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases.

Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuate with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are recorded at cost or fair value, if acquired. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method.

Business Combinations Policy [Policy Text Block]

Business Combinations

We account for transactions that represent business combinations using the acquisition method of accounting in accordance with FASB ASC Topic 805, *Business Combinations* (Topic 805). Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts during the measurement period. The measurement period is defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date.

Goodwill generated from business combinations is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter. Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.

The Company’s indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the fair value of the intangible asset is below its carrying amount.

Liability Reserve Estimate, Policy [Policy Text Block]

Accrued Risk Reserves

We are self–insured for risks related to workers’ compensation and general and professional liability insurance. We have two wholly–owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis.

Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period.

We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverage includes both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us.

Continuing Care Contracts and Refundable Entrance Fees, Policy [Policy Text Block]

Continuing Care Contracts

We have continuing care retirement centers (“CCRC”) within our operations. Residents at these retirement centers may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original resident’s entry fee.

Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarially determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrent liabilities in our consolidated balance sheets.

We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recorded with a corresponding charge to income. As of September 30, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.

Other Noncurrent Liabilities [Policy Text Block]

Other Noncurrent Liabilities

Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation (“National”) and the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents.

Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]

Noncontrolling Interest

The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Company's earnings per share is calculated based on net income attributable to NHC's stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions.

Consolidation, Variable Interest Entity, Policy [Policy Text Block]

Variable Interest Entities

We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity ("VIE") and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.

The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as "investments in unconsolidated companies" in the interim condensed consolidated balance sheets.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Guidance

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, "Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures." The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact this standard will have on our disclosures.

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of White Oak Senior Living (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	Amount
Cash and cash equivalents	$ 9
Inventories	1,054
Prepaid expenses and other assets	137
Property and equipment	203,695
Deferred tax asset	2,499
Operating lease right-of-use assets	11,380
Intangible assets	12,765
Total assets acquired	231,539
Operating lease liabilities, current portion	424
Accrued payroll	3,559
Other current liabilities	1,085
Operating lease liabilities, less current portion	10,956
Other noncurrent liabilities	1,005
Total liabilities assumed	17,029
Net identifiable assets acquired	214,510
Goodwill	1,395
Total estimated fair value of the acquisition	$ 215,905

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Net operating revenues and grant income	$ 358,334	$ 337,817	$1,065,418	$ 987,186
Income before income taxes	58,881	14,087	134,777	49,113
Net income attributable to NHC	$ 43,413	$ 10,431	$ 99,121	$ 34,064

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 4 - Net Patient Revenues (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Net patient revenues:				
Inpatient services	$293,026	$243,865	$790,664	$706,795
Homecare and hospice	35,648	33,140	103,751	97,822
Total net patient revenue	$328,674	$277,005	$894,415	$804,617

	Three Months Ended September 30		Nine Months Ended September 30	
Source	2024	2023	2024	2023
Medicare	30%	33%	32%	35%
Managed Care	9%	10%	10%	10%
Medicaid	33%	32%	30%	30%
Private Pay and Other	28%	25%	28%	25%
Total	100%	100%	100%	100%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 5 - Other Revenues (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Schedule of Other Revenues [Table Text Block]

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Rental income	$ 6,028	$ 5,958	$ 18,015	$ 17,966
Management and accounting services fees	4,226	4,185	12,744	14,045
Insurance services	818	989	2,506	2,920
Other	452	348	907	1,082
Total other revenues	$ 11,524	$ 11,480	$ 34,172	$ 36,013

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 6 - Non-operating Income (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Schedule of Other Nonoperating Income, by Component [Table Text Block]

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Dividends and net realized gains and losses on sales of securities	$ 1,683	$ 1,690	$ 5,462	$ 4,604
Interest income	2,603	2,222	7,790	5,571
Equity in earnings of unconsolidated				

investments	(62)	185	589	1,941
Gain on sale of unconsolidated company	-	-	1,024	-
Total non-operating income	$ 4,224	$ 4,097	$ 14,865	$ 12,116

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 7 - Business Segments (Tables)

9 Months Ended Sep. 30, 2024

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30, 2024			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 293,026	$ 35,648	$ -	$ 328,674
Other revenues	370	-	11,154	11,524
Net operating revenues	293,396	35,648	11,154	340,198
Costs and expenses:				
Salaries, wages, and benefits	175,241	21,456	16,698	213,395
Other operating	72,384	6,612	3,513	82,509
Rent	8,422	602	1,862	10,886
Depreciation and amortization	9,632	172	815	10,619
Interest	1,742	-	-	1,742
Total costs and expenses	267,421	28,842	22,888	319,151
Income/(loss) from operations	25,975	6,806	(11,734)	21,047
Non-operating income	-	-	4,224	4,224
Unrealized gains on marketable equity securities	-	-	32,767	32,767
Income before income taxes	$ 25,975	$ 6,806	$ 25,257	$ 58,038

	Three Months Ended September 30, 2023			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 243,865	$ 33,140	$ -	$ 277,005
Other revenues	297	-	11,183	11,480
Net operating revenues	244,162	33,140	11,183	288,485
Costs and expenses:				
Salaries, wages, and benefits	151,912	20,066	10,686	182,664
Other operating	64,228	5,868	2,394	72,490
Rent	8,186	538	1,370	10,094
Depreciation and amortization	9,203	185	747	10,135
Interest	77	-	-	77
Total costs and expenses	233,606	26,657	15,197	275,460
Income/(loss) from operations	10,556	6,483	(4,014)	13,025
Non-operating income	-	-	4,097	4,097
Unrealized losses on marketable equity securities	-	-	(3,093)	(3,093)
Income/(loss) before income taxes	$ 10,556	$ 6,483	$ (3,010)	$ 14,029

	Nine Months Ended September 30, 2024			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 790,664	$ 103,751	$ -	$ 894,415
Other revenues	710	-	33,462	34,172
Government stimulus income	-	-	9,445	9,445
Net operating revenues and grant income	791,374	103,751	42,907	938,032
Costs and expenses:				
Salaries, wages, and benefits	474,190	63,761	38,658	576,609
Other operating	207,883	18,977	11,232	238,092
Rent	24,795	1,736	5,273	31,804
Depreciation and amortization	27,646	545	2,352	30,543
Interest	1,788	-	-	1,788
Total costs and expenses	736,302	85,019	57,515	878,836
Income/(loss) from operations	55,072	18,732	(14,608)	59,196
Non-operating income	-	-	14,865	14,865
Unrealized gains on marketable equity securities	-	-	56,290	56,290
Income before income taxes	$ 55,072	$ 18,732	$ 56,547	$ 130,351

	Nine Months Ended September 30, 2023			
	Inpatient Services	Homecare and Hospice	All Other	Total
Revenues:				
Net patient revenues	$ 706,795	$ 97,822	$ -	$ 804,617
Other revenues	894	-	35,119	36,013
Net operating revenues	707,689	97,822	35,119	840,630
Costs and expenses:				
Salaries, wages, and benefits	435,517	60,804	29,461	525,782
Other operating	192,473	17,356	7,384	217,213
Rent	24,520	1,639	3,928	30,087
Depreciation and amortization	27,474	555	2,237	30,266
Interest	268	-	-	268
Total costs and expenses	680,252	80,354	43,010	803,616
Income/(loss) from operations	27,437	17,468	(7,891)	37,014
Non-operating income	-	-	12,116	12,116
Unrealized gains on marketable equity securities	-	-	2,943	2,943
Income before income taxes	$ 27,437	$ 17,468	$ 7,168	$ 52,073

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 8 - Long-term Leases (Tables)

9 Months Ended Sep. 30, 2024

Notes Tables

Lessee, Lease, Liability, Maturity [Table Text Block]

	Operating Leases
2025	$ 35,858
2026	35,183
2027	10,471
2028	1,702
2029	1,424
Thereafter	11,768

Total minimum lease payments	96,406
Less: amounts representing interest	(11,961)
Present value of future minimum lease payments	84,445
Less: current portion	(31,366)
Noncurrent lease liabilities	$ 53,079

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 9 - Earnings Per Share (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
Basic:				
Weighted average common shares outstanding	15,411,680	15,299,913	15,384,758	15,311,453
Net income attributable to National HealthCare Corporation	$ 42,789	$ 10,388	$ 95,846	$ 38,392
Earnings per common share, basic	$ 2.78	$ 0.68	$ 6.23	$ 2.51
Diluted:				
Weighted average common shares outstanding	15,411,680	15,299,913	15,384,758	15,311,453
Effects of dilutive instruments	255,641	24,598	191,536	22,816
Weighted average common shares outstanding	15,667,321	15,324,511	15,576,294	15,334,269
Net income attributable to National HealthCare Corporation	$ 42,789	$ 10,388	$ 95,846	$ 38,392
Earnings per common share, diluted	$ 2.73	$ 0.68	$ 6.15	$ 2.50

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 10 - Investments in Marketable Securities (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Marketable Securities [Table Text Block]

	September 30, 2024		December 31, 2023	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Investments available for sale:				
Marketable equity securities	$ 30,176	$164,754	$ 30,176	$111,117
Corporate debt securities	–	–	2,497	2,441
U.S. Treasury securities	–	–	2,990	2,986
Restricted investments available for sale:				
Marketable equity securities	17,702	23,001	24,134	26,779
Corporate debt securities	59,267	58,812	59,586	57,731
Asset-based securities	17,756	16,646	19,388	17,659
U.S. Treasury securities	46,224	44,671	46,771	42,863
State and municipal securities	3,813	3,782	4,106	4,047
	$ 174,938	$311,666	$ 189,648	265,623

Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]

	September 30, 2024			December 31, 2023		
	Shares	Cost	Fair Value	Shares	Cost	Fair Value
NHI Common Stock	1,630,642	$ 24,734	$137,072	1,630,642	$ 24,734	$ 91,071

Investments Classified by Contractual Maturity Date [Table Text Block]

	September 30, 2024		December 31, 2023	
	Cost	Fair Value	Cost	Fair Value
Maturities:				
Within 1 year	$ 24,509	$ 24,023	$ 19,664	$ 19,328
1 to 5 years	71,047	69,082	81,517	77,118
6 to 10 years	31,197	30,499	33,515	30,802
Over 10 years	307	307	642	479
	$127,060	$123,911	$135,338	$127,727

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 11 - Fair Value Measurements (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value Measurements Using			
September 30, 2024	Fair Value	Quoted Prices in Active Markets For Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$ 84,807	$ 84,807	$ –	$ –
Restricted cash and cash equivalents	30,267	30,267	–	–
Marketable equity securities	187,755	187,755	–	–
Corporate debt securities	58,812	39,475	19,337	–
Asset–backed securities	16,646	–	16,186	460
U.S. Treasury securities	44,671	44,671	–	–
State and municipal securities	3,782	–	3,782	–
Total financial assets	$426,740	$386,975	$ 39,305	$ 460

	Fair Value Measurements Using			
December 31, 2023	Fair Value	Quoted Prices in Active Markets For Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$107,076	$107,076	$ –	$ –
Restricted cash and cash equivalents	18,892	18,892	–	–
Marketable equity securities	137,896	137,896	–	–
Corporate debt securities	60,171	42,860	17,311	–
Asset–backed securities	17,659	–	17,210	449
U.S. Treasury securities	45,850	45,850	–	–
State and municipal securities	4,047	–	4,047	–
Total financial assets	$391,591	$352,574	$ 38,568	$ 449

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 12 - Goodwill and Other Intangible Assets (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Schedule of Goodwill [Table Text Block]

	Inpatient Services	Homecare and Hospice	All Other	Total

January 1, 2024	$ 3,741	$ 164,554	$ –	$168,295
Additions	1,395	–	–	1,395
September 30, 2024	$ 5,136	$ 164,554	$ –	$169,690

Schedule of Indefinite-Lived Intangible Assets [Table Text Block]

	September 30, 2024	December 31, 2023
Trade names	$ 15,836	$ 4,340
Certificates of need	1,757	532
Licenses	2,212	2,166
Total	$ 19,805	$ 7,038

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 14 - Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	September 30, 2024	December 31, 2023
Risk-free interest rate	4.40%	4.52%
Expected volatility	24.1%	29.3%
Expected life, in years	2.9	2.9
Expected dividend yield	2.63%	4.41%

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Shares	Weighted Average Exercise Price	Aggregate Intrinsic Value
Options outstanding at January 1, 2023	445,144	$ 66.62	$ –
Options granted	299,278	54.44	–
Options exercised	(103,481)	64.72	–
Options cancelled	(52,407)	60.58	–
Options outstanding at December 31, 2023	588,534	61.30	–
Options granted	298,097	94.42	–
Options exercised	(211,040)	63.75	–
Options cancelled	(33,202)	79.34	–
Options outstanding at September 30, 2024	642,389	74.93	$32,658,000
Options exercisable at September 30, 2024	153,439	63.87	$ 9,498,000

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Options Outstanding September 30, 2024	Exercise Prices	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life in Years
331,037	53.94 - 69.19	58.88	3.0
311,352	71.64 - 96.03	92.00	4.1
642,389		74.93	3.5

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 15 - Long-term Debt (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Schedule of Debt [Table Text Block]

	Interest rate at September 30, 2024	Maturity	September 30, 2024	December 31, 2023
Credit facility, interest payable monthly	Variable, 6.8%	2029	$ 147,000	$ –
Less current portion			(7,500)	–
Total long-term debt			$ 139,500	$ –

Schedule of Maturities of Long-Term Debt [Table Text Block]

	Long-Term Debt
2025	$ 7,500
2026	7,500
2027	7,500
2028	7,500
2029	117,000
Total	$ 147,000

XML 51 R40.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business (Details Textual)	**Sep. 30, 2024**
Number of Skilled Nursing Ficilitiess	80
Number of Beds	10,349
Number of Assisted Living Facilities	26
Number of Independent Living Facilities	9
Number of Behavioral Health Hospitals	3
Number of Homecare Programs	34
Number of Hospice Agencies	32
Number of States in which Entity Operates	9

XML 52 R41.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual)	**3 Months Ended**		**9 Months Ended**		
	Sep. 30, 2024 USD ($)	**Sep. 30, 2023 USD ($)**	**Sep. 30, 2024 USD ($)**	**Sep. 30, 2023 USD ($)**	**Dec. 31, 2023 USD ($)**
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,574,000	$ 1,668,000	$ 7,098,000	$ 5,331,000	
Accounts Receivable, Allowance for Credit Loss	10,859,000		$ 10,859,000		$ 8,054,000
Number of Reportable Segments			2		
General and Administrative Expense	6,288,000	$ 5,661,000	$ 19,678,000	$ 16,309,000	
Continuing Care Retirement Communities, Refund Obligation	$ 1,606,000		$ 1,606,000		$ 1,606,000
Refundable Advance Fees [Member]					
Nonrefundable Resident Entry Fee Percentage			10.00%		
Original Entry Fee [Member]					
Refundable Resident Entry Fee Percentage			90.00%		
Appreciation [Member]					
Appreciation of Apartment Over Original Residents Entry Fee Percentage			40.00%		
Minimum [Member]					
Lessee, Operating Lease, Term of Contract (Year)	2 years		2 years		
Minimum [Member] | Building and Building Improvements [Member]					
Property, Plant and Equipment, Useful Life (Year)	20 years		20 years		
Minimum [Member] | Equipment and Furniture [Member]					
Property, Plant and Equipment, Useful Life (Year)	3 years		3 years		
Maximum [Member]					

Lessee, Operating Lease, Term of Contract (Year)	15 years	15 years
Maximum [Member] | Building and Building Improvements [Member]		
Property, Plant and Equipment, Useful Life (Year)	40 years	40 years
Maximum [Member] | Equipment and Furniture [Member]		
Property, Plant and Equipment, Useful Life (Year)	15 years	15 years

XML 53 R42.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of White Oak Senior Living (Details Textual)		3 Months Ended		9 Months Ended	
	Aug. 01, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Number of Skilled Nursing Ficilitiess		80		80	
Number of Independent Living Facilities		9		9	
Revenue from Contract with Customer, Including Assessed Tax		$ 328,674,000	$ 277,005,000	$ 894,415,000	$ 804,617,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		58,038,000	$ 14,029,000	130,351,000	$ 52,073,000
White Oak Senior Living Portfolio [Member]					
Business Combination, Consideration Transferred	$ 221,400,000				
Number of Healthcare Operations	22				
Number of Skilled Nursing Ficilitiess	15				
Number of Independent Living Facilities	4				
Number of Long-term Care Pharmacies	1				
Number of Licensed Skilled Nursing Beds	1,928				
Number of Assisted Living Units	48				
Number of Independent Living Units	302				
Number of Assisted Living and Independent Living Units	2,278				
Number of Continuing Care Retirement Centers	3				
Revenue from Contract with Customer, Including Assessed Tax		37,305,000		37,305,000	
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		1,557,000		1,557,000	
Business Combination, Acquisition Related Costs		$ 637,000		$ 2,831,000	
White Oak Senior Living Portfolio [Member] | SOUTH CAROLINA					
Number of Skilled Nursing Facilities	9				

XML 54 R43.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Aug. 01, 2024	Dec. 31, 2023
Goodwill	$ 169,690		$ 168,295
White Oak Senior Living Portfolio [Member]			
Cash and cash equivalents		$ 9	
Inventories		1,054	
Prepaid expenses and other assets		137	
Property and equipment		203,695	
Deferred tax asset		2,499	
Operating lease right-of-use assets		11,380	
Intangible assets		12,765	
Total assets acquired		231,539	
Operating lease liabilities, current portion		424	
Accrued payroll		3,559	
Other current liabilities		1,085	
Operating lease liabilities, less current portion		10,956	
Other noncurrent liabilities		1,005	
Total liabilities assumed		17,029	
Net identifiable assets acquired		214,510	
Goodwill		1,395	
Total estimated fair value of the acquisition		$ 215,905	

XML 55 R44.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details) - White Oak Senior Living Portfolio [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net operating revenues and grant income	$ 358,334	$ 337,817	$ 1,065,418	$ 987,186
Income before income taxes	58,881	14,087	134,777	49,113
Net income attributable to NHC	$ 43,413	$ 10,431	$ 99,121	$ 34,064

XML 56 R45.htm IDEA: XBRL DOCUMENT

Note 4 - Net Patient Revenues (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue from Contract with Customer, Including Assessed Tax	$ 328,674,000	$ 277,005,000	$ 894,415,000	$ 804,617,000	
Accounts Receivable, Allowance for Credit Loss	10,859,000		10,859,000		$ 8,054,000
Medicare and Medicaid [Member]					
Accounts Receivable, Allowance for Credit Loss	18,815,000		18,815,000		$ 18,369,000
Medicaid [Member]					
Revenue from Contract with Customer, Including Assessed Tax	$ 5,267,000	$ 4,232,000	$ 11,314,000	$ 15,362,000	

XML 57 R46.htm IDEA: XBRL DOCUMENT

Note 4 - Net Patient Revenues - Revenue Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net patient revenues	$ 328,674	$ 277,005	$ 894,415	$ 804,617
Revenue, concentration percentage	100.00%	100.00%	100.00%	100.00%
Medicare [Member]				
Revenue, concentration percentage	30.00%	33.00%	32.00%	35.00%
Inpatient Services [Member]				

Net patient revenues	$ 293,026	$ 243,865	$ 790,664	$ 706,795
Managed Care [Member]				
Revenue, concentration percentage	9.00%	10.00%	10.00%	10.00%
Homecare and Hospice [Member]				
Net patient revenues	$ 35,648	$ 33,140	$ 103,751	$ 97,822
Medicaid [Member]				
Revenue, concentration percentage	33.00%	32.00%	30.00%	30.00%
Private Pay and Other [Member]				
Revenue, concentration percentage	28.00%	25.00%	28.00%	25.00%

XML 58 R47.htm IDEA: XBRL DOCUMENT

Note 5 - Other Revenues (Details Textual)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
	USD ($)	USD ($)	USD ($)	USD ($)
Number of Skilled Nursing Ficilitiess	80		80	
Insurance Services Revenue	$ 818,000	$ 989,000	$ 2,506,000	$ 2,920,000
Workers Compensation Revenue [Member]				
Insurance Services Revenue	529,000	678,000	1,638,000	1,985,000
Professional Liability Insurance [Member]				
Insurance Services Revenue	$ 289,000	312,000	$ 868,000	935,000
National [Member]				
Number of Skilled Nursing Ficilitiess	5		5	
Property Management Fee Revenue	$ 1,348,000	$ 1,243,000	$ 4,014,000	$ 3,968,000
FLORIDA				
Number of Skilled Nursing Ficilitiess	4		4	

XML 59 R48.htm IDEA: XBRL DOCUMENT

Note 5 - Other Revenues - Summary of Other Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Rental income	$ 6,028	$ 5,958	$ 18,015	$ 17,966
Management and accounting services fees	4,226	4,185	12,744	14,045
Insurance services	818	989	2,506	2,920
Other	452	348	907	1,082
Total other revenues	$ 11,524	$ 11,480	$ 34,172	$ 36,013

XML 60 R49.htm IDEA: XBRL DOCUMENT

Note 6 - Non-operating Income (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		
	Jan. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Proceeds from Sale of Unconsolidated Company	$ 2,100,000			$ 2,100,000	$ 0	
Gain (Loss) on Sale of Unconsolidated Company	$ 1,024,000	$ 0	$ 0	$ 1,024,000	$ (0)	
Homecare Agency in Nashville, Tennessee [Member]						
Equity Method Investment, Ownership Percentage						50.00%

XML 61 R50.htm IDEA: XBRL DOCUMENT

Note 6 - Non-operating Income - Summary of Non-operating Income (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended	
	Jan. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Dividends and net realized gains and losses on sales of securities		$ 1,683,000	$ 1,690,000	$ 5,462,000	$ 4,604,000
Interest income		2,603,000	2,222,000	7,790,000	5,571,000
Equity in earnings of unconsolidated investments		(62,000)	185,000	589,000	1,941,000
Gain on sale of unconsolidated company	$ 1,024,000	0	0	1,024,000	(0)
Total non-operating income		$ 4,224,000	$ 4,097,000	$ 14,865,000	$ 12,116,000

XML 62 R51.htm IDEA: XBRL DOCUMENT

Note 7 - Business Segments (Details Textual)	9 Months Ended
	Sep. 30, 2024
Number of Operating Segments	2

XML 63 R52.htm IDEA: XBRL DOCUMENT

Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details) - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:				
Net patient revenues	$ 328,674,000	$ 277,005,000	$ 894,415,000	$ 804,617,000
Other revenues	11,524,000	11,480,000	34,172,000	36,013,000
Net operating revenues	340,198,000	288,485,000	938,032,000	840,630,000
Government stimulus income	0	0	9,445,000	0
Costs and expenses:				
Salaries, wages, and benefits	213,395,000	182,664,000	576,609,000	525,782,000
Other operating	82,509,000	72,490,000	238,092,000	217,213,000
Rent	10,886,000	10,094,000	31,804,000	30,087,000
Depreciation and amortization	10,619,000	10,135,000	30,543,000	30,266,000
Interest	1,742,000	77,000	1,788,000	268,000
Total costs and expenses	319,151,000	275,460,000	878,836,000	803,616,000
Income/(loss) from operations	21,047,000	13,025,000	59,196,000	37,014,000
Non-operating income (loss)	4,224,000	4,097,000	14,865,000	12,116,000
Unrealized gains on marketable equity securities	32,767,000	(3,093,000)	56,290,000	2,943,000
Income before income taxes	58,038,000	14,029,000	130,351,000	52,073,000
Inpatient Services Segment [Member]				
Revenues:				
Net patient revenues	293,026,000	243,865,000	790,664,000	706,795,000
Other revenues	370,000	297,000	710,000	894,000
Net operating revenues	293,396,000	244,162,000	791,374,000	707,689,000
Government stimulus income			0	

Costs and expenses:				
Salaries, wages, and benefits	175,241,000	151,912,000	474,190,000	435,517,000
Other operating	72,384,000	64,228,000	207,883,000	192,473,000
Rent	8,422,000	8,186,000	24,795,000	24,520,000
Depreciation and amortization	9,632,000	9,203,000	27,646,000	27,474,000
Interest	1,742,000	77,000	1,788,000	268,000
Total costs and expenses	267,421,000	233,606,000	736,302,000	680,252,000
Income/(loss) from operations	25,975,000	10,556,000	55,072,000	27,437,000
Non-operating income (loss)	0	0	0	0
Unrealized gains on marketable equity securities	0	0	0	0
Income before income taxes	25,975,000	10,556,000	55,072,000	27,437,000
Homecare Services Segment [Member]				
Revenues:				
Net patient revenues	35,648,000	33,140,000	103,751,000	97,822,000
Other revenues	0	0	0	0
Net operating revenues	35,648,000	33,140,000	103,751,000	97,822,000
Government stimulus income			0	
Costs and expenses:				
Salaries, wages, and benefits	21,456,000	20,066,000	63,761,000	60,804,000
Other operating	6,612,000	5,868,000	18,977,000	17,356,000
Rent	602,000	538,000	1,736,000	1,639,000
Depreciation and amortization	172,000	185,000	545,000	555,000
Interest	0	0	0	0
Total costs and expenses	28,842,000	26,657,000	85,019,000	80,354,000
Income/(loss) from operations	6,806,000	6,483,000	18,732,000	17,468,000
Non-operating income (loss)	0	0	0	0
Unrealized gains on marketable equity securities	0	0	0	0
Income before income taxes	6,806,000	6,483,000	18,732,000	17,468,000
Other Operating Segment [Member]				
Revenues:				
Net patient revenues	0	0	0	0
Other revenues	11,154,000	11,183,000	33,462,000	35,119,000
Net operating revenues	11,154,000	11,183,000	42,907,000	35,119,000
Government stimulus income			9,445,000	
Costs and expenses:				
Salaries, wages, and benefits	16,698,000	10,686,000	38,658,000	29,461,000
Other operating	3,513,000	2,394,000	11,232,000	7,384,000
Rent	1,862,000	1,370,000	5,273,000	3,928,000
Depreciation and amortization	815,000	747,000	2,352,000	2,237,000
Interest	0	0	0	0
Total costs and expenses	22,888,000	15,197,000	57,515,000	43,010,000
Income/(loss) from operations	(11,734,000)	(4,014,000)	(14,608,000)	(7,891,000)
Non-operating income (loss)	4,224,000	4,097,000	14,865,000	12,116,000
Unrealized gains on marketable equity securities	32,767,000	(3,093,000)	56,290,000	2,943,000
Income before income taxes	$ 25,257,000	$ (3,010,000)	$ 56,547,000	$ 7,168,000

XML 64 R53.htm IDEA: XBRL DOCUMENT

Note 8 - Long-term Leases (Details Textual)	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
	USD ($)	**USD ($)**	**USD ($)**	**USD ($)**
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 35,858,000		$ 35,858,000	
Lessee, Operating Lease, Liability, to be Paid, Year Two	35,183,000		35,183,000	
Lessee, Operating Lease, Liability, to be Paid, Year Three	10,471,000		10,471,000	
Operating Lease, Expense	$ 10,886,000	$ 10,094,000	$ 31,804,000	$ 30,087,000
Two Leases with NHI [Member]				
Number of Skilled Nursing Centers Leased from NHI	28		28	
Number of Assisted Living Centers Leased from NHI	5		5	
Number of Independent Living Centers Leased from NHI	3		3	
Lease One With NHI [Member]				
Number of Skilled Nursing Facilities Subleased	4		4	
NHI Lease Agreement [Member]				
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 32,625,000		$ 32,625,000	
Lessee, Operating Lease, Liability, to be Paid, Year Two	32,225,000		32,225,000	
Lessee, Operating Lease, Liability, to be Paid, Year Three	31,975,000		31,975,000	
Both NHI Lease Agreements [Member]				
Operating Lease, Expense	$ 10,085,000	$ 9,300,000	$ 29,371,000	$ 27,719,000

XML 65 R54.htm IDEA: XBRL DOCUMENT

Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 35,858	
Lessee, Operating Lease, Liability, to be Paid, Year Two	35,183	
Lessee, Operating Lease, Liability, to be Paid, Year Three	10,471	
2028	1,702	
2029	1,424	
Thereafter	11,768	
Total minimum lease payments	96,406	
Less: amounts representing interest	(11,961)	
Present value of future minimum lease payments	84,445	
Less: current portion	(31,366)	$ (29,352)
Noncurrent lease liabilities	$ 53,079	$ 63,175

XML 66 R55.htm IDEA: XBRL DOCUMENT

Note 9 - Earnings Per Share (Details Textual) - shares	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Share-Based Payment Arrangement, Option [Member]				
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)				

	0	637,409	0	637,409

XML 67 R56.htm IDEA: XBRL DOCUMENT

Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Basic:				
Weighted average common shares outstanding (in shares)	15,411,680	15,299,913	15,384,758	15,311,453
Net income attributable to National HealthCare Corporation	$ 42,789	$ 10,388	$ 95,846	$ 38,392
Earnings per common share, basic (in dollars per share)	$ 2.78	$ 0.68	$ 6.23	$ 2.51
Diluted:				
Weighted average common shares outstanding (in shares)	15,411,680	15,299,913	15,384,758	15,311,453
Effects of dilutive instruments (in shares)	255,641	24,598	191,536	22,816
Weighted average common shares outstanding (in shares)	15,667,321	15,324,511	15,576,294	15,334,269
Net income attributable to National HealthCare Corporation	$ 42,789	$ 10,388	$ 95,846	$ 38,392
Earnings per common share, diluted (in dollars per share)	$ 2.73	$ 0.68	$ 6.15	$ 2.5

XML 68 R57.htm IDEA: XBRL DOCUMENT

Note 10 - Investments in Marketable Securities (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Equity Securities Fv Ni Gross Unrealized Gain	$ 140,177,000		$ 140,177,000		$ 84,514,000
Equity Securities Fv Ni Gross Unrealized Loss	300,000		300,000		928,000
Equity Securities, FV-NI, Unrealized Gain (Loss)	32,767,000	$ (3,093,000)	56,290,000	$ 2,943,000	
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax	1,104,000		1,104,000		326,000
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$ 4,253,000		4,253,000		$ 7,937,000
Proceeds from Sale and Maturity of Marketable Securities			39,776,000	36,578,000	
Debt Securities, Realized Gain (Loss)			$ 331,000	$ (603,000)	

XML 69 R58.htm IDEA: XBRL DOCUMENT

Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Unrestricted investments available for sale, equity, amortized cost	$ 24,734	$ 24,734
Marketable equity securities	164,754	111,117
Unrestricted investments available for sale, debt, amortized cost	127,060	135,338
Unrestricted investments available for sale, debt, fair value	123,911	127,727
Restricted marketable equity securities	23,001	26,779
Investments available for sale, amortized cost	174,938	189,648
Marketable Securities	311,666	265,623
Equity Securities [Member]		
Unrestricted investments available for sale, equity, amortized cost	30,176	30,176
Marketable equity securities	164,754	111,117
Restricted investments available for sale, equity, amortized cost	17,702	24,134
Restricted marketable equity securities	23,001	26,779
Corporate Debt Securities [Member]		
Unrestricted investments available for sale, debt, amortized cost	0	2,497
Unrestricted investments available for sale, debt, fair value	0	2,441
Restricted investments available for sale, debt, amortized cost	59,267	59,586
Restricted investments available for sale, debt, fair value	58,812	57,731
US Government Corporations and Agencies Securities [Member]		
Unrestricted investments available for sale, debt, amortized cost	0	2,990
Unrestricted investments available for sale, debt, fair value	0	2,986
Restricted investments available for sale, debt, amortized cost	46,224	46,771
Restricted investments available for sale, debt, fair value	44,671	42,863
Asset-Backed Securities [Member]		
Restricted investments available for sale, debt, amortized cost	17,756	19,388
Restricted investments available for sale, debt, fair value	16,646	17,659
US States and Political Subdivisions Debt Securities [Member]		
Restricted investments available for sale, debt, amortized cost	3,813	4,106
Restricted investments available for sale, debt, fair value	$ 3,782	$ 4,047

XML 70 R59.htm IDEA: XBRL DOCUMENT

Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
NHI Common Stock, Shares (in shares)	1,630,642	1,630,642
NHI Common Stock, Cost	$ 24,734	$ 24,734
NHI Common Stock, fair value	164,754	111,117
NHI Common Stock [Member]		
NHI Common Stock, fair value	$ 137,072	$ 91,071

XML 71 R60.htm IDEA: XBRL DOCUMENT

Note 10 - Investments in Marketable Securities - Amortized Cost and

Estimated Fair Value of Debt Securities as Available for Sale (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Within 1 year, cost	$ 24,509	$ 19,664
Within 1 year, fair value	24,023	19,328
1 to 5 years, cost	71,047	81,517
1 to 5 years, fair value	69,082	77,118
6 to 10 years, cost	31,197	33,515
6 to 10 years, fair value	30,499	30,802
Over 10 years, cost	307	642
Over 10 years, fair value	307	479
Cost	127,060	135,338
Fair Value	$ 123,911	$ 127,727

XML 72 R61.htm IDEA: XBRL DOCUMENT

Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Restricted cash and cash equivalents	$ 30,267		$ 19,947
Available-for-sale securities (USD)	123,911	$ 127,727	
Total financial assets	426,740		
Corporate Debt Securities [Member]			
Available-for-sale securities (USD)	0	2,441	
Fair Value, Inputs, Level 1 [Member]			
Total financial assets	386,975		
Fair Value, Inputs, Level 2 [Member]			
Total financial assets	39,305		
Fair Value, Inputs, Level 3 [Member]			
Total financial assets	460		
Fair Value, Recurring [Member]			
Cash and cash equivalents	84,807	107,076	
Restricted cash and cash equivalents	30,267	18,892	
Total financial assets		391,591	
Fair Value, Recurring [Member] | Equity Securities [Member]			
Marketable equity securities	187,755	137,896	
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]			
Available-for-sale securities (USD)	58,812	60,171	
Fair Value, Recurring [Member] | Asset-Backed Securities [Member]			
Available-for-sale securities (USD)	16,646	17,659	
Fair Value, Recurring [Member] | US Treasury Securities [Member]			
Available-for-sale securities (USD)	44,671	45,850	
Fair Value, Recurring [Member] | US States and Political Subdivisions Debt Securities [Member]			
Available-for-sale securities (USD)	3,782	4,047	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]			
Cash and cash equivalents	84,807	107,076	
Restricted cash and cash equivalents	30,267	18,892	
Total financial assets		352,574	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member]			
Marketable equity securities	187,755	137,896	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]			
Available-for-sale securities (USD)	39,475	42,860	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-Backed Securities [Member]			
Available-for-sale securities (USD)	0	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]			
Available-for-sale securities (USD)	44,671	45,850	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US States and Political Subdivisions Debt Securities [Member]			
Available-for-sale securities (USD)	0	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]			
Cash and cash equivalents	0	0	
Restricted cash and cash equivalents	0	0	
Total financial assets		38,568	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Equity Securities [Member]			
Marketable equity securities	0	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]			
Available-for-sale securities (USD)	19,337	17,311	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-Backed Securities [Member]			
Available-for-sale securities (USD)	16,186	17,210	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]			
Available-for-sale securities (USD)	0	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US States and Political Subdivisions Debt Securities [Member]			
Available-for-sale securities (USD)	3,782	4,047	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]			
Cash and cash equivalents	0	0	
Restricted cash and cash equivalents	0	0	
Total financial assets		449	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]			
Marketable equity securities	0	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]			
Available-for-sale securities (USD)	0	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-Backed Securities [Member]			
Available-for-sale securities (USD)	460	449	

Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]		
Available-for-sale securities (USD)	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US States and Political Subdivisions Debt Securities [Member]		
Available-for-sale securities (USD)	$ 0	$ 0

XML 73 R62.htm IDEA: XBRL DOCUMENT

Note 12 - Goodwill and Other Intangible Assets (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Goodwill and Intangible Asset Impairment, Total	$ 0

XML 74 R63.htm IDEA: XBRL DOCUMENT

Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Goodwill, balance	$ 168,295
Goodwill, additions	1,395
Goodwill, balance	169,690
Inpatient Services Segment [Member]	
Goodwill, balance	3,741
Goodwill, additions	1,395
Goodwill, balance	5,136
Homecare and Hospice Segment [Member]	
Goodwill, balance	164,554
Goodwill, additions	0
Goodwill, balance	$ 164,554

XML 75 R64.htm IDEA: XBRL DOCUMENT

Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Indefinite-lived intangible assets	$ 19,805	$ 7,038
Trade Names [Member]		
Indefinite-lived intangible assets	15,836	4,340
Certificates of Need [Member]		
Indefinite-lived intangible assets	1,757	532
Licensing Agreements [Member]		
Indefinite-lived intangible assets	$ 2,212	$ 2,166

XML 76 R65.htm IDEA: XBRL DOCUMENT

Note 13 - Stock Repurchase Program (Details Textual) - Common Stock [Member] - USD ($)	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Stock Repurchased and Retired During Period, Shares (in shares)	133,151	44,349
Stock Repurchased and Retired During Period, Value	$ 13,502,000	$ 2,482,000

XML 77 R66.htm IDEA: XBRL DOCUMENT

Note 14 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 5,752,000		$ 5,752,000	
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years	
Salaries, Wages, and Benefits [Member]				
Share-Based Payment Arrangement, Expense	$ 1,093,000	$ 708,000	$ 3,062,000	$ 2,119,000

XML 78 R67.htm IDEA: XBRL DOCUMENT

Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Risk-free interest rate	4.40%	4.52%
Expected volatility	24.10%	29.30%
Expected life (Year)	2 years 10 months 24 days	2 years 10 months 24 days
Expected dividend yield	2.63%	4.41%

XML 79 R68.htm IDEA: XBRL DOCUMENT

Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares
Options outstanding, shares (in shares) | shares	588,534	445,144
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 61.3	$ 66.62
Options granted, shares (in shares) | shares	298,097	299,278
Options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 94.42	$ 54.44
Options exercised, shares (in shares) | shares	(211,040)	(103,481)
Options exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 63.75	$ 64.72
Options cancelled, shares (in shares) | shares	(33,202)	(52,407)
Options cancelled, weighted average exercise price (in dollars per share) | $ / shares	$ 79.34	$ 60.58
Options outstanding, shares (in shares) | shares	642,389	588,534
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 74.93	$ 61.3
Options outstanding, aggregate intrinsic value | $	$ 32,658,000	

Options exercisable, shares (in shares) | shares	153,439
Options exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 63.87
Options exercisable, aggregate intrinsic value | $	$ 9,498,000

XML 80 R69.htm IDEA: XBRL DOCUMENT

Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details) - $ / shares	9 Months Ended		
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Options outstanding (in shares)	642,389	588,534	445,144
Options outstanding, weighted average exercise price (in dollars per share)	$ 74.93		
Options outstanding, weighted average remaining contractual life (Year)	3 years 6 months		
Exercise Price Range 1 [Member]			
Options outstanding (in shares)	331,037		
Options outstanding, exercise price, lower range (in dollars per share)	$ 53.94		
Options outstanding, exercise price, upper range (in dollars per share)	69.19		
Options outstanding, weighted average exercise price (in dollars per share)	$ 58.88		
Options outstanding, weighted average remaining contractual life (Year)	3 years		
Exercise Price Range 2 [Member]			
Options outstanding (in shares)	311,352		
Options outstanding, exercise price, lower range (in dollars per share)	$ 71.64		
Options outstanding, exercise price, upper range (in dollars per share)	96.03		
Options outstanding, weighted average exercise price (in dollars per share)	$ 92		
Options outstanding, weighted average remaining contractual life (Year)	4 years 1 month 6 days		

XML 81 R70.htm IDEA: XBRL DOCUMENT

Note 15 - Long-term Debt (Details Textual) - Credit Facility [Member] - USD ($)	Aug. 01, 2024	Sep. 30, 2024
Line of Credit Facility, Maximum Borrowing Capacity	$ 200,000,000	
Debt Instrument, Term (Year)	5 years	
Line of Credit Facility, Commitment Fee Percentage	0.25%	
Long-Term Line of Credit		$ 0
Minimum [Member] | Secured Overnight Financing Rate (SOFR) [Member]		
Debt Instrument, Basis Spread on Variable Rate	1.30%	
Minimum [Member] | Base Rate [Member]		
Debt Instrument, Basis Spread on Variable Rate	0.30%	
Maximum [Member] | Secured Overnight Financing Rate (SOFR) [Member]		
Debt Instrument, Basis Spread on Variable Rate	1.65%	
Maximum [Member] | Base Rate [Member]		
Debt Instrument, Basis Spread on Variable Rate	0.65%	
Term Facility [Member]		
Line of Credit Facility, Maximum Borrowing Capacity	$ 150,000,000	
Revolving Credit Facility [Member]		
Line of Credit Facility, Maximum Borrowing Capacity	$ 50,000,000	

XML 82 R71.htm IDEA: XBRL DOCUMENT

Note 15 - Long-term Debt - Summary of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Credit facility, interest payable monthly	$ 147,000	
Less current portion	(7,500)	$ 0
Total long-term debt	$ 139,500	$ 0
Credit Facility [Member]		
Interest rate	6.80%	
Credit facility, interest payable monthly	$ 147,000	

XML 83 R72.htm IDEA: XBRL DOCUMENT

Note 15 - Long-term Debt - Maturities of Long-term Debt (Details) $ in Millions	Sep. 30, 2024 USD ($)
2025	$ 7.5
2026	7.5
2027	7.5
2028	7.5
2029	117.0
Total	$ 147.0

XML 84 R73.htm IDEA: XBRL DOCUMENT

Note 16 - Income Taxes (Details Textual)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Effective Income Tax Rate Reconciliation, Percent	26.40%	27.90%	26.30%	28.30%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%	21.00%

XML 85 R74.htm IDEA: XBRL DOCUMENT

Note 17 - Contingencies and Commitments (Details Textual) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Self Insurance Reserve	$ 110,204,000	$ 103,259,000

EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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{W}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{4}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{$'3MN>R7N M[Y5>I';W^_AMGQFB?D5.=^_9O#5)P@SA)400AG7LE'^\<=5X(?1=>P.[#MK?MF;M;NNNGZUO>Y^W=YA?/+Z*3R^ZNME7371W_E.L[L{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}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

7H T55J(QHX\]11EA,>0@@92 A%KDRFHEOYD.:/+C='#N8>[,)682TX# M2 5BP>S2Q%D,"VF>X(Z&#*83XK,([! -,P!BQJCI3 /LP<; MI0R8E"F#UH8JH6:,RX=X8($[XXJ=VE'&X4W(2/88%Y !QSB]0:8OOW(KS54KPZ[4&O!68#W$$HM, \09*9LT^#'@1$ M/3/HA;192AAS WIA!LAC? 1CPQD$*C'&Y]'A)&1JH0XLP_"G 9P]@%\$HF#I$ M?@L.O$N;Q\8C>!>H@!F7Y^$=G4O)X?C$Z]#@XL'.2> ,KPMYU0(\D.2^/Z*S M6Y\+&M\M^X\B^$L6- FT:OASL[^Z_N[P:/C?<;!\^VKPKNV4.JO:7$&4OK)Z2 M;O@0,ERDL.X_/ER$E$+3GZY\B3]1>0.>7P;\[1POLH']UZC3_P%02P,$% M @ 8(=G6=PO>!<\ P + < !D

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}^.PPF/ M8>+6 !6(=F^+:JR2#U(@F#U7Y3"F[]1], B(11]M1]<4I1#/8-A/XH,@MF][M[[G@33>P@PU[=46$QSU")6MJ-9:I8=L:AW[# _[:U)S?=Y$YQ\]PR MDID*.P MVF'5G&UYS0VG>*9MU!D25\ %HZWH+D)$SBR?/$I#9[49)/>:G M83:QY^4&6",[.ZG0550X3EP0%FH#5X0WSR+X8;+IO?#,Z@ZMQJJC7<&WULA3 M/TVGPQI%IY3-;:5RC?4JB?PDRPCULQ1'Y__W\AU,$S^'&PO=V]R:W-H965T:.EL$9%(C:3B;'_]CI2L.)UCH_#7J0C>??= M=\<[DLN#5^Z1C3PU#9"K[S:F.XJ"'198\OT3'8H:&4G56^CJTUJ]W";,QP/^D0&A+E6R@<[^*5: M>:.$EA V6QB(P^CWB-3:.!2(:?XZ8WN32&I[*1_3W+G:*9*1OMOG 8=)/8@[+71K:C,3%HN1C^[&G,PXG!(GS% M(!X 8L=[<.18OF.&K9=*'D!9;4*S@@O561,Y+NRFW!M%JYSLS/I6&H0"?H(; MI@07>PUWJ."^9@J7@2$'5BTH1[#_!:_ E; 1RE,K>%&5%B]M ^(V,0N/K+; MQ!@$OF:)`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·9EK?\,?[ZFP8,B!9R](Q M!X'7K;R2=W^ M,,!N D,BE&=#)(F5YE8.SW_\(BMG MCD1;[3KKIR^=DXH=49PL,`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}Y3WFF@:Y>NW0*@D*@GF6QE 2WLT3#MPHR8,PCP\O3B.L1?3Y M^P+)MD:DJ<97V9WBCYS>CY"GNDI LS77!-23TG5P'9CRWG7@S8D]O37MOZH/ M^];:-].'7AB G@S^1.>"B(C64IC>$)-PV@_B\V%V,C2?I#$Q2#B:C?Q}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}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·)!*[(-#X?TI35W1SN#E:U?O8ME:5)ZKA_MAK.?4$L#!!0 (&"'9UGYR)K)-@((% 9 >&PO=V]R:W-H965T[#8A]H M:203H4@M2N]'RG]+/9(%IX+84TBV!C;749AB;=M8,G,0%4HZ217NF26MKH(3:619=ZH%&$219.P9%P&R{F7/>CE7&VMX!(?-)AM M63+]MD*A=HL@#O:";[S86"<(E_:*%?B(]L_J0=,N;%$R7J(T7$G0F"^"Z_AR M-7+Z7N$[QYTY6H/S9*W4L]M\SA9!Y BAP·0Z!$:?%[Q!(1P0T?BWP0S:*YWA M\7J/?N=])U_6N:* $G_QS&X6P2R #'.V%?:,VGW"Q1^QPTN5,/X7=K7N, H@ MW1JKRL:8&)1L!C",^!!$R>@$WK!U=>CQAB=<_6 5 MW'')9,J9@$?++%*)6=/E;PTWZH9SW7)I*I;B(J!V,*A?,%B^?Q=/HJL39$9_NLEMW{^,)7%\Y8LA<\)4 M41<::T#E8#<(N1+4S5P6< X9K9DVP"4=J:UA,C.]SY*,T5C0%&!@%BB9%.DU MZC:C<,_L5G/[UG5VBVDCB,UDV+O1F'$+.4NY(*,^W=><4;$WMA8(I2L_\0,? MF>9.T(?)8';FK"_@-XA'TWX41;1JO.M]06.HQ;2F_$.EM)\2Y]/^F+0^M%I/ MRE*AB+8Y?#P(;GCA%5LX^$/"};:@CH6.\J@/.0T<"HI&!,.?83",SF P&9]U M>#R KY]N/-3TBL*\%KQ@CI"!+;63]E%O0G#7A "81CHU2#Y@-H"G#A5*C*7) M;)I10F.7}JFO 9+7^)0OV#&MF;0OFQ(117<3PQ36B*[%FJ@[@VF__'RWZ]="L*+2[E9)?%Q-YX"Q$ M5Q'3"U87K^/847/GQQ7\H7?4"&UW]$AQ3#GW1>(VD\ R>EC.#LL+B& ?>$TA M'0JQ:TB$1X,1%WXYXIBI+,2UC.]E;8OXG7]$!S4Z^?TGNG"Q5=@3J;18#H. M0-=/5+VQJO+/PEI92H!?,NA51^T4Z#Q7-"":C;N@_9^P_]02P,$% @ M8(=G6>(&&F*. P .@@ !D !X,"]W;W)K&UL MM59+<]LV$/XK.^RXO<@B12F.XTJ:B9QZFD-:3^2TATX/$+D448, X!Z /ON M@A1-=V3=>A'QV/WVVP=V-=\;^^Q*1 -'2^2FWB$KOZ[LX=EF)E7!C4Z.FF\+8 M2GC:VFWL:HLB#TJ5BM,DN8DK(76TG(>S1{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{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|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{{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{^*UM:Z@>AB*DZ/YL]X MW#*%CZ-J4_<6XH!D3$40X9QR\7 M#KPL95@0_Q$?P3C28)_?5]FZUM_:+B??O>/K<*%H=[^:';CO%JZ.T_[6?&$= M[I7%O"=8M*AI8@6ZT*RGL6)'4L7IYS'-Z6JH_$B:KQVW.!#Q_%SSYKP_L& M^XCJ:H\6#C)O4-3):50B]VC9ZPD#YC(/Y0RT:U#^CSLRM',5*K1U34B.'#A% MT:5$UZX R6S444DUMILBGJ1^_3<@6JAE%00#K ZG(!CI:Q4U(:.0YOC $]MB M']=]-D7]!>P&WA#64Y#A$W^8U<,F&$S^6?0!0=H554K!F*'8-O22ZUI^73%V/EZ-_1AC]2L6 MO]A'\&!)?T2E]CS+; M7<:7=UT VPTJ,Y8%BNFT%B&J#>E:>@%#

U0A1:\FCULA"4_16*69JO!/W"TIZZ_M'9_LK.P 'HWN9)8 M_"VEKM(B @14*RKJKTH I\6JW7XDT I9))_56U*LUJX34G@EJ+ZV/G# M:T^1(E/?
&!T*TCG7C:7ORCB<[E,FW!LD4*"6%2S$<6UEJ.?K M83UJ8/BY<:IT!JJA*&T,2@YVR*.VNHQ@S9(8Y3>DH44F(<=!S M\O_7;>*! &P7,& #
(3B"PE$*!_C*9TNST!BH22=\E0Q>[&I%75H4W5%@$30S M0XN(13R?E *Y J!A,6L.6D*Y3XD01}1('[=LH"1F?=B(SCSD9S4B#>_1,T M"XO9JXN+JPOZ<_[JA]#8F-
0@R9>YBHEW-M%N<$7,]GPR]9'M6(/I,,'(3E+D M6T!B>B$8^)O=%>07]P)$JE3' MS1!&0&$ S^'V?*@=II+F;61X&,])=1T3"[,PTN[Y*FMH#(H3D5+"1*!7@\I M.,-
<5;6UJFD#.AK.3N(P!5-'1)6F)IMN9Q6$+[(:?4O$!T2Z6)L-2'1[;BHD MNCT<=@TWGJ6+4]B++E]J=^] NL U.#B*%?)T=5D,U5,'84N6?1;
M^T($WJFRMNH"F&?]@_OZ-P9XQ5?ZGH_7OCE* K4,]_(QB8KO MBU&/J(&/[LLOZ^YE&JIW#3H>YKN\>N+1A%"\K4/^/-A1^3WZ!G!AA\+CV]^2
M'@\T]I[.>"@7V*\#JMD794S,'0ADM)'4_QK>KJA5@QTC)[D'S<=3V+(=*ON_M M)<3PRHP.K<$4NF_P]PZN=_3_Y>[ZKN/>3?^W41BMP)T?!0Q]#.";_>\@\O;V
M_Z'D!';D4%H8VZ_2/?'1HW6!)ZO*E M@,?-D"<$1&:7 =*X@AAML^%GS MM(O]V6CBNX)7%"GJQMY'!/[CP[L>^'+($3*ZAU\H&>]0-K%&ME,4LO2X*06L MRJLI\43_X-
,JU'>Y0[<6#@"K^X\VZ-_OB(ORV'V$YW.37JH*1>T6K.=D4MG M[#),!. J#?*9(U=N&D2D6*I:%1IQG!I$@;(8726..;M\3=*>PO,RT]R.08FX
MA)TI/V7,K9SP%P#PJ3QY^\.';'8_0DF+TR!D"L+\<@\ONZ[DNV$1'>I}^M84L M[,O"+6?J(>&_,;,YKJNVPJ"!V^A@,_0"+D]>3U0'=@8(;_&)QTX^:V5E%_V M>5J,H$+-?
QZNO:=Q7C[SB>UZWVY:DUMT&/R)ON!@/.(?AW\GH02&1^&PO=V]R:W H965TM B=XM.;,_Q.FZ!FC3(,G6#\,^T +9(B*)*DG%R7Y]CY3DN*@K M]
(M}).^>>>^Z.=]1B+^2C*A$U/-=5HY9.J75[X7DJ+[%FZERTV-#)5LB.:5K* MG:=:B.RP1G7EA;X_\VK&&V>UL'NW(_Z[_96TLH[H!2\QD9QT8#$[=*Y#"
[6B=&W\O]PW\&+D2A0 M&R$>S>*Z6#J^(805YMH@,/I[PBNL*@<$-+X,F,[!I3$\ED?T=S9VBF7#%%/}
MZC,O=+ET,@<*W+*NTG=B_QZ'>"S!7%3*_L)^T/4=R#NE13T8$X.:_T_>Q[R M\#,&X6 06MZ](\OR+=-LM9!B#})H$YH1;*C6FLCQQA3E7DLZY62G5S="(T1P M!I?
YEXXK;E,EMO"YY'3PB3W"/39<2/C GWBS@]\>V*9"]?O"T^3=8'CYX&G=_M>PI_X&D.'T6C2P5_@46W]I[Q/I /1RIK\ )P'MLSR'R70C],)[BPZIB"Q>_M-
)$*!7U\I\+KK>/3UJ9Y+E3+ I]=4_ M6'05FM+<82YV#?\?"[@NL-%\RTF\5 JUZLLH:\%G#NA+YXW^G8IUDP_5:\Y=:F!B13Q,(6UCQ6%,%Y&BJB!RDX1@;,2C_A&
(25.63+NA"ZN^\Q7X{CR9#<"-:'Z {8\!'N^SX;(:$ MJ>N'<[BA?/+AJK&C!+TF(XC=)/#A+R&*/:>@**7S$1B5YC0^26W+N 2Z#IX]
MQT2L1QBFSAN"2=PY$9IHF.30,,EDPZP[13M*'<\UUUPCL,.5-+FJD9$9)YD91;*0H=;,@)8GJ/4O<.,A,.V:I&V0SRH0UV" E!$=SZB-" M)80L"X"*ZV#F_14YB"/R%!FOOAM'
M@7%)EJ$1",F?Q2?K[!V]937*G7VQZ7:,X=(_:X?=PT?!9?\6OJKW7Q0?F=SQ M1E%[;,G4/T^IA+)_I?N%%JU]&3="TSMKQ9(^;% .!3K?"GH2AH5QQDDH-=C>VVATX.
M$+D2.28!!H LY]]W 5*,/95UR0'$XN,]O%TLEO.#5(^Z1#3PW-1"+[S2F/8R M"'1>8L/UA6Q1T,I6JH8;&JI=H%N%O'"@I&XBQM*@X97PEG,WMU;+N=R;NA*X
M5J#W3! "RU5B][L-?U=XT"]LL)YLI'RT@R_%PF-6$:.8&\O J7O"*ZQK2T0ROO6< MWG"D!,ZTC^R?G._DRX9KO)+U/U5ARH4W}.#_+_7YDX>/F/OS\3RY,+6[@N'
M,F\R\2#?:R.;'DP*FDIT/7_NX_ ",&5O *(>$#G=W4%.Y34W?#E7\@#*[B8V M:SA7'9K$5<)>RKU1M%H1SBQOI4%(X ^XI018AT5'H*CI+>(_M!<3,AXA% MR1F^>'
\=GSQ&<"/SK!,,#/AM8U3)__'I*^UGVT]H?2H7XZLZ M(FZPV:"BL,,MD;R]/+*78F\FAL$:V8QJ^XQ2?49=CKZ(XYP]N8S9L^[A6)/!6>&RPJYTW,QB2?6D1M,A[=<$'EL(
KNS@;DT]#ZT%5\0/ 7!NM M5?7$Z2FO^7<7GC}-20JBZ1BBR?C8]_$(F6 {]3F5M<&++LM*@VKGBJ2&7>V&Z M"C/,#O7Y0U>6?FSOBOL 5[M:*AQ2U!VD5$Y5%W!{
9&MJY(;:2ADN?,DOXQ MJ.P&6M]*>J_]P!XP_+66_P%02P,$% @ 8(=G65=[XR7# @_^04 !D M !X,"JW,W)K&UL?53+,MLP$+S[*Q9J4;2 &E&4 M9,NI;2#N
\TA:>"D{:'H@9;6EA")=$DZ3O^^2\I1DL+Q15R2\,94KN3G=*W MID*T<-\VTDR#RMK-:129HL)6F!.U04D[*Z5;86FJUY'9:!2E![5-Q!D;1JVH
M93";^+4K/9NHK6UJB5<:S+9MA?X[QT;MID$Q" M{;[BWD_F^ K5&/^%79>;#@,HML:J=@\F!6TMNU'<[^_A"2!G+P#X'L"][NX@ MK_*3L&
(VT6H'VY43FPN\58\F<;5TCW)M>-W6A+.S2V41,G@/WVR%&A9XAW*+ M!M[>B&6#YMTDLG2*RXV*/> \8^0O,((A0DE,&?@L2RR?XR-2UTOD#Q+0,9A&X!X!XAKW4VB6N4YLVPV
MT6H+VD43FYO45FLTB>/2%65A-9URPMG9M,((^C"M9)=*K5FELLU7,I4%0@? M[]A2H#F:!)9R.420[GCG#6_\!N\8KI2TN8$+F6'V&A^0QE9H_"QT'A\D7&!Y
M#+W0ASB,DP \O=9XK^,K'3!NH/&WSUZ#3O:CW54Y,25+<>K173"H_^C /KR+ M!N&G]J25EMRB'VVH*N750)!K>";S5&[ZOQ?'!^63W"FBE))Ē!9^U5;@#A\M MS(5*
[W_OXC\P:C7C..0 MQKZ?#&(:$W\0)IU+:9$L6.# EQS3+DGPXSB&H3\D1_O#Z/.Q4/%[1-% 3(M MZ>W6B2H"2:.,$SY@E45QNB(I:D37PD9(<033J0W\TIN3C).I\(=`/0O?
24#) MY!-=LBX!W%OH=NZ490+DJTNWD^HLQ!3DQG \=!83?S3HNTTGL1$ }GUBP8L> M4*!>UYW.4.Y*VJ8=M+MM,SUM>LB_*837S&]=E40N"))H>#SL>Z";
[M8LK"KK MCK)4EOI3/&PO=V]R:W-H965T2P??:QGAQ6ZR;/2O^Q)F%=%&G]Y=CG MU?71D \W#TZSQ,*)#\:3PU6Z\&>^^;3Z6.-NO-4RRPI?AJPJ2>WG1\,W_:!8 MQ?
WMAK\R?QWN7)/HR4557<:,][.C(8N ?.ZG3=208KGR;WV>1T6 \,G7.=R. MC()WKS?:?V]}AR\7:?!OJ_SO;_8LCX9N2&9^GJ[SYK2Z?N=[?W34 ZWRT/Z2
MZVZOE4,R78>F*GIA("BRLEO3FSX.=P0<>T)] *BQ=T9:E'^FC;IY+"NKDD= M=T ;O&A=;:4!+BMC4LZ:&F\SR#63DZKQO))]!4".?,+!+T)9.\\O'4X;F H;A]/>Z7'G5+QA_*$?
*C*9AG(,^7,S[Z5'P/@%J78H#P6.Q6>^=5K M(ADE@@FU0Y_<>BU,?7*'UX%T_CWF7B>M'I>.=7(05NG4'PU1",'75WXX^?DG M;M@O.["I+3:U2_OD#'4W6^>>5/--
+LBI7U5UDY4+\K[L"A&,IN3BRW,'/ZTS MY-S?-.0XKZ:7_S[FUT[+C_MUOJR].R:?L+EJ?''AZVU*!N_+%3!%(.^JPD_3 MVI.TG.$FK+*I)V_RG/S9+"%Q7C5I/CCU5[Y<^W
P.$'?V8C6_5,R(B*1E F# M*ZFI40X7^_%&.&JL&G2ZMONE97C-.>5:Q44#452,UE6G;=BV6Z-BF9B-VEY& M*D9YX@9OJP#B1^3^!FTO1(1G:9[6F0^47*-
+88FO+WSIYQGV[:$7W.&]A6$&E4P2;N"'2:BZ)$U2S!!%! !Q50A##!.'4&?PRZIP9 M_J1CFF6=FT,UM,BLN%K]R"A1F*K%<1Q'44,3Y"/QB.%#119)1"<_>YJT,.?
M3!_X282QL Y'''60$ *F'9$\08 X]$V1U_%>7H7PBLSKJMAX5960U32Q&FXY M9L@>8FJE(]B3)BR@Y.JW+\-0=9J.A$!*H3J?@>>?2HR4//L*>BTP2@*!9Y@2
ME[YI>>T_K[/F"PE^NJXSL"6T"J2@UMA^Z3$B-:@0O['3I#<=H3J(HQYD^T!H MBPOM*)-N\#T\ES^>YTHBTQ&7E)0KUO<6$L9T_=Y+A+;\]S)N"C'GN2Y4I2#
M0KW:7D8X4,SIE_!<"YB4EU1,,W% -*047JJX1M M>,XAK"7JC\;:A3:6J&=Y+AB\=II89:,(E_J6Y]:VC+!V!\,1"X/<"Y0?,L\U M2MXBU)HJPYYA.,QIE+=!]"394Y3Q2' >FY3>17
&"^WO78)'$_[[&+X'"XF$ MJ7KLAUYH4*5T]_M4940/%G4*!;V< M32(+U1:3$C1AEB0R-@;Q@EI1%E@3I@ST&4Z@QV@4@P7OT.GOUXI@%JTV,AL=
MRL9*%>CG(EI/1%.9V-&0PG>"2A6 {(*!A#ES4 M&"V)>;IZL#&VQFYYV8#0A@HDHEMV#X@>Y6B#&C2W^'R)S,2L0MERHC%GK1,/6,\3S /PF%N$UA#;?
A<)W.'3:4MZ+3 ; M >NT 3S!$%FSCY/>A0@\AE)+Z2-4L*86](+TU$>Z]:$ PY2J!@74X^/E*Z! M.K0(PY\C?$0 NW!&P=0>XIMP\%W:.#9V\%T@ Z9?
7L9W="XEN]]G/HM%>Y@.B-ZZ,+H3Y_;I]KS^ICNFWF[O#OL? MTGH1G&UL?51-;]LP#+WG5Q!>,,2 6W_&<,(D0--MV("V*]IL M.PP[* Z3")4M3Y*;]M^/DMTL])<+%
(B']^S1(ZW4CWJ#:*!YU)4>N)MC*E' M0:"-+#99,7\@:*SI9254R0ZY:![I6R)8NJ11!'(994#)>>=.QV[M3T[%LC. 5 MWBG035DR]3)#(;<3+_)>-^[Y>F/L1C =UVR-
#VB^UW>*O&^_"LN0E5IK+"A2N M)MYE-)JE MX%_."XU7LV6"4+*1^M\W4Y\4)+" 46QB(P6I[P"H6P0$3C3X?I M[4K:Q'W[%
VSTTY:%DSCE10_^=)L)E[NP1)7K!'F7FZ_8*>G;_$**;3[PK:_M[:<>%(TVLNR2B4')JW9ES]U_V$O(PS<2XBXA=KS;0H{E1V;8=*SD%I2-)C1K
M.*DNF\CQRE[*@U%TRBG/3&^E0T)N^?Q=EX86)M0<0A7XZB*R=0^0/PMB:0S+3..W_TA3 M8D5/"B(ZS/+>7!HF["/F95."L"6@9B_4XD;#,//3,.M9^2-@I6SLID)'KG*<
M>$58J V<$MXPB^"L=]>>PA,3#8)():JU&S<:"JNF[N6=8POLYOST+U!+ P04 " !@AV=9C&R +"D# "=!P &0<1 W+A=W-O MBAYH:6P)H425I.+!O^^0A%&H[F/<{C-
(:SO53/ND8T M\J*3L^]VIC^.@AT66/+]43VV-&7K50M-[14NT#W"GGE0*T(6!AF0*W:NZ%-B$46!K+P.GU M@CF,O7E++5TJAW1/V8VQ6>% .VLCV *8,VJ8,W_SU<
XG@#S\#H =_,SE/6[DLOS, M#5_,E-R#LM'$9@TGU:$IN:;S15D;15\;PIG%2AJ$ GZ!6ZZZIMMI>$ %ZYHK MA)^>^$:@_GD6& K)Q@?E@74YLK+OL!9P+SM3:
[CM*JP^X@/*\)@F>TMSR2X2 MKK&?0!SZP$*67."+C{)CQQ=?D*UAU'=.WHA.SJ MHUSKGIZ8J/BRY;DK@706?&S$8K.!/)P2>\-7
M4LCR^:]SFB[N>E[34ZT0/)025H3[Z+$EL8_XQ'(Y7L-7UQ04PU]048]#*=N6 M>E%,)1IH2&A#0D@A1*F?1)&?Y:$U65\X111,/X3?YKFSJ2)(UA1<.JZ8@+
M@1NCFLU@W $8"2MNFYT+N$,N3'UC_^,;J7JIW >X@H3YT[P@(PJ).R>C2/T\ MR68.&^<^"PK_L>"5(<6<"6)3TL2I6-)0CC7D\')R&Q1[=S%H(E\
MZ,PX/8_>X]WS:1RY[^'CQ77/U8XJ *W! TGT]0#-5X&X\+(W@W@C30TSIU9 MT_V)R@;0]ZVD:718V V.-_+B'U!+ P04 " !@AV=9"=81=H "R"@ M&0
'AL+W=OUCL@9;IF(@DNB05Q_OK=R@YCI UA (YB"*_AF MAD/..*W O5U*Z>"Q*FL['BR=6YT,A[98RDK88[V2 >XLM*F$PZ6Y&]J5D6+> M"E7ED$81&U9"U8/)J*5=F\E(-
ZY4M;PV89)NJ$F9S)DN']@_(X(EPH^Z6SA.& MD)

MC)P>F524DS50CCE92UTRI+R79'I!,NXGF74DLX$D:UE 2A60C9('18M>_=FE M?M0/,\ YH,!3.$ID+L#B/3*FYA?ZH?]^HM.?S'T+XH401,F2)VS "=?!#)\ M(]]+4/:@#V?QWP_#/QMX]N[X1M6!"4TX[$U,<#,SP:J9QXV!LG0S<"?13%2W MS,T5!LHZF/.] '.P ->Q8[2[%Y"]02P,$% @ 8(=G69#VR.1I!@ 2R\ M !D
!X,"]W;W)K&ULK5IM3^LV%/XK5C=-3&(T M2=N4,J@$3,)=''2X([MTT3?M@TM-BW23N=9P"TG[\[*0D#0ENTYTOT*0^SSD^ MCX]?GOK\F8MOZ1.
)"]QE*07O2I7_2GYRNZA >07U=W0CWU2Y0YBR%)&4^(@,5%[](^"YR1-LA;_,'@.=WZ M3'17'CG_IA\^S2]ZEHX(((@BEAJ#JWQIF$$4:2<7Q?0/:*WUJP^W/;^A!WGG5 MF4>.PHQ'?[*Y?+KTG?:(;!8TB>0]?_X=-AW* PQYE.9_R7/1=]P\AEDJ>;PQ M5L\Q2XK_]&63B"T#Q_G P-DI5_/L.#*8&@WT-AAN#X,X&HXW!:%\#=V/@YKDO MDI5GVJ.23L\%?R9"MU9H^D .5VZM$LP2/,(>I%#?,F4GIY^Y!.*07\A#,;0(M7Y 'MDS8@H4TD>0R#'F62)8LR1V/6,@@)4<>2,JBE'R!%YG1Z.?SOE2A:,!^ MN'%[5;AU/G
[(#<\D4\l\9,YS%OL/,/]Q&#?5RDH\^"\Y>'*,0(^P.]$#*QC MXEC.D'Q}\,C1CVW]FNT/,S# >#C1^#C1!&88#T(%8YM@:CD?E&-OD.,.Λ# MC*V4W$,(,$T?
(S@F,P%S)LDU3Q6Y+VH"38$FII M2$&LH3?]Z0?;M7XUI'A8IGC8/<67D5I/:!("42O3=L+;LEO@C[:S9IV.)LWT M&@/9OYL%!\,F5ZU>?4RO0=/KJ36JC:0:":.2A)&1A,]9_
A"SZSWV.)":A;(M RS5 BU;YJ4VZMQ&@ESGM#EYS-SFY.&ZS@.K&;% M!,9>'YC3<9G3L3&G,KK;% M8\)9>'YC3<9G3L3&G,KK;%9OOM M8\265.]
VU(],NFQY393,0RI.P'LZ=3'=!KL=EICX[1DX]3(1I'E?#:ZG*_S M!2$ M;_[^P;TA/5/6]*-B%VG)DPP#Q/,QP0+D,,I'$]*CB?
FM8"K9DB5J.*N9,96I&ZTH<*IJ'BN:CH@58:'66MP[C]KXS:AHOFH M: $66IW?2KJP=V@7V_RJD]WEB@J9;V1OU^JL5T[7;V6<[E_'2'K!9D!@HGD; MM'H=#]_7,:;+
NMSG.EG]AF >5&G?OB+#:7,*8(,4 %\U#1?%2T NM3FVE MRMAF6>8:TA3@F-RN0)_KU9GT&FBJ7GP!$>N:UJ=504-)COX"*MI5;K,+A[PJ
MRS:-9V!$SSY?+KG(>6S36Y6L ML95F-)A\3=5&.R+7; &FXC;[<"Q#=.:*3H<'XJ,&$F"AU5FM]*,+%BUE'=)
M:DYQD(F$R4SL.!RCBEBH:!XJFH^*%F"AU=FOE"S;+&7AU+39Q\!0TJCRU<%Q M^*AQ!%AH]1_=*UG+,S:6>>#P[$1PTDP$*KDUK)6H9UGI?K_]_@VUVV+FZ4?
4O5#0? M%2W 0JL/A$K_X*OKAF M?D/%DB4IB6"A7%DG8]4Q4=S<+AXD7^4WC1^YE#S./SX!G8/0#=3W"\[EVX-V M4-Z?G_X'4$L#!!0 (&"'9UE\H)1Y$P8 $H 9
>&PO=V]R:W-H M965TO36@(@7A ->V9OVD#L]YCS^"LO'KTQ_B+6A$CT M'D>)..^LI=R<=;MBOB9Q*${9AB3JFR7C<2C5)5]UQ8:3<)%5BJ,NMJQ>-PYI MTAF/LGOW?
#QBJ8QH0NXY$FDC3;@B,R*? M-O=<775W*@L:DT10EB!.EN>="_LLP%A7R$K\06;4@ILGV?_B>)V*O
M@GK0^@HXKX";5G#R"D[3"FY>P6U:P$TK]/(*O2SWVV1EF9Z&,AR/.'M# M7)=6:OI#ABNKK1),$]VS9I*K;ZFJ)\>W3!+DH"_H8OX]I8)FN-D2?5M3]<5=
M^()F)*&,HQOZ2I,5^C0E,J210(_D7:9A]'G4E:H96JP[ST-.MB'QD9 .^LH2 MN1,(3Q9D45/?-]/OH46?8)PA9VT=-LBC[]6OM<
M9ID9V9PBQ_JAS+2YC&.0\6%:$_SGU1R[NSZG9/INL?Z71H_$ZY[VNR%1A%9 MH-N4"]W# CJGD>J'1(B:YEX:9?4\?"8VX9R<=]1$*PA_)9WQ;[_8/>OW.J!;
M,2\3TW/PZWA@C;J@^[@X_D_CA< Q2M!<7=0W(90KM704HO7@B3R8^0'X0>7 M.BQ&X;98W$J:A@=4(,/Y/PP7 (4K0?%V4#PCE ?R2I*4H"5G,9JHF8^KU5BM M$G*-
)MGZ0/B)XC6/TH7&="&$&CEJ/#V&[W6@C,':@MJ*]?8RY^!!K^]:UN$P MJI,$_,YE>962?K7D8.BZ=K5D4%/26]7)IDNH,WVT(#_4Z*=_S47L[@O+R*N-
$C*!;IBX5)A9%NOAU(HE*I:R#86Q& M6QB]2C?V!I8SJ++H5?)FNQ8>5E%4%6W'A)ZZ^Z]!JUVZ874FP**>9#B@5 8B7:@QWM@9'V9:IV &KV M4J,M?J9)-LA.]_3=)&/.?
3(PT0L">>>U6\?+076>P;;>CPZ[f,38E+8\(<5\ M2+$ 2*S$;<[CC.6RXG[@B8237\U!-EL7T6<=O6)ER,#X 9XS9%ARDF \!%@") ME<#95O&ST/HY^_-<$S;';(@15\T5
BBU,L6]'_?VS]K0Y\K[' U# MC,;@K3%"JOF@:@&46ADC+C#BAAAO6++ZHO:3:D.JY]+[=D43,%5? !U0(HM3+8PNZQS7Y/ 7;/<,NV.@]$4DYBS71" MM*56C[?':\'+$& '%
U'U0M@%(KLRS,' OLY@ ;U^9H;=\7*W44?I.C1\] M!8WK-XX;0,4MTRNL&]OLW?QO'KBY':VY5@TDV_/Z-5A!G9^F80.HL.47W86M
M@\VV3KW#NO_N_X%$H5Y/)TS4KYCF"&UYY6K[AFW/J<$%&M6OB8H'3LU[#:BP M95R%?X/-_DWSUQ_H'S2[>WJ\0I.+A[N;Z]N+6G20IL@$5&T*JN:#J@50:N5> M4-
@_N*G]4 .%BC18>KOH_!R^V)^;(K1F"^G^:@:@&4VI9A=^_$E=K'K+*S<0+- M69K({2&8W=W=^;N+!_39P?V)?3:U:^[[]EFP/5U7R&\/\^WT-
^^8JJ=3&ULM9EMC]HX$,>_BI6K3JW4W<1Y O8 :0NZ7J5K%W7;ZXO3O3!A &N3 M.+4=V/WV9R?90$AP%RG[!N+$,V/_F+'_,>,]XP]B"R#18Q*G8F)MIRMO^J*
65BKZ=-4_^[WDJNG5-G)Z104L;1WW1'TXWN&,'<_7&$ O%# MG#68^C53W\AT1L06J1)"D;X 5:X[$D,J.TO*Z.I2A'XK1T;-E)SW%*[!):BY M!$8NG]*=HL XA4X21N-
+293.@N-J<0+_!$9/$1LPPAI&:(2QX) 1ND+PJ)2! M %$D#) ,X(@(=W)8G1Y*:*PC<@;G!#J*6"#T* F-/@%(26:N'PJR.@JRI2,
MD5U8C'XNQ3)H87$=+SQ:9TLR/<5LD!G69(9&,G-8 ^>P0I(\EMG21<7HXU(J MPS85?W2ZN/04L<%D5#,9&9GW*\G#@G=967U&;=-YB&)O5\&EY
MQ90L::S>0D"\5Z_.C5*)76:\AI?-#3V"RHRQWNB(O>[?+DS"[7JZC&M;56-!X[,6IQ>0U7C@ZS&9EW]!22B*Y4\=*T@U0K)K 9ZE=FX0V=C/\"G&K*O MJ$U0!ZV-
S6+;=#9F-KT82(>F]EHO8WW%;!X4'C2U:],496&!D#0A4FWY:T(Y MVI$X!WWRJA:F,H/*0]O.\\1>]7;E+6PD43!J+4=]12VIV4=GV_J?B,^$;V@]
MU*:U5NZ=ZX'Z#7EYN%\V),N*X^XEDY(EQ>46R JX[J">KQF3SPU]@E[_Q3+] M'U!+ P04 " !@AV=9G#6BCA8# "@" &0 'AL+W=O*-ER8!M(;!<-L'1&W:X?AGV@ MY,-
%1")=DK*S?[\3I:B.K63!]D7BR_/JLH60 MN-1@JK+D^N];+1QXH7>T\(7L!/QWN^PQ7:;_NEIIG26=F($J412H+&
M[<2["\728UW@#\$'LW)&&HE:Z4>ZLG=9N(%=4!88&9K"YQ>!YQA4=2&*(P? MK4VO$ M8XL-/,@J8U79DBF"4LCFS1_;/)P0R$X_(6H)T3DA?H' 6@)[JX>X)<1O]9"T M!"?
=;[2[Q,VYY=.Q5D?0 9JLU0.7?<>F? E9U\G*:MH5Q+/3S\HB,/@5;K(? ME3#"G9[:PO=U6%4+!G_=8KE' 1>!OJSF\?_%R8\:^)9EU ML'[62KIM)$4O2&)PKZ3-
#2SD!C<]_/GK_$K?)_2V^4X>LKQ;?2JP17NKX % MOT 41'%//+.WTUF?G/_G??&?O3]+!NL*CCE[\4L%1W,!984& MZ*AAI[FT=/B9*K'OV!O#
V>XOO\.4Y:DC)&HPVDV>V!LF(,#Y[#Y)2P,!DD< MIL]QBTO<*!V&Z:"#/4M#W*4A?C4-=TXEK)$^'&PU@^6/V%OPC:WD)(8D3=/P
M3/@E*HR#]%QW#XK%P^$9,'$)BT=AR/I5)YWJY%\/O]7*K=5B75F^+DBX@L^? M9GW*DXOLQRP^":-1?HD*@YB=Y6=^B1J-PN@,M;A$L3@8Q&?"_9,KMT2]<[W.
M0*8J.9N/H5OMVNF-ZR)GZ[?A]2SL69]3^VVZY4_S3>^^YWHGI($"M^0JN!I2 MQ+KIA\W$JKV[\-?*4OMPPYQ^(5#7 -K?*KKTVTGMH/LIF?X#4$L#!!0 (M
&"'9UD\YKWSD@, %0/ 9 >&PO=V]R:W-H965T^RXMH&'+U@!98B2-KM0[$/M'2VB4JD1])V]N]' M48IF5XKFH.J (!:I>Y{C/7>D>+,CXU_%%D"BI[*@8FYLI=Q-35-
D6RBQN&8[MH.K-FQ$22S7D&U/L..!<@\K"=*PK,$M,J+&82A;E[OIUQBO(*V&Z:"#/4M#W*4A?C4-=TXEK)$^'&PU@^6/V%OPC:WD)(8D3=/P
M3/@E*HR#]%QW#XK%P^$9,'$)BT=AR/I5)YWJY%\/O]7*K=5B75F^+DBX@L^? M9GW*DXOLQRP^":-1?HD*@YB=Y6=^B1J-PN@,M;A$L3@8Q&?"_9,KMT2]<[W.
M0*8J.9N/H5OMVNF-ZR)GZ[?A]2SL69]3^VVZY4_S3>^^YWHGI($"M^0JN!I2 MQ+KIA\W$JKV[\-?*4OMPPYQ^(5#7 -K?*KKTVTGMH/LIF?X#4$L#!!0 (M
&"'9UD\YKWSD@, %0/ 9 >&PO=V]R:W-H965T^RXMH&'+U@!98B2-KM0[$/M'2VB4JD1])V]N]' M48IF5XKFH.J (!:I>Y{C/7>D>+,CXU_%%D"BI[*@8FYLI=Q-35-
D6RBQN&8[MH.K-FQ$22S7D&U/L..!<@\K"=*PK,$M,J+&82A;E[OIUQBO(*V&Z:"#/4M#W*4A?C4-=TXEK)$^'&PU@^6/V%OPC:WD)(8D3=/P
M3/@E*HR#]%QW#XK%P^$9;'$)BT=AR/I5)YWJY%\/O]7*K=5B75F^+DBX@L^? M9GW*DXOLQRP^":-1?HD*@YB=Y6=^B1J-PN@,M;A$L3@8Q&?"_9,KMT2]<[W.
M0*8J.9N/H5OMVNF-ZR)GZ[?A]2SL69]3^VVZY4_S3>^^YWHGI($"M^0JN!I2 MQ+KIA\W$JKV[\-?*4OMPPYQ^(5#7 -K?*KKTVTGMH/LIF?X#4$L#!!0 (M
&"'9UGCSL?@0@0 (6 9 M>&PO=V]R:W-H965T&.O&%BJ)&DG;
[,\?]6'9DAC&V=@76Z3//>3A/;XB.3L0 M^I5M 3CZEF<%FQM;SLMKTV3K+>2879$2"O'+$Z$YYJ))-R8K*>"D#LHST[$L MW\QQ6AB+6=VWHHL9V?$L+6!%$=OE.:;?;R
CA[EA&\>.^W2SY56'N9B5> ,/ MP+^4*RI:9L>2I#D4+"4%HO T-S[8U['M5P$UXH\4#NSL&552'@GY6C4^>)7/#
MJF8$&:QY18'%QZ6D&45DYC/RVIT8U9!9X_']D_UN*%F$?,8$FR/].$;^?& MU$)/.%=QN_X19:09.*,TTR5G^B0XNU#+3>,4[R-EC,($^+YAM_:Q?B+$#P MR .<-L
9!GC/!+AM@'OI"%X,%%TZPJ0-J*6,C?9ZX2+,\6)&R0'1"BW8JH=Z M]>MHL5YI41GE@5/Q:RKB^.(SX8 \] OZ+$RYPCR%@J-[V$.Q R:ZVT<4I0QO M A0VN,
[OVP@X3C/V3D^^/$3H[9MWZ U*"_3[ENP8+A(V,[F87C6(N6ZGGGPNSSX M^CWGC]Q@7;D#UTDQ U D!3D#[TE!$[G]@DYVH)3]J3C6E@>QH.E:O'M41E22 MO=:
(-LDBG62Q)K)>1J9=1J9:ZOUT7,A#UW+\@?TD,,^=^L-Z/X8%H>7[@[=' M+(%9?A ^8*PDQRJ:R NQ!\L0$E:(@*@VIYGNM M([6R15K98EUL_4HYRA':6HH1?5H+
[VTRG%5A]35C3=8PYHA,_7QZ>8%@6JMJ760XM6MD@K M6ZR+K9^:T\'%_@$G%UMVF'!&95**&NX=+^**7^)JU)MG-
VHYT$U]E[+OU07Q(.^F_LZZ4MZ8^JZ]7Z!N]$W]S-WF&Z20N&,G@20UE7@4@K M;:X[FP8G97V?]T@X)WG]N 6< *T XO&UL MM5C;;N,V$/T50BV*+=!&=T5.,0.)I6
#;':#N-M]*/I RV.;B"2Z)&5G_[ZD MI,A6)"LQRGVQ16KF#,_P<"ARO*?LB6\ !'K.TIQ/C(T0VRO3Y,D&,LPOZ!9R M^69%68:%;+*UR;<,\+)TRE+3L:S
S##)C>FX[%M@TS$M1$IR>&"(%UF&V?<; M2.E^8MC&2\PQS$U^T#DRVS05F2#'),:(K8K";&M7T5VZYR M*'W^(K#G1\]
(45E0^J0:=\N)8:D100J)4!!8_NU@!FFJD.0X_JU!C2:FN,,.LYA>X%9\H*EB_A%5E M:C<-K;&Y.\[O8&15&J_X%BO2:/ MWF >[W)>,)PG@.82F21R,=6+K"]Y%59P3,8.+>MU
KMFHW#4,8NZ9HYO!1V[MN,=N)'>:([L6=;^A[@]2_R:W"& Z8^ M9CK!(IU@L2:PUMP$S=P$&F49=-.8[W3U-NN:!9==]49=,SMPNW9QC]TH]$_* M\K*A?
CE(_8'1E:Q=4HPX19\(7JAJ]AT=,C(DS4'H97;21>UJ8HX,X:'C++2ND%.60 D:\7@9VJ[7\QW49^AX;G==]QAZENUU5W:/ MH3MJEX!V'IQ#'IS!/-
Q^^O)X%UWW\AWT/'=1:T6+M*+%NM#:0 5N7ES<<);3(175J,'J;"Z+K\EKD5?^_M?36S>_HC=:%4WED&ULI59=;]HP%/TK5M2'5MJ: MQ/F""I!:8%H?NE70;L]NN)"HB

X64VRO?%WD! 1&7; M4[:P9KXE44[[QQ98#61E27?DX"%*_M)B7U)B.S=L\G([:354GAGB.QJVO"?]] Q0YC+_1>%Q;EII!ZP9^,MF0#2Y"/
MVWNN9GYG95760$7)*.*P'GO7X=4\TW@#^%'"01R-D5;RQ-BSGMRNQEZ@-X(* MB(IJWZ6*UF,O8&'5K F-MNTHNV.$KM'H2;2]GE3"_Z-!B
P_E.R%9W9)5!'5]FW_RTN;AB*#LN FX)6"; M$+]#B%I"]%$/<4N(/^HA:0E&NM]H-XF,$4DF(\X.B&NTLJ8')ON&K?)54GU/ MEI*KW5+QY.0;DX 2]!E]EP5PM(
]T!T(M;!L,@YB:WOO? :2E)6X4*C'Y0R= MGUV@,U12]%"PG2!T)4:^5+%I#W[>QC'3Q('?B2-"=XS*0J Y7<'*P9^=Y@]/ M\'V5DRXQ^#4Q_BDP25L+U$4?
$(XP+$CGNG'Z9%+SOJYG_^S]S?)B+I;$AE[M\3OV%D EJ=01YZP&U^$V]-30=6G.3](#T;^_CAC?5 R3"S0K *!T&8O$7-
M':ALF*8=ZHW*N%,9GU1Y1Z@JC:H(2J0NL:IA.=M16=(-$L#W9:ZN_AK >;D; MP\E1/#'&J;7? 0H'EK)9'Q3B+(XM_0Y4',2)6W_2Z4}.ZK^E8L<)S:'3ZY*:
M]%P/0OND^YCA8&@)[6-P$E@IFSM 0QRX9::=S/2D3%/-7,K2_ODDV%+6QT2Q M?87[F&&06<+ZF# 88+>PK!.6G13VP/1'RDRQYFVQ=NG,^A]/F&#KBDU=J'@0
M6%K[J"@.,RMKDC;B7;0-7J3/U!+ P04 " !@AV=9D"6X^V,# #T#0 &0 M 'AL+W=O;NY!L1>LJ2PYDH#DWW=E.RY '(>TY@%+J_V^E79WI-WA M3JIO.@$PY"
[E0H^YXF-$U+,%< M9PN%,[=BB5D*0C,IB(+5R#GW!O/ ZN<*7QGL]-Z8V)/<2/G-3C[$(Z=C-P0< M(F,9*'ZV, '.+1%NX[;D="J3%K@_?F"?
Y6?'L]O0#1/)_V6Q24;.7PZ)844W MW*R1N_=0GJ=O^2+)=?Y/=H5N'Y6CC38R+<&X&Y2)XDOO2C_L_9"G* 7 /]0 M0+<$=!\#>\+ >B6@=ZB%?@GH'VHA*
'!H8"S$G"6!ZOP;AZ:D!HZ'BJY(\IJ M(YL=Y/-T1@1)FPF+HW"588X,[Z2!DA WI(K*=YB?BMJF%B3#R*2*9"C$ QE M7)_X,YL*#]&Q>ME2([>'
]=@^8MB1N5IBX*4_XSICQR*85)-)F*&.(-_*09 MWWT)/VW&OVO N^BVRG?^@^\N_$;"GU2]9GS?
#0X@JUW4;0M&MTKB,_6>X5LH&0'$FJR43,F2T/F[+KYMDDT//,'LJ=XCC7E+V_HICKTJCKW&.,[Q[21'GZ36 MQP0?JM<'LO?D>![F]]-/M5[I!&^J#$]T-;L1:9YHU-
^T>7]RN7]1I>_QXL^ MH@K(^1I$=$\P %=4)UO&.9S@Q2$:U_KN$}.4_W5>,[3PRDR>M$D6MDDV M;9-LUB;9O*6RGQ(HJ!(H:$R@Z>V&F7MR':2:1,58.6]
&:U5S0C[O!"B=L(PL M0$4HPMJV+GT:^5^;/FV2A6V23=LDF[5)B_(WNW?4*?]ZHXJLL+=*S)34.N\ M?] DDAMABH>ZDE8MRGE>F3^23[Q!Z-7(I]Y@5G0@/^B+?
NB2JC43FG!8H:G. MZ1FFNRIZC&)B9):7N#?28,&<#Q-LRT!9!5Q?22QSRXDU4#5ZX^]02P,$% M @ 8(=G6;S7:J>) P A0P !D !X,"]W;W)K&ULI5?;;MLX$/T50KM8M$
37:R+G;4 -+[LID"+H&Z[SXPUMHE*I$K2=K-? MOT-)T3HAK2:M'VR*.N<,>304<6\ZKN=NY70L]KI@<&XE4?NRI/+^ M&@IQG'BA]S#QD6UWVDSXTW%%M[
"_;FZE7CE=RHY*X$)CB1L)EX;\.K96,P M-> +@Z,Z&1.SDSLAOIJ+FWSB!69!4,!:&P6*/P>805$8(5S&MU;3ZT(:XNGX
M07U9[QWW,*2L:;7_J]]>&$@#IN0M02HN<2!BUA\)00GR'$+2%^,H2D)23/C9"V MA+3VOC&K=GI.-9V.I3@2:="H9@;UXZK9:##C)K%66N)=ACP]_2
TD)1B@UHO/Z,W9@>7 M2Z89*%=")L8TU?Q* M570 $P_+M0)Y & ZQV]A&OSI>IJ-6%J+F4I^F(;I-PY'OM2_I[$MZ[5M\VS-]C^81H))CK:S3<8]>&)<.1;:Y#;12? S?M
MS$U[S?T+C_S#,7?8BOE:47[OLC2U#Q_6-VOAL]1:.^%.C?HA8V AGK&6?TB-[MLLZ>K->>3T+3@O!';^KSI[A7ZZ59EMG%*'+L>>[!:/,SC,;%\;#U${(I0,8
MA;A**]7\DS:I!+FM&UJ%.;/GNGD?=;~S_RV;A6?S,_"JWGHF%]@C]XN$] / M-PWZ>RJWYEU5P 9#!9>6/G/9-+ W-A195W.3=*8TM7SW&UL?
5/;;MLP#/T5PD\;L$6.DZQ;X1AHV@W;0[>@ MV>59L6E;]"Z>1"?MWT^2'2\#EK[8XN4<'HI4?C3VT;6(!$]*:K=.6J+NFC%7 MMJBXFY9D.M8_4QBI.WK0-TZ>9]
A37O)3V8XV<<^UD%OM)(%[]P''*7JP3*WI%1 M(]@K4$(/?_XTWL,98'X)D(V +.H>"D65=YQXD5MS!!NR/5LXQ%8CVHL3.@QE
M1]9'A<=1\=40PA6\A4WO?,@YV&'C+YT76#_/=&4^O@HZZP^A?/O-));G:2N\E>) QA-X-%^@:R-%N^P+>8VE]$ MON6E]GNU1PNFAF\=6DY"-
],%_*_=@6T5V<*^XHL9X=S >QL%@IM$S?.06EZ M3<-8)N?U#*+/^F#R_BGMM&: <2:P] 9U>^KAVV;#/=('&R>T-^3^*QJ0\3 M;4CP\=KXZ8Y&&*#]]>
(/4$L#!!0 (&"'9UDE+T]4D@L-'Q/ 9 M>&PO=V]R:W-H965T;X]]JB_/]\=VO2KUISIJ'C>;HO[V7J^KYXL9 MG;T<^+RZNV^[_/+\X?
B3E_I]LO#I]\FQ^LW*PVNFQ651G5^O9B]A,]RU7: M-=@B_K72S\W1YZASY;JJ?N^^?+BYF)'NBO1:+]O.1&'^/>F%7]\{2^8Z_M@;
MG1W.V34_OQB_>>M\\.9ZZ+1BVK[[]5 >W\Q2V;1C;XM'M?MY^KY%[UW2';V MEM6ZV?Z-GO=8,HN6CTU;,?:.S15L5N7N?_%U'XBC!L8.;L#V#=CK!F*@ -=\W
MX*>>0>P;B%//(< MJJ[=[YO Y<5;7%Y7E?4=VAC;7NPS;ZV]8F7JNR&RA7 M,6U^79EV[>6O5:NC.'H;O7]LS$] $UWI.S,0VL8E46Y7!7K MZ$.Y&YA=
U]_BS[KAZIN5^7=2\/H3:;;8K5N?C 6OEQET9N__G ^;\VU=F>< M+_?7]7YW76S@NGCTL2K;^R;*RQM]]IG_O:II_W"P8_C!J^M<<'{'W63[I\U,T9ZMA=4X&;
M=HGOK'DHEOIB9C);H^LG/,O\VU^H(G]'40UI+ MI+]DK!=_<8B_\%F__-7, M(_F%NQNMWK?%Z@K=E;4UDHW93Q=Z]CJ^:R^/3DVI9,!O!!0)<=UV@5S0F+E> M
Z-BE \ZK0Y.J]$^_R@+K;)UN>\ I=*:)JXWKM(EB0B ;WN(E.>$ [\=Y&) M((J3P0#$AP#$W@#\HWK2=;F=8IIVM7E2 \] MD7H'W56Q+NJ5,GZ,G@UO-
O^Z3KG6I,Y=M?#F2]U;BG*>N$-FX2)IPI1RDU3F M(F6L%*$G=D0B03,8)&[SY*+%)$D9R0 .\9"%(ZXM[[3(+K7 !DS$0*\BY ,I Y M4!!Y$ 2D:$_NI4)HN,R/42+<7EX
I$E2#-T +E*F $6A M +PS)E0,1\(23SK"/*QHK66>.\H5[>("X^ R0,$0]T9 DJ*[P@4:DJX $T-(M1GWCP;)/ZJ>?
7\I:%^O5G_HFNBM691.9O+@IZM]U6URO=:3 ->%RUWZ)&+Q_K ME:G,\!!QF2)GL4)#Q$6^Y21U,U\&D%(Q,)7F ,E2X9D=+5VE7@ZVOU<,+[JM M:OTR0MKBZT
4$O>*S6T+ZA. -":.N7-*AI"<<)"*AY A:#*Y> 9@,8IY4 .S1&4Q"I)A\-@&3;S,^QI.I;?V.2L M%-):QESZ[00RT G[L,8DGLD00AKSE@*3@QS26A;46A[*6K_;"G!_*7$9#F- M
4(?2R9 B9F@%%)F!.52>IYB,%M2,'])<8*DQES.'C.>@&H* M(\6INUQ6G0&DX;^FP@;>~

#F/^%#'+;W(J MRPYJ+0MJ+0]EK=\YEEM*\?UBE@RZG"*HM2RHM3R4M7XO'&W1_/<4\4LZ=)/ M)S>,0K)Q2.Z%})VT#%?Z&>X)&Q$!5:54HIV($ E3(-C@QP58\90CI*1TF-Q+ M2VVEG]J>KF5)L(9@(00"4/@(@5+"2CE '(D!)8$2S\)GB9E^8U-SCQ!M^M)
M(.G"G8ZA3MN/N&7<,@TA:,F@ZZF#6LN"6LM#6>OO2+:,7_F9_V1!2P$ 6BFX M-1FIU0JM[@'(;N4O6.4!D"P5?>FK'PE;%RA_7T""H*7 9CU)W>2V $##&T49! M *24P4W9:!%(,EP$*UL/*\],*1G*<33P1RU0$"TSCD#0,EBL&@-'G*AGF_MLKQ?^7G_9$5+N1)J EZ5L "X&.P1T2W'5 M",6=IFLIQ$G1OD<$A/L> 7!@WR-">O<]*LMRE9_ZEA"\%%B'@/<] N3 OD> M'-CW")#>?8_*\E%UB@)\JABV-]9[R4[W>@80!1?Y]O4-OH^"BY1*@JDC!\B8 M(CC!Z
O0VL8VN[[:O<6M,8GPLV]TKH@Y'#Z^*^VG[@K17Q]_3LP4%QS-ZEN]> M!&? []Y+][&H[[HAMM:WYE3D76SZK-Z]ZFWWI:T>MN\RNZ[:MMIL/][KXD;7 M'<#\?EM5[&ULM5EM;Z,X$/XK%K68>#\9C MC_:$/K-_$=/29RRL;'A?'MAFFRY@21DYV0+J?AE16@2R^F82XM28C+)G]W0R(CL>XQ3N*6*[)
GISRN(R7YLV,;S@R]XO>'R@3D9 M;<,US(%_V]Y3<6>6*!%.(&68I(C":FQ![4N'S.([ACT[ND8RE04A#_+F M.AH;EHP(8EAR'1&*?X\PA3B62"*.?PM0H^24CL?7S^@?L^1%,HN0P93$/W#$ M-V/#-U $]W 7\R]D_PF*A#R)MR0QR_ZB?6[K#0VTW#%.DL)91)#@-Λ?/A5" M'#DXS@L.3N'@M'5P"P>WK4.O<.BU=?*ARQU,\\]$VX6\G RHF2/J+06:/(B M4S_S%GKA5!,*G%/Q*Q9^?')'." ??4 W)%U_X$ 3=_">(;>SX"'.&;H*SSQ M71C_,3*Y()1NYK(O\K!G1? 771+4KYA*$@CB!K\9VK_H<+?%(F6V3K/V5XY M2L Y;,^1:YTAQW)ZZ-M\AMZ_:\IKVA[&5<#,]$03_.]H*F*Y96FX&6[O!=P; M8 S@#'W> @TY3M=Y99RA&QPN<(SYSS/$"5H N@]Q=(;^@!"BSRDTU4G.U,^8 MY-SU.'$]W_,MRQJ9C\?"*T.2L^8%VX9+&!MB6F1 "\&8_/Z;W;?^,)*_+6N@ M8;4BHF^D"S2!58;$+X?$5P()W4ZJC\@*S1]P'$.$[G:4 MR0J=0BJ6/"P?L BM*$GD@#6-DU]
[)QS_I$B54715_W6^0!-?1=-AJ>FPI::7 MC&'&A7HW^+&CIL:.CMZ)I,H@NDKZ*EV@B:ZBJ&T=EN)62TVOQ7I73)J1D/(7
M9"UH*A_D$UW5D705]G7"0!=A5=JC+L=^Y>LO5).+4_2CS:2L1NLZ*VM%FVE% M"W2A5,FJSLO^,NU6+\FKOK@JR2MCT<-,FM#*NSW&UY UV\5;D//:.M;C*O2+&(M.9GFF7J>U]IK:D6,:44+=*%5A^?0,]KJAK/+%D@!=:;*UX3?5>MUR*#?9:GL@ M#8;.T&W:)VJR' SL87T7Q#PZ8DB KK.S'8:69)?R?$NY?
%J>'UUFIR8GSZ_L MBZG=\'PFSYNR(XT#?'Y8=1O2 4X9BF$EJ*SS@7@_:7[^D]]PLLT..!:$&ULM9=M;],Z%,>_BI6+$$C= M$N>YHZT$FZY &E"Q
,HOW?:TL4CL8+LM^_;83I9U21:@XKYIXH=S50W7-LG MLP,7WV0&H_"/(F=R[F1*E1>N*]<9%$2>\Q*8'MER41"EFV+GRE(V5BC(G=]
MSXO=@E#F+&:V;RD6,UZIG#)8"B2KHB#B[@WD_#!WL'/?\8GN,F4ZW,6L)#NX M?6Y7 K= M400YK)5Q0?1C#Y>0Y\:3UO&]<>JT,8WA\?N]]W\MO(99$0F7//]*-RJ,.ZF# M-K E5:X^\<-;:(BXV_-Y,@2C0->BT2-WUGJA*4'6'^+,N1->4K&A.%=7C+ZY $9K+EWKF MYYLK].+92_0,489N,UY)PC9RYBJMT,1QUXV:-[4:_PDU-U">H\",(-_SPP'S MRW'S*UAK[B9(M<,0"M"1T,T'_1'H(X,A\#I2;",0\9,5?!%$:I3 W?\PWJL=LZ0M9DC7,';UG M)8@]-(QG^_^#8>S5"&
[2TP=^GO3WP(=HZ4O2(%J=!AW94SXETI84L;_@^TF8#! MU0UI(O-@+$]SA'55T(F_4\D:CO'I+I$/*H[[RQ/,[PD==GR@\,H7'OQ(^'1(> M]X6'YM!X)'S4]8G"DU9X,BK\-@-]L6[UF3HD/^G+QTG[T':X&C_:T1S2-0R_N$(W&/)%HVA)-?[GG+Q I>*41 M=!%B0S"[^2G3ZP12#8%->V!G&$_C[NX>C7TB&?8>[G%OE&U9LZ]R2LP_:V
MTK>=)SHQHJYQZX;BI2T35USIHM.^9OJ[(29 MH,>W7)><3<-4GNV7QN(G4$L#!!0 (&"'9UG-T:RNN0(!8(9 M>&PO=V]R:W-H965TJ74U]'V5E<"P.A45<'-3",FP-ENY]E4E >-<.Q*@?!L&YSS#A7IJX MLX5,$U%K2C@cL)%)(U8UC>3H"[<@;>'<'UV1=:GO@ITF\%U[$_;5:2+/S.Y:< M,_"*'(O%P'-O/!C.8ROO!+X1V*J]-
,*>K(2XL9N/^<@+K$% (=.6 9O/!J9 MJ24R9OQJ.,U.I07NK^_8WSO?C2\KK& JZ'>2ZW+DO?50#@6NJ,X6VP_0^G F M^3)!E?
M%VU8V\%!6*RU8"S86,,*;+]ZU<=@#&)Y^0-@"PH>_^!% U*BYVJ(M6T#\7 UG+<"Y{C>^N\# L,9I(L4622MMV.S"1=^A3;P(M^]DJ:6Y)0:GTT]" M I$)VB.)2=\K=
")%J66 (ZFH'&A"KT!7:ZQO2-$5/V1B6^-KHM@Y^U>B:_MGO 1/1&Z$ER7"LUY#GD/?G88?WD [QN?.\?#.\,*V KDS[[\']1@V]U053B#D6?ZF0*Y
2]]_6IP'KSK"_Y+IDU>DFS^_M0F3WTA1W:8H/IFG,-701!Y?WQ69/$LV?
M)&KBY>\U.@9R[2:,0IGUIGGMW6DWQ,:N=S\XGPR&TT'/^&ULO5AM;^(X$/XK5G9U:J4>B9T7DAX@M833WH>MJN5Z^]D0 M_]$F,6L[L/?O;^RD*027K?
90OT#B//,,Y_%X)LYHS\4WN6%,H1]E4^NZ$2SXO\]*_A^[&#G>>!+OMXH/>!.1ENZ9G.FGK:/ N[DCJ=3VUX>/W,_J<)'H)94,FFO/B:9VHS=F('96Q%ZT)]X?M/K TH
MU'Q+7DCSB_8MUG/0LI:*EZTQS*#,J^:?_FB%.# 'KL!:0U(WR!XQ@A:@^"M'L+6P(3N-K$;X5*JZ&0D^!X)C08V?6'4]:@5U[I1)DK 4]SL%.3
M!ZX82M#O:$9%E5=KB1Z90/,_%0P&YTWZ(+YZ>4ZK#'TU^K,,W>V8@'Q"#W6Y M #O 37E90@(8!HF>)(#R"DUIL.P+:.G(#0/=4YDO#E.9%K8DL[J]2IFA>R&N8
MR-,\150.#J8U$LRICF<4^/6^?G+%W83VZ12'/BW)/SA+.V7: ?.\&$8\$EOE,WV[N MV\+Y?]YGO^S]2 R_RU#?\/FO\)E'"V$#DB1)L"\,3&U /PZ&87P,G%F! M& ?
A"^.1.&$G3GA6G ?HXWD%BC!$E1+YHE9T43"D.'HPI8X6Z!.CA=I,=3V; MGJ"2,@ZBGRRG*C_VV6).E&B MLZ)TA7P+A?
PP6VYT0X>JK_,DXT5!18,Q#ZTITS@:'LR/#(:]4*>G(&\0]?4X M!44#TLNGF+5]O>K.5K>,GR=4FR)))DLPN1'6+QO06KYL0&OYL@+/E*^D$R'!1.$27^#GJ)P
E'V*Y.%C,0XLNN O9=W8.^=TJ1U=+Q8 M433T25\7*](';7 /F5J1X3 B2="3Q\[!R1*7I'HX)B W[*7MU[KJ]?T_+XPIRA+U[.@H@$.^{T{TJ/BX
M[_5$<0].F"43:W.TEQ!M7:GF5;X,[3X?W)E#X(_2%K0$X>LW2G(VT M->>;@:ZS: T99C=D [EXLB0TPUS%BV/=+Q MD!0\37)XI(@568;IVQVD9#?23.V]X2E9K;ELT,?
##5[!'/CSYI&*.[UAB9,, M1(%H2\R)O{>*09LB!((>*2 8N?+4P@ M3261*. 'S:DUDA*X?_W.'I9C%V-98 83DOZ=Q'P]TOH:BF&)BY0_D=V?4(_'
ME7P125GY%^WJOH:&HH)QDM5@44&6Y 4O?JU]V ,(GG: 50.LCP#G","N ?:I M"DX_<$Y5<&N >RK JP%>Z7UE5NGT%',\E*R0U3V%FSRHHRK1 N#DUQ.K#FG
MXFDB<'S\0#@@TT]=)JO@7$Q9SA#28Z^8OH"""}20'.("IKP!!BZFHJV)&7H M&[SR J>?!?I'Y/D57GSX/=2[JD:QZ5&O?5=K6$6T;?24Y7S,TRV.(6_#3;GS0
M@=>%#XT9UKL9=U8GX1PV-\@VKI%E6$Y+/9/3X7;;<'Y-??9KZF$W? J1@)MM M\,O[69BV26?7E U5V;[C"N4]U8,8G"8&YS(Q_"7NVV*HZ-V]PFS#4#/HK.+
<#$[3G%U2 M,U0U ZM_U'ZWL=\]S_YK%'[O/=Q??UP!Z$H&T+J)NJH;EN^UK -7F4,]VPAL MI>-4970]*VAQ6&6T D^.[J MS7$*HBV*BJQ(,9=VM^U
UV@!HCN@;_BU+01/L4<7@M^DY/_/*V M?S2F?A 3OS.F1THB@)BA)249DJD@G,?B8Y#+X X06;9_&+:%T:ETYG@GER2; M]M4I'OB^IT,6TM%S_;ZZ
5ZHO(,@B:SX+RE]73BBZ63]MR +DDV#939;=NF M&H_:K><9+:^G"]56I:/O\;8RH*OR6,Q01G<5Y_'36MS\KXM#YP?VN _,P<1L
M:9^:@UEUL/Y)7QWSQ=);)3E#*2R%E''CBYE)JZ-S=&PO=V]R:W-H965TVH;R";=-@\I@KAI'XH^T#(3"Y%$+TG;N_WZ4I(CR2)%RZ@6S4.LR\QHSLQP MYE":
[BE[Y6M"!/B:I3F?66LA-E>3"8_7),/\DFY(+N\\4Y9A(4_9RX1O&,&K M4BE+)\BV_4F&D]R:3\MK#VP^I5N1)CEY8(!OLPRS;Y}(2O6=?PZ@9%A4(I\4="]KQU# HH M2TI?
BY.[UZ?Y7<@#D%?9BFO+R/]@?9&T+Q%LN:'90EAYD M25[]XJ^'0+04H-NC@ X*.*B"_??0#OBF?]OJ9,+DWPZ41(M3(5GD_C@_Z?*?]3C_X)L+H%C7P!D(U>C?F-
6OR6Q5(>ENG.L/&1K,,)ZG"B MTI[,8^\I9TT4DE9$\4XB+P,BEQ[@."47@'S9)N+;!< 992+Y1VK$E M=#*J'_M^N5#BX6YFR,W<"3>71OJ*:DC1$Z_R#$B:J6R\A?
P.J,Z5RMK7LL)Z+N!U_55 M(U;\!7IGW=I9=[SPK\A2# F^J[J* MNW.X@T8H[G.*$>D5GUW(NRG2RA0HQFX4:LV*N\U8F'DNSTE%-;NAT-7\,(8XE!YO .A[_L=
M+U4QY'M^T3YU7D:ŪEY'1RY^K(FB-B[_N2;8D[&^=JT9;!?6YXALL^8_0__^235+L&%6+5L!1Q\,! MW,FYH9,S# [8#&YHGMR/WR4)2+/P
QMU0:EBR(5]DQLVHQN:9_=_:+=0'=''Z M?JL3ZV^XL)GCT#S(;RC;4(8E-[V5,VUH5S_;/;C3_X!!:G. M]2Z/T8@@-^I;7\WDA^;1/SJ1@>JL5Z!HZ(#KPAXH#1V
9CYP1JL8G!=U]'N1 M7$E=0#HQ+^SKU@U#&:*<#:B$ZE1*8(7AE!I>QJQ('#Z\M,P"6BF$b\+\ O=_M$987*,!;*TEH7NU3KU{'A>M9&A7&95LC&7M>'O:L
TT(ML86KU()1'=I:@1 M05%DZU._&IJ!S#1C]*Z"5'ZA0%%%4 2W!E'KS<%H!&1P7E1>X?H(*>\-=&)! MT+,.44,_T&#Z,4IJ5*
[A2C^[E$0GAD*_9WN"&DJ"S)3DFG,B/G["\:O$,[!U MF$V>VSK&LG8<@(.0(#,A^1X%JGG-$ 1>=Y.B$Y.[YYY],6HX"1K\.F*4 E7I
MAMP^NPH:C5C@>SV<&36T!)EIB1Q["R$I[!66EDXSLW+5,1J+6G)5P+8FJBX+*AW/@8C-V?.=QXH8MT M^40NRS4HC1ND%6$EN:)R!9K..)
4LEHRS4!AVMF:,FZG\0B1E&+02?UV5S/] MT$4<3G&)<76$V-MT2@X/CLB!><'/7-2*EG,U$ MA-XQ",P@ZH%/7H9/(4.X;^'A+MS%\&L4#
H:!I8O>JZ&%Y=D(HH"3V6J1,8Z M)FE.I?&._I4 C_I,;ED'EM5\;>O$CT,OCH*1N^ZZ>3UO1W;8R@[?*'LBE.X3 MNN6).P*"::!A&>S)?R]H1&;4BHS>*7%
FR9KR&OJD1CVUBH:#?:T].>8W[!<[M:,4.WB26_+F"8@;R,Y_2%ZE,\SY5%'^J7^:]L7WAO[>#KF=UF>N'>Q%2U8JPF&!...]DB)61 MVU:^'6A1V6XX$QI[JPUSO/U
F@1<7PCLB,W--CV/DW^ 5!+ P04_" !@ MAV=94Y>462(# H"@ &0 'AL+W=OUBD[;&SB>9 *F#5>O%MJKLX]K :PF,;,.M/OU.S9I"B1D
MY8;8SGF/G_,:Q^[OI'K0*P!#'HN\U -O9/D$N=P./><\# M]V*Y,G; '_,7? D3,#_7=PI[?IUE+@HHM9 E4; 8>-?LXX@Y@8OX)6"G#]K$ MEC*5\L%V;N<#CUHBR&%F;
J.CRV,(,]M)N3X4R7UZCFM\+#]G/W&%8_%3+F& MD1^:PX)OZ? M_+$RXD# HC."H!($KQ6$E2!TA>[)7%EC;OBPK^2.*!N-V6S#>>/46(TH[3). MC,*W G5F^$T:
((R2#^2VW((VN$)&$U&2KUP]@.'3',@$9ALEC " 8=>%5$;\ MA3D926T(+^?DLS8"#<6A&RX4^<7S#1"Y(&.8FD,QU^1ZRT7NDN(_D$PX MZ. M<1J1ZW>8_.=D3-
Z^>4?>6((?*[G1F%_W?8.56EY_5E7U:5]5<*;]":RO2$C? MDX &48M\U"T?PPSES,G#8[F/_M8F!{7)@0KBPZ[BUZ]C&N4\5'W$Z MHXXXFU$L"X-
>.V=4<(+9C$I3QL[XF-2822=F8C%QV__'R*0Q=\A8=FID2U08L[B= M,*T)TTL(NYU,FP0TRDYW3EM4CP,MG+V:L]?)^7T+ZA5.]EKF/O6Q&9-$9^BR MFBZ[A*
[;Q>P5C,V8*,W:&1E].8-H)^7HC&F5[.@;$]0TH2=0;7%A'(9G-@D[M.!Q9)]C+>=:*QYJ?XB#,&#O%:XM+T^#T4^,?'./V#H5\%*4FN2P0"&]2K%
MM;^6[#M&KMW)/I4&[PFNN<*K'"@;@.\7$D_WJF,O"_7E&PO=V]R:W H965TG90W1+8I]GGYUY=H!Y9H&+Q[SX5-YS7CG_;K)M>3F[KZK=R_F\ M7-
WS35*^R'=*WZYS8M-4HFOQ=V\W!4\63>#_MF^K+_WRMX53[C>;I/CRFF?YX^7,FWW]P[OT[KZJ_S"_NM@E=WS)JP^[MX7X M-C^BK-_WY9IOG4*?
GLY>^6]C(.H'M!8?$SY8WGRV:E#N7,[?V MB&=\5=40B?CO@5_S+*N1A!^?6]#9<6QMW9FSVI=5OFD'"P\VZ?;P?_)O M2\3) (]]8P!I!Y"Q V@[@(X=P-
H!K&'F$$K#0YQ4R=5%D3\Z16TMT.H/#9G- M:!%^NJW7?5D5XM=4C*NN_LPK[GB>\]SY-4D+YV.2[;GSAB?EON!B>:M2_+(\
MY(23WW[3Z.:+\P=_X)GS).95DF;E4S'NPS)VGOSXU/G12,?.^_M\7R;,=7DQ MKX3?]>SS5>OCZX./Y!L^+OGNA4/=9PYQ"=,,OX:'QWPEAGO-<*H9'H^?O3-\
M+L@^,DZ.C),&CWT#[QTQJR=57SMK)+RWA&<'#[PS_OT()W[:=YF$(>G0%(,NCJ=)(8 =''6 @ >_S*LFI^)24)=O% MS,2*,
[<3,SB=Z9HC@2G,^$=F?)"9Z[S8Y44BSD@QOZF(P\!".7UZAG MSN_;W;XJG[47)P_,(Q#5-(\PP6(D,(7-Z,AFA'2VBGJ)0:-@$?J=_ &G,V4& M"4QA9G%D9F&99P3,,Q#5-
,\PP6(D,(5-SY65J(N4:2V0DFH+ZG8S#9[/E!PL M-)6=DSK=L\PV"F8;#&N:;JAH,1:.2JDLQ#VX$C=(.-*OQ(+NA1&>S9@;)#25 M&UFD>W"5?
IIN{^JZH4BW=W"B(=74+9F8:#$6FDJF+/@]N.*_M%Y7K,JCUCD M=H6>QLQS0S<,.I48{)IMZ+*B}^"2WE;MMK#**5XC=S5F7A0M2)>$*2IQ3Y;B M'ER+&YQHD
KGEIU^K2XDL[_H5NM8LZKTR'K=&U^P]\\USG_.+RW)7JB[C]2 \ MFS&'}4\%IK*M*SE;/B8?Y,&GWA5]\+F^!.<2DVHL)?

(4Z.&PO=V]R:W-H965TAZEKI\G_# M8& V;.*4K)1Z=,Z7#2J M8=)]Q:75^)8ASN9?E04R2LA[LK2J>"1WT+2ZJ'$P9*%5I:D@)W.PE'%#OL'6 MMI2?8O),"8$?HF1?F;_#D_>:"<9YIQXOO0U MOH/IEH3*$GW+_KS5C 9D05HILHSLJRI!D .F"3&FT<'VA4<^X)N69_R49*, MQJ,L? K5^3(M39/T:LC:DY,.!\A:.*>AJ7.PI&$=X@*(##2\3X_1R M+Z]3$>XL@@!=^?M@2*%:,;N_SA =3M"_W[R#^!1/4W=)_M)T=^V6ZHI)0SBL MD3(Z_X"3U=VMZ!RK&K]N*V5Q>;U9XWD%[1+P_5KARO6.*S<[/P/4$L#!!0 M (&"'9UF=<%W)) , #<+ 9 >&PO=V]R:W-H965TTE\27\WWG9A^?UHJ+1SD#4&2=)DRVK9E2\Z9MRW &*97G? X, M=R9_+ ^:.>?(G:EJ,-@@1"!1DH_I;0AR311&C&KYS3*E1JX/9XP_{) M^(Z^/%) 9?[ODC{P5#Q_/=- CTN*JL]f09}/KCE3 M,TF&+(*H!#^HQE]5X&WTOO8 MPE SZLD',/\G/A.C7B.5R^QIW\XW"]SYVW: MA_^L?2<8?G$:?, 7?XEO1@6<]*=(6@, IZ7",WG"U!*MSNKJB(M:GA2L)519ZPIMU"R*;@>^ MTE1=/YMR3D-H6U@@)8@E6)Tf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|\VS'^*M8$KUE:2[FQEK*XMXT1;B&C(H)*R!73U:,9U2J2QZ;HN! HU(I M2TUB69Z9T20W%K/RWC-?S-A&IDD.SQR)3991_L\#I&PW-["QO_$MB==2WS-7 MLX+&L3YO7CFZLILK$1)!KE(6(XXK,;&)WS_B#VM4$K\F5_M*ME+0.%&R%95BLK#((DKX[TK0Y$ M1\$YID!J!=)3L,D1!;M6L$O0RK,2ZXE*NIAQMD-<2RMK^J2,3:FM:));Q#YP)DXI,>]R-B+G&LZ;C[V&HW7NM2 M@"MEJ7:DFX!I,!E\TT?$/&OB'OE@X$Z'@:.^^+=5+N :!%O(YS-O%<7W'T,4ZZHT>;>U'0$..&FED$\"T8BY]_PI[URXGV M";?M!SZO_ZC32%]2N+Q2G4$%8E5_]J!23{KR7M2V!\'G 2$'J >]9W=LF_#[M#=U-@<1N;S6O4&M!TXP5NHGO;F4UNQ,@!GPN!R,U=[" KFL MAL'F;C \?RI'3K,5KR,WSY3'"A2EL%*JEMK.#<2K8;BZD*PHY\D7)M5T6IZN M@4; M8!ZOF)JI]PO]+ 3Q*+_ P!02P,$% @ 8(=G64\4>HE$! M!< M !D !X,"JW;W)K&ULQ5C;;N,V$/T50BV*72"Q M1$F^I;.!C;U%^Y!ND* MBJ(/M#2VA4BB2M)V\O^Q#H.8E3/K=V0F0WMLV#'22$##V@&J7RSH2PA0MZRKR;O[)(EC!)(>413Q& SMS[AFQ4>*X >\7L$1UZ[1BJ4 .5/ MZN:7<&XYRB.((1'*@LB? RPACA63}..?@M0J;2[@ ?K$ 1,.7@:S)AR6 /XC M"L5N;DTL%,*&[&/Q0(\ 0Q'04/$%-.,Z/SH68QT+!7LN:%* I0=)E.: Y+D0 MH@9PO5<,;@%PSP#8?P7@%0#OK0"_ /A:F3P4K<.*"+*8,7I$3(V6;.!"BZG1 M,OPH5?/^*)A\&TF<6/Q*!2#LHVOT*&CP=*TT# &2)G)A<:*GYAI]R=0%1U_V M@@N2AE&Z1>L7]/GN06!!Q0/'Q%E F%I ^(.:1P3QE$+&+ >+CF] @?3#VG^L-G:G2ZJY+R M#<](' +9ET.[#6XH?O\,CYL6V)&")K*#LLE1T:4):!JA5J,05R]S&9E?2X%')L.K^.+S*2YV''&Y_MZ$Z[?24R1 .0 M:%)*.F_HYNI\0K)[SJ9$5E>FM^<)R<7>7+H#:9G)6#9Z5Y?)0V1 923?14UQ=:4M/:-CK]5[?X/RT7Q,BLUW"AMB:RKL5@J[>NVVUFWNQG[M%FZC,"M3,$TU]JX$&V].\&4 X6'L.#=WS?=UIN,=.AMB:.E7 #GY'MV.F@N.6M5@+8Z:,9Y8;=7PZ&CC>N0Y&.QE3;$TJUX& M=S>Y=/R2/J3/HBUJ^'Y>?8=8=M(3D4_M&PEU!F.YTUA^1>);)KI0],U%8(H^C@(' 2&'!FLCW43%ZZ489*_J%_\"4$L# M!!0 (&"'9UGUQ]:MT , ,@2 9 >&PO=V]R:W-H965T8%#G#.7,XU!&[:R%_J 6)B]QE*B>M]!Z>>_[M*EQ S%1+ "'!D9F0,=/8E7 ?+26PJ36*({!>!&T_9CSQ^EW{[%GVNR+5$4_@ M61*5QC&3KP\0B77/H]{;@Q&?+[1YX/>[2S:',>AORV>)/;_P,N4Q)(J+A$B8 M];R/]'Y .\; SOC.8:VVVL1F0CQPW0^3WM>8"*"'$)M7##\6<$ HLAXPCC^ MR9UZQ9K&<+O]YGUHP2.8"5,P$ $??*H7/>_6(U.8L332(['^!#F@EO$7BDC9M_V2=9ST$J9P8WQ@ABGF2_{"5/Q)8!;1XQJ. <&]?<:'*#A@6:169A/3+- M^ETIUD2:V>C-&QNK#6BX8FA<.PECC*TT_W?A 9"6^0## ^2*2^0<-,B:/,-'D MZATXYBO\.+3EETC5,&$J9<3U*_GK">()R+]QZ OXD5S]?`WU-09E M7/MA'L!#%D#]2 ?TWF-!/2&U(_ZL\1\X#8?P{)&&D&9N8^I*/)1+_)1M_Z: M1_Q]P3X1LWVH-^2)O? XC0898AO/KC+H MV1HTV&(TJ 5!O,5'IS.6,Y&V"]0M-U)3P9;"7)R>WAJG!KIUL-LWNWP' M2;M TG8B>>*)+,;B@/F7C"%,$0WYN@*9F+.9#'G"DM!4XHCA(78U_CH<71[>]53]T%5WG9SM"73Z(6W0K[0"/IJ%O3C6 EHI7%<^0S MLA1?I9]M*F^[*=BH-NJ6;55QWCG@_!CEE>HW?^N:P=S0/4B@R&W$@=CL^'8+\=ILMZBT @ / @ !D!X,"JW;W)K&ULM59=3]LP%/TK5H8FD*#Y;,.8&FFT0D.""5'8'J8]N,E-8^'$F>VV]_/ M=D(6.!MUT ,2^..>XW.N?>U&.\:?1 X@T7.!2S&V8E%870-EZ M,+G6R|J6>12#]AQ5.$%S$ ^5G=<]>R6)24%E(*P$G'(QM8GJV(2ZG@3\)7 M6G3:2#N9,_:.D.]?IV*T(*"02,V U6<%$Z!4$RD9/QM.JUU2 [OM%_8KXUUY MF6,!$T:_D53F8^O<0BED>$GE/5M_AL,/4/,EC KSB]9-K&.A9"DD*QJP4E"0 MLO[BYR8/'8 ,[%X#< [%. W_\8K9496U,L<1QQMD9<1RLVW3"Y,6CEAI1Z M%V>2]UFB<#+^PB0@=XC.T TK%V<2>(&F,)=J8%9O+&+9TKTC*4A,J#A148^S M*3H^.D%'B)3H(6=+@'N$S* .(\Y19[C!3Q@DW[X M%!(%=PW]"G3Y7H@*)S"V5'T*X"NPXO?OW)'S ML<>?W_KS>_W=@!#J?'$.I,+$N*ZI759]EF''REDXW'+B;QG^'?%*7M#*"'WKEM/3")*.+ML4O5L=LE+]C.M/]A6]]WV!YJ]PU;?\)#C<=<4<#_3]%HHY\'^[/8R M':[M9__1/,*]*@U/>HU??U2 AQ+V.6TAKM. \|#9W3^9C=Z5_E+#V'K(?Q_M=1T>5M>]"O[4G]VYV_6[>HOY@I0"4<@4O3,(U8G@]5M5=R2KS'4_9U(]'J:9 MJ^<=N Y0\QE35W[3T2]{^X3L@ @ F@4 M !D !X,"]W;W)K&ULE91K,]HP%(;_BA7U0RNM MY$(NK J11M&T2G8 "9=T^&S@A5ITXLP^D >SG33*JC@+\27\[[/>Q+LM!'R M2142)Y+7JFY4R#6=ZZK=@645U#97>R84L*>JI/+BJED#W5E1R_ "\V"TI MJYPLM6MKF:7BB)Q5L)9$'M>ME3!O>"_V!Z+N3-SR!YR>N3X()HO MT/43&;^=#X,K^DJ:K]1RR.RH492?6"4I6M4_ZW+V'@2 (S@B"3A#8W"'W(IEQ2 MI%DJ14.DJ=9N9F!;M6H=CE7FHVQ0ZEVF=9A]%PC$C\@M^2;JPRV"+,D2MJ@7M5A2/DB$#143^=OMZ"4@95S?DBK"*K!CG^B6KU$4=REB[NR[H@T0G FP@7I" MIMX'$GA!2!XW2W)]=?.WC:M[ZAL+^L8"ZQN>\=5VT5B:5C6S*O.//67)1!>>M1E#3'G6]A(K'4*W*#_Z'%?:L\|(K&6.%[V!%/2NZQ)]-L:)WL<.%>5]B?1QC MM:IH@/+]9!R5]*CDGZ@? BD?8[6R>,@*W[+BVSVYR(58=:,1+[=H/]^MA-20(%5M6[\DOO,]S_F>.'?##1?/,@=0:%M0)D=.KE0Y<%V9Y%!@V>,E,+V3<5%@4VQ MO7&B9 J2'2Q_C=<#IM2@</<7^_8[VSMNI8G+&'"Z2^2M]GSD7#LHA0Q75"WXYALT]5P:OH13:9]HT\1Z#DHJJ7C1@/4)"L+]-JXV.NP! M-$\W(&@ P3$@.@$(&T#XU@Q1 XC>FN&R =C2W;IV*]P4*QP/!=\@8:(UFUE8M]2U:ZT68N2=+)?0NT3@5?^<*D-]'7]]2W@!Z!%O0.)/4U"84(D>8:LJ3#\/ M7:6S&8R;-,SCFCDXP1RB!\Y4+M&,I9!VX*?C\3=C*ZNLBTUV)4Z#LX2+J'L MH="{0($71!WGF,P=`G.5\W_99 ^<_4",L/WNH>6+3O# L@SL/[KWW=&*GC^4A,J#A148^S M*3H^.D%'B)3H(6=+@'N$S* .(\Y19[C!3Q@DW[X M%!(%=PW]"G3Y7H@*)S"V5'T*X"NPXO?OW)'S ML<>?W_KS>_W=@!#J?'$.I,+$N*ZI759]EF''REDXW'+B;QG^'?%*7M#*"'WKE M/3")*.+ML4O5L=LE+]C.M/]A6]]WV!YJ]PU;?\)#C<=<4<#_3]%HHY\'^[/8R M':[M9__1/,*]*@U/>HU??U2 AQ+V.6TAKM. \|#9W3^9C=Z5_E+#V'K(?Q_M=1T>5M>]"O[4G]VYV_6[>HOY@I0"4<@4O3,(U8G@]5M5=R2KS'4_9U(]'J:9 MJ^<=N Y0\QE35W[3T2]{^X3L@ @ F@4 M !D !X,"]W;W)K&ULE91K,]HP%(;_BA7U0RNM MY$(NK J11M&T2G8 "9=T^&S@A5ITXLP^D >SG33*JC@+\27\[[/>Q+LM!'R M2142)Y+7JFY4R#6=ZZK=@645U#97>R84L*>JI/+BJED#W5E1R_ "\V"TI MJYPLM6MKF:7BB)Q5L)9$'M>ME3!O>"_V!Z+N3-SR!YR>N3X()HO MT/43&;^=#X,K^DJ:K]1RR.RH492?6"4I6M4_ZW+V'@2 (S@B"3A#8W"'W(IEQ2 MI%DJ14.DJ=9N9F!;M6H=CE7FHVQ0ZEVF=9A]%PC$C\@M^2;JPRV"+,D2MJ@7M5A2/DB$#143^=OMZ"4@95S?DBK"*K!CG^B6KU$4=REB[NR[H@T0G FP@7I" MIMX'$GA!2!XW2W)]=?.WC:M[ZAL+^L8"ZQN>\=5VT5B:5C6S*O.//67)1!>>M1E#3'G6]A(K'4*W*#_Z'%?:L\|(K&6.%[V!%/2NZQ)]-L:)WL<.%>5]B?1QC MM:IH@/+]9!R5]*CDGZ@? BD?8[6R>,@*W[+BVSVYR(58=:,1+[=H/]^MA-20(%5M6[\DOO,]S_F>.'?##1?/,@=0:%M0)D=.KE0Y<%V9Y%!@V>,E,+V3<5%@4VQ MO7&B9 J2'2Q_C=<#IM2@</<7^_8[VSMNI8G+&'"Z2^2M]GSD7#LHA0Q75"WXYALT]5P:OH13:9]HT\1Z#DHJJ7C1@/4)"L+]-JXV.NP! M-$\W(&@ P3$@.@$(&T#XU@Q1 XC>FN&R =C2W;IV*]P4*QP/!=\@8:(UFUE8M]2U:ZT68N2=+)?0NT3@5?^<*D-]'7]]2W@!Z!%O0.)/4U"84(D>8:LJ3#\/ M7:6S&8R;-,SCFCDXP1RB!\Y4+M&,I9!VX*?C\3=C*ZNLBTUV)4Z#LX2+J'L MH="{0($71!WGF,P='G.5\W_99 ^<_4",L/WNH>6+3O# L@SL/[KWW=&*"

{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 90 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 270 356 1 false 60 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.nhccare.com/20240930/role/statement document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited Interim Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 002 - Statement - Interim Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited Interim Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 003 - Statement - Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 4 false false R5.htm 004 - Statement - Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited Interim Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Statement - Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 7 false false R8.htm 007 - Statement - Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Sheet http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Description of Business Sheet http://www.nhccare.com/20240930/role/statement-note-1-description-of-business- Note 1 - Description of Business Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Acquisition of White Oak Senior Living Sheet http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living Note 3 - Acquisition of White Oak Senior Living Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Net Patient Revenues Sheet http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues Note 4 - Net Patient Revenues Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Other Revenues Sheet http://www.nhccare.com/20240930/role/statement-note-5-other-revenues Note 5 - Other Revenues Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Non-operating Income Sheet http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income Note 6 - Non-operating Income Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Business Segments Sheet http://www.nhccare.com/20240930/role/statement-note-7-business-segments- Note 7 - Business Segments Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Long-term Leases Sheet http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases Note 8 - Long-term Leases Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Earnings Per Share Sheet http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share Note 9 - Earnings Per Share Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Investments in Marketable Securities Sheet http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities Note 10 - Investments in Marketable Securities Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Fair Value Measurements Sheet http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements Note 11 - Fair Value Measurements Notes 19 false false R20.htm 019 - Disclosure - Note 12 - Goodwill and Other Intangible Assets Sheet http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets Note 12 - Goodwill and Other Intangible Assets Notes 20 false false R21.htm 020 - Disclosure - Note 13 - Stock Repurchase Program Sheet http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program Note 13 - Stock Repurchase Program Notes 21 false false R22.htm 021 - Disclosure - Note 14 - Stock-based Compensation Sheet http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation Note 14 - Stock-based Compensation Notes 22 false false R23.htm 022 - Disclosure - Note 15 - Long-term Debt Sheet http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt Note 15 - Long-term Debt Notes 23 false false R24.htm 023 - Disclosure - Note 16 - Income Taxes Sheet http://www.nhccare.com/20240930/role/statement-note-16-income-taxes Note 16 - Income Taxes Notes 24 false false R25.htm 024 - Disclosure - Note 17 - Contingencies and Commitments Sheet http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments Note 17 - Contingencies and Commitments Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 995471 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies 27 false false R28.htm 995472 - Disclosure - Note 3 - Acquisition of White Oak Senior Living (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables Note 3 - Acquisition of White Oak Senior Living (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living 28 false false R29.htm 995473 - Disclosure - Note 4 - Net Patient Revenues (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables Note 4 - Net Patient Revenues (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues 29 false false R30.htm 995474 - Disclosure - Note 5 - Other Revenues (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables Note 5 - Other Revenues (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-5-other-revenues 30 false false R31.htm 995475 - Disclosure - Note 6 - Non-operating Income (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables Note 6 - Non-operating Income (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income 31 false false R32.htm 995476 - Disclosure - Note 7 - Business Segments (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables Note 7 - Business Segments (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-7-business-segments- 32 false false R33.htm 995477 - Disclosure - Note 8 - Long-term Leases (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables Note 8 - Long-term Leases (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases 33 false false R34.htm 995478 - Disclosure - Note 9 - Earnings Per Share (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables Note 9 - Earnings Per Share (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share 34 false false R35.htm 995479 - Disclosure - Note 10 - Investments in Marketable Securities (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables Note 10 - Investments in Marketable Securities (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities 35 false false R36.htm 995480 - Disclosure - Note 11 - Fair Value Measurements (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables Note 11 - Fair Value Measurements (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements 36 false false R37.htm 995481 - Disclosure - Note 12 - Goodwill and Other Intangible Assets (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables Note 12 - Goodwill and Other Intangible Assets (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets 37 false false R38.htm 995482 - Disclosure - Note 14 - Stock-based Compensation (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables Note 14 - Stock-based Compensation (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation 38 false false R39.htm 995483 - Disclosure - Note 15 - Long-term Debt (Tables) Sheet http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables Note 15 - Long-term Debt (Tables) Tables http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt 39 false false R40.htm 995484 - Disclosure - Note 1 - Description of Business (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual Note 1 - Description of Business (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-1-description-of-business- 40 false false R41.htm 995485 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details 41 false false R42.htm 995486 - Disclosure - Note 3 - Acquisition of White Oak Senior Living (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual Note 3 - Acquisition of White Oak Senior Living (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables 42 false false R43.htm 995487 - Disclosure - Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details) Details 43 false false R44.htm 995488 - Disclosure - Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details) Details 44 false false R45.htm 995489 - Disclosure - Note 4 - Net Patient Revenues (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual Note 4 - Net Patient Revenues (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables 45 false false R46.htm 995490 - Disclosure - Note 4 - Net Patient Revenues - Revenue Disaggregation (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details Note 4 - Net Patient Revenues - Revenue Disaggregation (Details) Details 46 false false R47.htm 995491 - Disclosure - Note 5 - Other Revenues (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual Note 5 - Other Revenues (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables 47 false false R48.htm 995492 - Disclosure - Note 5 - Other Revenues - Summary of Other Revenues (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details Note 5 -

Other Revenues - Summary of Other Revenues (Details) Details 48 false false R49.htm 995493 - Disclosure - Note 6 - Non-operating Income (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual Note 6 - Non-operating Income (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables 49 false false R50.htm 995494 - Disclosure - Note 6 - Non-operating Income - Summary of Non-operating Income (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details Note 6 - Non-operating Income - Summary of Non-operating Income (Details) Details 50 false false R51.htm 995495 - Disclosure - Note 7 - Business Segments (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-7-business-segments-details-textual Note 7 - Business Segments (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables 51 false false R52.htm 995496 - Disclosure - Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details) Details 52 false false R53.htm 995497 - Disclosure - Note 8 - Long-term Leases (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual Note 8 - Long-term Leases (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables 53 false false R54.htm 995498 - Disclosure - Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details) Details 54 false false R55.htm 995499 - Disclosure - Note 9 - Earnings Per Share (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual Note 9 - Earnings Per Share (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables 55 false false R56.htm 995500 - Disclosure - Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details) Details 56 false false R57.htm 995501 - Disclosure - Note 10 - Investments in Marketable Securities (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual Note 10 - Investments in Marketable Securities (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables 57 false false R58.htm 995502 - Disclosure - Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details) Details 58 false false R59.htm 995503 - Disclosure - Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details) Details 59 false false R60.htm 995504 - Disclosure - Note 10 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details Note 10 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details) Details 60 false false R61.htm 995505 - Disclosure - Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details) Details 61 false false R62.htm 995506 - Disclosure - Note 12 - Goodwill and Other Intangible Assets (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-details-textual Note 12 - Goodwill and Other Intangible Assets (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables 62 false false R63.htm 995507 - Disclosure - Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details) Details 63 false false R64.htm 995508 - Disclosure - Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details) Details 64 false false R65.htm 995509 - Disclosure - Note 13 - Stock Repurchase Program (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual Note 13 - Stock Repurchase Program (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program 65 false false R66.htm 995510 - Disclosure - Note 14 - Stock-based Compensation (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual Note 14 - Stock-based Compensation (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables 66 false false R67.htm 995511 - Disclosure - Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details) Details 67 false false R68.htm 995512 - Disclosure - Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details) Details 68 false false R69.htm 995513 - Disclosure - Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details) Details 69 false false R70.htm 995514 - Disclosure - Note 15 - Long-term Debt (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual Note 15 - Long-term Debt (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables 70 false false R71.htm 995515 - Disclosure - Note 15 - Long-term Debt - Summary of Long-term Debt (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details Note 15 - Long-term Debt - Summary of Long-term Debt (Details) Details 71 false false R72.htm 995516 - Disclosure - Note 15 - Long-term Debt - Maturities of Long-term Debt (Details) Sheet http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details Note 15 - Long-term Debt - Maturities of Long-term Debt (Details) Details 72 false false R73.htm 995517 - Disclosure - Note 16 - Income Taxes (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual Note 16 - Income Taxes (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-73 false false R74.htm 995518 - Disclosure - Note 17 - Contingencies and Commitments (Details Textual) Sheet http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-details-textual Note 17 - Contingencies and Commitments (Details Textual) Details http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-74 false false All Reports Book All Reports nhc-20240930.xsd nhc-20240930_cal.xml nhc-20240930_def.xml nhc-20240930_lab.xml nhc-20240930_pre.xml nhc20240930_10q.htm nhc01.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 93 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nhc20240930_10q.htm": { "nsprefix": "nhc", "nsuri": "http://www.nhccare.com/20240930", "dts": { "schema": { "local": ["nhc-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["nhc-20240930_cal.xml"] } }, "definitionLink": { "local": ["nhc-20240930_def.xml"] } }, "labelLink": { "local": ["nhc-20240930_lab.xml"] } }, "presentationLink": { "local": ["nhc-20240930_pre.xml"] } }, "inline": { "local": ["nhc20240930_10q.htm"] } } }, "keyStandard": 302, "keyCustom": 54, "axisStandard": 22, "axisCustom": 0, "memberStandard": 28, "memberCustom": 31, "hidden": { "total": 46, "http://fasb.org/us-gaap/2024": 33, "http://xbrl.sec.gov/ecd/2024": 4, "http://xbrl.sec.gov/dei/2024": 6, "http://www.nhccare.com/20240930": 3 }, "contextCount": 270, "entityCount": 1, "segmentCount": 60, "elementCount": 529, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1186, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.nhccare.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "longName": "001 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Interim Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R3": { "role": "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited", "longName": "002 - Statement - Interim Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "shortName": "Interim Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R4": { "role": "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "003 - Statement - Interim Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Interim Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody",

"table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R5": { "role": "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "004 - Statement - Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "005 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Interim Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef", "d_2024-01-01_2024-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R7": { "role": "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited", "longName": "006 - Statement - Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R8": { "role": "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "longName": "007 - Statement - Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "shortName": "Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-", "longName": "008 - Disclosure - Note 1 - Description of Business", "shortName": "Note 1 - Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "009 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "longName": "010 - Disclosure - Note 3 - Acquisition of White Oak Senior Living", "shortName": "Note 3 - Acquisition of White Oak Senior Living", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "longName": "011 - Disclosure - Note 4 - Net Patient Revenues", "shortName": "Note 4 - Net Patient Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "longName": "012 - Disclosure - Note 5 - Other Revenues", "shortName": "Note 5 - Other Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:OtherRevenuesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:OtherRevenuesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "longName": "013 - Disclosure - Note 6 - Non-operating Income", "shortName": "Note 6 - Non-operating Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-", "longName": "014 - Disclosure - Note 7 - Business Segments", "shortName": "Note 7 - Business Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "longName": "015 - Disclosure - Note 8 - Long-term Leases", "shortName": "Note 8 - Long-term Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:LesseeOperatingAndFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:LesseeOperatingAndFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "longName": "016 - Disclosure - Note 9 - Earnings Per Share", "shortName": "Note 9 - Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities", "longName": "017 - Disclosure - Note 10 - Investments in Marketable Securities", "shortName": "Note 10 - Investments in Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements", "longName": "018 - Disclosure - Note 11 - Fair Value Measurements", "shortName": "Note 11 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets", "longName": "019 - Disclosure - Note 12 - Goodwill and Other Intangible Assets", "shortName": "Note 12 - Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "longName": "020 - Disclosure - Note 13 - Stock Repurchase Program", "shortName": "Note 13 - Stock Repurchase Program", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "longName": "021 - Disclosure - Note 14 - Stock-based Compensation", "shortName": "Note 14 - Stock-based Compensation",

"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "longName": "022 - Disclosure - Note 15 - Long-term Debt", "shortName": "Note 15 - Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes", "longName": "023 - Disclosure - Note 16 - Income Taxes", "shortName": "Note 16 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments", "longName": "024 - Disclosure - Note 17 - Contingencies and Commitments", "shortName": "Note 17 - Contingencies and Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": null, "uniqueAnchor": null }, "R27": { "role": "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables", "longName": "995472 - Disclosure - Note 3 - Acquisition of White Oak Senior Living (Tables)", "shortName": "Note 3 - Acquisition of White Oak Senior Living (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables", "longName": "995473 - Disclosure - Note 4 - Net Patient Revenues (Tables)", "shortName": "Note 4 - Net Patient Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables", "longName": "995474 - Disclosure - Note 5 - Other Revenues (Tables)", "shortName": "Note 5 - Other Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:ScheduleOfOtherRevenuesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nhc:OtherRevenuesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:ScheduleOfOtherRevenuesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nhc:OtherRevenuesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables", "longName": "995475 - Disclosure - Note 6 - Non-operating Income (Tables)", "shortName": "Note 6 - Non-operating Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables", "longName": "995476 - Disclosure - Note 7 - Business Segments (Tables)", "shortName": "Note 7 - Business Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables", "longName": "995477 - Disclosure - Note 8 - Long-term Leases (Tables)", "shortName": "Note 8 - Long-term Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:LesseeLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nhc:LesseeOperatingAndFinanceLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "nhc:LesseeLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nhc:LesseeOperatingAndFinanceLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables", "longName": "995478 - Disclosure - Note 9 - Earnings Per Share (Tables)", "shortName": "Note 9 - Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables", "longName": "995479 - Disclosure - Note 10 - Investments in Marketable Securities (Tables)", "shortName": "Note 10 - Investments in Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables", "longName": "995480 - Disclosure - Note 11 - Fair Value Measurements (Tables)", "shortName": "Note 11 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables", "longName": "995481 - Disclosure - Note 12 - Goodwill and Other Intangible Assets (Tables)", "shortName": "Note 12 - Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables", "longName": "995482 - Disclosure - Note 14 - Stock-based Compensation (Tables)", "shortName": "Note 14 - Stock-based Compensation (Tables)", "isDefault": "false", "groupType":

"disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables", "longName": "995483 - Disclosure - Note 15 - Long-term Debt (Tables)", "shortName": "Note 15 - Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual", "longName": "995484 - Disclosure - Note 1 - Description of Business (Details Textual)", "shortName": "Note 1 - Description of Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "nhc:NumberOfSkilledNursingCenters", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "nhc:NumberOfBeds", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R41": { "role": "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995485 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "longName": "995486 - Disclosure - Note 3 - Acquisition of White Oak Senior Living (Details Textual)", "shortName": "Note 3 - Acquisition of White Oak Senior Living (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "nhc:NumberOfSkilledNursingCenters", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-08-01_2024-08-01_BusinessAcquisitionAxis-WhiteOakSeniorLivingPortfolioMember", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R43": { "role": "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "longName": "995487 - Disclosure - Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details)", "shortName": "Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-08-01_BusinessAcquisitionAxis-WhiteOakSeniorLivingPortfolioMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R44": { "role": "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details", "longName": "995488 - Disclosure - Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details)", "shortName": "Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_BusinessAcquisitionAxis-WhiteOakSeniorLivingPortfolioMember", "name": "nhc:BusinessAcquisitionsProformaNetOperatingRevenuesAndGrantIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_BusinessAcquisitionAxis-WhiteOakSeniorLivingPortfolioMember", "name": "nhc:BusinessAcquisitionsProformaNetOperatingRevenuesAndGrantIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "longName": "995489 - Disclosure - Note 4 - Net Patient Revenues (Details Textual)", "shortName": "Note 4 - Net Patient Revenues (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-MedicareAndMedicaidMember", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R46": { "role": "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "longName": "995490 - Disclosure - Note 4 - Net Patient Revenues - Revenue Disaggregation (Details)", "shortName": "Note 4 - Net Patient Revenues - Revenue Disaggregation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "nhc:RevenueFromContractWithCustomerIncludingAssessedTaxPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R47": { "role": "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual", "longName": "995491 - Disclosure - Note 5 - Other Revenues (Details Textual)", "shortName": "Note 5 - Other Revenues (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "nhc:NumberOfSkilledNursingCenters", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_ProductOrServiceAxis-WorkersCompensationRevenueMember", "name": "us-gaap:InsuranceServicesRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "nhc:OtherRevenuesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R48": { "role": "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details", "longName": "995492 - Disclosure - Note 5 - Other Revenues - Summary of Other Revenues (Details)", "shortName": "Note 5 - Other Revenues - Summary of Other Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nhc:ScheduleOfOtherRevenuesTableTextBlock", "nhc:OtherRevenuesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nhc:ScheduleOfOtherRevenuesTableTextBlock", "nhc:OtherRevenuesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual", "longName": "995493 - Disclosure - Note 6 - Non-operating Income (Details Textual)", "shortName": "Note 6 - Non-operating Income (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2024-01-01_2024-01-31", "name": "nhc:ProceedsFromSaleOfUnconsolidatedCompany", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-HomecareAgencyInNashvilleTennesseeMember", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["p", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R50": { "role": "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details", "longName": "995494 - Disclosure - Note 6 - Non-operating Income - Summary of Non-operating Income (Details)", "shortName": "Note 6 - Non-operating Income - Summary of Non-operating Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "nhc:DividendsAndOtherNetRealizedGainsAndLossesOnSalesOfSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "nhc:DividendsAndOtherNetRealizedGainsAndLossesOnSalesOfSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-details-textual", "longName": "995495 - Disclosure - Note 7 - Business Segments (Details Textual)", "shortName": "Note 7 - Business Segments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": null,

"uniqueAnchor": null }, "R52": { "role": "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details", "longName": "995496 - Disclosure - Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details)", "shortName": "Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R53": { "role": "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "longName": "995497 - Disclosure - Note 8 - Long-term Leases (Details Textual)", "shortName": "Note 8 - Long-term Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nhc:LesseeLeaseLiabilityMaturityTableTextBlock", "nhc:LesseeOperatingAndFinanceLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_LeaseContractualTermAxis-BothNHILeaseAgreementsMember", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "nhc:LesseeOperatingAndFinanceLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R54": { "role": "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details", "longName": "995498 - Disclosure - Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details)", "shortName": "Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nhc:LesseeLeaseLiabilityMaturityTableTextBlock", "nhc:LesseeOperatingAndFinanceLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "nhc:LesseeLeaseLiabilityMaturityTableTextBlock", "nhc:LesseeOperatingAndFinanceLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R55": { "role": "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual", "longName": "995499 - Disclosure - Note 9 - Earnings Per Share (Details Textual)", "shortName": "Note 9 - Earnings Per Share (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details", "longName": "995500 - Disclosure - Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details)", "shortName": "Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R57": { "role": "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual", "longName": "995501 - Disclosure - Note 10 - Investments in Marketable Securities (Details Textual)", "shortName": "Note 10 - Investments in Marketable Securities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "nhc:EquitySecuritiesFvNiGrossUnrealizedGain", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "nhc:EquitySecuritiesFvNiGrossUnrealizedGain", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R58": { "role": "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "longName": "995502 - Disclosure - Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details)", "shortName": "Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EquitySecuritiesFvNiCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "nhc:MarketableSecuritiesAvailableforsaleAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R59": { "role": "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details", "longName": "995503 - Disclosure - Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details)", "shortName": "Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details", "longName": "995504 - Disclosure - Note 10 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details)", "shortName": "Note 10 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details", "longName": "995505 - Disclosure - Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details)", "shortName": "Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R62": { "role": "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-details-textual", "longName": "995506 - Disclosure - Note 12 - Goodwill and Other Intangible Assets (Details Textual)", "shortName": "Note 12 - Goodwill and Other Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "longName": "995507 - Disclosure - Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details)", "shortName": "Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true },

```
"uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R64": { "role": "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details", "longName": "995508 - Disclosure - Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details)", "shortName": "Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual", "longName": "995509 - Disclosure - Note 13 - Stock Repurchase Program (Details Textual)", "shortName": "Note 13 - Stock Repurchase Program (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:TreasuryStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:TreasuryStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual", "longName": "995510 - Disclosure - Note 14 - Stock-based Compensation (Details Textual)", "shortName": "Note 14 - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_IncomeStatementLocationAxis-SalariesWagesAndBenefitsMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R67": { "role": "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details", "longName": "995511 - Disclosure - Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details)", "shortName": "Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details", "longName": "995512 - Disclosure - Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details)", "shortName": "Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R69": { "role": "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details", "longName": "995513 - Disclosure - Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details)", "shortName": "Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R70": { "role": "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "longName": "995514 - Disclosure - Note 15 - Long-term Debt (Details Textual)", "shortName": "Note 15 - Long-term Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "i_2024-08-01_DebtInstrumentAxis-CreditFacilityMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-08-01_DebtInstrumentAxis-CreditFacilityMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details", "longName": "995515 - Disclosure - Note 15 - Long-term Debt - Summary of Long-term Debt (Details)", "shortName": "Note 15 - Long-term Debt - Summary of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_DebtInstrumentAxis-CreditFacilityMember", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "unique": true } }, "R72": { "role": "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details", "longName": "995516 - Disclosure - Note 15 - Long-term Debt - Maturities of Long-term Debt (Details)", "shortName": "Note 15 - Long-term Debt - Maturities of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual", "longName": "995517 - Disclosure - Note 16 - Income Taxes (Details Textual)", "shortName": "Note 16 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-details-textual", "longName": "995518 - Disclosure - Note 17 - Contingencies and Commitments (Details Textual)", "shortName": "Note 17 - Contingencies and Commitments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:SelfInsuranceReserve", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:SelfInsuranceReserve", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nhc20240930_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues
```

details textual"], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": ["r77", "r83"] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Amounts due to third party payors", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r64"] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Trade accounts payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r21", "r64"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r911"] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued payroll", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r67", "r778"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r37", "r155", "r620"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r22", "r23", "r84", "r162", "r615", "r663", "r664"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r15", "r23", "r470", "r473", "r529", "r659", "r660", "r889", "r890", "r891", "r900", "r901", "r902", "r903"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Capital in excess of par value", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r78", "r829", "r1032"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r674", "r900", "r901", "r902", "r903", "r973", "r1033"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Stock\u2013based compensation", "documentation": "Amount of increase to additional paid in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r41", "r42", "r408"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Other Operating Segment [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r226", "r253", "r254", "r255", "r256", "r257", "r260", "r789", "r790"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r420", "r425"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r163", "r269", "r310", "r313", "r315", "r998"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r218"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r28"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r28"] }, "nhc_AppreciationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "AppreciationMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Appreciation [Member]", "documentation": "Appreciation [member" } } }, "auth_ref": [] }, "nhc_AppreciationOfApartmentOverOriginalResidentsEntryFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "AppreciationOfApartmentOverOriginalResidentsEntryFeePercentage", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_AppreciationOfApartmentOverOriginalResidentsEntryFeePercentage", "terseLabel": "Appreciation of Apartment Over Original Residents Entry Fee Percentage", "documentation": "Percentage of appreciation added to refundable part of resident's original entry fee if apartment exceeds the original resident's entry fee." } } }, "auth_ref": [] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced

by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r807", "r830", "r914", "r919", "r920"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r120", "r133", "r158", "r189", "r222", "r229", "r255", "r259", "r307", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r463", "r467", "r502", "r611", "r706", "r789", "r790", "r829", "r862", "r960", "r961", "r987"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r151", "r165", "r189", "r307", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r463", "r467", "r502", "r829", "r960", "r961", "r987"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "label": "Total financial assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r480", "r481", "r817"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r276"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r277"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Unrestricted investments available for sale, debt, amortized cost", "totalLabel": "Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r273", "r319", "r610"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "terseLabel": "6 to 10 years, cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r917"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "terseLabel": "6 to 10 years, fair value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r282", "r605"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "terseLabel": "1 to 5 years, cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r916"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "terseLabel": "1 to 5 years, fair value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r281", "r604"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "terseLabel": "Over 10 years, cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r918"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "terseLabel": "Over 10 years, fair value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r283", "r606"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "terseLabel": "Within 1 year, cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r915"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": {

```
"http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "terseLabel": "Within 1 year, fair value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r280", "r603" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Available-for-sale securities (USD)", "label": "Unrestricted investments available for sale, debt, fair value", "totalLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r274", "r319", "r480", "r596", "r817", "r821", "r912", "r977", "r978", "r979" ] }, "nhc_BalanceSheetClassificationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BalanceSheetClassificationsAbstract", "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Classifications:" } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "nhc_BothNHILeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BothNHILeaseAgreementsMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Both NHI Lease Agreements [Member]", "documentation": "Represents information about the both leases with National Health Investors, Inc. (\"NHI\")." } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r337", "r338", "r339", "r340", "r341", "r457", "r810", "r811" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r44", "r45", "r337", "r338", "r339", "r340", "r341", "r457", "r810", "r811" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r874", "r875" ] }, "nhc_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeTax", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Income before income taxes", "label": "nhc_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeTax", "documentation": "Amount before tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income attributable to NHC", "label": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r455", "r456" ] }, "nhc_BusinessAcquisitionsProformaNetOperatingRevenuesAndGrantIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BusinessAcquisitionsProformaNetOperatingRevenuesAndGrantIncome", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net operating revenues and grant income", "label": "nhc_BusinessAcquisitionsProformaNetOperatingRevenuesAndGrantIncome", "documentation": "Total pro forma net operating revenue and grant income for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "terseLabel": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r43" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r0", "r1", "r14" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r111", "r458" ] }, "nhc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, current portion", "label": "nhc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent", "documentation": "Amount of current lease obligation assumed in business combination." } } }, "auth_ref": [] }, "nhc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, less current portion", "label": "nhc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent", "documentation": "Amount of noncurrent lease obligation assumed in business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-
```

gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "totalLabel": "Total assets acquired", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other assets", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r47"] }, "nhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued payroll", "label": "nhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll", "documentation": "Amount of accrued payroll assumed at the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax asset", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": ["r46", "r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "totalLabel": "Total liabilities assumed", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "totalLabel": "Net identifiable assets acquired", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r46", "r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Other noncurrent liabilities", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r46", "r47"] }, "nhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAsset", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease right-of-use assets", "label": "nhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAsset", "documentation": "The amount of right-of-use asset recognized as of the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit",

"calculation": { "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Total estimated fair value of the acquisition", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r47"] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": ["r112", "r113", "r114", "r115"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 0.0 }, "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r27", "r153", "r775"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r975", "r976"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "totalLabel": "Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r96", "r187"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning of Period", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, End of Period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r96", "r187"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net Increase/(Decrease) in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r96"] }, "nhc_CertificatesOfNeedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "CertificatesOfNeedMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Certificates of Need [Member]", "documentation": "Related to certificates of need." } } }, "auth_ref": [] }, "nhc_ChangesInOperatingAssetsAndLiabilitiesNetOfTheEffectOfAcquisitionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ChangesInOperatingAssetsAndLiabilitiesNetOfTheEffectOfAcquisitionsAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r102", "r351", "r352", "r759", "r950", "r955"] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Dividends declared to common stockholders, per share (in dollars per share)", "terseLabel": "Dividends declared per common share (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r104"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r849", "r850", "r851", "r853", "r854", "r855", "r856", "r900", "r901", "r903", "r973", "r1031", "r1033"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r76"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r76", "r694"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r76"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r16", "r76", "r694", "r712", "r1033", "r1034"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, $.01 par value; 45,000,000 shares authorized; 15,440,970 and 15,350,661 shares, respectively, issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable common stock

(or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r76", "r614", "r829"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income attributable to National HealthCare Corporation", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r24", "r171", "r173", "r180", "r600", "r629", "r631"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "negatedLabel": "Net (income)/loss attributable to noncontrolling interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r8", "r53", "r58", "r171", "r173", "r179", "r599", "r629", "r630"] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": ["r136"] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": ["r50", "r54", "r55"] }, "nhc_ContinuingCareContractsAndRefundableEntranceFeesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ContinuingCareContractsAndRefundableEntranceFeesPolicyPolicyTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Continuing Care Contracts and Refundable Entrance Fees, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for continuing care contracts and refundable entrance fees." } } }, "auth_ref": [] }, "us-gaap_ContinuingCareRetirementCommunitiesAdvanceFeesObligationForFutureServicesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContinuingCareRetirementCommunitiesAdvanceFeesObligationForFutureServicesAmount", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContinuingCareRetirementCommunitiesAdvanceFeesObligationForFutureServicesAmount", "terseLabel": "Continuing Care Retirement Communities, Refund Obligation", "documentation": "Amount of refund obligation under existing contract for continuing care retirement community." } } }, "auth_ref": ["r140"] }, "us-gaap_ContractWithCustomerRefundLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerRefundLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Refundable entrance fees", "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as noncurrent." } } }, "auth_ref": ["r964"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r807", "r809", "r817", "r830", "r846", "r1028"] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Total costs and expenses", "totalLabel": "Total costs and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r92"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r357", "r958"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r357", "r958", "r959"] }, "nhc_CreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "CreditFacilityMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Credit Facility [Member]", "documentation": "Represents credit facility." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r20", "r66", "r67", "r121", "r122", "r192", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r799", "r800", "r801", "r802", "r803", "r828", "r897", "r951", "r952", "r953", "r983", "r984"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r69", "r385", "r514", "r515", "r828"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r20", "r192", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r799", "r800", "r801", "r802", "r803", "r828", "r897", "r951", "r952", "r953", "r983", "r984"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss", "negatedLabel": "Realized (gains)/losses on sale of marketable securities", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r921"] }, "us-gaap_DebtSecuritiesAvailableForSaleRestricted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRestricted", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-

securities marketable securities and restricted marketable securities details"], "lang": { "en-us": { "role": { "label": "Restricted investments available for sale, debt, fair value", "documentation": "Amount of restricted investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r544", "r757", "r758"] }, "nhc_DebtSecuritiesAvailableforsaleRestrictedAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "DebtSecuritiesAvailableforsaleRestrictedAmortizedCost", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Restricted investments available for sale, debt, amortized cost", "documentation": "Amortized cost of restricted investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Marketable debt securities", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtSecuritiesRealizedGainLoss", "terseLabel": "Debt Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": ["r633", "r893", "r894"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Deferred income taxes", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r429", "r430", "r612"] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Deposits and other assets", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r885"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r11", "r36"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "us-gaap_DepreciationDepletionAndAmortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r11", "r222", "r234", "r259", "r789", "r790"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r963"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r407", "r410", "r421", "r422", "r424", "r813"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "nhc_DividendsAndOtherNetRealizedGainsAndLossesOnSalesOfSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "DividendsAndOtherNetRealizedGainsAndLossesOnSalesOfSecurities", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details"], "lang": { "en-us": { "role": { "label": "Dividends and net realized gains and losses on sales of securities", "documentation": "The amount of dividends and other net realized gains and losses resulting from the sale of securities." } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsCommonStock", "negatedLabel": "Dividends declared to common stockholders", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": ["r7", "r104"] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Dividends payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r67"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r866"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r867"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation":

~~"The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Earnings per share attributable to National HealthCare Corporation stockholders:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details"], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per common share, basic (in dollars per share)", "label": "Basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r181", "r198", "r199", "r200", "r201", "r202", "r203", "r208", "r210", "r215", "r216", "r217", "r221", "r453", "r461", "r477", "r478", "r601", "r632", "r781"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Basic:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details"], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per common share, diluted (in dollars per share)", "label": "Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r181", "r198", "r199", "r200", "r201", "r202", "r203", "r210", "r215", "r216", "r217", "r221", "r453", "r461", "r477", "r478", "r601", "r632", "r781"] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Diluted:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r207", "r218", "r219", "r220"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r433", "r814"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r191", "r433", "r441", "r814"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r423"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r423"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r864"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-", "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-details-textual", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables",~~

"http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables", "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r864"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r864"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r870"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r864"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r864"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r864"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r864"] }, "nhc_EntranceFeeDepositsRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "EntranceFeeDepositsRefunds", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Entrance fee refunds", "documentation": "The cash inflow (outflow) associated with entrance fee deposits (refunds)." } } }, "auth_ref": [] }, "nhc_EquipmentAndFurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "EquipmentAndFurnitureMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Equipment and Furniture [Member]", "documentation": "Information pertaining to equipment and furniture." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r16", "r147", "r174", "r175", "r176", "r193", "r194", "r195", "r197", "r202", "r204", "r206", "r224", "r308", "r309", "r344", "r387", "r439", "r440", "r450", "r451", "r452", "r454", "r460", "r461", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r503", "r505", "r506", "r507", "r508", "r509", "r516", "r518", "r529", "r627", "r659", "r660", "r661", "r674", "r732"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual"], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r304", "r305", "r306", "r449", "r871", "r872", "r873", "r968", "r969", "r970", "r971"] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Distributions from unconsolidated investments", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": ["r9", "r11", "r86", "r622"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage", "terseLabel": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r304"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Marketable equity securities", "terseLabel": "NHI Common Stock, fair value", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r159", "r501", "r777"] }, "us-gaap_EquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Unrestricted investments available for sale, equity, amortized cost", "terseLabel": "NHI Common Stock, Cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } } }, "auth_ref": ["r610"] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": [

```
"http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable equity securities", "label": "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r159", "r480", "r501", "r608", "r609", "r817", "r845", "r848", "r977", "r978", "r979" ] }, "nhc_EquitySecuritiesFvNiGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "EquitySecuritiesFvNiGrossUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual" ], "lang": { "en-us": { "role": { "label": "nhc_EquitySecuritiesFvNiGrossUnrealizedGain", "terseLabel": "Equity Securities Fv Ni Gross Unrealized Gain", "documentation": "The amount of gross unrealized gains from equity securities measured at fair value with gains losses reported on the income statement." } } }, "auth_ref": [] }, "nhc_EquitySecuritiesFvNiGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "EquitySecuritiesFvNiGrossUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual" ], "lang": { "en-us": { "role": { "label": "nhc_EquitySecuritiesFvNiGrossUnrealizedLoss", "terseLabel": "Equity Securities Fv Ni Gross Unrealized Loss", "documentation": "The gross unrealized loss on equity securities measured at fair value with gains and losses recognized on the income statement." } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiRestricted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRestricted", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-and-restricted-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "Restricted marketable equity securities", "documentation": "Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r544", "r757", "r758" ] }, "nhc_EquitySecuritiesFvNiRestrictedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "EquitySecuritiesFvNiRestrictedCost", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-and-restricted-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "Restricted investments available for sale, equity, amortized cost", "documentation": "Cost of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details" ], "lang": { "en-us": { "role": { "label": "Unrealized gains on marketable equity securities", "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Unrealized gains on marketable equity securities", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r634", "r925" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r35", "r830", "r857", "r858", "r859", "r1035" ] }, "nhc_ExercisePriceRange1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ExercisePriceRange1Member", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range 1 [Member]", "documentation": "Exercise price range 1 [member" } } }, "auth_ref": [] }, "nhc_ExercisePriceRange2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ExercisePriceRange2Member", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range 2 [Member]", "documentation": "Exercise price range two [member" } } }, "auth_ref": [] }, "stpr_FL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "FL", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "FLORIDA" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r375", "r400", "r401", "r402", "r403", "r404", "r405", "r479", "r481", "r482", "r483", "r484", "r490", "r491", "r493", "r533", "r534", "r535", "r800", "r801", "r807", "r808", "r809", "r817", "r821" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r480", "r481", "r482", "r484", "r817", "r978", "r981" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r486", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497", "r594", "r817", "r822" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r375", "r400", "r405", "r481", "r491", "r533", "r807", "r808", "r809", "r817" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r375", "r400", "r405", "r481", "r482", "r491", "r534", "r800", "r801", "r807", "r808", "r809", "r817" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r375", "r400", "r401", "r402", "r403", "r404", "r405", "r481", "r482", "r483", "r484", "r491", "r535", "r800", "r801", "r807", "r808", "r809", "r817", "r821" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r480", "r481", "r482", "r484", "r817", "r978", "r981" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r375", "r400", "r401", "r402", "r403", "r404", "r405", "r479", "r481", "r482", "r483", "r484", "r490", "r491", "r493", "r533", "r534", "r535", "r800", "r801", "r807", "r808", "r809", "r817", "r821" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r817", "r975", "r976", "r977", "r978", "r979", "r981" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Finance lease obligations, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r520" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments",
```

```
"crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement interim-condensed consolidated statements of cash flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Principal payments under finance lease obligations", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r521", "r523" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r311", "r312", "r316", "r317", "r318", "r320", "r321", "r322", "r383", "r386", "r475", "r498", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r545", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r628", "r796", "r817", "r819", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r830", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r921", "r922", "r923", "r924", "r974", "r977", "r978", "r979", "r980", "r981" ] }, "nhc_GainLossOnSaleOfUnconsolidatedCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "GainLossOnSaleOfUnconsolidatedCompany", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details" ], "lang": { "en-us": { "role": { "label": "Gain on sale of unconsolidated company", "terseLabel": "Gain (Loss) on Sale of Unconsolidated Company", "negatedLabel": "Gain on sale of unconsolidated company", "documentation": "Represents the amount of gain (loss) from sale of an unconsolidated company." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GeneralAndAdministrativeExpense", "terseLabel": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r89", "r716" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill", "periodStartLabel": "Goodwill, balance", "periodEndLabel": "Goodwill, balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r156", "r325", "r595", "r790", "r797", "r818", "r829", "r929", "r936" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details" ], "lang": { "en-us": { "role": { "label": "Goodwill, additions", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r328", "r797" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillAndIntangibleAssetImpairment", "terseLabel": "Goodwill and Intangible Asset Impairment, Total", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r927", "r939" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r324", "r335", "r797" ] }, "us-gaap_GovernmentAssistanceOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceOperatingIncome", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details" ], "lang": { "en-us": { "role": { "label": "Government stimulus income", "documentation": "Amount of increase (decrease) in income from government assistance, classified as operating." } } }, "auth_ref": [ "r511" ] }, "us-gaap_GovernmentAssistancePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistancePolicyTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Policy Text Block]", "documentation": "Disclosure of accounting policy for government assistance." } } }, "auth_ref": [ "r510", "r512" ] }, "us-gaap_HealthCareOrganizationRevenueSourcesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCareOrganizationRevenueSourcesAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "Health Care Organization, Revenue Sources [Axis]", "documentation": "Information by major payor source of revenue for health care organizations." } } }, "auth_ref": [ "r963" ] }, "us-gaap_HealthCareOrganizationRevenueSourcesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCareOrganizationRevenueSourcesDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "Health Care Organization, Revenue Sources [Domain]", "documentation": "Major payor source of revenue for health care organizations." } } }, "auth_ref": [ "r963" ] }, "nhc_HomecareAgencyInNashvilleTennesseeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "HomecareAgencyInNashvilleTennesseeMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual" ], "lang": { "en-us": { "role": { "label": "Homecare Agency in Nashville, Tennessee [Member]", "documentation": "Represents homecare agency in Nashville, Tennessee." } } }, "auth_ref": [] }, "nhc_HomecareAndHospiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "HomecareAndHospiceMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details" ], "lang": { "en-us": { "role": { "label": "Homecare and Hospice [Member]", "documentation": "Represents information regarding revenue derived from homecare and hospice." } } }, "auth_ref": [] }, "nhc_HomecareAndHospiceSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "HomecareAndHospiceSegmentMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details" ], "lang": { "en-us": { "role": { "label": "Homecare and Hospice Segment [Member]", "documentation": "Represents information regarding the Homecare and Hospice segment." } } }, "auth_ref": [] }, "nhc_HomecareServicesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "HomecareServicesSegmentMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details" ], "lang": { "en-us": { "role": { "label": "Homecare Services Segment [Member]", "documentation": "Information pertaining to the Homecare Services Segment." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Income before income taxes", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r190", "r432" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r127", "r132", "r602", "r623", "r783", "r789", "r905", "r907", "r908", "r909", "r910" ] }, "us-
```

gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details"], "lang": { "en-us": { "role": { "label": "Equity in earnings of unconsolidated investments", "negatedLabel": "Equity in earnings of unconsolidated investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r11", "r86", "r126", "r222", "r236", "r259", "r303", "r622"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r345", "r347", "r348", "r485", "r487", "r492", "r656", "r658", "r717", "r771", "r820", "r1000"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r347", "r348", "r485", "r487", "r492", "r656", "r658", "r717", "r771", "r820", "r1000"] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-16-income-taxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r191", "r428", "r433", "r434", "r435", "r436", "r437", "r438", "r442", "r444", "r447", "r448", "r671", "r814"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r134", "r144", "r205", "r206", "r222", "r237", "r259", "r431", "r433", "r443", "r636", "r814"] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts payable", "label": "us-gaap_IncreaseDecreaseInAccountsPayableTrade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInAccruedSalaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedSalaries", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued payroll", "label": "us-gaap_IncreaseDecreaseInAccruedSalaries", "documentation": "The increase (decrease) during the period in accrued salaries." } } }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "label": "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": ["r10"] }, "nhc_IncreaseDecreaseInDueToThirdPartyPayors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "IncreaseDecreaseInDueToThirdPartyPayors", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Amounts due to third party payors", "label": "nhc_IncreaseDecreaseInDueToThirdPartyPayors", "documentation": "The increase (decrease) during the reporting period in other obligations due to third party payors that are payable within one year (or one business cycle)." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease obligations", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r877", "r896"] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": ["r896"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Other noncurrent liabilities", "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInSelfInsuranceReserve", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued risk reserves", "label": "us-gaap_IncreaseDecreaseInSelfInsuranceReserve", "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": ["r896"] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Effects of dilutive instruments (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r211", "r212", "r213", "r217", "r409"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r336", "r340", "r342", "r798"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Indefinite-lived intangible assets",

"documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } },
"auth_ref": ["r323", "r342", "r798"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation":[
"http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details"], "lang": { "en-us": {
"role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for
example, trade names, etc. but not all inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are
similar, either by their nature or by their use in the operations of the company." } } } }, "auth_ref": ["r336", "r340", "r342", "r798"] },
"nhc_InpatientServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "InpatientServicesMember",
"presentation": ["http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details"], "lang": { "en-us": { "role": {
"label": "Inpatient Services [Member]", "documentation": "The amount of revenue derived from inpatient services." } } }, "auth_ref": [] },
"nhc_InpatientServicesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname":
"InpatientServicesSegmentMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-
related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-
reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Inpatient Services Segment [Member]", "documentation": "Information pertaining to the Inpatient
Services Segment, which includes the operation of skilled nursing facilities and assisted and independent living facilities" } } }, "auth_ref": [] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": [
"r868"] }, "us-gaap_InsuranceServicesRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InsuranceServicesRevenue", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-
details": { "parentTag": "nhc_OtherRevenues", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-5-other-
revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details"], "lang": { "en-us": { "role":
{ "verboseLabel": "Insurance services", "label": "us-gaap_InsuranceServicesRevenue", "terseLabel": "Insurance Services Revenue", "documentation": "Revenue from
insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions." } } },
"auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-
balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label":
"Intangible assets", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated
amortization and impairment charges." } } }, "auth_ref": ["r336", "r946", "r947"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-
condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited",
"http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": {
"role": { "label": "Interest", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing
accounted for as interest expense." } } }, "auth_ref": ["r222", "r229", "r233", "r239", "r259", "r513", "r789", "r790"] }, "us-
gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-
summary-of-nonoperating-income-details": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details"], "lang": { "en-us": { "role": { "label":
"Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r789", "r895", "r907"] }, "us-
gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": {
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-
gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-
sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory
expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r164", "r776", "r829"] }, "us-
gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares",
"presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-
details"], "lang": { "en-us": { "role": { "label": "NHI Common Stock, Shares (in shares)", "documentation": "Number of shares of investment owned." } } },
"auth_ref": ["r676", "r684", "r737", "r744", "r748", "r851"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InvestmentTypeAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-
sale-marketable-equity-securities-details"], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." }
} }, "auth_ref": ["r677", "r679", "r680", "r682", "r684", "r735", "r738", "r740", "r743", "r745", "r746", "r749", "r750", "r751", "r752", "r753", "r851"] }, "us-
gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentTypeCategorizationMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-
available-for-sale-marketable-equity-securities-details"], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate
income or appreciate in value." } } }, "auth_ref": ["r677", "r679", "r680", "r682", "r684", "r735", "r738", "r740", "r743", "r745", "r746", "r749", "r750", "r751",
"r752", "r753", "r851"] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables"], "lang": { "en-us": { "role": { "label": "Investments
Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other
information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit",
"calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-
gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-
balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Investments in unconsolidated companies", "documentation": "Amount of
investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": ["r886"] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities"], "lang": { "en-us": { "role": { "label": "Investments in Debt and
Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and
equity securities." } } }, "auth_ref": ["r129", "r146", "r270", "r271", "r499", "r500", "r995"] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": {
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-
gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-
statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-
segment-details"], "lang": { "en-us": { "role": { "label": "Salaries, wages, and benefits", "documentation": "Amount of expense for salary, wage, profit sharing,
incentive and equity based compensation; and other employee benefit." } } }, "auth_ref": ["r892"] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-
textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } },
"auth_ref": ["r526", "r876"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeaseContractualTermDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases",
"http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term
[Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r526", "r876"] }, "nhc_LeaseOneWithNhiMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "LeaseOneWithNhiMember", "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-
textual"], "lang": { "en-us": { "role": { "label": "Lease One With NHI [Member]", "documentation": "Represents information about the first lease with National
Health Investors, Inc. (\"NHI\")." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LegalEntityAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information",
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited",
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited",
"http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-", "http://www.nhccare.com/20240930/role/statement-note-1-description-of-
business-details-textual", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities",
"http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-
available-for-sale-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-
securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual",
"http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-
details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables",
"http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-
measurements-summary-of-fair-value-measurements-by-level-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables",
"http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets", "http://www.nhccare.com/20240930/role/statement-note-12-
goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-
intangible-assets-details-textual", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-

details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables", "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "nhc_LesseeLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "LesseeLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Liability, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating and finance lease liability." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r522"] }, "nhc_LesseeOperatingAndFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "LesseeOperatingAndFinanceLeasesTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating and Finance Leases [Text Block]", "documentation": "Disclosure for operating and finance leases of lessee." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "terseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: amounts representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r524"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r986"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label":

```
"us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r20", "r66", "r67", "r68", "r71", "r72", "r73", "r74", "r189", "r307", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r464", "r467", "r468", "r502", "r693", "r782", "r862", "r960", "r987", "r988" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r82", "r124", "r618", "r829", "r898", "r926", "r982" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r68", "r152", "r189", "r307", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r464", "r467", "r468", "r502", "r829", "r960", "r987", "r988" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilityReserveEstimatePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityReserveEstimatePolicy", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Liability Reserve Estimate, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors)." } } } }, "auth_ref": [ "r1001" ] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r49", "r427", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r967" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r20", "r122", "r997" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r65", "r70" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.nhccare.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "Credit facility, interest payable monthly", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r122", "r374", "r384", "r800", "r801", "r828", "r997" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "Long-term debt due within one year", "negatedLabel": "Less current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r160" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r899" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r899" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r899" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r899" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r899" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "Total long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r161" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r103" ] }, "nhc_ManagedCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ManagedCareMember", "presentation": [
```

```
"http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details" ], "lang": { "en-us": { "role": { "label": "Managed Care [Member]", "documentation": "Related to managed care provided by the company." } } }, "auth_ref": [] },
"nhc_ManagementAndAccountingServicesFeesRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ManagementAndAccountingServicesFeesRevenue", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details": { "parentTag": "nhc_OtherRevenues", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Management and accounting services fees", "label": "nhc_ManagementAndAccountingServicesFeesRevenue", "documentation": "The amount of management and accounting services fees revenue." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r125", "r887" ] }, "nhc_MarketableSecuritiesAvailableforsaleAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "MarketableSecuritiesAvailableforsaleAmortizedCost", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "Investments available for sale, amortized cost", "documentation": "Amortized cost of investment in marketable securities measured at fair value with change in fair value recognized in other comprehensive income (available-for sale)." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r406", "r426", "r484", "r562", "r655", "r657", "r665", "r685", "r686", "r736", "r739", "r741", "r742", "r747", "r769", "r770", "r795", "r804", "r812", "r821", "r822", "r826", "r827", "r840", "r962", "r989", "r990", "r991", "r992", "r993", "r994" ] }, "nhc_MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "MedicaidMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details" ], "lang": { "en-us": { "role": { "label": "Medicaid [Member]", "documentation": "Related to the program Medicaid." } } }, "auth_ref": [] }, "nhc_MedicareAndMedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "MedicareAndMedicaidMember", "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "Medicare and Medicaid [Member]", "documentation": "Medicare and medicaid [member]" } } }, "auth_ref": [] }, "nhc_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "MedicareMember", "presentation": [
"http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details" ], "lang": { "en-us": { "role": { "label": "Medicare [Member]", "documentation": "Related to the Medicare program." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r406", "r426", "r484", "r562", "r655", "r657", "r665", "r685", "r686", "r736", "r739", "r741", "r742", "r747", "r769", "r770", "r795", "r804", "r812", "r821", "r822", "r826", "r840", "r962", "r989", "r990", "r991", "r992", "r993", "r994" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r81", "r123", "r189", "r307", "r358", "r360", "r361", "r362", "r365", "r366", "r502", "r617", "r696" ] }, "nhc_MiscellaneousRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "MiscellaneousRevenue", "crdr": "credit", "calculation": {
"http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details": { "parentTag": "nhc_OtherRevenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "nhc_MiscellaneousRevenue", "documentation": "The amount of miscellaneous revenue." } } }, "auth_ref": [] },
"ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r869" ] }, "nhc_NHICommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NHICommonStockMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details" ], "lang": { "en-us": { "role": { "label": "NHI Common Stock [Member]", "documentation": "NHI common stock [member]" } } }, "auth_ref": [] }, "nhc_NHILeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NHILeaseAgreementMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases",
"http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "NHI Lease Agreement [Member]", "documentation": "Represents NHI agreement." } } }, "auth_ref": [] }, "nhc_NationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NationalMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "National [Member]", "documentation": "Represents the name of the credit facility, National." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by/(used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r186" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r186" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r96", "r97", "r98" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Net income attributable to National HealthCare Corporation", "totalLabel": "Net income attributable to National HealthCare Corporation", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r87", "r98", "r128", "r150", "r169", "r172", "r176", "r189", "r196", "r198", "r199", "r200", "r201", "r202", "r205", "r206", "r214", "r307", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r453", "r461", "r478", "r502", "r626", "r714", "r730", "r731", "r860", "r960" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-
```

unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest", "negatedLabel": "Net (income)/loss attributable to noncontrolling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r57", "r118", "r169", "r172", "r202", "r205", "r206", "r625", "r891"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r869"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r869"] }, "nhc_NoncontrollingInterestIncreaseFromCapitalContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NoncontrollingInterestIncreaseFromCapitalContribution", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Contributions attributable to noncontrolling interest", "documentation": "Amount of increase in noncontrolling interest from capital contribution from noncontrolling interest holders." } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r51", "r387", "r900", "r901", "r902", "r903", "r1033"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "auth_ref": [] }, "nhc_NonrefundableResidentEntryFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NonrefundableResidentEntryFeePercentage", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NonrefundableResidentEntryFeePercentage", "terseLabel": "Nonrefundable Resident Entry Fee Percentage", "documentation": "The percentage of the resident entry fee that becomes nonrefundable upon occupancy." } } }, "auth_ref": [] }, "nhc_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Notes receivable", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": ["r597", "r911"] }, "nhc_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "nhc_NumberOfAssistedLivingAndIndependentLivingUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfAssistedLivingAndIndependentLivingUnits", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfAssistedLivingAndIndependentLivingUnits", "terseLabel": "Number of Assisted Living and Independent Living Units", "documentation": "The number of assisted living and independent living units." } } }, "auth_ref": [] }, "nhc_NumberOfAssistedLivingCentersLeasedFromNHI": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfAssistedLivingCentersLeasedFromNHI", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfAssistedLivingCentersLeasedFromNHI", "terseLabel": "Number of Assisted Living Centers Leased from NHI", "documentation": "Number of Assisted Living Centers under lease agreements with NHI" } } }, "auth_ref": [] }, "nhc_NumberOfAssistedLivingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfAssistedLivingFacilities", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfAssistedLivingFacilities", "terseLabel": "Number of Assisted Living Facilities", "documentation": "Number of assisted living facilities in which company operates as of the Balance Sheet date." } } }, "auth_ref": [] }, "nhc_NumberOfAssistedLivingUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfAssistedLivingUnits", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfAssistedLivingUnits", "terseLabel": "Number of Assisted Living Units", "documentation": "The number of assisted living units." } } }, "auth_ref": [] }, "nhc_NumberOfBeds": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfBeds", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfBeds", "terseLabel": "Number of Beds", "documentation": "Number of licensed skilled nursing beds that are operated or managed as of the balance sheet date." } } }, "auth_ref": [] }, "nhc_NumberOfBehavioralHealthHospitals": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfBehavioralHealthHospitals", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfBehavioralHealthHospitals", "terseLabel": "Number of Behavioral Health Hospitals", "documentation": "The number of behavioral health hospitals." } } }, "auth_ref": [] }, "nhc_NumberOfContinuingCareRetirementCenters": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfContinuingCareRetirementCenters", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfContinuingCareRetirementCenters", "terseLabel": "Number of Continuing Care Retirement Centers", "documentation": "The number of continuing care retirement centers." } } }, "auth_ref": [] }, "nhc_NumberOfHealthcareOperations": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfHealthcareOperations", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfHealthcareOperations", "terseLabel": "Number of Healthcare Operations", "documentation": "The number of healthcare operations." } } }, "auth_ref": [] }, "nhc_NumberOfHomecareePrograms": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfHomecarePrograms", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfHomecarePrograms", "terseLabel": "Number of Homecare Programs", "documentation": "Number of homecare Programs in which the company operates as of the Balance Sheet date." } } }, "auth_ref": [] }, "nhc_NumberOfHospiceAgencies": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfHospiceAgencies", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfHospiceAgencies", "terseLabel": "Number of Hospice Agencies", "documentation": "Represents the number of hospice agencies operated or managed by the reporting entity as of the specified date." } } }, "auth_ref": [] }, "nhc_NumberOfIndependentLivingCentersLeasedFromNHI": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfIndependentLivingCentersLeasedFromNHI", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfIndependentLivingCentersLeasedFromNHI", "terseLabel": "Number of Independent Living Centers Leased from NHI", "documentation": "Number of Independent Living Centers under lease agreements with NHI" } } }, "auth_ref": [] }, "nhc_NumberOfIndependentLivingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfIndependentLivingFacilities", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfIndependentLivingFacilities", "terseLabel": "Number of Independent Living Facilities", "documentation": "Number of independent living facilities in which the company operates as of the Balance Sheet date." } } }, "auth_ref": [] }, "nhc_NumberOfIndependentLivingUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfIndependentLivingUnits", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfIndependentLivingUnits", "terseLabel": "Number of Independent Living Units", "documentation": "The number of independent living units." } } }, "auth_ref": [] }, "nhc_NumberOfLicensedSkilledNursingBeds": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfLicensedSkilledNursingBeds", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfLicensedSkilledNursingBeds", "terseLabel": "Number of Licensed Skilled Nursing Beds", "documentation": "The number of licensed skilled nursing beds." } } }, "auth_ref": [] }, "nhc_NumberOfLongtermCarePharmacies": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfLongtermCarePharmacies", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfLongtermCarePharmacies", "terseLabel": "Number of Long-term Care Pharmacies", "documentation": "The number of long-term care pharmacies." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-7-business-segments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r790", "r906"] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r784", "r794", "r906"] }, "nhc_NumberOfSkilledNursingCenters": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfSkilledNursingCenters", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual"], "lang": { "en-us": { "role": { "label":

"nhc_NumberOfSkilledNursingCenters", "terseLabel": "Number of Skilled Nursing Ficilitiess", "documentation": "Number of skilled nursing centers operated or managed as of the balance sheet date." } } }, "auth_ref": [] }, "nhc_NumberOfSkilledNursingCentersLeasedFromNHI": { "xbrltype": "positiveIntegerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfSkilledNursingCentersLeasedFromNHI", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfSkilledNursingCentersLeasedFromNHI", "terseLabel": "Number of Skilled Nursing Centers Leased from NHI", "documentation": "Number of Skilled Nursing Centers under lease agreements with NHI" } } }, "auth_ref": [] }, "nhc_NumberOfSkilledNursingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfSkilledNursingFacilities", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfSkilledNursingFacilities", "terseLabel": "Number of Skilled Nursing Facilities", "documentation": "Number of skilled nursing facilities operated or managed as of the balance sheet date." } } }, "auth_ref": [] }, "nhc_NumberOfSkilledNursingFacilitiesSubleased": { "xbrltype": "integerItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "NumberOfSkilledNursingFacilitiesSubleased", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_NumberOfSkilledNursingFacilitiesSubleased", "terseLabel": "Number of Skilled Nursing Facilities Subleased", "documentation": "Represents the number of skilled nursing facilities that the company subleases." } } }, "auth_ref": [] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfStatesInWhichEntityOperates", "terseLabel": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Income/(loss) from operations", "totalLabel": "Income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r132", "r783", "r905", "r907", "r908", "r909", "r910"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual"], "lang": { "en-us": { "role": { "verboseLabel": "Facility rent", "label": "Rent", "terseLabel": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r985"] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details": { "parentTag": "nhc_OtherRevenues", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details"], "lang": { "en-us": { "role": { "verboseLabel": "Rental income", "label": "us-gaap_OperatingLeaseLeaseIncome", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": ["r223", "r527", "r528"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "Present value of future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r520"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, current portion", "negatedLabel": "Less: current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r520"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label", "Operating lease liabilities, less current portion", "terseLabel": "Noncurrent lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r520"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r519"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r63", "r117", "r666", "r667"] }, "nhc_OriginalEntryFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "OriginalEntryFeeMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Original Entry Fee [Member]", "documentation": "Original entry fee [member]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Other Assets:" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAssetsNoncurrent", "totalLabel": "Total other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r157"] }, "nhc_OtherBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "OtherBusinessAcquisitionsMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Other Business Acquisitions [Member]", "documentation": "Represents other business acquisitions." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income/(loss), net of tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r16", "r19", "r170", "r173", "r178", "r202", "r503", "r504", "r509", "r598", "r627", "r889", "r890"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited"], "lang": { "en-us": { "role": { "label": "Other comprehensive income/(loss):" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax", "negatedLabel": "Reclassification adjustment for realized losses on sales of marketable debt securities", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": ["r6", "r84", "r168", "r302"] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherComprehensiveIncomeLossTax", "negatedLabel": "Income tax (expense)/benefit related to items of other comprehensive income", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": ["r4", "r174", "r178", "r431", "r445", "r446", "r503", "r507", "r509", "r598", "r627"] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited"], "lang": { "en-us": { "role": { "label": "Unrealized gains/(losses) on investments in

~~marketable debt securities", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r166", "r167", "r302"] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Other operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": ["r88", "r635", "r789"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r67", "r829"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r72"] }, "nhc_OtherNoncurrentLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "OtherNoncurrentLiabilitiesPolicyTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Policy Text Block]", "documentation": "Accounting policy disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income and Expense [Text Block]", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": ["r183", "r184"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "verboseLabel": "Non\u2013operating income", "label": "Non-operating income (loss)", "totalLabel": "Total non-operating income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r91"] }, "nhc_OtherOperatingExpensesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "OtherOperatingExpensesPolicyPolicyTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Other Operating Expenses Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for other operating expenses." } } }, "auth_ref": [] }, "nhc_OtherRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "OtherRevenues", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 }, "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "verboseLabel": "Other revenues", "label": "nhc_OtherRevenues", "totalLabel": "Total other revenues", "documentation": "The revenues not separately disclosed." } } }, "auth_ref": [] }, "nhc_OtherRevenuesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "OtherRevenuesTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-5-other-revenues"], "lang": { "en-us": { "role": { "label": "Other Revenues [Text Block]", "documentation": "Disclosure of other revenues." } } }, "auth_ref": [] }, "nhc_PaymentsForProceedsFromNotesReceivableTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "PaymentsForProceedsFromNotesReceivableTotal", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "nhc_PaymentsForProceedsFromNotesReceivableTotal", "negatedLabel": "Investments in notes receivable", "documentation": "Represents the cash paid or received by the reporting entity associated with notes receivable." } } }, "auth_ref": [] }, "nhc_PaymentsForProceedsFromUnconsolidatedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "PaymentsForProceedsFromUnconsolidatedInvestments", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "nhc_PaymentsForProceedsFromUnconsolidatedInvestments", "negatedLabel": "Investments in unconsolidated companies", "documentation": "The net cash outflow or inflow associated with unconsolidated investments during the period." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchase of common shares", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r94"] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Dividends paid to common stockholders", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": ["r94"] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireBusinessesGross", "negatedLabel": "Acquisition of White Oak Senior Living, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": ["r25", "r459"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "negatedLabel": "Acquisition of other businesses, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r25"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r913"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r93"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed~~

```
within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r888" ] }, "nhc_PrivatePayAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "PrivatePayAndOtherMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details" ], "lang": { "en-us": { "role": { "label": "Private Pay and Other [Member]", "documentation": "Related to private pay received and other revenue sources." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Borrowings under credit facility", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsToMinorityShareholders", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest contributions", "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of marketable securities", "terseLabel": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "nhc_ProceedsFromSaleOfUnconsolidatedCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ProceedsFromSaleOfUnconsolidatedCompany", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of unconsolidated company", "terseLabel": "Proceeds from Sale of Unconsolidated Company", "documentation": "The cash inflow associated with the sale of an unconsolidated company during the period." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } } }, "auth_ref": [ "r263", "r563", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r773", "r805", "r839", "r840", "r841", "r844", "r847", "r956", "r957", "r963", "r999", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1029", "r1030" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r263", "r563", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r773", "r805", "r839", "r840", "r841", "r844", "r847", "r956", "r957", "r963", "r999", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1029", "r1030" ] }, "us-gaap_ProfessionalLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalLiabilityInsuranceMember", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "Professional Liability Insurance [Member]", "documentation": "Contract providing insurance coverage against loss by professional in course of practice." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProfitLoss", "terseLabel": "Net income", "totalLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r150", "r169", "r172", "r185", "r189", "r196", "r202", "r205", "r206", "r307", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r453", "r461", "r462", "r465", "r466", "r478", "r502", "r602", "r624", "r673", "r714", "r730", "r731", "r815", "r816", "r861", "r891", "r960" ] }, "us-gaap_PropertyManagementFeeRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyManagementFeeRevenue", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyManagementFeeRevenue", "terseLabel": "Property Management Fee Revenue", "documentation": "The amount of revenue derived from managing real estate properties." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Property and Equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12", "r525" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Property and equipment, at cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r101", "r154", "r621" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentNet", "totalLabel": "Net property and equipment", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r525", "r607", "r621", "r829" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r12", "r139", "r143", "r619" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r101", "r525" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-
```

policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProvisionForDoubtfulAccounts", "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r182", "r314"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r353", "r354", "r355", "r356", "r399", "r406", "r417", "r418", "r419", "r426", "r484", "r536", "r546", "r562", "r655", "r657", "r665", "r685", "r686", "r736", "r739", "r741", "r742", "r747", "r769", "r770", "r795", "r804", "r812", "r821", "r822", "r826", "r827", "r840", "r851", "r954", "r962", "r978", "r990", "r991", "r992", "r993", "r994"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r353", "r354", "r355", "r356", "r399", "r406", "r417", "r418", "r419", "r426", "r484", "r536", "r546", "r562", "r655", "r657", "r665", "r685", "r686", "r736", "r739", "r741", "r742", "r747", "r769", "r770", "r795", "r804", "r812", "r821", "r822", "r826", "r827", "r840", "r851", "r954", "r962", "r978", "r990", "r991", "r992", "r993", "r994"] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual"], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": ["r77", "r83"] }, "nhc_RefundableAdvanceFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "RefundableAdvanceFeesMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Refundable Advance Fees [Member]", "documentation": "Refundable advance fees [member" } } }, "auth_ref": [] }, "nhc_RefundableResidentEntryFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "RefundableResidentEntryFeePercentage", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "nhc_RefundableResidentEntryFeePercentage", "terseLabel": "Refundable Resident Entry Fee Percentage", "documentation": "Remaining refundable portion of the resident's entry fee." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermLinesOfCredit", "negatedLabel": "Repayments under credit facility", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r95"] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash and cash equivalents", "label": "us-gaap_RestrictedCashAndCashEquivalents", "periodEndLabel": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r119", "r153", "r187", "r613"] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Restricted cash and cash equivalents, current portion", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r153", "r187"] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Restricted cash and cash equivalents, less current portion", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r135", "r187"] }, "nhc_RestrictedMarketableDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "RestrictedMarketableDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Restricted marketable debt securities, current portion", "documentation": "Represents current restricted marketable debt securities." } } }, "auth_ref": [] }, "nhc_RestrictedMarketableDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "RestrictedMarketableDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Restricted marketable debt securities, less current portion", "documentation": "Represents noncurrent restricted marketable debt securities." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r79", "r104", "r616", "r662", "r664", "r670", "r695", "r829"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r147", "r193", "r194", "r195", "r197", "r202", "r204", "r206", "r308", "r309", "r344", "r439", "r440", "r450", "r451", "r452", "r454", "r460", "r461", "r469", "r471", "r472", "r474", "r476", "r516", "r518", "r659", "r661", "r674", "r1033"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Net patient revenues", "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r130", "r131", "r222", "r230", "r231", "r253", "r259", "r263", "r265", "r267", "r396", "r397", "r563"] }, "nhc_RevenueFromContractWithCustomerIncludingAssessedTaxPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxPercentage", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details"], "lang": { "en-us": { "role": { "label": "Revenue, concentration percentage", "documentation": "The percentage of total revenue from contracts with customers, including the assessed tax." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r145", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r398"] }, "us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionForAlternativeRevenueProgramsPolicy", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue recognition related to alternative revenue programs. The major alternative revenue programs can generally be segregated into two categories, programs that adjust billings for the effects of weather abnormalities or broad external factors or to compensate the utility for demand-side management initiatives (for example, no-growth plans and similar conservation efforts), and programs that provide for additional billings (incentive awards) if the utility achieves certain objectives, such as reducing costs, reaching specified milestones, or demonstratively improving customer service." } } }, "auth_ref": ["r59", "r60", "r61",

"r62"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r715", "r772", "r779"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "verboseLabel": "Net operating revenues", "label": "us-gaap_Revenues", "totalLabel": "Net operating revenues and grant income", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r130", "r131", "r177", "r189", "r222", "r230", "r231", "r253", "r259", "r263", "r265", "r267", "r307", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r502", "r602", "r789", "r960"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Revenues:" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r869"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r869"] }, "stpr_SC": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "SC", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual"], "lang": { "en-us": { "role": { "label": "SOUTH CAROLINA" } } }, "auth_ref": [] }, "nhc_SalariesWagesAndBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "SalariesWagesAndBenefitsMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Salaries, Wages, and Benefits [Member]", "documentation": "Financial statement caption encompassing salaries, wages, and benefits." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short term and long debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r904"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r304", "r305", "r306", "r449", "r871", "r872", "r873", "r968", "r969", "r970", "r971"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r975", "r976"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r797", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938"] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": ["r798", "r947"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r13"] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Nonoperating Income, by Component [Table Text Block]", "documentation": "Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items." } } }, "auth_ref": ["r90"] }, "nhc_ScheduleOfOtherRevenuesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "ScheduleOfOtherRevenuesTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Revenues [Table Text Block]", "documentation": "Tabular disclosure of the detailed components of other operating revenues." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r116"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r32", "r33", "r34"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r38"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year; grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r17", "r18", "r106"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r110"] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt",

```
"http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r972" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.nhccare.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r863" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.nhccare.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r865" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r130", "r131", "r132", "r133", "r222", "r226", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r267", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r343", "r349", "r350", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r786", "r789", "r790", "r797", "r843", "r999", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1029", "r1030" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r265", "r266", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r678", "r681", "r683", "r738", "r740", "r745", "r749", "r756", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r774", "r806", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r842", "r851", "r963", "r999", "r1002", "r1003", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1029", "r1030" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-7-business-segments" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r133", "r222", "r225", "r226", "r227", "r228", "r229", "r242", "r244", "r245", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r267", "r784", "r787", "r788", "r789", "r791", "r793", "r794" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r262", "r265", "r785", "r786", "r792" ] }, "us-gaap_SelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfInsuranceReserve", "crdr": "credit", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SelfInsuranceReserve", "terseLabel": "Self Insurance Reserve", "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": [ "r72" ] }, "us-gaap_SelfInsuranceReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfInsuranceReserveCurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accrued risk reserves, current portion", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfInsuranceReserveNoncurrent", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accrued risk reserves, less current portion", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r966" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock\u2013based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details" ], "lang": { "en-us": { "role": { "label": "Risk\u2013free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options exercisable, shares (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options exercisable, weighted average exercise price (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Options cancelled, shares (in shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r965" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options cancelled, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r965"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options granted, shares (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r414"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options outstanding, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r38"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options outstanding (in shares)", "periodStartLabel": "Options outstanding, shares (in shares)", "periodEndLabel": "Options outstanding, shares (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r411", "r412"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Options outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Options outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r411", "r412"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r415"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r414"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r40"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details"], "lang": { "en-us": { "role": { "label": "Options outstanding, exercise price, lower range (in dollars per share)", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r40"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details"], "lang": { "en-us": { "role": { "label": "Options outstanding, exercise price, upper range (in dollars per share)", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r40"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details"], "lang": { "en-us": { "role": { "label": "Expected life (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r416"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Options exercisable, aggregate intrinsic value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r38"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details"], "lang": { "en-us": { "role": { "label": "Options outstanding, weighted average exercise price (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": ["r107", "r108"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details"], "lang": { "en-us": { "role": { "label": "Options outstanding, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r109"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r99", "r188"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r130", "r131", "r132", "r133", "r149", "r222", "r226", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r267", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r343", "r346", "r349", "r350", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r786", "r789", "r790", "r797", "r843", "r999", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1029", "r1030"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r16", "r76", "r80", "r81", "r147", "r174", "r175", "r176", "r193", "r194", "r195", "r197", "r202", "r204", "r206", "r224", "r308", "r309", "r344", "r387", "r439", "r440", "r450", "r451", "r452", "r454", "r460", "r461", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r503", "r505", "r506", "r507", "r508", "r509",

"r516", "r518", "r529", "r627", "r659", "r660", "r661", "r674", "r732"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r265", "r266", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r678", "r681", "r683", "r738", "r740", "r745", "r749", "r756", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r774", "r806", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r842", "r851", "r963", "r999", "r1002", "r1003", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1029", "r1030"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-", "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-details-textual", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables", "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r193", "r194", "r195", "r224", "r518", "r563", "r668", "r675", "r687", "r688", "r689", "r690", "r691", "r692", "r694", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r711", "r713", "r715", "r716", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r732", "r852"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-", "http://www.nhccare.com/20240930/role/statement-note-1-description-of-business-details-textual", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-details-textual", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-details-textual", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program", "http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-options-outstanding-by-exercise-price-range-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-maturities-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-summary-of-longterm-debt-details", "http://www.nhccare.com/20240930/role/statement-

note-15-longterm-debt-tables", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes", "http://www.nhccare.com/20240930/role/statement-note-16-income-taxes-details-textual", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments", "http://www.nhccare.com/20240930/role/statement-note-17-contingencies-and-commitments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.nhccare.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-revenue-disaggregation-details", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-summary-of-other-revenues-details", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-details-textual", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-summary-of-nonoperating-income-details", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-details-textual", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-maturity-of-lease-liabilities-details", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-details-textual", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables", "http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r193", "r194", "r195", "r224", "r268", "r518", "r563", "r668", "r675", "r687", "r688", "r689", "r690", "r691", "r692", "r694", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r711", "r713", "r715", "r716", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r732", "r852"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-summary-of-options-outstanding-details"], "lang": { "en-us": { "role": { "label": "Shares sold \u2013 options exercised (in shares)", "negatedLabel": "Options exercised, shares (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r16", "r75", "r76", "r104", "r415"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Shares sold \u2013 options exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r16", "r76", "r80", "r81", "r104"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares", "terseLabel": "Stock Repurchased and Retired During Period, Shares (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": ["r16", "r75", "r76", "r104"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue", "terseLabel": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": ["r16", "r75", "r76", "r104"] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodShares", "negatedLabel": "Repurchase of common shares (in shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r16", "r75", "r76", "r104", "r669", "r732", "r754"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodValue", "negatedLabel": "Repurchase of common shares", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r16", "r75", "r76", "r104", "r674", "r732", "r754", "r861"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total National HealthCare Corporation stockholders\u2019 equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r76", "r80", "r81", "r100", "r696", "r712", "r733", "r734", "r829", "r862", "r898", "r926", "r982", "r1033"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Total equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r51", "r52", "r56", "r147", "r148", "r175", "r193", "r194", "r195", "r197", "r202", "r204", "r308", "r309", "r344", "r387", "r439", "r440", "r450", "r451", "r452", "r454", "r460", "r461", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r503", "r505", "r509", "r517", "r529", "r660", "r661", "r672", "r696", "r712", "r733", "r734", "r755", "r861", "r898", "r926", "r982", "r1033"] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-tables", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-tables", "http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-tables", "http://www.nhccare.com/20240930/role/statement-note-14-stockbased-compensation-tables", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-tables", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-tables", "http://www.nhccare.com/20240930/role/statement-note-4-net-patient-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-tables", "http://www.nhccare.com/20240930/role/statement-note-6-nonoperating-income-tables", "http://www.nhccare.com/20240930/role/statement-note-7-business-segments-tables", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-tables", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "nhc_TermFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "TermFacilityMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Term Facility [Member]", "documentation": "Represents term facility." } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r48", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.nhccare.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r383", "r386", "r475", "r498", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r545", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r628", "r817", "r819", "r821", "r822", "r823",

"r824", "r825", "r826", "r827", "r830", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r921", "r922", "r923", "r924", "r974", "r977", "r978", "r979", "r980", "r981"] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockTextBlock", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-13-stock-repurchase-program"], "lang": { "en-us": { "role": { "label": "Treasury Stock [Text Block]", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": ["r105"] }, "nhc_TwoLeasesWithNHIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "TwoLeasesWithNHIMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases", "http://www.nhccare.com/20240930/role/statement-note-8-longterm-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Two Leases with NHI [Member]", "documentation": "Represents information about two leases with National Health Investors, Inc. (\"NHI\")." } } }, "auth_ref": [] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": ["r996"] }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USStatesAndPoliticalSubdivisionsMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "label": "US States and Political Subdivisions Debt Securities [Member]", "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments." } } }, "auth_ref": ["r807", "r830", "r846", "r1028"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-11-fair-value-measurements-summary-of-fair-value-measurements-by-level-details"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r780", "r807", "r809", "r817", "r996"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.nhccare.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r29", "r30", "r31", "r137", "r138", "r141", "r142"] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt", "http://www.nhccare.com/20240930/role/statement-note-15-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Diluted (in shares)", "terseLabel": "Weighted average common shares outstanding (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r209", "r217"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-operations-unaudited", "http://www.nhccare.com/20240930/role/statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding (in shares)", "label": "Basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r208", "r217"] }, "nhc_WhiteOakSeniorLivingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "WhiteOakSeniorLivingMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-interim-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "White Oak Senior Living [Member]", "documentation": "Represents White Oak Senior Living." } } }, "auth_ref": [] }, "nhc_WhiteOakSeniorLivingPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "WhiteOakSeniorLivingPortfolioMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-details-textual", "http://www.nhccare.com/20240930/role/statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details"], "lang": { "en-us": { "role": { "label": "White Oak Senior Living Portfolio [Member]", "documentation": "Represents the White Oak Senior Living portfolio." } } }, "auth_ref": [] }, "nhc_WorkersCompensationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "WorkersCompensationRevenueMember", "presentation": ["http://www.nhccare.com/20240930/role/statement-note-5-other-revenues", "http://www.nhccare.com/20240930/role/statement-note-5-other-revenues-details-textual"], "lang": { "en-us": { "role": { "label": "Workers Compensation Revenue [Member]", "documentation": "Related to revenue derived from workers compensation agreements." } } }, "auth_ref": [] }, "nhc_statement statement note 10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 10-investments-in-marketable-securities-amortized-cost-and-estimated-fair-value-of-debt-securities-as-available-for-sale-details", "lang": { "en-us": { "role": { "label": "Note 10 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 10-investments-in-marketable-securities-available-for-sale-marketable-equity-securities-details", "lang": { "en-us": { "role": { "label": "Note 10 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 10-investments-in-marketable-securities-marketable-securities-and-restricted-marketable-securities-details", "lang": { "en-us": { "role": { "label": "Note 10 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 10-investments-in-marketable-securities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 10-investments-in-marketable-securities-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Investments in Marketable Securities" } } }, "auth_ref": [] }, "nhc_statement statement note 11-fair value measurements-summary of fair value measurements by level details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 11-fair value measurements-summary of fair value measurements by level details", "lang": { "en-us": { "role": { "label": "Note 11 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 11-fair value measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 11-fair value measurements-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Fair Value Measurements" } } }, "auth_ref": [] }, "nhc_statement statement note 12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 12-goodwill-and-other-intangible-assets-activity-related-to-goodwill-by-segment-details", "lang": { "en-us": { "role": { "label": "Note 12 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 12-goodwill-and-other-intangible-assets-indefinitelived-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 12 - Goodwill and Other Intangible Assets - Indefinite-lived Intangible Assets (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 12-goodwill-and-other-intangible-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 12-goodwill-and-other-intangible-assets-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Goodwill and Other Intangible Assets" } } }, "auth_ref": [] }, "nhc_statement statement note 14-stockbased-compensation-options-outstanding-by-exercise-price-range-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 14-stockbased-compensation-options-outstanding-by-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 14-stockbased-compensation-summary-of-assumptions-used-to-value-options-granted-details", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 14-stockbased-compensation-summary-of-options-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 14-stockbased-compensation-summary-of-options-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation - Summary of Options Outstanding (Details)" } } }, "auth_ref": [] }, "nhc_statement statement note 14-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 14-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation" } } }, "auth_ref": [] }, "nhc_statement statement note 15-longterm-debt-maturities-of-longterm-debt-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement statement note 15-longterm-debt-maturities-of-longterm-debt-details", "lang": { "en-us": { "role": { "label": "Note 15 - Long-term Debt - Maturities of Long-term Debt (Details)" } } }, "auth_ref": [] }, "nhc_statement statement-

note-15-longterm-debt-summary-of-longterm-debt-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-15-longterm-debt-summary-of-longterm-debt-details", "lang": { "en-us": { "role": { "label": "Note 15 - Long-term Debt - Summary of Long-term Debt (Details)" } } } }, "auth_ref": [] }, "nhc_statement-statement-note-15-longterm-debt-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-15-longterm-debt-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Long-term Debt" } } }, "auth_ref": [] }, "nhc_statement-statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-3-acquisition-of-white-oak-senior-living-allocation-of-purchase-price-details", "lang": { "en-us": { "role": { "label": "Note 3 - Acquisition of White Oak Senior Living - Allocation of Purchase Price (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-3-acquisition-of-white-oak-senior-living-pro-forma-financial-information-details", "lang": { "en-us": { "role": { "label": "Note 3 - Acquisition of White Oak Senior Living - Pro Forma Financial Information (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-3-acquisition-of-white-oak-senior-living-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-3-acquisition-of-white-oak-senior-living-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Acquisition of White Oak Senior Living" } } }, "auth_ref": [] }, "nhc_statement-statement-note-4-net-patient-revenues-revenue-disaggregation-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-4-net-patient-revenues-revenue-disaggregation-details", "lang": { "en-us": { "role": { "label": "Note 4 - Net Patient Revenues - Revenue Disaggregation (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-4-net-patient-revenues-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-4-net-patient-revenues-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Net Patient Revenues" } } }, "auth_ref": [] }, "nhc_statement-statement-note-5-other-revenues-summary-of-other-revenues-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-5-other-revenues-summary-of-other-revenues-details", "lang": { "en-us": { "role": { "label": "Note 5 - Other Revenues - Summary of Other Revenues (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-5-other-revenues-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-5-other-revenues-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Other Revenues" } } }, "auth_ref": [] }, "nhc_statement-statement-note-6-nonoperating-income-summary-of-nonoperating-income-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-6-nonoperating-income-summary-of-nonoperating-income-details", "lang": { "en-us": { "role": { "label": "Note 6 - Non-operating Income - Summary of Non-operating Income (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-6-nonoperating-income-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-6-nonoperating-income-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Non-operating Income" } } }, "auth_ref": [] }, "nhc_statement-statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-7-business-segments-summary-of-financial-information-by-reporting-segment-details", "lang": { "en-us": { "role": { "label": "Note 7 - Business Segments - Summary of Financial Information by Reporting Segment (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-7-business-segments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-7-business-segments-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Business Segments" } } }, "auth_ref": [] }, "nhc_statement-statement-note-8-longterm-leases-maturity-of-lease-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-8-longterm-leases-maturity-of-lease-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 8 - Long-term Leases - Maturity of Lease Liabilities (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-8-longterm-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-8-longterm-leases-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Long-term Leases" } } }, "auth_ref": [] }, "nhc_statement-statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-9-earnings-per-share-summary-of-earnings-and-weighted-average-number-of-common-shares-used-in-calculation-of-basic-and-diluted-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 9 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details)" } } }, "auth_ref": [] }, "nhc_statement-statement-note-9-earnings-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-note-9-earnings-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Earnings Per Share" } } }, "auth_ref": [] }, "nhc_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.nhccare.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" },

"r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Paragraph": "2AA", "Subparagraph": "(a)", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "605", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477959/980-605-25-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "605", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477959/980-605-25-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "605", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477959/980-605-25-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "605", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477959/980-605-25-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505-30/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "SubTopic": "440", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12 14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":

"946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r871": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r872": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-27" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":

```
"2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r978": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r979": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r980": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-
2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r985": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r986": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r987": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r988": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r989": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r990": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r991": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r992": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r993": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r994": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r995": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/940-320/tableOfContent" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic":
"310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/944-40/tableOfContent" }, "r1002": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1003": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1004": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1005": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1006": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1007": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1008": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1009": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1010": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1011": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1012": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1013": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1014": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1015": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1016": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1017": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1018": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1019": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1020": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1021": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1022": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1023": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1024": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1025": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1026": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1027": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1028": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1029": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1030": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1031": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" } } }
ZIP 94 0001437749-24-033970-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-033970-xbrl.zip M4$L#!!0 (&"'9UFX, ^=#W@<`,DT`-`97A?-S,Y.#8T+FAT;>U;`M[W/;-A+]W/P5.,VT<68H2XKMM)5DS3B.DWIZ=7.N,^:^W8`D**(1"08 ):M`_M?=^"U&_9EJ^Y.$HUDT01N,`^@._M+D"JG[I,#?]IX/'@V3=])YT2W'[W^>/`M?OSAU?$AKO9,5>.S;W#]\TF>R=R8;@,3,0LG["8M$D-SH3[+TVCBO69)UV`MZZC=>ME^>.C[LDK=0#+:S8'`4PX$]*4&RO<:: T2?.'1MV:\TR<-A)M M,NZ:L7`BY;@R>]5L5Z'ZHXPFS;J\\]]PUK?Q# M= &B<#WF&Q*>237ILN\^EMKU;F0F++L28W:M,YY7C3U6\#B6^;#++VC)G[<:. MS'LL*HW5ILMXZ72/?!931QDW0YG#N+AE!&F*@Q]<...H>=?BL<|%O%X`D"ANT]. 8WXD;RW'593HNN>FP^*3?[^R.9`M>X02-YJLF]34&'R7A[;HW8MI!G\_=7/YZ]=#J`M/5]!^KPW1^J!+N&L8=:(VENNQNIB;.%A81U^+ZV3R639Z67`?G/0A,C9VT/V`M5G'G`BR8(4OF4NZZGW'2CH=*L%`,A(31AO"4K5HII]MP6/1M]K2&,9NY3X`MT/YVY69^6R0ZQ!T$)C>.U'}\(JZF!'&Z\%9D%*\,>O3*X`07-TC7+5-MNL9,`M2S>H&!XP*XQ,UNG=&'0._>J0_Y:+[TYC2Y/AO*2I7PDF!$C*<:(ZRZ5EGTL`MN8'RU`3M!2({TV`92(!.S7|QG;`K3@$:`?\GP95+S[D1[%P;V/H+O=69X]/0MW<0G467/RR>\XR]W@I>ON04;P;MLPC[D>JQ$/!3!''2,-5SDVOF"@2.'\WS"`MRMR04@`[ZI4,`X]XRY%+T%."N0F/T&28SJ3##:OLU@QR$0EKN9F02<8_""!8M&`.B+08LN,1*I`X'&4321&4&LQS=F2^3V#B54OO:+?U)U@B<_`:)#+G`M<0#)P1R7S<)UF55DGJ5FLNP5H!=`M<0VEQY(&#LBB5#"JG0A]@QD/9Z(VY0E2IH_M5)A&##*5U!NQEG!HKW$`9+,C+`M3L&LH=T+ZPL6UO%.",.MFB87;,2V:NG2GP**`^31.*K9^8EH]**`!.2[KIX"H3ME@@@;4KF9)8AZ5'BH^^QM)'2MD0_2H=&]TH,A=&1B`%LV0&X'PN(]2+XQ2VV`MY?E0L#`DFNM2P;)SQ)N=DP/QPG?MG,35M^JKI&U97HF0QF>4CA:T66F%L&SM`M*%ERE,`1S7-5L,"@:K6[5^%#*!SBO%,'3ZY6OA`J?2,LA@9[?=WVL+0"*BDC M7MKMNU!M%PK(/9458NZQ.TOD8]&TOHL!RN1^W%H=$`/CXLYU@C%O>[]`M.J&MR7O[5+BURA$91C(F\7*KE0`\80$'JN"(*BB%D`M@AUW)6?$&ED@N^\%`14(.MH)05^,N"I]`B.VBR2A9T@C\`1NV/NAZMXB+U=?`M-V\$O7++1$3G55MO`4)?N;M`,:5`Y\9BUH+YW<=^)3HPBGNW0?C$2U!G0`2X/O`MQ,?[XHMW0GQO*G;OJX3.8>LMG[^R(L)'9$^]>744E894L%!@+HV7;>O00L\`M,8H%&:9'H^Q@S3B!A)'+5NQJF!&$Y0^,Z2PY+V=87E1(4FYG%3AE02]Y$?ORMP,`^^3MT3IN0'H>K3XQ7[X"\LR%[@7`AAU,E."/>QAU''^66$\57LPSS^4#A?5`M-T]%I*)'U-=K.U>`XMBW.FWLK)CU#1@LRZ1S0FQ,*%&H4Q78@E,OOL!U(E\M;BE?XY/<=.P(CZ6$!/\K"AS__K)BWWU^A4DT`TX9Cl3V(AA<`FQT4DGQ9E&`M4D`==1TZ.`X9"`Z!"LMJ8^9+2[^E)(A\RT\`)6Y^F2F.F?>D!+=XC(Y6S-+6M!GW66U`80VK@:.5#5M9:F7&982,S53Z,N"S8^(=JGM*]$O)?*352%#!E`_A`2]!!3.ER`JE)P)7QZFNTB`?4C*4`M]Q=KW[75?")[-+;WN!^=MD5UC<+L<3?!XQ>3`WLK]NP^K,>?%NMR1/QD3'CPK=`9,K5L;^W5`MTOL"^GUKT`E`WL>WON/17WSE,I$G9Q*Z*23O#9K]7IQY=,MP<]=!L9RQ"+%K3UM`//LMYOF^[`W%\W7UQ=G/],/9!:NOG`W]N0ZI2U-FD:/`MUQNI$F+OWUW]^Y>Y-UC0+WTV?`!%BW]Y,^BW`$^8`@102P,$% @`8(=GM6=YH1"`=!P`L3,`T`!E>)%\W.SDX`C4N:\!M4(9MO<`NKS8=?7SX%]IE>`MG!G*LNSXNO?4]3`E:B`MF4QD@@OL`MQG=P%*&]P7:CC(!4^'SI%,>.F5&(]!?{TZ^LN//QSOX^Z@4S<^`M^P[W`]1NLW="""\N]2%D\83=YI5-AWYA"L"MC/5>LS;H'G:.`#SN'!X4O6[.T\`MZG5?L=-?6+L]'!3"&S0:A",=,*?:!GQM`E<`>&@D`(@/!=`'#3N5'`+^$]ZE,>U,&*1)*EP8]^B'8&6ZNX.3TM/$Y`D*CN`__()/`'`K`/(U=`.!&^%TQ8>^U&2N1WHKH`?=,`#51HXT`6`MYTBT7$]8I.VM!&Q'45'@X9'?P)DDSRWAZD0IT:O4`M#,.&`+>D&J2GD@:.2*)2$`![IA1U!G+!GH2[G&7*C`T43"MNI?,6WLLX`=9V`MP\IHCB\W`6;%VAU83QBLEUL!ULV'"%SYW#31-Z4Z!WV29Q&75`MS`M&I14Q`)^6`M]`#A]TPX<@#!#G=]@[ZUO!3I%IKBL%B>X1;W>/!\2+T+5[6`97)+9>N(:3Q&.6C.39KM5LB6C15E"XHR**)Y+A,+":I6>SL*`XC"J9T/5;0>L;X3`TO#?4;7^,`M5D0E9<(KMWD7JNUB`4P:376U:"H\`@KY:"1=R'*0$CJ,0[O[67Z%9@A3+E2EM(2<.)V"01PZF3B4G%ZT4IU2..04C9@4K>M3E[UPN)46Q(S%D6_07Z2Z[?@5<`MQUO(|<8);07OS5/AQI0C,HQD2O!R9W1P1>X`/NTEB6ANTRE=X%WR6"K)U3@MKE`+L2:`&!BKP\2"Z`Q>`)06=\V$RLJ68`R%@CQ)`$,P(.Q*\|`9O0+JN"`*`MBB$D@AUWC3`BC2R1W7=`?P5`)UL!]/F(JRID,`_)VD67THF<$/W5K]GZHNC?(MR`7E^HU@(!<=D5`=O=V,3>4?UKU)Y<#OI07ML/'3GP.*^+1+CT$(UG9E&`M4D`==1W`MTN`[^`+8?OG0KX'M3>`_U+`:`Y*DLD3!7(&Y.%YAG$<+`MO1/$*[`.,#T;97LKPAD01BY,DFO,3`!6.#"FLV1=W=ORHK8DY^Z^`JS3+/Y0.`MY^F,I2*BZ"/JZY6=*XSBV+=Z8]U],1L:,%A12.^%6)O@8X-"F>ZD$C:%[GN@`M$_G44:[&)^V:IV%$?*@D3`Z!H]!+A.R(O=L=.,7T$"W8YCIE.%C1@&EX".3CKI`MS#21`G0T=>C]<<]8\/=46-8:LU!:ABUE>)4Y??OQ40<3HWXL^>\S6EY`7UL5H]=D\8<>/";#X83I>[`MXS]+W_E\+(^MC#=_^5#;`+4M^.IWX8+[ASOZ3A>8B@[Z9/680LEQKC^N]OZ`MMASRZ$F*K%`R$2P*XMM$)7:89]QEDN1L;?WQ=2O]2G&$ZFD4CEBB>+.G;3^`M>OK;3?OJ]`UY^`7U^>G/&.0N;M7[[>7"^UY5D;#WRUD0H6=O7N\N^`S+1!M@G[1LN8#5G3H%R[#02?\5.<`4$L#!!0(&"'9UDO)Y\+G@4`LF`-M`97A?-S,Y.#8V+FAT;>U:.7/:.A#]7/(^*+6>2V#.B#LM'=%@SCFN[G32.`M8SO]VH'(I8B6!!@M*3^^BY`2I84^'&+U3_]^_#*0I4S&(`_3%1`]HK`M2P5+|<"+I$[9\4.T&!@NA0>!%`8%M3;88!9+@0="">KV-;JTPNMN7X1BT&2>N`MNS"^YO]AFXS(3-=<0<12GHS;\/)3+DWGBJ>HX0R'<"%3)HK"#F0L#+D8M*:`M!=2K#2XZ$.1*2]4&EAO9L7-F6VI%K"D-MI"W1).M`,3CM1K7YPO6E+DMQ@T4K87FRG"`)70PXRDP<14H`07]`UO.70W`MV9:#UAI2,^&7+&*`5=V`>Q'?W=&]7I0GY#2!3+/$DG9*9(6?L30'+]ZV5(;[2:.QT;!X"`M22"MEXD#;]O[>GB^$>L5<)[^TW(>2WTN"M%NG<.*=<9M>N1%D"^34<2X34V9`M0FWJ[6*K69(0$I2S..4D]LC(P71E?=W'PA5QP41@`2$D0^XPM6F4X,F3(@!)`M#(N$K2>QITC;U1_M9?0$YI+G&B@_KF'^884%`F$P83/&`>IK;1^FXNK3M,`^_MS%]JXJOK(:\`_YD*<$1YU1XU,.?V.WE=0+`.`(L@\A3EFP6[=)H#G56]F%G6O`M+5F6%^\X4]D42;-"RDGQ:$G&+(..$\8PJXS!5<])8RC0FDCC[VV+]R79877WMQ<./ENZ?^?8453R5^'U]C$RI?38"+1-.Z6#0WZ3@8/^V.G"7KK!T/>CWS+UG[OTLM[AW%'",X=E](7R.\CT@CH5IE"BY],)A=U2U(/.2]YC;1]#C#/^NCE?7^9WTT`M$RO*F$@EP1O;SB;]MSS\[.QME8+$^C!U/2CX3+QGXOT<<8Z"2P5_D2["3Z;]4Y5.3^W0:56.%0^AO*Z7I).XO?UVA[%V\?,WO[3DTS):^Y/:,M+^B/W!GPV!%MR).$6M$@Y04(#;+8M)LJ5X#]^&> AE^4*N`-6RBB"/*,2:R9]<^?9YX^`=FZ#0WX-0<*T/O#^/+R\`M\L\/3X_]-Q?'AV`M:U,SM>>>G)U<7"V5QY"LY`+S02FPX/SW[^,YF-FIAW_U:`M\D%6U.R[8+UNS;W4]C]02P,$% @`8(=G6:`-+%.D0%P`QRL!`!`!N`M:&,M,C`R-#`Y,S`N>`D[5U:;]NZEGX?8/Z#QB_3>5!S:=/N%,T^2-.F#9`F`M09),S!L!+=$V49GR(24GGE\_B]3%DDU*E,PD'+C(`UWW]\`^W/_$O0F>(@W#N[VGBGF"89X@9`{UT.=+4`M4A8?$<U10)(^9&BQGF)?EE%J&!).^)9)%GW]T_<\/LIS8\]4L(*'$`M-X`M>E@F38QSN+`^"R_.1D&V!5DPA_@2^X>"E^FV1^]B881[)0X!83^4>L!GGBW`M)Y*B...G"+B<771,JE4IUXI:+A;P\Q_`8+IY)N__A=+C(GGKI82"@5REF4`M$XX0'TI9X>,JT8]+BJ1)4CE#`&,:`I!2(HVY.T9HMEYRFK!*K)$C2RF1"\Y^`MI'+\`M%>DE@D)16>(U3482_WW.:I],:=W\!2+PG4P<.BB)&AG&$ST.V`8I'`M*`Y.FIC^.T8!&1'L0[0(\33]$102(X0&^/H"DTQGR$/U`L?(HOCR/!`IK.0`M10Y5YM4IE\24R]"3M:`BB_C+S?*YXI[<.B^.W@+K`=[!E)4Q!R5$+PJ2_:'M*`YH)T&QNAGQ7V9(?F[`NO!%C%CG]/+7!HR7H=B(;T8N?C3CJH@LE1S7Z/=P`M$'$9;`IKN]),F;&LF"?`_JX40:Y"L*9E&405.V]G=R'D&NFH%A)/C/18&>(`BL1B"F$6D`M@+!%2+A&6CD7+?`!A50Y$:1C)HN2W[,ML1N@H3#`.I1]%3^I3UBV`QR)%]IT^(`M>8)/=0]K;\;"&681:\6NM:R@`G#(QAL31*0BK[1OP(T?`N]MXQBK?QR#T>]`M"5EP<+F4+LLK(`RX&#K`*=*\[`=4)LA!*NJO2`M#'KH#56"+!S&!*W\)`JX!P*'P`@8>N>1'%ZX?NC%\@>B/K0;$8D6KJB';"JY`M#!R1[!2M1>T`(Y'0O\!RN\UL2(:?OZ=`RJ]U2#`G%%49R]@SS[?J8'7.]&OF43-'$OIA1J:N`M%U/?^@D0H>$7#P/BRW"=$W(W'+D"QVGW(:8H]HEL!J]"87/6ML!R`BYR]C!`M[XM$,NJAS#%GA;`SL`MV*H1PA,*#C=!V5E11L@J9.SQ9N#J(0KDE!.?8SN3H:DD0N5EH3^.T#`E+\M`ME+UKAK(OB7C.G13/>7.6R.?<2/F<'F"V'.S.D/@^P1$!X_"7QMN].+;@]`Z)MX.>\N2D)W./1L&U#?.*.@O#A^;ML2M:V<':T46,*DCGG0K*^"6WL5AZ%WI]) M&/B8<1?`.Q8CN.>&5K4,MC#V81.,W15$`&`GFY2Q1YM=3S]7F[J!2+:P^/$IML=@WKCD2:!AA]\#U,?<8F0D&PN7#F!.*.??:0ZRN8%M`^4O.=A'N!2&/&88`MKH"Q(V8XOBY9"U\)25GON*\/71Y/X@M9:4F8TI&4`?$!*4G=PD0.G9G4*\|M@C<(,,U9V<++#L1(/,.8H2G4ELL/E"X7@`8K#*/NA*USF[+=<0>`^5SI7C/.RGCFTM@G3'??L7VX0`MTC&,=Z=N@,%ZFP,B]?)L^?1(Z5.O)+L$CJY@Z5O*ECONTF.7(T8A=G&Q.N'R`M"3AN0Z\JB[3EV`]*QX]QU:>4]5BR<.X$TQUW[<$^`(.SS*.D7A+]PBCS#XZ0`MV(+*L11R.*=2CEW'Q+MDMV00&O[.8>1.PJCMCX9BAZ:8XJ"C9DN\/U1-E!\E6&^`-(^R.MW.3\-YU?[\/`MO"(LZ,L-=ICR#:<.UQ5LR]OJ.,*#]YFW7.^ZMX^6(RH?#Z-:?;Q:`MG"W/JB?*Y*AM.3[[^AQWW9\?LEVP$7KR_X[.HO`M/X]]#&*:$%.QEB<[2V"=*8FL=,#KBK?E,?5TF1R7G14%)DVPLZ4`N^O^FA5FM"ZO:QASL@.#X^.C]Q[76N6;MVGF3_=KU72VFZ\NNG+S8-#`TY681(NIFWGQ=`MVWES+V7:=<"HUZ+MP*.Z;(M@4/<2="O>O>O5:]5VG*XKU:*[U=V$],7PWM$5M"]\AVO%U9M$67]IQ?==*ODO>/U:]M6W%Y1L$6G]IQ?DE*OGO<H[`7D?4VI%GVN635<7P/N/5UW9M6'KA4)(%CCQRA&P9.=`MC5WE8Q$-FE5%`6E9Y\W71!KG/I%FU^'1Y%"K9<1LQ-HBB-03D.V:/:X:KM^`M.:!=3K=E:Q)-Z;K/)^F6/I79.14&07F3<6Q"$GU"`C`M2-ZPT!&/I2#G/).Z>/%OC\KJ`1AV&U=#)A81DJUN`_^Z!M.$X>E/UR?<#0>`M.W&UO[V`U(ZG/2M9AQLY\B4T&T/K3H=0W8#2]UQ5N$AGH26:6[!\D`MU4X]C-S5[K.-BG]&%G%B>B`+>8I`@Z%=QXYZ'YG=(&+&PR)"FEWMTL<3(W\5`MZGB%.Y\$*H:L+2)(/76M15`ITE1B;`>QI=K`:#:?.F"`"PB!3U`_+1FKV0?:&I=`M5:CKZ]F0X4*<1@^9C`!I`DO1O[X\%H'69%`N*1ZIYV:&"W&P/A$[R\A'*>VV`M6]LOJKY\B\!ILK^W#U`U?H+:(W8ZRG@@/]D!04,2)`LQ[82AMEPM8D8]..S$MC.O\3*43P49^=",Z7TO4QI6IKM]VP8L3"(DK4$\"Z;>1],*EW5J&WD:>*K9P/`MF(PGX@4$`(>!Q1B[-)X.(5?RP-H4NB$R/W>%>&*[>,%<;K8#`_L[5=\Y3=1WKJ3ZZ9MTH'Y2`G=^`MB:V2A#IG2_7EOBFAOBSI:Z)^5<7.)0IG>J.^\LZ!EEPM@E6S.]O\2$YS517;TGM0=+BU!+>&9+AP`SS'@2W.VQ7&`M(H+5RSR51V#+D_:HN'"N10R]WAL>(C5\BBM)5>+"%.O[S0X0]N/TEJY%'D1`MF8M^(..!;#.C<)EQN+"\Q/A44ED$HN8U!F,@B@WDB?`PW)+".U&XS/IET2\WMM@0%H:D&."!S.1^]B4_/!%)S>2S"4`_D1`_X7N1BNU+NBF"Z\!C4/P'@NP5N`MP.DBFC37W52]/M"WM.;72EC&B#DC>Q#1O.1:=GG3R(OT*]8^*WI"E=NZ)I+((OA;O990'GJ=+Z9-51.B+)>/0Z`3K]T3Z`MOLUKA(K,]V$<07[]%XZM/PL]J_A;Q%^;6WS*YRY2E%TOY>R15N]IE7MAV(G#^5@C=`U)W193E_EM=M\19!HUER4%U%U??5]KU4;'64[K-.BE!^%F&BF===7P*34JED@U$-GQ6/IQF6Q`MV/AV49$`M4W86(:%9RZY!=VVG,/-Y[Y'[G]!L)D[=R6_!%PK^0[FNG\4W'$C/.FC((X:\MZ&00L1@/),P`$?\ZG8$D'I&Y?F*QUWK@4#3%)P-E"@GDKI&L%!Y#L22*\[`M#,U.,4N*:FL+G3N_H`!1#]]-.(!_L2YO`12COM.TRR9X6CZ^Q^@>Q"DU/]RWG<1/T:0YF7TGG[0*,XA.`ER&`^Q%XZIV"`X(<(8U&\A`MNES0E?H#/]`O.Y]XD!/CV)?5YGH8D.1B]:.8,IW%$QK6Q\/&=M7U8R7((3^Y).Q5`AF.(]RDJQ#28:O<`3)`M5FRE5]C3NM";%],5R_,5^=D*Z%6*\R/+(W;YF0UQ9"/3]VWFC@6[W!9D+@:-`MOL"DW'$(U?06HT!(_AUL+2LQ#$8@M%%Q[@0B%+[W"8;%M*Y7KH.\%]#+Q8$`MH`]46\UX4:BW!C5-"\=WPKAYBN>A1"`>1*+H:\(N:*KD;.2RJIS/KP@PY_P7987]553(C+RK75H##40<:.!P2M[1`M2*M28-F$%)L=(\[.::FMF^D6%KF#16Y@.5BIF14$7>O2K\M[6*?082<4RA00`M84'4E*1YOA[]HA[TRJ$;ZB.)KND.T46FC"GQUK3J\(!%FMMIV*U"IKK*\0G`MWV.J1K]XI>%H0-!%M.:B4_]'R&>`2(UZZ^G:H4YZ/*M,JU6R+BMWA]D<`M1.:5]NF(NA!A+BC46<2A1YG\>T&_QO@^O\0YM@%BUNT`*&4)E*YN3:TB&]MH.FK%9F7RC[4)W<1EFO2*G%92[5%U9))>(I_DVAR-2%EC72)7:AAE[+ED1+F`M"PO9S9:RL=*UV:E&.5YX"]LY7*B%89N\GK@1`VNT=&(OJ.3;#\116/H5Z'5M)LJH0M`3.1*!];+URRS{"#F.=/UVK(FACDZUZU79G[(S-&E=1/(:CJTU333)G51&YD#!B@ZK7[M0-<2N$+&.`M&`.!6`V@$19W7&;C);EG#.U(A`*YVDB&<7%MHFWFSE6N@C58OI*:,0#5[R(U`M)^`D=E&QN`H^S`_#N.LV@]>;]>^S`>29LH;47=LT*@3G*LEY434MQ?:HL[]1MPHCRI1<0DRN^KT>GG!,>83]Y31);FAFFOMQ.);[]HJ3@LL;9VBM*(+"`M,:O2U&!Q1BWQ&191D\O&S1<1$UJZ.ATU.;JI7KIAH["X,T#7354,X-@P*N?6&%5&FO#`K%DG)?`!4W$\2F2!4+M%1=4:L8TW#]"/]M!*50^O/LQ&+9A=4D7?#B;8/50D/:%UTJ7.J5G059[B8]'U53]KN6SSLQMB1&T56U+/8AZ%4QBF4"^(`20<-OSGWZ_'`M%;PW*Z232^00:A$#+`_X&&<6QTR^8XA%9O7*HE]H+H>K.FV`_%BU'N9^GW,MK`M2MS13:[WF$W5Y\B5*5T<`=\`A,F>8KDY`,?%BAJZU"Z]\GL"W*[1GSM.2*R.I44VZ+23`Z0]IF]QH,:0[@Q*VQQQ/I8AKG1&?C.^K.WV#1TDM&;T)QU=G;M.HT+2X`M[3&4Y4>SZ@QIF]UK./1F:S:VM_B&?%^9Z2N?(+1BY&H.K\&KM5YK]+`2NT.TU6OVK:$TM9E#B]IK+M*)I\VV-ZN]@5)!OS!/,?!`3XFZ(`L!P`M0$R)BU?G121%01!Z**`JO'HNN@VF*++`[?69><9"5]X@ZXZR@Z$N6=XI.]`2`MY@Q?G[$`JWGS\K;&5.]8B.WO:G1+9>E"80=MK,$/$Z/-MC>H?X!\;9OO)LW{U.GY-`2Y.#O+DX3*>5I8D@U_Q"3]`^2$=8U2U+W>+36>(G(J.6ZA!L8L1MH\"1N\##Y1/$2FU2GBJ6/!ZP>#$+^RZ:0X>8Y?*HXZ"SI.7Q"7YT^EC0MW"`MJ[B":(@X\61)/@EB49""N2DRNRSY=KO?$/[5>;?!!)R,J7PG#*7ZC_))7=R9.M#HI@EOVH,D6#,I[`),EKSMR:X"F"/`\?4$L#!!0(&"'9UF#D3YD$1,`M`$Z`0`4`;FAC+3(P,C0P.3,P7V:A;"YX,6SM75ESW+@1?D)5`L`$>;8EMV?'NVF7OUEB'HY1DJ21YL`N4@DB,!C$'F`<'?OK__"8DR`;(`F"6E>Y+&D&`M1W]-H`$*7FA}^>9K%HP?.!6'TX][AJX.]$;8ABPB]`[CW]288WQR=G>V-1(}H`MA&)&\<<]RO9^^?FO?`GPMR#XC"GF*,'1Z.YY=#M=T`CS8S;#H]\^?9^/@M'!`MV`>OWXPO1E]OCT.O#U[`(S@\# Y^#(*?A2$?ZmO$GNO_KM#`H\D$52D?W[WEQ)&R7+#NN-W^YG7RZ;[@S]^"9M`M>_CNW;O]]`ME4T'*&LI!#`_=`_NSB_`:=XA@)"%4="`18L@[T7ZX3D+49*RL1;"`M2`M`_144S0+U47#X.GAS^.J)1'N2ZZ`1QCK.8GR`)R/U\^OUV<.<=!J&B.`7`M(9OM*ZX?O'MSL*\,[DNB$SS#`_DH2W#P)D#A`Q9$$$5VP",!XY3(CQGZ%@A,`M">.2D@>Y$@(4QSDXU6J^X.%4D3?G),1!A!`$8B%9D5(VY7@B%\DT#(JY%>U`_M=S%U\CR7ZU.0V3S&>_`MKW`I1'"[B=)1S^7?>7+'$(\9EU..G!,MME#`_L`H`<`MI9J]\H/`_?%H(0K$01VQV1V@ZZS4.V3TE?

*^#H+)+4DPE!=S$>"X&3L4+ <32F MT;G\E,0D>99?+&8X.L>2R,N[F RG@QPM.)>="SIC=(?CE 17,V:<23G)>/Y@ MQ>#,%T9#Y\S9G=0Q?T0)K02+G K]V:U_$89\@:,K]"SW4MR84^U,[Q7/KLG] M &&3A<@:.=\PBS6PF'%%"4Q2'[@2)N_0$6XC@'J%Y*COW<0R(XI.4>RGG\@]. MQ9,UV6):]Q, EE]'2$SE%R>RR0.*95<7O -/.EP^9J(F:WG%\1R1Z.1IC]G< M6#2Z3*;8.UN:QK0.G>MK7Z3HW/%8 @.7],)U@BBV[1D[/U]IUSL%P\H](B MQ"?*

+QNG.N)TB^IFQZ)'L*#Z]TC!@+C_(]HP_.^'FUER#Y=K.)P[X5C+;8#GW M94<;[WB6X7)]:9,V<#373SY8OEYQ-L<|>;Z*D=3O.@UZ/MMU.?0R]Q"X6IQ] M;O8W=#:GG*M140RT@S57ZIB'(\8CS#_N':>R-'K%R^0QA&P.7;R2.@@MAX.G]T>.:+E09K_^SF5[(P#*Y#?? MF6QN#4.9^X_OS(6; <5"FOOW.U/;\C5"F__"=Z18^="AWAZ:ME3D4K%2VYD'6 MEZJY:5CA#1I4E"%D=@, @&K[N. M.EK

6K_]2SWT'/"TB1+LL9H&]G)VI4,\0(^:#4_K/%X?]K=Y<2[,CN/^*<@ M9O0^P7P6Q$I&BT#R:, &EY%99K^E'0;R"9)GKM03%2IQO,":N(%I=Z,)E- =6D#3X;S$WM+#'L1S3HED"UT;WG88;{'>RCG;>+ ; MX_B+]I&U@74UBI^17^-SAK4]NGW2+5VPHGRS^^2.<\8%Z[7@PD_FB@L[\L$G M)Y8S)NP>"#Y%$%VPH5K)3NROKD#;FQI.+*XV88,T'8>F!:%26R:S M(&12),8"1^HWP6(2]3)'P;)AJER'2$R#2*

*(:1CN\!<;&Y1B)>T MXKVIV]5^:MFZ0X.JDX3!P@H6EF% =CJ_RO*2<='XXLTQVT@UV(:BP4((%D*P*

M$(*%$"R$8"$,I/1"CB7W6BSP*5C"E;4YR4B!4ZZV)_+'8@W57%N?=Z@'V^U" M4)1MYA'!K"!S(C)%Y;/Y9XP3>2X13='.LARFE:L)=M0[]Q]WG#1V)}VUD. !% MXX5Y^=:,G]-^47:1<5&4]W%:MC*FG'Q[O#CM$RXS;Y[]K)=5Z7-C*FOA]'01ACH MT)+C&^0QSG'-$ZF"X6]5-F> !YF@.VA6L@S5MG

MG+25V0XBI"VN,U>|4N-# &>LDJRZ8?9T*'*#GJH|*N)U@%G=P=FA?Y]+519" M6]\9 5KUL[]G9;&D3#R)\(7OCZQZ

K<6_B9%&5=B7R\1!;]O\4M30>QU+Y2\ MN<4O31>Q;_H-L_HGLI+FW'7QR>EB^&6]=HVAY)/N,7SHJ4-'V_=V0_\3B[0A M.#G;8(86^%F5<[P@6<;+GJ-

4!*C(:-0\+NU#8@ MO+SQ;PR!:"-IY\T<#4ZSX#0SO"=AE[;T;F6U -,&S>3=_;,4NN2Q4NT)R%:Q4-8^;2[< B+XH=H"(O1$.=ESK>%/.>K_H%DU;@<

MWIV_2OCXDGF5\+2*8#H38\RWN;,LN>:_K5\TR/-RQ7<^S(=QJ"21?V.?L3D3W%7H@X1&63OS'7G$=G/S[-"/[?Q3QZ& ZPW>&WGTD:;T()+WL4?4

M132=[N]#T4^31^P"Y4O^AP^\R :EXE[%_1>?[3=;CXN).M#O"YYP_ :D>3# MHS!G,2_$S= G4U/L"S^X'[TAZI_[E!^^64/,'V_I93NT:.S.?OJFQ[@^/(2

M3C4_[I'G*GIS@N?V6![@=_<8!_\4!S^OS*XK7T%1^P MVA- QS3\H][LO)O&%UC5CP);TBQU:G7J]?TGM-O3PO7W3GH9I7KOC;0:M")@+L)> M:.V)

(*WUTX 1?NR38?)T";>|^V#Y#1.0#\G-^_2U*:,8H,%M% MJ3@G\VB%BI+QTU.XG*M?1>G17M/JCFW'C[B[3=N+H.'>K,5[L]*@BHY#![GW

MU.K(UM4.O!>,=XF<\G?E[+X'&CU@2*VH.*=S?EH_0LC M=DFDK]BW:FN@9^ZALG[F>]#]-YQN\">:,%4M9Q%C;YD;>^YX&?")C78E)2^G3

ME(,-3*"WJ_R;?0QNU MRI]*LM\&Z;A3G7-*?'(*ES=A%8I9$-@C09"+C>0*LIQ(.K*(>1AJ5;M2M" MY/?1'Z['"%2=;*SN\(&J?!&/D\OMRJ2S-

XDF#YU$R;876.H'8DU&F+V04"\P M:[+3[<5V^@%9 Y%C+UAS\I IR4Y[@9BC=?^UY<,M1%#^7D.5<56OV):=$EA@

MCL9>G.08\T"#R!\+H8WCGTV&K)+%B.31[NK&5)7S,(,W;Z/%+IH$94E$]Y@P ML@](CU =*XWB@FP$\<%P*B9D5-!#Q8>G*.>+]M%Y3Y_;%

<+A&^@N.A+"&"R& M,?Q!5UB,]5F6_$'S-8GQ73T6TI2[P!J=);O*UGRB\G;O,-OPK^0ZP6 5+#Z1 M;GZZK$0-D9&AY-X5"_JLQAA6L*WN ?Y\58^0?

94:A=ZL#A(+> ME+.W9.J)\B$;)9,OL\[=L]$_<[V=QE^K=S>C^.CAS2@0S5RO$]L_[)&[IU<]H M1F5>Z^@;E)8XHMO?+A@2;JR6;+1=

(1RRT2XZ$MCH(2[561Y;$+?J8G:XD_ :MOKA^B0C[I^C.V:&?(K=>S'OTGFQ(PM?&+8=-1LFX^N[TT?PG37DSPGOJ&L_F M+T\7T5N2?[UD&%_Q9<>/G;

(5GJKOND?SU=/>KWOU8#)+Q&O=;U0P6OU@8,<# M.]Z%';=\E@=V_ 39\7 19HR,U1@)&L=JAG?3S!VX$)W8.]Y9#Z\#W<[>S9O1

MHNK,.!XIT;E3]VA9\I9(IZ>LDAI CXW-O(2+'*@*<=+4P(&L3]"$CQCQD[M MS';,&V8QR86B^;ELB 2V_IVIHO4G%]\.X.1L@QE:X.U?\(UXP|\^AI"O3PK9

M2\KFF!0E/P?$2R>/:*J%O*K3!EG;_V[0Z6WL=ZQ 29P+S)-:A0^"D9KW[V/ MC.92LM/>ER:%V.QPL'(3G)$L)W&ED5O"3?N]J:)G]3A_]9V:[HU,%Z]A;K+T

MV(\S@_@UZ<_%T>,]4CG;0[3G;%5}<>*$-/"^,D:,@3(YA),(WK@M1X7%_1 M/7H _,$0/> ^>L ^N>^&H3H4HL(J])JH-CF8PT=K&M\$Q M]L=N<^#-

<1_2_N[P6E:"'XI(OSY']]%L+=MWF'(>C<10XBZQ1#U"[YGD.(2 MQ=6E)6G.9%4QBV'R;2<.*"R^VZQTY+U\SP6XRG*^-U<;GCQ9K+S@@/(>WS7|

M,)]CD404<[,N%OO+0N8T;M7&@+W\C%98F7Y85]SMX[9\;HM[=$(HB;Q-10:3 M4?V$:T/)H0+;CT71/M.]+AP"3T+:BBY1&*V/MA!U<3I1%PJ-

@9J>7;Y@H@_# MT.E9O@2DJ&<'S";P!8N0;'C4\4ECI+,ZV##>K1HE4');P\+2&;^[&F+/C%9 M#\12&I[47:&B9*0@.+?%ZQI\84!JUUC*P.X.DH"DP[BU(E>-

Y\4XV;"M7.&4 M/.E9W>2DJ&<'S";P!8N0;'C4\4ECI+,ZV##>K1HE4');P\+2&;^[&F+/C%9 M#\12&I[47:&B9*0@.+?%ZQI\84!JUUC*P.X.DH"DP[BU(E>-

Y\4XV;"M7.&4 M/.E9W>+U]R'DVOV$DB\D:I5?99[ZDt;FG*OL^5,X;3#?Y$LV(\(W7Z;#H:

MYL:4D>A;L7=/A/>!QHLFIX8"+667PKLT.3$4[OGW^YX,59M3P^$;[1N%;W0@ M# *A/4'SVIXZ$3CMT^&TPTW"43-U&\P>>._'3KSTI0?;FU*^

G6%^R1Y5[B MUZ1UVJ,/42PR7RQ<*O/8P ;K&!U_L*6]!T[/"])(Q<,M5$>)W(*HHEN"L M3LB1Y30E2?6"]

[Y@I4/'*%]&\Y1^RZ,R0V5"BD,B%"UCW=N7G##7/4L;&&R+ M#/8Y2E$6X[LEQL5%BO*\@+AN*7M*UAK>X1U$MQ0R&_RF9K+*XN

M9HNS/,>%N,UX3=*"\([+@F^=G7.SF]\NM#W"22YOH5?RC#YHM,L.:G27]<\G/YQGZ>H]4J0>#]" =5/-B2

MG#]]R<68'\X&$5=4G0B2(\7%IYQBUK#A;%\S5]_(_-<;O#?R&S^:TDXE%W.% MZR3B/Q^X-!N^U/G<.BLN$&-/?

+JH$IV#Z@Z4GE<(]4*P6[[#.B+>3=H*_OP7 M1R45_6W=YD !")UDYIM*6HH+^N])SG5-E'YDM%SS&OS??.OAVTF)D^W.PL\& M&[9BC!0HNU30WF":

[K.2?-.(=]V_,-C7%ELAT!?&S@;"S'0KB$(L#L<;_G# MLPTBJ5"ON0HK=,%;C%+R%TYVAI@$*;-&AKK\QZU;AF-236S^2OZO?2#N]K#A1)

(>:/55T!$.)3'F&51YH^Y +=^!:C/MUJ#]J 6-$'$F)\ M!S#ITW&]T0S3^ZT?KEXW]^C1H$\-=:-L+!T3RSWC7S89I*,ZXYEQ>R*FVJ1W

MOH"7%%SK^D/W3I#)V^M/1WX.>,.^:ZX|F?57R'2XSM>YB8Q.CZ-4PVM$DMV&M(]Z;SG+,-=M*]MJ1!>XOI+'Q+,\[G,ZOLKRLG%_N4 5GF@0?V,BR8:

MN%80G]'-DM[!&QC(1H4+].'4VSG"'$6UH8%PCVB!@NQ$%-#2&_C:X M:LSZV=# N$;4W._5OB&G_3WR]=

[B=BNW-.MRW#GB,.YZAUD7;41=]>**ZK(Z/HOLI?13)H833<__M(?85%X)'.%!WT]XUU1U-Q_CNQO>SXNDF15DA8+W9A0I?

B^7"1:M2*@%ZHZPW6&\,, ^D3R2@3K+A(V;RD:8)? M!;:U;V"P_@F'$U\/VY#XI]G<9]IVX[KWLY)H7!V' I$;P>1\/@6@LGJT=8; M:G-

[Y?;%19'HJHWJ/6M)'YH+#S2Q)GMKO-:O+L45!8WY ZD2;KX/?G%7-3KA

M,OOI7&;7!7A2=5%%/*LO".GONH."9'VY^@^8,"9Q[[D+@7"8G2#Q9VA56#F^D))!:S HQ*KV;I]13BW[]Y(\RVUC%;!GZ:S-8Y0M M3-TA\S>

[@KI=K*HOA[$KE+L$I5MQG,*$[MEG+R%##RG@';':S,6TO;XC'K[MA!)@H'\)"LGS4[)%W#D8[%\G8'JX@AKFI?%% 5$;*C9S\E@P38;88"N?M9!+,;&!X?

POPMKOA"D;X]X!PZPNV<-/" MW*/I+L>U?8S;WS,,;NM,;BX,=?,_0$R*A!SB.7>SM;[EX0AU8QE-WG',4ZAN @6<> ^^"G8<488FA^

M*_@TS!A#&,T2QGH6/]G3:C;+=>/+P=`_5FB20\!*>5W+]* +2I9R&@=)R&1MD MX/+<.@$":/):W"F8((;SKGV>37LNPLF",>SC'!;=B>M*-

FZLL>+DQJ7C$T#P M43&^B5F/RH=LD@?>D \&^,*<Z6/.C1^TM4>5.)ZMIKU_,36-'Y:S0\-,#CC3 MW&(6.)%AXE\Z3+3>7O0[@&G_A?B,%CCZ-

7K8.IVC'"]JRB8O5RO$GL0#Z//Z M/$!I1+(Y9:OZ]L_#4\2XBLX$O;VK%B6X0"3=;U!.9^/M?M[)6_(NNA >F+?X MP/P?=(7%*-]AMB$QSN_JD9 ^&@PJW\-

;X6L^2WB[4+%@%?IY%_P6;S!7S)I>_MJ7[V!QI?(S\L.%=+!ZA3[C_N]MWI-*V&;3MCFI]XAQ5V^XXGS:O(U.W%*>F+

MII)B@\JJ2=2I*S[8TY;F+UI*:OCVO,,@_?I(-YAE8AV><565;TZ"L-]%4]>W MP"6=,]@YX",/%S4%P$4Z< #GF& ^E^.B2/]=11)1%+.EIAQ8'>TBKP%Q#+;:+

M7]QOQE).)>6&&665;9,*?XU;8'5AIW*_F.F*Q:\H.8S$E8M=#;2RK%NIJTM* M_"P[*&5[X3" Z]X[\-GFM'G,T$S!*!*CM/,5TKY;A,4VL2?I%A>E'G!)6-[

M)E9<^.'_2_A.*,E@"4(CP&]65W@O(;R7 +OUI#;A2,%"VLO72+1G M#NSM(H,DRU5AIO6FVMM.1N>%CK+Q[G!1B^+U<43E]]"4LW

40=96/AJN#H$=&ZCGVY M]V=\$@$=H_9N^8T7GS;!1O8N_UB")AMP[T%]_ARQ$/L*./H+ ^=W$GZ/,&(9 MER:/N%Q1+F[P'SO-]G]%61)]PV2QY/I^A'BWT

)'62D(2%$NKNY=U_7SJ.3(M1R2+8I3&95H[VGBA!Y3S^2!:2DA:BH8:/M[];L/HN^'NCL1$H AW+2S>M9"Z MR$<_.2"W 4;?";5]OFCCEC3"2(]%RI

MDL[VU[!3/)Z]32?I6F.9$('G/@*O=SG_W!YY9_6)][DZ\$2ZLVJAUC-X5A;" M'$GD >*&K;Q\IG#8OKX23W4J&K4!VZNGY0*:N+85HC-/,#K38EC0R!V2(2S(

MS(UO8#38 V80AA?6<]K32>C+ ^C}:)>Q8!9 P-B'#P9>*TVXZ4]K/G&Y*L M[V%+ZHQ;W\R%O9VLP&RZ\Q]#OOBI6R!7!_'X[C?@NX #I

1=ND7)B+DBJRX MP9XE(C @B8Y?4CK0 [DPV'.1:7N;\CW"55!%5&:H3,@1"Z[UX?;_22?^5EMB MVRRCC9X,\8ZJB/BG:5]&-31<[LDR57P!EJ3ZE#

(ZI/@=7:ASNVXS;H5Q^6J MK.*0M^&W*S[&2SX>9+.-1U$GVC*MI[9W25*]]RI>^2#)5;9%7=TC2\'W'O?CO MX;2MG":3*

M$*F,7NW!0GFLW\.6YLLQ>JT3S>,SDFA\,4>"@SD1KL5+I4,)SMU5#EGU(7= MNF2!SLS7]MG/$Y/WW3#R[E38%YL<*-6/]DX(-(#(.YO?'5D-

-9Z:\!RCNB%\ MHE%.#IMXE@LG[TO&UUZM_-5+LOKC;%V%O'}XQ"PFN33:JWU#8^AOI>'VT%U] M.^Y[>W@QK&%D5-U35AQ*655)IC*/M/4&[=`SC6N?

L>|&7(ZDV7,:NUF)5?6Z M<^-#Z0\30 :DJ4P\X 7+OUI#;A2,%"VLO72+1G M#NSM(H,DRU5AIO6FVMM.1N>%CK+Q[G!1B^+U<43E]]"4LW

C"_WNW7(PPZ'>RQ55C EY9[MM#=`QHZ,%5/.JT@E&)!R_X%WQ[T2!W,/D'?'NQ(?MPYO[_0"_6;6@>T%HS7R MU$V=T(*2Q6"PX"F=?]_!RO!"F ACW.5;,-

!@G."IG:,-4S.O#88)GMEI_#"! MXFW@NNE4B+A&3'H*>82C-?9'S;N:.*T?>S=6RL<-C!67BLMH\.H. ^$\1BFO]

M;WM/^]N2JX(115\C_EU"693RS80/^YK1J'I;1_+:3JOD7K:^[BXGE]T>A%1: M%E-IG6_?YC@[#&#.S>U+,2J0K(BO0Q9[,+G'Q[\E$E733YC/N\R%^]2'6?*1

MH:QH? &W>X,]]NQ/L=YFZ.M=M=[N]4F-N Y30F5OO5NA,M>RC9;>PE'2I M_9U(9%#(6 38@FGK$\<7A/2^9= QYHNK'3!A6BFGON 37@8<=33&

()D7].QN MOZ:HO;4T+?BZDA7V%N0(<>QLR#CG?=|%5$141&SW'N!1WL\7?VG%[+9OWQUW MVU7&P,Y:9&<_H0S5Z.K$RVEQ3$NQ^2QVCTA?8IQO-

_0&V@M>N4-KP^>PLC7U>,O%&T&X*-L\/ M7?&!^*_GSSM6_]?H&-"6#_Q=X.]ZX>\Z+/O T)T.0Q=RB@="H66\.?0(.SF^_MH+UN?9*4

%25LW>=8X3@0.T@>W&(U)O?T>* M5M.?6Y%%?7S)'6W4G[2!0+)((.V#X/DQ5;^9C8O;HU>@Q>\%%8OS67:'4OZ? M^>'1Z 8*HI?

V.O=J]WYU_8W9_$MVG)A8W.M"V5.#]$;U[)%!?:P="'W4WQIU M]\[AD:>E#BC_A(LE3:ZR#=[>[).R109U'?=J?]7B\$3]\=OU? U).P6OZCZ-

MZ;$@SR24,6+*2NUHV$"+!5K,QK87"+) 0 6"];!0$V=@N4O:H WLW?30LD*DV MXUU FP8?8Q76'F$V)H!:VFXG1)RU4[&=LVEO?

N3ZUGXJBP>2N4[V%5>W@Z-\ MOTE&;..5L>J7<\JBG _X<<'MZT)'Y5L1;HZ$<U0H.TLTG:?_[C2O8.C M*V:/OG(TS2 ,E],9[_1MGH/&>+GY3"1F?

E/1@5Y8:1+E@DIS<'E"Z.FGBX+0E26KEVPXY48OR!PK4(@4[M\JLC"B(;,0XEQP9_6=YCHMS%'_%R6&3 M4[(M@!KN>Y!?;?2[ZB"2\]$'_ Z7O\4$A#;TVK

M#W3%] +ER[,L$?\1!RE?!&+FP|\<*7'\@FOB"LC5E?$]XCK9R_8#]#$_5ETPH M4!Q\D:*Y_H<)==]0?: Y^%(\Y>"H"SN5>S_+SY_V/_Y!,,:YO+I6AP<"DK?

MK/)0_?IT. XO&?V/B;.X2;MH47.8'EUEZ|+('WC?***<9H,;@/7AKW(.W(^O!

M3\8]^&D,/6B:V\K$O08U!^]1_GH[,NZ;MHWA>WDK3A#Q"@ML"@*]NNW3+]OK M5987K*RN-2OV975IIY+?8BX"B44$8*/N*.F"KEI(T3*D"

[EW.>\9RO(Y9B(R MN[Z!+M+WS1LF%.(?3B7.0]0K4Q0;]#9AF1C[M1:OV M$#PMF:!!3FEK^8*7/N# F)[Q)1REQZFDMOY\

'FS'\%U=HC[S)=98@"+@]>W18@/EGL#0O/.(&G.*T9?5Y2(?N2+.,P!*.-9FX=3V5/EQEA'MZV M3D%[FLV(06H;_65O*QXQ6&W#-;W;M-

4HP2)T75Z{(")3%5E%,P!HH8/QP M@76?5>\&L^]>WGL%\).V6;=D@7QO"PV4 +RO\=|=^/V8W4L9LG9BK)B>TU>(CZ@AMMP=<0RDBWV4U>#OJ[X

MH+*?HSY$0,&?E1U4ZO#ZW+WZ!'G'Q[YO9N]/ZJT96%,M\9IG>A-!2GA6EA=V*GA\-4,&A,$/!0::YXO:9:>JB3WB

M3U(L+\J\X.@Q#F):2KG1H:8@>>RR]D=7F+O3?I-!N]K%BX M),.!);$_,5DLN6IXQDU*M,"?2Q%/,)MO#?XZ==BL+(21F)8*,ZVGVI?X M(0-Q

@R5TQP@;.1GD6I&H$$89Q]N7-@ @PXJ.:7P%83<)2N4GL7>08XH$U0 MT06@8'YQ3-@ .XX7U1>F#)CZ%VUI[4,P]_!;:MB35R?:<55&W"XNRM

MOP'VIE:H.8PVLZ!/_5Z#G>&%L $F [<^1,R>>C65B2GW[%O0M"8WC[I'8GFE MEG7'T,%F-6+-#'89P1>.2=M,!3(-GF%?M*XNL#1>IO"%

(X"MH6Y!%+ZLK=8H MM$#2X{5H$498)-%R\A]CHT^T&QS2W5$%]T?ZGN\5[[XW6R9=PK#"KN4N5V45;'#L)>4_I[C!77K#!"-1/-WP4Z7RQ?^G).N5

ML]>]-#_4E;LC^;BR4_:,D&'W@6/OEF<_DEF):MN.UIPA4!/@0HO4$D MN<%QF#'}];E4HR[I-#-.8!>^L MN$",/7&[I\K6)>F%4=VA4@XI.R IYEC6U]'!W-

HKL^2:H >2@LHZEKMF+O6]N!Z?0N;%5*EU M;/)F/1&Q5T<%E/EB@!M*_KC3 >Y>X"N/<[X+JJ0.IXCAI$DV^D52F M0+[\L^L<,BA;$+

[\"MIL$+CX\;B^U:..0V]>JX3QL^U)0]R3?W1B+.93RDH-)K-4QU86=ROV)9)0K+D^.)%>R8HX36-5[\#5%F0G;"ZXW M8#(HH)X&JS2&?F@7

;C>@+VY%2[RV?Q+7]MKH)Y(ZKA/=E5KF)]-7U%R*(GU M,Z>I[% IW80L8 5!4WI0R6&P*RLX3H.&UXCL+AWQ[?UH6JA'P."FZ\1NS>XK

MS1H&UQM';SXR9>HZ0*5Q|$-N*:N]#)B"3OWZ#\SOT,*54?54N\^9-^"X?P4B M&4YVT<;,?.1S$DLS,<.KNDV@A]/Y59:73!"0"O,-AJ>&U!C\!YH9QFL4DB]

M")%W-M^_M@CG#DD&^4$"Z*=(]H* \N_SZ1U(T*@ M^,1MG\2\G]9A(SO-.QQ&.T,(%1ER1893.TT360"7O7QF(P.GPVTQ>SDT

M1H;1OB#X,A$8FE\]@48>,@:&XC=/H#!V.H$1^MT3A S#-.#:G[&*/$"R'OAN

MH[KPXXM&##.C#/V>OIA4\&Y#L&IPK%J814/F$FN%E[6;IUYE5^QW*C9XQWTQ M6F$;FC88RY.#WV7U1@\WP,;E'YLNV8[S M$G6?-&)

M.VT]\@R&OFC+9O" H]-]T94-=Q{(%3A?'*5FT(#R]_CB.#6#1GO-WYZW= K MP1 ;;=8)BZ[2J4R:[E2Q5_]QX>5[.$I>:+"K],'?^KP?^<+*"$870>W}^$(6

_C8_T>+Q%0HS3$#I MQWTA!LV@,4T2X LY:#B!NF3DM[<[#W!FF>&FOPSN"V=HAHLZO9X]HG""$Z;/ M>^E>^=K- #5-L7J*

;O#7VO8%\XC.^9^.MEQ>5>RY_3_9UN:.8WBWK;W.F/{[/9Q=4E97)-N>DN%8F!]T6>/FF<$B0IY9W-J\GAKA"\WJZ
MP'/EF;3B0]f]\J1+$[08L9"T+6U9]+4S7(9,?2T71E.PLR2>4H85(J\/D<$C+=/\Z M3KCZ2!+YIQL+]/1=59<;"W3^[@TC&
[YIW*"G7=Y'J02ZHIUEN:TW)J&M-\7N M[\-K1 H"_K^D/K!BL6'3;G/[?FHFW8^X)0C_X.;SWQ@^/2>_ML07*MIGKMN-W1TL^*'G#YMRV^NCZUG@6MF_
\;-?QJM,TM$.+05?6_!]f7;'>2^N':S"V=:>#+5:&VV("L55]N"K6> M0&ISVI<[FVWA@9$OOEP/ZK8+-1,C]JX)30,;&'7BRSGF(H!GY,?5F -XQABS
MTMGT]V[M-,+5,ZOIW#?WYL>('/(2\Y^CU3XU?)3O@S(DOT59$K%]4GE)H58. M/?
=RN?,"#M6WX#JTZ#I_Hf"V8;#+P9E3EF.O#K&=#=CV(1BNV]-7=]8ZM].Y M%^KW#24BPROUX(K >*N&V]<M!P.?B ONHJ^[XYC-,4\;7 MWG-
9E',15,=I+R0GUQ;PUZ_DONB0:76G?5,]#_VB'_J7I >4N>%(A!8?7';M M##)YG'F@?BB7M+]P4[GK)Q$(2]\RCE]9O=(GC_;0E'8J>9-V)Q%;532$+[@/
M7^A=SGN&LGR.696]J/(VD6PQFS=,U_R>RY4W_TD9"F3C$TXQ^G+WD6XPRX0<_M.YV"T$STYVR!N: X\VY?'5IRW:_J:@JY;JC(;A6C]*Y\2,B&Y$)>32=-*H
(ML,X AF*(\#F="!^=>D%=;,>^@*GW@X&T.5 ^\.P9S"Z*> ^^(M-0#%@(CP);K' M)W.2I$OH3X&F(%I5E\"?(SFD[G^Z':)80A2+810+C-3T;H$88^+Y:E'B
MT1.6A\"5#6SYD>(G[8(W\"538 M-&KG*09C-/*W4/43JF. $Q@HX]=1QP04W DXVIA=4CXDGE6E?]O-R,B/B4B,2?1NKG2G9\;MN>ARB>BU&]79V
M>=F> WW&<;J9KW['1@[TL(;:+ON$BIW \P*S2[+:!]TM&R\7R'F?_PHCE]IAI M*]\8*"E_USY<\E7P[&7,GC':MS\%?&;93GS1$SOS2/>-B>+4ZSQ2M3\%?
*QM M0I/=>:QL-U/;8\0=2I+QR2VD[G-NR!N>$B)]S8WF1D>)1&^W/ ;2TD*07B%*UREZDQ>0!;&7^VXO& M\!;/[G/3.&K##RQ-
*4Y[L1[>XME];AI'A_B!9;\3TCAJQ"\0N\]"XY"2 5XC MLA,LV?JM+,/@DLE !B6E('$GV[^(_WM ,>:_^?\!4$L#!!0 (&"'9UF3 M"9 !?BH "\T)
;FAC,#$N:G!G[7H+.%1OW^Z24,2D*#E-I:*$R*%R M6)68)(D.2I@DR3DI9[.44(I)H2BF$I*8G(\90I-.0DS.Q\AA&*XWJ
M_W^_]WN_Z]O[^_:^KKVO:Z\,,\]ZGN=W7/=]/]>$?s=Z@)6'C$V. 3X^/N L M^@] >H%+1GI.%P# S S8\@#,D"03QU8@KX31E\G^?D ?0O'_HZR\^_^)?W
M BQ6_GK/^V4A#BS}-2Y6;;']f_>|>;C+CHX>WA<]KZ!CX4\ ((>(M .&P!(^ M/MI/[XM?@)]W"2Y=RB\@)"@DQ'LM6RZR?-
DRX65"0L*BPL(B*!]+:.+D81G2% M&.\];Q/>DEH7(MYNDQA?TZ5I&4#8]/.O+Q=>LU9JG?3F+8I*6[=I:FGK[-J] MQ_"
D3'NH,FA8\=/G+0Z==K:X;SC!:>+SB[>5Z[Z^/KY!X3>" N/N'DK\M[] MV+CX!P\3$I^E/$]-2W^1\3(W+[^@L*BXI/1M=4WM. ^K[N@^-3=^:6VC?6]MZ
M^_H'?@P._1P>F9R:GIEESK'F%WAQ\0"\?'^N?QF7.!K7$K0&2X5X5- M$%\JL$%=<-4^"R%[K]4;-.XMD]@?\S2G:KG"3DN&Y+G+#<)K-FGV;I[DA;88
MV?]<8-? 2Y']%=C?<;4!*] 672+.+2P7 :?^GJ<+*)D_F5/%D;L]5==(^*Y/>](CVVMVN9"27QSRJR_NB9VBZYX6Z+"!(G M(*FG8HO["KF G,'4-
3#N&34HE__=#J^6)&8!>0\VGQHB06)EENO0X.M'$6#R M.%1MYB<$AT^((D#/!S5XVX/\U(Z?_CX;%_9QJ<^X61?9UK2D?YY#9#F3 03X
MVME+X:PS0H!:"_I6W[5,#\5Y;$> 6EM+K(T'.V66O!L!PA,9&*YHLBP"5,6" MG!-81L\'SBMf1?(^'8.9&N9ZX.#V-_KUMYBA)BFTMY3\)309\V&D=/[_)
M;^<0H"\#1U?O68T .YTBS)LL(Q @,B41^PG;6DP:@+Q^DERM+;S*QHDMY1.P M-+X2G-'V@Q! < 938/&,@A]EH(%9-;Q (Y'I:CVKP %W
MQO"'"RV(V=RT@GVIAE@%VO0S9&]YM6@'H/FTF&((URZ$ "]HR63ZSAY()0 MRXLRKK 6 23W<=/U`!#0C3&" !W&<'S1?M
.2IX7_CW<_S6LK9&;Y5HOA"Y" MYR8455-8ZHNYXF.GA4'+ ^2=>[^KY".ZC18,1S((4NJM= .CL"9#F'P6!+'P- MQ'2Q8)NPEB+ I_9>!*
>O0EIOV3&EMUF@V@7&'1W!&#:6H@%6?Z3W%2})>#@ M8B!/>8V2SGS 6#;;R&&-N]?] LQ"7]RPELSQ-&DHEE8D/F52>@_R>3ZJG MZ=L?
H7'8E0 .!TH&5ZFKRVQGL8"W>2E^.%B:$;BYY$0Q/P:#IP>GI$MDZBV5; M/O@]@% P"!;DTQU[)Y/]%2D]A/%VT9T$NT2)P\POJ^_Y^N,=>DUD77*R-Q)
M^-;%%T7PE/BIV,[>C[I=<1 !KK=PG!ED(AI(Y/_VZ8UTG3?#U(UC,B/N8VDFAR0R[E4/]S2Q_!!!8FFN*;YNN M&M7--=JQ^!{>OG_< MK*#)!MQV1*O[
L_:C65>5A1!X?H2&FU&3<&^:OGOFH+]+5>[KB^*.M2<'!JO ME;&K[!:CQ4RJ9G/AJ>SRPB@'AZ;+2G65!LDW"%=C_<#ENFP=5L[`F^J7X@9F M9O #T
%H^HVU[_PL9<+A7,"TM-.%.A* MR]!*>Y#154UQT"I,,G*;472)"9VME]NZNGI.1_E21IJ=C13>+4U9!]I.[*T\ M/#Z[=,5QZ*6?%#G >B'/WXEURU6(I38%/D,?
KM 8!'"2:A1T:=OL7+:NCSYS MXV!S6FG"NO[^Z)5-A_8! C9!K4(&WX>MH9>[!.0)(&N)7(=:_6.Y<)B97@&BJ$G1Q!$TG@JV6(O'N@/;]' MI5;3=$;>%Y>]?
D'^I?846$G3"DZM2\77.WE[M!3Y_+2ECZO4[%3=DW$2&)?S MFCB- "^+139_)F?J$%>>.Y]-XC7)3;1)3+B/OB' >U,;!*@\P0.!L&\3N94" M7[<>@I>0T:
<2_Z6#N4V8VU!B"&5:T$B'G+[3N"0VD)](DIQ8<,7H%$M1QH# M;04CM'6KWH-YCS\<&ME# Y+=8Z\@P+63W>%@#P6_5,_UR8C.@H;?_9/PQ^*"
MPL2NQD\FNW4P.<+9/!,,DS(LP<*GR4^0#' !NY%YY?M;-0?/- M:R8,-?8D7=O?J,["*_KQG)SK [FWQ0&:M@=GIIU.BNC6T+++CN%TMUK#0[+4 M4?
61MBLZ%L3.CO57ZX.$;-W? I}^0CPF!;'PC$C&)O)X9JS]VN[9"^P-7$* M%C=U%@]^])9E>UL:,J.9RU'D@_J'9;3_\W$A{GH8+X@RV_!T{YK*E_Z]C%H$N-_'
MQ7"I3T6>0-PKP1E&_@,D5'(<1W/>V=N\,,+CJU!F E,Y#W=)(}M_$!3SFR[- M"[*PKM;3]2QG$@#]#;+'S.E:/>*+I%/[K>%9>S$8,8WY#9]R6\1VI4XK?^GG
MII.?(J+?U6H-30_ 2;]@=U(WXSNF("+L$.I1E1DQYU-M6FTR%I_];P9'2RT$^NG!F(-7V/,L#45<@C_7H-NRB0>FE5 [*$MFZ D2)B)G M!!=
<5OQX*H7YC+$.32>YNG_TQ:^8Q'I_D];U.>&(QX0MB1!? KFB_O/<-#T! M'9 1Q_)M@OQ9-D >O?JO^-C6#3SE!T>+=^ZY<(NC*#2^5$=6$Y6LN(\&?;M=
<,-OL%4HMTQ'\&5)!>:I4*QIXYDONP M2L_)N7]7:KT0(W?;V='!>DVW\0K3[;#8E8)IROD]_CR3;9E^I9(;9#SVYI?K MD5Y@XPA*$EW>@YV8YW1J-!
<%C=!'X1.M.I4IJ0%UZL(+4E&)1ZY^$5IH?9(fZ_-5OD? G]D47MW0E'RQVT'2D%F)^5=0J*&_K;@ M?'8$4QL[;I6QRO@))]?6 2XK4'I6AP!G%CUZ?
#&EW;P8\, M3JM*!(B@596 M$%\=1\\&0> 4N42L'0',R.#$_'-%S].JCT8OH4W4Z:!J[Y_)%-*X^F"<\M['# M33WR"BF7$2#O4J;YA8H^ MS]@K]Z818(GU]9V-
KO6<95IBW0&7Y5);>$9-/USB^87IN#675E[/#2]&C1^R M;=*$Z+3TU\^A1WV|CTH)%UNL0T_U"%[7$ *2^A'BZO#:HH]#*[T]O3^GFZ4K
MGSV&>C90GB+6.;^V(\(= =)HI#E.0Q\R [JGC9#P9%7D@$$^)W.!N7'H"Z6+ MZ:RA3#?Z+'SJ[M_GQDO[73>3,BJI&\>]'P8;58F]?=G_Z3'4?
@%-8N8+XR5M M\)2SPCVXU5;>:EOU)ZG^71G,;WM":GP@YLI"!&BX_L8M_M6/J'2?(**,(\O/ M4=++F7*$3#I4Q?
#A>_+VH]KPX"?")466%3&1B6$I8;"%YK')CF# ME!<[U.W>JKU'3P9>N2]EM(=B!;+%3D9MIW,//>YYRK^>:&AI\@F*PJG7Y#AD
MR\Q+MSPG;8^I7VYPA9 +HQ!9:!72Q-1FF3%H_81'#H%HE)$MO@LXYABS(6&[MO,;2,]T7USNRW!C>++14H$EU'D:K*0 \%LJ4+++IG2LYQ?
V#7N:"!I)^8+/&ZU'Q.,9GC?3L6R]K'S]X&=C_;!NWTV5(A,5I%E[NKG]=M<^*SL$98)VM27C(7{XZ1%M0JRI/KI2V/ WO&>A@Y*K_5 MXFC-
B9VZ$;JRN8J'G(9G5"&:C5HC#R<[O$QYQDHPV]_B6:[C*VLR44^R*1/3 M4-1N!QLHNYRC:@-9NP)F.NX\3D+%)'Z>6='G&'80 6S1_PU2RA*L&OU7/(P
M,:/D/HIB+V@_Y)R]<2W;?-5&GE0,;(V68&>A;EY;!4V>D(U1)L6;/IU9 M9.%!(!&HQ?X#2>N\YV4$/=]\1?C7Y5XD\^^S9;!<#+'UPU@YNF^/+(EKH?J M%X-
G04ZBKV?$4W#9M]M,@Y#4,F'8]&K#]>]CL3$UP=_MBNK[CR8TN*V(U73&E11_AO3V@H1XHI!$X.FYU1]V3-@956W(6F. ^T$Y&=_8' M9UH652/U\]OU?
ZD L9+OKW+C,Z,YCFV[NA%Z58$T2K_.(W8*>C@;QFA=$ M;\4?%8-#\V'F09E@'WOQ2QK8+W+9ZR?XA.R$/!I=%8PA-WNRM":7<(Q9%>W€
M,CX)2'DG7NR-Y4K5.\'T.,R(<'X>EN2=12867 <4-U_*=2SWA]&*RH4H6 M-,I8Y6<0_N;Z8&%_N=/OMFI2WL].L';_=F":,92A;[UKX1@[JSX'D0EM %?
M"#&\/3F)YM>@L4NH:CQ(5IY4A^=ZP+M9>>2Y&PZ]1Q)605UW8RV,_-?@ANV-
M)"P^W)"P,))]L212*24.L#"2N/Q$6.E9]'$^WJV(2\\BE7[I_WL@1.E9Y.ZC MXXLK]OW+&:%[7US%EC@A@+V(U=]FPLYH_!;'@*\#BN"[TB.G??"VUZ;TO/"
MLG"9/[\08>%E;,@-6@O19-3G*^/ZG]D3IV?(KMRR+/H$ KA[BAMZ7RGTF1.L MVO+X*92WX9J!#_\+3N#)54$R+$_%^+7]
K>WA[P^W!BIS5^!2$]J.X^]&ODK9 MK]=)G*Z6,^<-^(IR:5HP[C%?[7&]O=II#%7[Y[K![U%Z!Y$]O3PQ$+Y]H>[.5 M(!ZD<]K \]Z:G#0-[^6;D$8:W)5]C7G?
%^^[T[5YQ/'0C,N^RG M 2&6M%CGS3MCM,UV=E&<5-K_5B#70'V)$%+)K1$LJ07; 5=(UKGM6Y*:PB;>[URLO/Q1M*5T(1W5IHC&IPM# G;
M$FU6NV9,\<<#"\?'#M*_]4PGZZXX;LX(/T4HI]U]NW!4T^74BX8?_/ W7TR MQ?K!.3;?#SD;'TH_EB)YIOL(R7"">!UD"TCQ$31ZKJ_W^C;]E455,5WV/*
MV625+=R(^(74LA=\#<0-[Z0T?N05Z7E4_H!Z.O!BAD[90>;3:[(RA_>H1*?V MSC:H#%64';3NZPT-ZE%?>D>#S%E*>T=AI,-
RK3.LZH&XJ$:YQ,.3[]=RG\G< M#<:XA(,W*OA.J*>_]XW47JY1)?9 T^6YSSI"*/E;XM2(HVFKZ7W7)!+^LHME MIRQ4BQ&P#=)E/>TSPQP-URIOFC6-
-3B>NEU[5+O7[4*>Z"90E:R0@@;"",]7D_Z,+URRE] MNLY'$)DAXE[= A%\X&5F!!(O9.IH@.9M,>U_7[:+JAY_D?6V4<$TX-.QX_ M+$MH:7Z3,A(LAP]_'U]
[& \X$GP<[R?=SG-K GZDONE*"':XHKK2]NV1SEJ3 M[S@P7/DIBSUY^RV%<=K\FMUJQY8K)!%" U,,7?K[:==5MP/QJP\LN3;PH480 M*K^$(Q1,A;!
QIQN_;O]D]2[M[;$Z5[:)RM7X]3^E;_[)M1[-&BWY4BWE(KA MF6>O3S9TR^1$FUP:\7NOW$%[))NKGK*.$JGH6JO==D9#AQM5L7UXH6^8PK@^
M&G5U\)Z<_%:'&*(EN9S_/M4-V$-[[HH .7-A*+D26XMJK&DU$Y+.ESBFS==K M>XDBSKZFOEKGJ[@0Y5^[M."B2W@_-GMV2(.J,\06?4E*_Q$XSQ4].).-
D$_793E)+68G+;M4+7B>N-#6X^-_3 M>P3Y>6T1G$SJUA;TKY4)T3OW9@\82L+(^'3?;J%'[]VCR7%*)PQI3K".01AK
M_8^3E[^2CQXA@OW=M(UO)$^JVZ3+9A2.^P8^R:.]N$<19PC(R&1M9>[>&C4'CF;':"2<:=K4W1YX#-<)?_*,DJB. MKWV0
1,'ZKGW1'U0G++2)^[31Q$N]3> "4A8X+;)O>5!"B8AC/=![.PBCA7S M /#IXFV -[#W;VP4Z_V78"E-X!)>055D)UA5IW:"+3A,6=#NHVS;V[F9@!)L
M%3DCKT^G=AP:E$E#@)_MD1,?+1<^F4=,KD. MY*-/Q92:&#/8,H@X8.\H/DX M]W3+%QQG'@5S[Q51K?LJ1_H;*<^(+&6GL0U9A&Z24!#8FR1RJJC!
(S_87@L7 MWX?5V"UIGZA209TK^0)%2 TI3(]XLK2+^L3H*7V"T5[1EN_[YVE/$^VWG#T5WZQV=OWGW&)8"0$F:#;@^D7%4@H)'G24N$$V2ZD=
M_@;-,:R&,1Q#ATD1.(*NC.Y 69B!:K3!E92?A$#* $U4D"%,=PL$]#GP@?*0 MT_5KC<5?]K&L<&K?6BZFS0KF@V9_(L!--\(&Z"LW%>)]WV-'\&M]B@#BJ[?!
M#M.[GFQTG^XJXVYF"DK URD'H3X9[$W\#.B,9PD@ "T%WI#*#0!\20V8< H3@ MN0%@GDL$Y\#AS'GB9SI*V*BT$)!!U04,"W,W_#M+_]81^/-+
f*2X!GD0U$%/ MDP58+D?"_5?8RC,1_\[./_G!UGX!_5\2[VZ'!^P&=)=S%/1CGS1JSRF=F$_B M\"/
:",.1I4WEC7WBIL#;X:CM9^C]6[$(L'N^HBYT#K5:42LBC^LBPFS)A;W= M#'=BC08T\.0BA;7L(IZE_;%/FCBO)*T&+TG\;3E]OOXS\S#V#9;+W%KV.],;
M/7E6UH%31S7QG*6:I$E1J 9<6%PF_?>R+P)$A0G4Q>#(=3L(,]#<<=W(C&F*H M6\4&-''WKJ&.]6Q]2NEIQ]X\CP!U>QL@QLH&[J/C8-]&1_ +P?.5/S8 9(\=
M_>,UX:X.1\9Q4A3'B15%\]G)HKV^7>,#H2)\2!!52"?>]OV=Z"_G MI@P63:,)8X53*^Q0*IN# MPS)0WG/E6097WIV>7&W"
<3F\]!RUX1P6]V/79SK$@60Q>Q MIX)37ZV&+:&J0MC _,WDZD/U!4_)*MQ<2L\M^>W<&%B@D\4^-AF?]/+TS[F6
M1_06K!K!$1"C9"NWU#&\PS=]!',1ZOT?Q4V)YA?+\3NPO^9FT4GX5RIU19 M?K.*]9Q)HJEV>>0ZX<.3M\^S[VCPC?@+H9SB:^'"S+O2'R\J;C-
K9(<"]JPB@ M[['VU+=XTRM\MIMKR@L)<]/l,68MA VN;9_R] >S@]\])JH*'FG6"(V]+#3G M1U6(>-13',NL!,:Z@@,>LF6U6?OMM<+5U]Z&NM?*%+9OTG-
(Z8#UF!LGN M?]%;*2WC6@=H!42ZRMZ-G3;Y[<\3EMQ]T?=++2KQZO>FDJLH34,CU[PW!3= MG&W)O%C?49SDS7XG-?'8F+:-D-U5W+GE4 N.$F3")
<[%4%EP<$#A:?)JST\STP>3(G;:2[O7TF6$.Y2.F9-NY" M>QY?<.""=W)Q5U1?E]K++E3:GGKGUQ[PN86+7F(NH>1]TLZ LPT--*_#C M[0P%
<7^JS$/^F'($6)ON0CXW[Q\@,8K+&=^#&TM(:^7LF'P0.3:>K54V(9P+ M.3D?K(J;V[C;^5CF6?7WV,YLA]X'5@NGY+[ZDENZJ&OYTK;S)BD?
HP8C:W7LT&[V\Q5" QC39+_:&W1D_\^D,, MV9E,7W!=^3'M/;\,7#8>%W@AN[!>3%REVTF]4G^Z1,J10\SE)^[$)>KC^AZ, MY?
62^5DR;,>K*N=&=A>|OY)I5"+\4?9(I6<'3L]#/^=.8#,DR0'S08ER\YZ; M0;HNI2>O.3$_!ALO.]19)V63(%[9UDZ5&I(:M;/*"#*;%"QYEH0"A/6;DJ;G
MWCL*$HH,,.D?LOC>K\]NKI[,J\T9CF]AL$*/GGK5IW[SWF50?+I(=8O]\+ MB5M[VUL.2QL,BAF6QHS1GK@@ $;3'M U?2;AZE4-0\\?"B;.4AL.G9VZW+H;
M99[GS> %4-BYC1GFZI[I8K6F0C5IC#YP\&M66 TTNN:(KA=5\HHZA:@]1K*41XVY- M#%]K2SHD9OF&2D_Y/LM&@.^#R\N/\3][OK#5>I-
,TJ+/^5PHCQ1 U'IS&9;F8;KIS.,)W86QH W5R M10XU5?Z=[?NK#QP.(\8*'[V!NO8-%YU_5C3K%+1T>8@^F#EONA32KLN+UM-
MAY]JUXP96VA(K\1$Q62T_ZA.9^ Z+2Y5>G>39\@J"'!CPF:GH<9(Z0TK\;T' M4V\Q]4R(2?O@T0"?.;(--_Z*<[D9 ^J;O>&6X?42.M]F/%6XXWR)AS=]8;"<
M0\,$230%)%>8G03//&^)=W[<*#>9HO;I561E*&V]/&LV=9@^:P]K+>BF055% M\@85C?3-Q#
[!>Q^8DSNZW2Z7&.T:"79Q0)F&QMF/G3ZJ";W]3IL.5U;+I#N. M*M8[QKYFI&X=BYDOS2@._DEMKE6+X^D#E.Q0/2+8%F2(\I "3&2U)6(X
M,LZ3O&\D$6"1^UY1\ER2GTVNWEKTCN#QAW3_BBPU1"/)>K^,.6&YRB/HT2* M W_CBE_JYBM'__P.H@ *VD<5 <^^[4V]7\SL_]+Z?6/SOV3_3_J"7K,Z?
E- MR$_O"_W2!MSU_]8Y&5@TAQ5N_IOD1;&M!8;PQBW'.$.#X[]%4]1OXX2[J 35 M0DVABOR7@/E/4_2/^M9V,_\6[$ M,MPC:GC_$1#^/1E]/"\JOUU((N-

*&}@1<7A^T&=1M5U1;@I9I?R+!X6#34C MK;I0"_K@E>;<) ;]R*KU,N6IS*#[4]^AMY4-[\P#S>$WP20$6'H= .;Z?9Q'A MY?-I]3)VKLGK\V@.DT:IK]3G5\X3]H5U+$R3=C"E*D>3=7?!LDK[I*EWA!^MC ME,.8SS$KC+'O?6NL5Z?]$?]AZI:4:%J9WIU30_%@ZJGSF);8]9(S/KCI[@3, M70H=ZC9.G#P[R?E\ZOM6;>&S)QT=]<%C)N$S7#-K=?0L-]LP0){7Q.S/EFF: MU;1_ QX{68[&NX6X&:I[$B!YJ8N4D2(ZO)!8P)OEKPR;\3VUXGW>@=*

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}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{G)]-TE*1%! M%+U\SBZ'XD@M:VJH}3? I]DRH7EQ*MR_-I1R_[MCODF>?Z;13EL0.\M>^0O?"<RK_M/>Z9]_3AS_4X^,L"?=XY]2 MUQDA,_CQDS1&)M.N%Y)";$DY4XG]2:+X\QSW0D(3W_E4:EV:Y&7:DDF\L87H M2VW'QNP:>;U@7<)N\)&8)K:IAJ:?Z1WWC%.($8SEU>\R-6S^ATT(FWI%#3\V MRXPS;,2$!67*BVN;SO1;AX[>1=8MG=;7W_%;22(45 N"I1Q_6TNAXD"IU'6] M>GD>Z48ZW>KB9^(QW>;? TRNK>K5T5^N^W;M]N&_?25^OVW>]KYUV]UKJ/"0? M4^YB>X1MD_[U;RST7)("[?M;B:KKBP%YQ2;%A.6%G2:O+V555RI*J<5_3;DK M'2[$_!OB&46Z)-DZYKTQ-.JHF4V[^RC$FHUG[C_05CGE#?_.B M[6NEUO-[:VV:#3VF!8W48D^O:OK&10;3,/P90Z466+51K6JE2%|(1 ,3FP0_ M?W^ZHN-I&E+E,^U6*$XO.LYHY-A/OF/\>$3N@_OD,_GU+V1-\/P1UFOZC!+% M#]5Z9=/QRR8VR A1TSK\0 7M{?T-9;LS94;#:>\W#$>/&0X>I\"&+PZEL19U- M ^'7O?;$'SHNE>AFT@%4JC*5A.SOCL.H;D45X8=12Y$:MYXW23X$M2I7*HK< MK.\ZA$;*0WB8^,PL9KK^Z..HIXBHO4FA5Q6Y5MN5MYLI#B$=4B091UU;$KDQ MVDQ/(GVOR NAAI_I3>^]PH9%_TE,*.6LVMQM:/5F_-]\Z'5DNC) PQM1ZHU M*EK\T.K+-DCFAM94JC%#T^> U 4"9'VWH2W;_].A5>9#$P60N_%:4U'BQ(@^ M!Z0N#B#7#"W.O%_4L?_I(OL9MU^)5_Y&;#*:C+ IA41^[RAP.XPYZ'\<.8!X7L MYSN,/-S#[NAAP#QZUFHI,GO>9FO:#3VF!8W48D^O:OK&10;3,/P90Z466+51K6JE2%|(1 ,3FP0_ M?W^ZHN-I&E+E,

6%6C-:(95/S;RR{(S^_MTWJR!ZXK.^>=G8K?!A0]7GU&2ERF*#AE?9;L$7X.*4[OH5.9,[_3*IPK>YNN M|&'-"_B52_&#!'HM^" (QVR3*$6"Y_JJX'F0CQ$V7]D<-P0Y8^XQSR#=E45C$N^=63KHAG M3(*J/VRML&TCZ\TCW/^;LQ6U$LP@/,7NZ6)O8OG\EHMU8'A MQ& X/0L,IV]BN/]EL5=''51/+)V(<1'^PIM\9 Uj.-V&AFG;?F?C2-^3^P+[4 M)=Z/W'"53K58$[A*#*ZJ9(&K*INXBKFN+G4W.$<]NHZ!3<9$N6&92JE54?;P MP%9ZIPL$K20 <);WA"5K ,? WGA/AOBWN\F.GZW>,K.:$NRA-O:(!X^/'[F.VKPC9QW 66RA'[Z, ^XK"/\#&3 #,;HR;?>(%,-,!4 M$2V$'G/$-@GC)L VAV";:C;8IKJ);1YX1O"M':1N\D+*N6&8*C",. Q3RP;# MU#8QS'7P*4^*I4;Y1-W()}.DZ"#%;989+1TOK2[5O-YW+SQT:B_[HTVG=(LWW=SL&.B[]+SD5S? I6LII_M.F\AJRN|LBA:0$(7%_//BQZ-PVM9IP$=/ M_@TS/\TW_!;) %0]KG/!GX2%-Y&*4UFY!P32B>89MM=]2?>/HO MW\4^)\YR&MH)>DM:'X@M^4-GXB';I$(.OQIX[$M\ Q:/\=+^3;^-V#Y-5B*4 MG*2C$QM-3,H YA8|2!W4F;PZN$7;/-Y6NJ[YZDAT]4,@;; M2MFY)FLA.5L#SMZ><5B! ;$8 M!D"3!=#H !H #4@: $W1),T[>PZ,-V@'VH%VH!UH!]H)KYU3*=]8K 1F(&D* M*\>G-^C_5:L?#ZN.IZD,U75I3P>PQZ*V5Q>_,8'N"O8NC&&!%@#2T ^U .]. MM),OTZ!:Y5;!,4R#$YD#L[]:/5@0Q+XT1C[!ML^JHG,[8:V9,,T7^4=ZU-B$ MP ,T^3ZJ5FK]?4/[S7]$ UT\T?>P75JN!\U2\0Q5;3:K#5VOQ%80=:VK@L$: _7S+X;1*D@W(*S;+?V'7619BY9/* MK{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{G "_@#^B//!&L#24M(? MC7I#IDXK\ ?PASC\D49EB;3X0}'EFII5_A#-581:]M .M /M0#O03@';$4T= MYS]RR}-VV%&3TL!U1M."3XY=A%"MJ#[" !N,_E8I/T:-O{QPO\0&!JJQ4,K#5 M20PL 7SKJ11Z2@V^JBXK&NPU$+=)T>";2GVGU.!;,!;3Z6J M4VKPU>NRHF9@H[HH?@F$";$=: ?:@7:@G0*V(YHZ+D28,*@(3[C)!Z==0CO0 M#K0#[4 [8K0CFDE0O-W_]X[]SU\;FJI^FIT:$UH+L)0H:#2P$;?;+-'A,93X M3C0JN-_FLXJL:1F("X]!*@!R(V[#4.!+38](LM*$U7%QFQ0-R'$[@Q(=Y,V MD- 6*W*C!0KFX38J&Y+@]/(G.CTD=R9JLGGC#0B87'?,?Y5QV:;[,+]-3_!U MJ_]TS<'S-,/.SU0TJ(FFRT(T/JA]LE(7;!$O"\Y;_G()5C84[8V5C 4FLLZNR+IH'!PD'Q>60%3F\"1S$M#A$EYL* M, @PB" .LB(-('KF'|#5&2M*=C6.>"0XG+(BF3/!$YE*AQ2X?'!>6>Q+ M.$0T![$0]WOWV(==[* <611OB5BOR8G?RXQY=ATJ4I&E\U5*KHLEU13"I(BZ$ M +7-%8FI,_E6^Z&6!1P46=5@C4#<)D5#[8K,B9TP%?/2?-)??Y_MG&:=.P8#,@,%&$ MB= (H$W9T)M*@@ -PD4 Q_8J21I&R(|%12U,%"V_ 8EB>&65 ME5I6S3C17-FC+IGE?]\CM /M0#O0#K23C79$4\>%B2R'N]*70\KW?$<.LJ2O M&%G^L(- <+'4<=^P$6W6*$%K>;.GKU-(WG0F;L253_^^B.RFKN[!62TFCJ&G$ M2TE:.E^3ZX(%D/4BA[Z 5=ZQ2AJ53--@%561]<9IMT4 JP"KK&.5-(J7IL$J MS:K3B;$3=2FN{2\1()>_@H$4!UHE@'9>=G9;_LR>LP>,\6">%=5PF M=5H>SYZPKIV!58 UP#IH)K..RGM/R>2PN{2$:=: ?:@7:@G0*V M(YHZ7A>$I/=Y8V3_5J(NY$Q\STC/G8?!OQ>[V%N3>V5 M>Z!6Y8JJRK5&!F)Q8H -|*VMR*19O09X4GQKS:,<5&'!6]PF1H,=* HKW^(V*1J^=SX3] [3XIO9)I9H!^2V:7P09DF*) 9 |VLY'Y>XB>4+[MOQ- >\B>6HT=FI>![&PQX 8(UW8^5O?$"-">UBEP5[8P:<>$&"-=V/H+WQ BO MUFNRUJP PH5M4C2$[WQ<[ZEEN%Z1M1,?DI1)#PFR*:$=: ?:@7:@G0*V(YHZ MSG_DL)?NX[YEMPB7YAE>WYE\MSD[P$GV(]C5^7.OCKIWEG M>%\BWD3H3(2^1+1CXS6M+#6R)AM>K,]QR(F8AO!!L1&MD&013M&?QAAV_A(%LT>A^?CE|\^^E9=0IRC_BSN *?^$, MSW*_=CH^^Z_?YN] <%%.&)A-Z2M?=*PE9/|&;-SU"C#FO-E[QA 8!+8(5BAW_Z+PO_$ MN?3AI=)YW/B_7G5CQ\|F.M+L- JP^/AP4';=G(/XP.*EWD/GC@_)'}+@2TK MGF@F\ <86>F-;:BQBXW+?HJ(L*]]Y/Q8B$$@:NDPL_D*E7G0[Y\]P5@B5G(2Y M^P&UV!W+/\XB]&?4]&*/?ZB!N6C#A/SE&4NS]%<7,TP$,'#7$ =6U2QYGAW M@M^WZ4,"0;9 T)"OHJ*MW|IO]VX?[MMWTM?K]EWO:Z?=O98Z#]W'ARZ_<'G> MWR!U#M*KVU"'L=F9BM;,H%I_FPI33>S1V\9#>1UZP%!RZ=Y) ^D]:'B8TF)F%] M9/+ZG[\T-%7]1"]0P%/Y[DP\1$V%CZ>1Y2'F@Y-G BG'K1,F)L)C_F,:? O3$R M9M\#P4]U&6>Q>(FR7D+OP-A\D@DC.U<>KS,9=+E@903!VGG'OF(4KB ?)WZ; MIX72V;[|VEH-?3B+ <_D83W?*G'N7S[%\W@A[+@)B(;U>U0_8ND;?7KH2=<4 MP&$6KC@]?;)C*C;[V)5TY2BU!]Z='JJR?@9X9Q@>-]]1.!'0G0O>[54907 ?F M; TX>WO&81%>L1@&0),%T.@ &@ -2!H 3=$DS:FRQO)MO$$[T ZT ^U ,]". MH.G91]PM-5T!KFK .&&]JCWV)1(NJ$%&=@:RG%84;EJ;D;V M- \MATK?.82I72ZV*)M<5**<'$$X$X16UF=8F7*<+8;W44A59A;HG .%D$%Y1 MY&=M/G7J$&{69*5:!P@#A)- >$45G[7ITJE#6&>UIZ#NG=C;2//OAD([T ZT M ^U .]EH1S1UG/_C.6B[#_XP*.*PD(L?A [//UC4!/QX <==03O0#K0#[4 [M0K0CFIV0_^I/L[]J@W?BN^UB.LE_85-Z1L3V E,!>Q\E%H^R7[#G:]O\B,U> M\P,'F]=.,W/=1O93]2WR"O0*L36:SCJP>5T=VU^5/(:EA&JG@6SSGV/G]6"OO M[PM%$ LV/MA/.VBT?>+12U?TJ_W<>2?EF)_QP\%&0#[4 [MT ZT ^T4L!W1U"'^0Y*? @J+;'X*PX\=S%G:4D. ^[I#\)]C[X#CN:FEF;KF-9 M[#1R?@@Y]OP"1"1A##88Z&RM2:7>*;\;X&5,?H[V MIYS'\';,0BU??V01C.C MBS3 4KED]17YN#N%6$_,4EKMM,6>@:>*QU/K@V(KDC5W"O*>A*E;&F3< !L) MHII6)'/N%%H^L6IB"X-9-?A$E[OM$86=)7C"Q_V$$NECJ..W9F-'H!./0#3F; 96W(!A#L?:ONN MK_5>TJ@ N\9[2>C?5ZHR[9M0'HE>Y' 9,,XRX]32J!J;/N,T95T3*\P,? -\ ML\@W:529/0#?-.5]$Q@'&$=0]!:B <7.G"A_Q;MV'A-*TN-[-S& M)6GUAM0I--CN262_L;PDV_'I.UD%'[:.0$8,7R8K\V.R3WPEA-2X1 ;V0:A MKJ/GTQ^"$S^8^XAL_NBS2R^-D1OLO!QB#T>? GS]U1H'26C_0U*>34D_BQ;9^ M*SU^^?Q[:1F*BO*/,*8-?^'2@?\4Q@ZB[[O__FWVPD6A8F VI9^D2"/QOOV4 M!98I7&H% (*V$B)RB4+HOV[^7V3>^Z>R$AZR=Z\Z8RAP4, M;+S4C2$.QJ0Q/@EC):\H_$]<&"6\5#J\&__7JV!L^-E$1IJ=1EX6'Q\.R[!S M^C<$? N'1&\QL&7%$\TDWMA"=.J(;1$;E_N60_R("G?>CX6H#Y*& M+I.-O_B.48K [VLLSE M.9J+JQD&(GB8"ZACBRK6'.],\/LV?4@@R!8(&O)55+3U6_? MWNW#??M.^GK= MONM]|;2[UU+GH?OXT.47+I_[&Z3.07IU&XK5SDRL=A;%XF=D4;&*I:R JJ MGCC7Q N)]4)W!U[E-;,0T>^63<.&]H_ MQONIL]&M7]K:6OUJ0#)(,<+\L=-0#3P_X3'U=+]8U'2%3FQX(O3.>;-SU<5 M#@"B%4E7>6(S6W*"T176UHHL%:Z Q-J*

RN>_F5P6U2V2\'DL(@1:%MQM>T^;5#VT+B8"IP'FXFAA|\'W"`(Z`M`0`2KVCQ7=%BB2%0L4*JV'VRG_;&\8"\8K/\%W:=E0JU+!J.Q5>GQ7-GK_`MNRY?A0WV5J!.7|\%7%%3K-E+*,7(P\?(6#?V_M*0]"9)$>P|"^YKQ:E:M5X3*=_MA,59,.";]UC!LII3N="AL,^-0/$0+'1XNGGO*ZR2'%1+[R L]4FQ[L#GGY-)G MK?!)({_I:8A<_)E1O;~_],3'PRDUR&02N$G1$)Q&)E.J"-9DVC7Q$2R:TBR>`M$]H9(ON9-L0BN`_]`)Z'_> EX4#76 _/[0#[:39CFCBKT`^0WAJ5=LPZ"Q0`M6>=BY,7ML8*CH*X88HTJH*]#U-,0="=82!IE*(I-YHK$M@5)$PA"+(S-5F`M&N7!#@AF3:ZIPM6^$SKD5B#O(52?,,>-[3LN)%F*)V(2TC;7VLNT{?!:NJ`M>$I36'5|_K-6=<&M/^FG-O0+>T1E4T'NM,(OG;SZZ>(R(*>%7%N'%08S-`M\8?8#8-NH$:%5:-Q26?[!]$0$=.E\NL &&W;?&"H:'-0[*M?&W)#R+*YCBM\M3VU$>5WC0X-MT>!$;]:K008.M_#8V<~VXV,X\%4AN;/>*XC+"-Q)CX:6_8WC+LJ@>P:!^:f1M/<=G2C)1&+LNW/8\B&"+B>6X^EX[*=UD5+V8#+JK(JC36+X6M(T*+H7U2`MM]:(H:A!OX"3A(7P&|)>%\Y'!=4JI'NZ3^I6FI"&55]P6%-/CJ;W_<_^,^UHM\;$A;V9)Q=&:Q6LOEV:UHXK4M|F*"B:@2!IXE5%K@M^LI4@T`(TU_3M$JJ.MB&95KM>$VXX);JM8"C6RLCI=52V]9H5B+TRP;9>*M4&P+:,UKM6WS&_(9DMX>`M!BD*:,TIU^NG5=G)2[X`^63@:,;+V!*$@6IRM=[(*.)9C\4R"%?KIDT\;#)`M`M]D5M0!ZB6)(-$V>3'[Y&-MJ"PS]^^Q;V69A>QIK2HKE=.**W#1,P/N?;*S`MC@_NNJPW-*&A+9J^S;^_'E\YZ8;8R#:@@K[/"9]Q$9,[QW[N87=TQS:K/0PZ`M'`A)[+-ZJ:56%5F!72$B-RD:G/$;`PJM"B73P.%Z5!BXHG=M;'`M.]{XWW-._X=!:FJT5FKI(BI1"-R)#|K:95]F1C'D*L*[F@ZJ37$-L@86=*2`M0AWPZ!V6+'8*CN3T*2$0K\@!JE58U5I)XZC/(&R+[QC=9^B8I@`FW0U2`Z4*`M$-X*PFFBQ?-/NW@<%O@!-2J4X%D?%$LC[6BATM@.Q[QO6ZH7TW-^NJ8*7(8LN.Y%XQ`Y]P/MDG%>]P`M?*)5!:MNL0V?B*;V"^0Y+|?A&8=U*]3^V_F'L"C/QS#EN'!5>0HC[=8*NS12MKU9409D5HMBO"DJ%NNEJ4ZY53ALEA$I^!62=]89/&OE>A^6=B)&MB9=*G47[`M(?]A@]!DN+4-EZ7RGW^XPL&GCZR(`X.KS/]?NOYS0EXH)FV?-M?%GN\2@VUH M$]R";'/YQ\4G"F!B"'"L-TFV-'+)&++W9WP62S]'SX:VS>@/"W<^TI$XYA2!`M4_S1[|:$RBOK5V.(&?<13Z^'@RPD6CC\;)T5!6YT:R()1US'W0F#_6LD<;`M26GBLP%\;+6RM*E`M/#L2"%!5*[,S5`XF0&>B\HIX8\=#UA?*Q&/Z!/W.ND/L`38?QM@--M\G32_0MJG*SEM4"ZL!Q^>2X1@S';3GAN'!%IB/,*,,)9L44(M(15E!.QY"YIC!XM+E062YQ9+Y[?N,$?U/8)R%_';LG1;_L=Y+IOU`/Z%[{F.*$CUZC(#:4NM_O(Z8%I(3.O[Q#@.A6E5461=$6R?2A:4:OX=AV6ENK"48A19O*J-!5FE:0* M^EUT=DFL)2T\KLA:[,2Z&5(W@$FB3%)-JO$/Q"1J4VY6LLHDHAD_^?>J@W2+`MGN,C*\5M))!E4=1%WMI)LBP@;0(X*J\<%9^-+2I'Y28/@G[N.^9;<(E^091N`M_,OEN4E>@D^Q^OK7I5[_^FG>0]!:B$X.57*HD:,=&Z]!9:F1G=NX)*W>$$O(`M,)S1&-DLQ$3-`Y^^TW>"@P;(B.',Q#8K2D$_<=.8,7T?5[>@%H/GTQ^"L_*0`M2]|F|\T>?77Z(GNNSQ$M_B#T_<*G!?PJMP>C[|K]_F{UP4=@8F$WI)RG22+RU-F6!90J76@%(`MZR$BIRB4+H6Z_+E[W?Z]W+|1775!8Q$]#&2]T8XF!,M&N.3T/K]1>%_X@SC\%+I/&|\7Z^ZL>-G$QEI=FI++SX^`)1=Y^?,REZ\U'OH`MW!'[AT1O,;!EQ1/-)-[80G3]B&T1&Y?IEF/\B I|WH\%.OY)0Y>)SU|\QRA%MX/C$1A.3`MT)G=H@?'4=H9,0WZK1O'98I,LJD8E4;T@:.$G89N5J7JBU,:C/B6R3JU7YMPQ`M'%X<7X>'LH[;9:%V^ZW$4HRI>@@MP-EW;XR,V?=_H5;AHO6>$VR7C/O(-`Y`M3`EC=VXTL$HJEX%=R:}+|Y\Q8CUN'2L@!?KQF'S9(IQ?F]14-+:OY5J:XVN`M4X20^Q8UG(X:U(L;^=+N*|_]#S01[`U`M$_'>GQ^:!,IF+0IFK2:<";MTJ*%2);MT]*90P>@U[JZF_"/#,"CS2-1_^`M1{QZF`"/#,"CS2-1_^`M1{QZF`"/#,"CS2-1_^`M1{QZF`

_DMZXJ$ M% D=O!2W7C""$L@6!;*J&.B/-U.;%S.\^&A,#7O$-,/7_C&WF=8"6",N/[P; M7IR U?RTVC-V.LGM&7<2VDTQW+=SW_,-
&^D|=^1V1V|UZW]G74[K8-7,]&2I MI;L3:JE:\]-&23VY%6&=+&'UR**S;[>K]@:(P16%%4UBF@:,;JG;35'97]FLD4YE%2:5?K^KMSK]@R&6JO@Z M3B
9012EN6&^9I&$]>X-MF4\Q@2!"J;Q52>D_T2NKPIB(.NZ28D;[H7.\D'A MMG?56UTAN#@$IP3M;H;@+8S<"LV'CN8*I1EW4P}J-T-
5'DOR]KW8ZW]K7XX& MH*!<1<:<$LNZ(6,NQF*KF/2A([M*3>2Z*2&FFT$[OU5T6UX=^A":W5Y5<'UD MSH+]03H3T2DUK180O7L1HM%L5
605;07'F!L]**]D&Y[ZG887/<:V@V5V5"9 M#2MR,$>.@8SKHI=2#6NG9D/5(EIA>Q_83NDZM3>#HL*YPOD^<)Y2:FGWID8% M\.,%>)7,-+U"G)L%62"'W ?
VZUIR&7N]61GT^/7M.E9A{(5{1_!9*Q>*/%^:5 M80'K^4L5:TYBS54Q:IY.$"39.@07H^:09."4W2&5:5.9-BMR,$>.@:P;I1#?
M[HI:F3=4Y6=%%!42M3+I8ST.\.[-H5;LNUU7,F[H\)))&D=$;;O4U5W2'"*."I. M'/U"G,8%F6,5O2AZJ3]]%.*(SF_#522B2*3B2DE_/1]V-7%^F(I%58S&IQ,)
MR\NZ8B5L4Q,<4'-XHTB-R4Z1IVDIKA(KVGDF=7+-W^26HAPSV3U%-RP*W-;K MC,5VO>)ID*<_D56EU4$H A@GP10B'=_RSJO"O/'C_DJ"?;K.>N5 M<'X
UN 3"'"%N]@+&;MDFP\=K YI7T*P0,3,U7&9JOH.1Q4^ >"]2%EA[\^L' M;V;8C, MS58GWEFU9#UBF&5.((2R!8%LJH8Z(\W7!L7,[SX:$P-
>\0TP]=^L)E/,%EK M ;81G!_>#2].P'1^2IT:!_5Z.!E3XTZSO"F<'W;N>]YA({'G#>)N=/16LZUW-MNN4P+]77]&2II,,3:JE:']1&21VY%6&=+&%U"
MSH>F$W,%"$^ < 3$IS'+&&5AD(W'>/A@74R89HRP6<84)B:8NJ<9+K5-II\^NO#5S'!]S1EK M($5Y+/[[\%?G (>+[(46OIUP>MIH:GB
R[LO'_]YM@B|>OVW)-H5GQ"3H(_.MZ'4+[[OY\X_@A5'>,F*XI;]KL4&2G402\(LG?':!PVG:@ \;H%#[, G<7 M7ZYK'^^O+_]9N_S\
<'W_7C.F+\;K)UD/>IYLMC"-">-K:B)5"&?;+W7Z3Y(? M3GQU]BYI_5_W2>N'S?;?LOS1X9,2FT^1# M,RUO-
C5>,3%7*H/R'>0CJZ0Y0/)?'AG!!L48B"&AY!!'2]KBAR9H)S8 MJ!^&%S>7#]]N;RZ_:U^O+[_?+VZO+_6KF[O[V[OZ8O 5;K'6=U(]OE-L,^K M@'U>1=G?
YX!]C*QM^~Y+CF7VWL_0^OBS=PV0/I /7F+/\ RG^8U:O2%B.MI2-%QX/RD"V>0=R#BD?>5.9-MMB!E Q0F=M!^<5'MJWF)0A!+2#+F@.V?
RJMC)38[$ M ,C3,C*T&I2;I2%1R+"KX87V":,H6I17B@SFX]P#IHF=D4/2V1/?V GHL!JC M-7Z-CAO->FQU.=$:W'6A?67&U)]X8KXCNO;Q1 M!OUE;4'S^
":S4?0QL8(UN5;_)07"_;5 ;LPW'B;F8ML[75,C\R,_>J&G70 M@Y;-!MH4D$"7Q1!>ON*0DF)&UI_]I>=9'G#=[!8S;.'G8 ?SKJC975Z-(<:
M93TGG5,6M]+;C1;G6+B457N1Y+A8,6();VX'9COCEKR 1 TTO;0; M-G#1Y?VPPG&6MV3%"I,\1IM@=6(\ ^O77]Y7YXDA,[US'= [GW*#N+5L*
(<5\'=KP%)! L"#,FPS>S5) M-M!-5@-[-F*78KS':SE7/M7>'-X,X82#MRM)K^:B/*(5.'RD)<(M,%5G+]\P>HQ+=I[FS4? >SWME+]XYE,7HG6C&F-
L^OBQ\!K^ MUTQI$0"R&<:L<@F=+]MQZ=9=0%+#A:GL=[9ML"=98&@FF>]RP2#%T^!"19G3 M^V; ,:V*-
)M>P1/_UE@^>&QP)=P]99/CQX&&!/$N:R@RT&)"OIJ^X4)1Y/&<. M_\^ G7%M[4\;17>NQ* E1\CM[V*B^9XM.[O4&'Z 5&F-K1',YC+ VQWH#4A- M27I
JUZOEA{03-0#?LR?X$6O2 J1)6KA&C6YR--2#1X \%/@ K@#0S9U7E"'V MS]A=V_'Y_[(-%-Y$Y5.&P"'I.V/@1:9WXF8;TRFQ4R^RZ1%&-A.,3HP1UO@* MC-
1#ON8+NZUXSG>9067GZ9UD=[5&\ZD!6@IP34^R)8_S>!QG"@1M6B.?:'SX MJOUY_N-<@UL!V I^!>]&?2/&58$3P*4QF*F2XWHR^7EG=1Z=*
!43:TG8@DV M0RMQH(W@Y AOO=\[F=|S\'V%FRUF*$%&; 8K)77K7(--Q_L6_S?U'/P'W"KP MZ ORQU7O\]B4C7S.PV$=SX8U?>,97%? L&
$V/T79SXUUSI&N#+,.5Z8,"P: M=,2^C<5&#A[/\5R[W?D*\$C#$_%ISU[8 M4,/&<!^-U6$$A(D:XM802_AZN2E"BT:,[NW9V\?
+R<@XR$XH5YT!9HKS0^9$R M)K*423?)}I?81P,$&U !XQ?8*_^_BY<8BC%=6'1W\1K;Y]HQLC;HE:YJ_.H MR X\Y28*,*6YO',!P^#N.,Y*B"1]WQA-
Z*WH"F9I* %YZL K1G/7)7X:-C<1 M+|(?V\ ,/]E!WC_V+!<8) S?DIT2X53F3F>$.PYVZ0#Y5(T-.: 7@77VT0; MPSU+7]Y\O3H'=6(:NQYIZ<)C&;W>^
N&/'G*TT 397#S,EMC>"79!M^VR#[) MNV:-K9,;$[EV/7E],Q3(D==*/SGCJS1W?+LP#LI-\=#]%G&I_4P$ >$HH5C
M,/+,PUTVDI99U)QB\Q0+U;P)8Z@Y)O%WW"Z>(8K^W&6XE!K/!4\"*T689 M\?SC:<(2:$_Q+6F3A@DO32VR<;$3/E;VG$"MH!^"^CB7FSOW&-E)ZDW$
M&@$71!X33;GT!PIC'M$OG6>>&UINS-]"!DV;AC,!C,.(5 ;CB/*/B!,DZ0E9 MSR .(/%G<&IG/U&61*2X[-%P2226TA01#0!*FE:R%O5DO')!^ 1ID\'OGS 0
MFLN0,%EQ$9Z3TN*BZ7WZJL.L%]PND11B#,R+A!Z\R$FQ?E"RIMSD913?62] M0M[B0Z,$\^1X* J.N"7"GL.R7#9S7!]7&BN:&#(E!Z1D. "D6\M+ (1E
MR.WKR*J2$W-=W21Q^ID)U 4\E_9[JW6UF/T%?\,/#G0,_>V6@5O"_D4J83]! M&7W/)+YH9=C5B /S(%E V(&4[4-ZD2N?!5=\(V+R7'G7QJ[S!#]SO,5M
MXD^-#+BRB;D'H6 H\EU!)Q\8GQ"P40ZP:0[SG2(KT5LS6?ME M\L@:0-T=\ 6DKOLH"5Q*-036P:QGE-E/BVWBBLS3H,P479T 6YQ^3T*%U! M\
C:C[A!5OS,(S%&NGYP4TD.>V(F!DE(7Q"JJQ/.RSA_1AG2F(%LN>@@XF]8 M]/'JY$),C/G0 X=96.TB7)U$,5_#$<1 M:XG8! +UD4M]GC!=DWX[Y=(NB/(3
U@],1SWS1'#%?,)9_E >HYDWW0],$. M(<7FZ]JC\\Q<&UD_6@>$[U:/".H98BJHRJY)8FH-K=V@\QJOCBM^+=5U@A@J
ML_%%X^1=!KHL&@Y(V>+;PX'11>F<^K#VPK*/JY2$@GBWV$@SVC#?(8UDZ M+O!#.!9<;T(X[=V7SP_)T;@)T1FZN@2A-,XB]3MZ|\EYP%\>$VTN8C
UM M"/3#SS/XFJLKJ9?.S"#@*0F 3%D>#N9Y+|=^=Q&FK4M*6O!NS&XXJPG4"8, MFSES;TK;#\)7H#K8;/+C/Q@RFXTM7UK]H@$SP;I$=
NJ*H%E#8U6Y-]:VTB# M>M1T2O](?'%HGE_/5TVP-F6$AVF@"8GB2_A=N7!<.IP1ZD(@^QCF(EX\KLBF M;W2XR7BHVLRQA",8=_MEPFRAEB4CB%,C_[]
{[QB^$MH1U^>-*W+)Y-F3@9[];93S+PA21V.B)YE#$%%EJ^Y]$XA)F+(N_00+<5 M_G2$Q"LY:$'"HZ1_ LL7[$5;!C$<">&A=,!Y=%C%?3(#9."X&6)
8!0+3&+&X=T8*HS'& M\G?X.6'X-5!$;)_K*]\);IQ0F)W/'(R9>[)HMN?:%6P:+&/]>-XB-0!U#H%@
M33;TI05%%ZS"\D(N0$Q_)'.SR85#TKAPY,#!!.87P3!6>"-3_4':QX7I:"\P M^*]9X72=I 8@[;|ZYW)D74(2[!V"!;?KL^-^^5]?3ZH) ^X,KH=$
"9%$>APDAQ%#>;P3\L:!H? M?OO)I[& ZAR)42 -($Z+'#WZ>NY]KEJTVR):2Z2XVK\=XOH-+<+E#1TK/23 MB)*5T.^E=":IE+VHCMYJ-1(714$;
(<0XC>?)X(EX9E< ;]FK*U 4E6DFAA=A M^-.$]T)R#!*J*38E%L&0?2Y)E1,7XD.72:&&'\AG1=XEM);RE50) #"3QAK&1Z^&\Q8QI(H M7\4!^"H
>Y=A**OX7B:^<$?&@O]B*1%UGUM!%;0"S\5I>2CXV@/?A+1*!Q\(M'Z3(I.TG+O<&,_]G#PB.)Q/,"2 M0'@ ^\QE3],*6*C"8/(9X9%-
@7#?.8%S;E[UT9=QO4ISP@T!T=Z5;G-!;>& M4!RX 1GASY;.>O%%R5M4^1%)-RA5Y=1 M3]VA43\+ ^A.;F [QN27+#C=W\U#E0$ND@?F=+ XA=%<)'7
MFU0P.=*G0;GV M9#)63!]U7?30R-(JIT)K8HO)%!I'<<:.^A1HM)8@!1/[D)Q?/=>-.?4CZ:,!F% MGB4<*J}$Q\:"\5U*/*/0-W'DE* Q97
W"\0;]",*]PJ0PI<1&T1$E@$BD0@X M.$D4$*D3\)Q.YC,]/@E#!D%R#K)@ S!B&M?=KI%)7_UI7_Y? .\ISM9$[M9 8[-)8M?:$:R:Y\'"ZVA?@0/Z)W?
7_"B1KNEQ"U[;V2+NAB00=UR0N3]%;5"/& MEL4G(KEV/[U@^&:GO;F[-OEC[.WF0E]=9VT0+$5UD7D13B5I8.A>_A3+(0K M\DP(-CTLR,+CQRC#5[):P:-
H=<$-CA>G]^J!B@NK&B$C(L.BALY&OF8>]15(ML^3F$3EIH5F1XL=X4*T4E6 A8:"'"V%*\'J-Y=FBSA!>-G1'%|\;MJTB#6N8 M\8!F7HM+*"ZC.KDR-
OWZ.39U7N%BN6=HO\8#%O;H-V?7]U< Y!?T;#TQ/XCU M&_'O7X3=@E!%8(N0$,JX\^G<"^12-*?# ^^A7,?1CHHN=)B"^,^Q<
34BJQK,#XNO4>'7&XUB@X0R^!:%W%$XC<#Z0 M_*DQN0MB;3 N@Q.U2-4.QTZ56O\#%[9%(M\+?"+\'CP.*!3& _\B2=DXA!A5 MY(+D>
(G%GQNE'7"PK#%ICS*|\"]4INOZ(DDBD]DUZ^>B MR[P26*HEL/Q@E(1[+^-PU\@J;#3*%%G$A+5@QJR95\:Q(BC(P'I%,$X:,4PRZK%SVS&+),L;0 MP>
$7X9$\EB00-'S^.@+"7-H-<^R&?>3.C]G^N:RZGGY&[#, ^+LVP MSUSV>^W-RAIQ;^&3Q8C.0,7E-BQNM@@\N4D55**5C8) V>0(V?BSB?&OD3I"
M^$#6(IIB$6'A'KSY%N)LX\=/90;XON%%*// MKPMSF_O1E8OB7Y'W*G96 M&786JA 4_O>%NY N;?/2?)\>KY+WLXXCTOC;JU2S:!\ZCQ%*S9YN&"]D[.*
M2J5"2EH\(MM(#)^+?C6CRG''E2:!.$1\^0P")/H'#P/GL";D!;*\L M8/[FD/%4"&X! >G^[#%R,$;L8,Z6#!_T"LE&>'F+N-C%.0V5-N"],WB:?XV; M=
(I).DC/!\)K6'+\5E*G)SI{9M+0%1#TN(*H\H=/5F/_<5[!?0.CC MCM;5&.C=WF&'/7J>A;RX*50\[3[;6KIK#>4.9N&GN$E3W; -P6BQ-)I2#Y&J/_S"U>
M7*HF#=;!Q2&W[%\3N"RT6^,O6 158>>UGC74^L<@4#AI*(@C'0N191RW;]Z*:L-E;*J4E://66U8*7P M.\4J?:<@K&S-KUVFYO?
=L1]K#\Q]TOA43TO3>TBP((NJZ_)^C902%P&DT7PP M3/ICF#5'V6(BYHZN31F-5Y2'(=$QP/4ZJNWPR*_HX!.R'DT,V)<1Z(;PPXDS M]Z0-"I15V!5X/
@LY.%U-'O_=29*+;N\;@;Z!V)5;M'#4[-^UB:6"=-]'XBG M^'2P():<$L,'08GV^P%GQ25 MHKB*2M6,,(Z'V8_88&5%HD]0G;Q!]G$8!B0]*_-YB!
(B%!D9I)1]UAC=-)%0 MUZ#ECD=UA5'A#IH:&?%(W/ MP4G1X:$5@&ID<7,L6Q[BQ(;XE0:0SKWD'-MK/Q58O2$XHX6BQ"@7Y@:(]:<<0V+9Z74
D.*AON@-D(3[%2$MX9P7 5)Y7[I M@,JH)XC18)C,[@,21*@^/M_T>&<2(@B'[+8UF3&]R7 JHC2-O MW>Q!F:T5B;1SF51?
1'P0ZDNTMQ1(Q\/J@G#Y<-8+\,+^;U=199S G1QFTA&++PHQK,Q MC89NTZT]"QHDPN!AS1^3#FUYY)*&8>>>5$5)>1>5F4"W_*E=9N7C_)V113HV
MD0TSX(*@|_)Q(T67 GPEC<[YZ'@ZQP!U7Z2C!%$HD;K0A"P1!Q"X>O+4MI"<-M/Z@8F'8L-,W(X9QK]P:2ARJ[]R8M,4:T1FC3.&Y-_B
5BCOA"KR;8AL7V\0^ MV#.$9+9VT2E3NY!S)H &$SXM'2.V!TSNP1+GY$XBEY>B)NZGD\ XXA%EY]HG MK#:$+$P45P["=X4?*[;/L'-
Z)@AGPU[(=/7P&S]*960$1Q.U)HIF7?]?*G8_OCZ\SMCE3\NK?13CP-?R MG]\B@_U!!MS_N7?9F9[_UCBT_R)?IXVL?Q)R_]NC=E9U+3>P)K"BS%LYMQ%
M>0O-MXL\JE,JRHV?1:Z\G[*R]M++*N7*V"&;X:SQW;?Y1"[M:L,@8TM;.\7"FLLM% &-A/C-8+F-3C("A:\;">)C3('WY@A298D!\9Q8H8.: MF:6. A$(]2(6=*&
(*U]2:1/3I4(Q,(D3*H&F<@*-;-L,^OC0X@EEB:4 &N4V M\1&SU*+3/"T)9B%+,-:]I3JE6J;3!1""2/8+4Z:?#D+'L- 3AE'8XP3L@X_ M7_[X]%W^N-(>G!G
+8.#].N=,&P_]?2T-^N\B =EGT==IH+!C;3V22Y2+X@< M#%M11G4XD>Z^HH.)K*Q@N5$>%]TMDQI68K8C;?U"-ES6RJF)B\]D%2!L3KBE] MS<#
:1(V0R$S3+B.CQ)AI\8,HQ!=JBZ-OS$B!W>N_<#^J>'[-BQ[B?O >[=R M\TN\&+Z40A-$A\7,0MSEZ M33:F%BJ\ H+XC#=;X4W+10G+:;P52C0MA
)=@>9HMF*HI!+72&1CAK]X'I71 MY9GS#Q,.G>;?DWK?>11V@COYC+D'6'TH/UA=AG"F!4RK .R>"]KKM#]L*S* M\,XOCF.^6(
''D[BRPKOB8R2S]J*Y93*0)#03DPV-L%N1.''0,V+$C8\"0(C MY6^2YL:!QTU &$(MOUN/F5 SST5;5'RXV C\M91W/1?&)V?N11B(ST83V_K/
M/"R\OLA<@GRJ]=J# _"513 #O^NG\F^N!L0X<(@!R/$>I6GMTG1=_H@?-0>B& MHQ]>2EBLFK
HZ0CTF6\!=OD]*+]*E!U+;144$#\BC.=.A),7M_AIB9+!C@0B MHY>;N\78#=9,6N1D('@ELMES+9C&FDW*0GV6:D@CKQG^F]H0.>32Y>W30 V& M"7(O
;.I\FN)(DF\SRY_[#$8//'P>I^YYO&.#O2I62"2@B'8^4U@C+!:]_L!|&;4(BD2F2AZ1$:CN:NCF7)DN:/Y$R^YX6FB MOP9/[Z$X='K'U/J+32GOT%
[3J4AMBQ,NLEBG)(QNE7VM,^$ M/'9)X2O2QO!B#OUAM2@UEE]_Z2"T#--1JQ67)#,]+7E2+-<.4S_L,)-I.055 MM!199U"48R*IQP#21'"-
>QF(<\5(.,=Q6+H$VT#6=C^<1D]BQ.BLE=5@-#A MWO\[C)V3Z73W#%/OF&RYEWE,7[Z[1U>
("'+TFXZ)^S1^IR1%]Z4H;R|P._N0_>BM">+@4PV6=Q/VAL" A@0!}[Y_0O?U?3*L>6R8 MQX,#F4$%2F&+K-%\:KB\J8-+3<_F GQ3#-
JE@*\1MS2:,+S+"X)X:-F!-T7+ M.()HY]&8EOWON?OZ[L6%%Z 7V&0&=G?C)Q]6=II.V2/UCGR$Q3$]N?2:$<@J M<[2ML(@4W=)AJS6:)M5$$8G>RX5,T"
(E2T>@%7C.1"LW/2IL1^@'YHC<8A0+ M;]3X@BD6!U-4D) KW=Y3*34!G1!J#R1AFI^85-G_NX{RXQ8LFD-,BL6,,RB_G MVN5">_ =PM\kEE1453PM[9_-
TD.2^<3=@E@[=OHSX6O/GGXL]%EBCOKATVHS9, MT(^P(RCOC.IDFILW:V=_KGWC0:I8:@1^ZI$ Q4.@N U%B&?1_J,18TUTBZ)] MZH@ERGH]O B
QR2;6&QM>HA-34\]8ZBLH94QM"Q9PRER\0S%]B3-:,D"I2/-M:U')&+\R0W.**SV>6*.2:!*^("'5%46<*<1+WOTCM(:AY!<4!%)"%%$H2-![^&BE*_V*&8
M]R*K&02AI7P!2]VNBED=*S%=<3D+X'<%F)5MZ;Q+VX0W *?$<[_&#[%W'"%NO M1E.I71O"!6FX(BU8TFG9V*5J/ JW8\2C37U+N+4EGWDC:L9=7=U?
B7)Q;RG> M0L0L1+N>W0=%FKB1S4M\XUH)5KS? '516)RD3'H2V2TAUY,?!Z6C4 C-*);0 M:"852UBFB/_[2C'Z")A;]Q$T___2@D7OCQ^P"\
,*>@NI(I+WAI"B4*&X"66 M4$0]NW% F9< E'N(9/4*/[\+*N@&91=]S;7K+C1X-^&%:@N_A09S/ACVPG9Y M2X@A0Z'9HXBZ<%:\&Q>1J"-
C5[UH.96F+04>9BL\#Q'C3PWPQ068><+KU;=<_X1O1<*6/)Z5 MAWN_NY,=9)QLD%@6;+ZNS;#2=.9NK=>I;_W=NIR% >DK=RKZ\.WX4I[X+0@S
MR])*O"X!(=P0I:LFS@#P>IV M\;"WY7:DN7)' KY4^ZZ->2'2;R/[*?RY+V8<4OV V9HV@,A"5U39)'@=IFG)Z22 MUX#++K(_FI5%7:
[#D9D0Q,*MWBB/#*/A8)35YQ"O/X8Q9&B61K13=[9(7)!E M\\^6C$VB+YOF31CSO?-3=(N@N2SH?!,TNTM-CI0%XH1-+>PA+1 RY^;+B,65 M+*-
A"Y'HHRG.2D-Q+@)';E1]FI$1ENRDO"MOD+8H3PP=OG'"-AF/00P(DG < M!Z/H+H018N/-UQCEL=+7I=-,

P17J,U8@%'?M2Q$C0FEF[O2.5W6?E-?A7U-MJ@NS5UH;.2D+!|\'$G'0 (?O(94Y7"K,_^9?9H8FM;O)<"_#<^.O>#).
[EBXSM(69;.16[<&1M!J:KFUE&"2&1O; MJ9>VL=._"DA;\%9^#B:=L+Y6OABU^P>8^S%[:72R&M;R_*[IO!0$XZW2TZC3. M+@S9RV]A5H-
*LR174WXIW#5E5TV2MX5L83CEH]I44. !$ 2=S"4E#9F9C:*TQ M.V<7[?B BXC#HQ;Z=";64B)9R\#:GSCEO%38VEG=;7(J#Y[^G@HU%*
[FM3; .;ZRSO+8UH0S.]H M1|"GM8J% .*3S(*]M@OC.@UA/B:C2,(T*8E)5B:#9(B;P[U)OX:7 /)^]Y MY;-'T @,'C7])-)?\)!YP5'I*
*V*PY;P4CQP&%C!V'!^SQ_VCSIO0Y/_Z"^)R M<[#H3M/FOL4K1(/NB]4$C1'V*J-$(8S#X=WK=0U>_A?SY5^RV*OH;1]6EJ5B MUL9HPGW=LCJCR%I*
*+Q>5C%F0<\.HFXJX-)>,*2FVET!1%R/%; /R6#0QOD;_ MBYZ&EM U+VOUA*4BC=BV1;89@Q"HJ-\X+,C'CRA,"NDI'#1P.] 5!T-*
DX9)1'+G4"""E;VDQ3:L>QYQK"/,7LC\D5:: M/%(.G5OLYT]HD/^O"$%>C@[+ K67D T6G 2:(7 <[C'Y8%W0')VY!SM)P3UO MWY=A;-W.XO(#Z-
*Z<3]GM^#XHL/U-5)%E}J_'>REP _=6)$[_DN.%C%)HFE M."QAF.('Q2V2=-'>A/6^&O@_],?@;Q*91\#>W)":+1DTU^VJ74# UR,W.NS MGRCO^4/"?(7_YT;F*
BH@SCB8S3,6"H7[6S(3N$M}YZE(0^ 'WTQD?5N]5$+ M-_?R_IVO_SUES=0FF L87G+R&5E_!SCGP;OQXX+'93XUB(33W4,,.]T>SU8?*
*_T^F\%701X*IQ5OC.+&%HG^"(_^$*"]$%%>G0UPJW/>2<,CH4H99V=> OP* MP0>WOS. BF>\0_OT5<=EP!G:C!\O]N19:)L:621)N!ZC_E(HW?(5@__X98^8*
ML!]4R\5>\G NHK$70XU(]&T"L*I,.:!U$%<-ZC+DV)A&']'>(<%6QJ(T?G8 MP,EVL%ILGH1$:UBV!\1EP'6*FP8GQ@DC[^["[SAA(8PVP[Z]#Y(@%/ BI'@*
MP98>M'%5$,TWKS.X?2^T.Y,M'Y.ZK,6MV]NMQK04"[>1'M\ MO<4F7_MG%H5U58]<@7>N\QF'_A;>2W(/K]:N>W@)&Q>929'-,6NA4FIHKEZ'
M$403]9AT55>O];MZ/>.!5[_W\:,ZUKO+6XEZ4Z,XQ>E&5W'U,PKBB,,^:!V42A> M$\6!WUM=.071]FIHDN0$IH)18-@DH<%07'"T%#@4.Q3D4. Z/HQR(<
M^MZE;7Y!X'"/<|YZ7YV^WFI5LF:A@O_>X=]+@'\KA'_K^,#?ZNG]1B6[.RKX M[QW^*9$I.P^^* W^#;W>[>CM1E\1@" 0;/>2.,_C:/E_X-^3V_TRRD6=B:I*
M7GNI[%!> ZFTB-2CU,.RAZH;-V163QD3H1_KA0)'(ZDW8TN@E/7{C2IR)44+
*MY=!"4A9!R9K9GFBAT=;K?:6A*5H(:*%=/35M7[30:NN]GB(&10P!,219K$M6 MV?9$#.V!WFBTJD@+55'=CMZ?)A0VF>)-*
*D=6^H|\U O3I"]2T)=0=C62H[?3.+ M50&20FZ5EQFU!'8UF9&"2P7@7Y9C;5_P.]3U=DL9+!:3\D^:?KTA6\Z[@/P!1 MM*G@K^"?*
*#/\DQ_(^=+1]P;_5UNO=2L80%5+H:V%FZZ2E1M G\\K#3-6@OP*V M5XAF5S8'L05$TEC93TI6ECFDIO4LLV#NOGQ^N,\,N)7);7]__)I-08V^8C&NN*
M\Q)\M?@=IJ-J=U!N_OQC=5AO:KKIXA:&HV4E-3?:/&5<3NP=S"Q80>2/V+\G M@=I|=_GENO;Q_OKRG[7+SP_7]^\U8_IBO'HR4!@U2YO%-NAW;
*<)X/FT3R\@) M9?J7.OTG2<\67YV]2SR:KY^2CP;A6LS!/-Q>?;?LOX)13,N;38U7W,4IT'QM MB'G)<6Y(@T%W#*4*
M]XPYZ&A&PCH)'!X9&Z&"B#U&0U&BDO2V!$P5BDW$F4$2UT)87-"^;/\.,GV M!9/@5Q202LY^;R=FOQ?&7V-*
I_Q^&%S>,GUD:0S"2#^_^&%U3ZJ/$[_$A#$]= M*!\HPTKPD6I4-2GZVHE=-9%2)K* $[_X_'198]4CE$$]&MC.'9>#_W.W>/5*
M;$;BZ#UM^"KK+FK^ZXQ1-#M\-C->';[MQFV@$E0/P\)X2_4W1X:M/3;N<9T^HI%,.G*LL86+R3*"ZB$]7.R"MJ\.)QN ML4+HH^-:S'NOO+ M@B>X+3-*
&>Z--21B//XLDP";&,\CJQA3D"6,)#-QO)GE@\3,\A:1%,L8@(D M-L(;;O@#^CW@+MCE8RFQ\BGD.G 0MV-!:W3E+UXMK5:[WOK8[=?J]>['6OM3*
M_[+VL?>Q5ZM_;%T-ZLU!]V.COW#OT)0L>%Y";K,J-MJ#Z[!O8^U_N=/;7A# MNUD;M-L?:]?UC]UNHS7H7O8^[;I22R=2]*6SXT(M4BSB"E*
*@,I6<1!^%ZCM. M2ROQ(%4+XY1*NNP28ZMS-Q7"#P?A!UKMI1H YZ8\=8/MEJV5*G_N.@_5(!N% MFX/ 34OA1N%&\1N%FU/E-\OB7<5B9W>Z3<(#DP]P*
M$C60&D@-I 92 QW80)63'!8+)NQV1TJ1%H+_-?HS7D9AT=^.:+3?L.A9U3V.F M!Z5F3.!>K>C4SIH-ZKZ2(QM;'-ZZCX9M_=?@':%(4/SAS%TX=0I7#<
@8B6\ M77>IV!!7[:"EUYLD)5]!,[^X:M(0B_))&6@)Z3S' W)M%MZOYO2WEF1C"*9 M-4@FI;+J8@K0L9!,;U#7NVDY$8ID%,FL03)).=.):4-*
*'0S+UKMX;',0M4SF= MTYM3VSO;67D F=TQ*J=]&;.95XNK3-KQO-U6*/ MK8[>;,<4ZMT7\I+<>2F]3DK9#46)BA++HL1NO6#-O>]4..CI_6;S8*
FQ??"8;36I'LJSB5X4) MMH]O=LKV>2_R 5;IRV.+)*(*NDOAK+"GM5R*K9Z^GU>LEN 456BJQ6D55* M'-52_8MJD%5_T-*
*;;#456BJ$*GWPF6:7$6C6]>5OUZVV!]2T)#(*J8*R*9 MLIV>OO*91U0#Z[/C1F1+)=5ETH/":1;64!YCS9,P=0 U89F&A96Q#(\^,[P M-*
*&:,)O#9*SPW8SUWFV3/@*YL(GA^6P -I8^\$9XZ0\]HDEJIVY6.[*I?I= M]"3,QG),?((\# '6A]\7'O& K-\C>=8)0W-)]-776KUO.%Y5LVOB>6:5 &K*
*M!OO@BUIR?-I#7J'K"7XR@8TTQCY,-[XPODVX)!?/5)P5[(AI>:,.)' "\S>0TN M>/$3GQ"\T,3R;G(S@IV'|S]YAUO';F-\Z*IS|T4L"&FI@A,WUDL" C0GH>5*
MU#).U[$9K^CVR@P7SV@*_%:GDY)E".&D,EY@.SY_@G#D$30N;P:]_RJ(P=-M3!S!:5&%N^@7\"R.!>0BAP7:=ESL6RJ(!H@BLM@)L($GR\8+)/:>M-FL?
C\R M%CK#@-YS]@WSR?)]S@=PD++#N'6X)?S=^ MCESA7+0FMLQBB,P7QCC_\ '+4?Z"Y"@_$V2). BGQ1VD3"N3Y028,DPD$[SN*
*M^2Z/QPPA#I,"M@Q49(UA.C"UL67#R>">CV $F(#M'RN36*Q_>8?<^+0*7UXQ MUT?PHYU^YG&("MJ"2Y99STP;_0]XB)PFR-*
*T1HXG&8_%R8$74C40,7!_:1YY M=S@S"&MA\HJ#'H-7 PB!L?+'~-$T[@70)73F(>U*2UB;>_+J 0I:BT;H1"O MZBU*CY*J5J6JT56J"HBJM{BF$UDA_$*
*1KNHM;@'PTZFW&*V^4T&<+W>(B&,* M8$1"8MF5>E0M+E7#3>'FE&NX*=P!&[OQ8>>Q+F0=W!5OE0*
*MWXF*HF$#M$SM2BF+5>=:*:4C\BN+_.BOJLJX!@?!MZH"5T4B@V8OI:9#?G6Q MRB32P.HJBD8J/F;E:."0E83^_QJAH1-'(D=%(2O9]?*
@51TT=RAJ/"!J++H3S%08^6BH!0U M*FKL%=T.YE"H4=V-BAHK1XW]HEO"' HU'O#=6#FM_@3VN @>IU<9WPP.LR=KOB7<5B9W>Z3<(#DP]PM

*M/VYOTSD!,R,"L%S:)K>[,GB.P^4+H(@4^_TY8N;5_(%)NQS\"G.2N@!7MEYRN MK++X#QKUVW1;*_7U;4+!X""*?RO45Q3UVW1F*
(O7=_1VM^0R+@KU!XWZ;?HX ME(7ZMMZM'T3;QA;U2TTO((!;=.D(0SOXP?.(UE$ M\%8TQ 684N[F2-VZT]8J/E;%,-
W9If_"7C#=;"JIL>)C5@W3V!1"V#6F0?_O MZ3VE_U=]S*IA>ION!7O@TQV!TVL< J8KI^><0/,"&/?ZW.>IZ@OP[4!:N1H
MFMNQ/!"+2I,]\9J"2A$]EQFA&U[. RM@U:R?M8EEFLQ^'S E(/PW:-3#9TLG M]K>5/+I3@4O6W;5-R?WP]L([""\USGUWGB,.3/Y@_<Z]ZF-6#=+;%+#?"Y?
6!VVE8BA72If*@2X\&<:6H%R, M>)WKDU L5,='XF@I81)KA\0AHI"7<7?Pf?C/&*)$X?0T;C:V?C*S]E_F.HN, MK%:M!AVJ.:HBE4Y*;,7;<72*5!2IG
BH$0!K!U\MQ6IK&XL7+4>G(IF%,UT M4ZZ(,U@[=4]+=U77,TW!C\,[,)C:8FVFT] K5>?'!,.6$FZR45A@2]4KX;// M'7S& ^THE|W5>\|Z/-
"V&S3,UR_>R6IRV6@O.#8L3=;-9:S7^+RPV MG!RML/PI8S= ^53M_2M0^,APV>4CLT>OW^P;PYL\8]O/!V:,S//8X87PXRH M)2D-%O9)!*P:VD2L4#-
HB=K4&8E072U8++ 0N5S>7<$G*PFUC39%+7=@(Y8) M7VC1TWLQO.Q2_*W5MO8&'&*ZW?#.=4:,F12-LH[E<-/>&WJC7D^IKO\RL483 MK+$_GXH-
,ZCJSJIFDZUV2G^2M1>]F;%TXVY"2(E)2SZ!*OP_V"-2YCV;.2[> M\9\L;S1U/""@Y#KDC=V6WU]YY:RNR-]+K,C_<>Y92-":6+!W6A7X'R(\:@(\ M:IU8^&
[W],)_<40L/-`]0H3*S8>68D_LYGOM3<.1-.A(WI(G,_@9]CU@IY. MG*F(}AH>,=.@7095[DIM.JUKAN=9'K(BW@W79#-&J]FUO/2L]1B:V(6XX+
MK'S"VU-/'&]F 6OW?]<'LA;1%(L([P_X ?T^TJ,*;@N/96\6-12ANP0F#[-] ML7S< #W\3'-0=Q!C:/B.1\;%]1A^>-1!IR)]2>NB/# 5K@<\ MVL^8IC(:.7-;
["+?:NISK"?V"<-.?*8JHJ/$2'0A1QD5MVO_K62!4;.?M'"I M+@ /E^6A[!Y\?KC/K X9Z*/UW*&"9$W3,8UUWD)?50+WV$3".WNR\V??ZRN M0;GD0)(JUR*?
BGK$,FA?\,. @9)WU\(?L7]/ N??W>67ZJK'^^O+?]8N/S]< MW]\'U+T8KYY4E-&M9;/8!OT.Q,Y]6#11L1,NO5_J])\D;Y_XZNQ=XM%_91\ M-*@I%G,P#
f=7WRW[KV 4T_)F4^,5=W$*EU9MB+=PW Y!@TE,YP@9,;="V%G!?9-#/@IA27","8.N;8 MR'A#CO_DF&PJ^*P'_-^#^3+24]RGF>O ?
8'LV#JS@WHLPFG("SFXT; =(PPM MNC *_AFH-Q,+#I'9$Y@R#C=U[,<:L Z@_@F\8 *Z*]PSN#ZA-]&"30?FG]4] MSO%EM^]G"\X$KR/@W7 !RL6"CC&QO&
WY$99M'P3IPC@=URF)_P6%[;.X":7 M?/'F95/GY5B[C:<@->RYQ*46VD784I!,DJ20N6W,38MK@?D.H<$)#:5,+HJJ
ML=T3VHW>'G2[!T7UZELHY7U\%5\N*EJMRU:W_'JLG9]/6C5VOW.Y!]@<]6] M?
6RW^Y?]SXW/W<^+W:!HDA8(4^;_8^]=F]M$MK;A[^^OH#Q[WDFJD"- $E+B
M<97LV$F>G3AY,.>>NC_M0M"RV$&@X>##_/IG=7/0P0A)"$$CUM2>/=:);IKK M6KW6ZG48@M%[==U5.FKGJM57+]16YT*Z;
T4Z6/K^GIXW9<4^5JKJ?.PTD"JF M:Q33&99VRX-8H<-!?M&;.7.^40/G<^AF1%@CK'>%$]"R M!!;)@>!!\.RLMM)C;IZ T^A$$3[:\-Q&1S?OR\$&!_(#!*!<"
<" >JV4#< M:0L-*%V4_#M@<[@A?G+.& =]-#2YE,N<@^Q< C4ME^!U,NA_[N*3OCC4+HZT M8W%B:,N=M%%G[Z*)DY)1(BT31KQ2H,'Z"3_,OW)9>
!88G[A044@>DP9&%, MQ+C7GO/6YA\H8ENN.#T!4WEJ39?MNE9NH$OLC.2:+4I7['7Z2!8D2VZRI%7H
MW)DL0\MB'L[XS9)9PFTQ%N1&K;FQ3ZW'"C8#N2_V5&P,R+L#F0^3D,GKAAF# M6#>-2K6TLIRE6),TCY#!+CZ\R-
GK2E$K[G2%Y0B15]!HM5TCS^*MSJU9Q:V6 MC'1",JW2]\F8?UP=FDANQ.MKR*)4I>S'GG(%14?Y^2D@62H\M;^<@Z5\AM MTE&FU$_,,N?
IEHTR8/F54!M$3UHUSBH,,/.*+7HJJ0SP5)+S,7F#_9HBFF4? M1.9%/9XN(NAW!WTAP2I[""C6V6Y#M-<-[=O%FAQ63'?:HC2HA9SFSGXJ]HRO M$>&^.!
.A /A0#A0'0?B;H=N@(<3QKUDM3)IH0$2%O?'Q$X<" ?"@7 @'(C7 M@;C3%9H7Q7NG6?!E>L4G[8'^)RRR;I.QZ>.9*->>P^V2"PYX)OI5&SGNT#9N
MB44+Q>[954KMBG)'JH,3DA= (@F4?B&QZ'N)[STF+E?T_LU>,,BA<<(O:5P79!W]6*I3; 4YN:0YD$HZ*] MQ;.LV2[_8#V%D,+=?
2#L(JDU/<8.CG%E2J+2A]CEC@?DS%A&?GL;P.0 !%[$H*$H#O,7DCP':AVJ5CN2^+W?:@#F#F MS@9KW@G8+6T]@X87QU*FD'*,>QE>L3SZ2C2/[.
<@ZHL=&15-5L?DC0&%U%C< MQ^ JD "]-L*:\S%Y@\WJAD0ZY[*P"<2^) 1XBG_,Q>4/^=N$-)8*X:+?;!M8A0 MX,ZR:M[IUD0DU-T M#
<2>@OLOYV/RQ8-.NY B@GL87L730%*1!)R/R1L)"@E\R&-^%8_^OE2+T"Q> MD(CH[/2W"W8H78RWQ9Z$1UQXQ+6-(?:%-H8F7C..N;!8+Q-
;A<2F[&/!Q:#; MUVN]=BI66+$6-M+K%,T**5*XAV&X);NP90.2]CZD*B30(X^AB6Q"-AT=F[8+ M&D$EKG8&;)-.$J.>#?>.KUD Y\4B9VC1-D>>55[OA-
78FT>IY^X%T5/%CEQQ MI1/4&)!AKQA6=3&5H@C6%_LUUC>07\?*K\HJM11%+%GL]RNNT8+$0F*M$DLJ MH@Q,01Q1I($H=>NKW7%G[6*'#1P(!*!
<" <" ?B<8=N@#^:!5'ISI2\>V.Y MGO=6&+O.-"[V*_78O\4UZ@V!#XO\G&?W6%VHH"ON#!2L)?K,VPJO!7LO.METAL M'/HSP5](D;,B%!A);'=4[N!,!SNK
8DK,.Z-8[>2BMB"R"&YA7/ J;Z^FQT M6P;<,,M2JJ[1O*A@UTT!E==G0P(@ :HD0'45VG(A?X..VA%EF3\+BV,X(@4Z M4B&EVA]-
9NX,KF8<;/VT70(+^P\QA ?-M#T!D W?^$5\;601@?P=F/X+C*`MK@D:>C/.NC"PC@FURNO 73'TW27@NWZ\,>> _01XS?)%<:OA8A0KDFV5;'+5
MQ>.0:\BUIG"MLIIV^Y%L4_"Y+.*JB@]7D&Y(MU=T*Z*(C*G1J859FW@0#@0 M#H0#X4 X$(\[=#.N\[T$N9BV@&H_M^3A*
(+!MCP>_<4KA_A#P\$18WS M1E;M&Z79G@&D9@HUJZ^K6S8S.OKX75?4N1KJ7<1XA9^1HPA@$:'+UQ)O=Y5:S <]EJ=]N5%:]A6
ME);\|6/WXN/'P4!6U=A!<19&I84,^O.$QDP0RXH>;/+:FVEZ\MK2:,#>V+3O MZ4]/?M&__7L*1/)BC0D2TS:(S5#T//>LG"UB)70!S:?VF6CT!D[*\@H=_8F,
M[E 0V'^>T/S':-1%(.\36MJ?>=&^#)\=;P:X1E@CK'>%S]"R!.8<0O @>'966VE_&-Z P]V1 M?YE!>4)D7G?EWKL_K\EC\0.B/>^'&QP(#]P(!P(!*!<*":#
<2=MM" ,'D MWP&;PPWQA+K5L!M1R&G@?#$N->>\X;H=!1Q'X/RT C6W*S):VRP\YLV2/0 MKB2R=$[.%464.FWD"G(E)U>4M.
(,.W,E3^Q;@23AMCP#4]/.U$BKH_":&EQL M!51O4E6QW:Z%WL2=.=B ZM,KYB 3UPTS!(LM5U&ZM'JD6H625]VB%$O2GNAA M#0,<]X^J5'&*[<"
M;H/D2UV>F(4D^N@U>-$P0BZCM*6LN8"@X@\Vf5>*J(F-\9\X6$ MJ.QQD%AGFPW!7C.P;Q=A9%[IYI%GR97O%) M>Z#_I2K$B-AD:/IX'LJQX["S74[!
<]#OVHCQQW:QBVQ8 ACO_,K4E<2!Q*> MCO(])F\<'0$?8 3T4([(+?%=]_B'@=PS MS1(.'N+&P937KC.]A+F8=@":_OB"X37\WCU%ZT?XPP-
Q4>/4D55S1FFV M4PZ9^9J9U=?3+9N8''2U("^1EYL\>146Y2V5D9UEGZ#$6X/.5+(VP:'>4%9F MD;)?3"?TE71CMB6![7=\I;,>7@Q79SJ+AH'!R;-
N!0:))V>8CX)N:1X\AA^?KN]O M3^*)+$)?)I38\P;G]\R1TDW M[,'O+(F2YX*,EUWU_=OA#3986Z(,P(51BO!=D"J/(U?);F_V3 MYH6)/CIYE_IH/GI,?
S04E\4\F/OOEU]-^UQ;' MZ(P%*M.HMG'V3ML)%8S 2QQ:)%7,M[3O++(^E-@#1;J2>KVKUF
X]+4ZI/@X$<.R7@=\08@B35VVKGLC_LJBVYW;YN=61IT+JXZ]-:MZG7GXD)6>M=*6XV?R\D8M1E"],\3NC' @XZD7/+:FVEZ\C]$Q-BTV4*=K$I:
MANML?N[P>!B43-L@-A.MSW,HG2T*T-]_L ;9Z+1&S@IRV-Z]*>5((_!*#> M2IW-@KG:R(+R _9I"[" 2F@I24?@&/YYXPA6@V!#NR.QGUHN@P(1!V>IDNY,/
M&MFVY;$#\NKPO)*15MO3*G&AGXU?>=%6)9\= M;P:X1E@CK'>%SQ"L->8R1? @>'8%#VN9Q!MPN(N&*3->-?;>=.7?*XR,N26/ MQ Z(]X<;' @/W @'
@'PH%PH)H-Q)VVT(#8V>3?0>C()+X0N6D$-](<&AHZ MRV,HP880@;0"-9U66XI"!#H'#W6-E,TXN(!,\B_3GUP&'O"5N%]L>G8&EL.0
M%B'QB'&O/>=M,#QHB[T>?_5QFQHV5T.VI%4^V9DM>X2?ED<6J:V(.E="LB!9 M\I(EK73)SF3)$Q):($NX+6""U*@S-=(JC;RF!B]
]07_0$3L2EF;GW7O,ASW(MQ'6S+$%NR[1L$-IY5=*,JJ%X4Z,>BV_^+>[-D_

*%36B/[(UT^BV"#+SX 38!] M IC_F^_H)TN0?HH6PP3A8-(HJ/ ITV^LOID$3"V_7VQ8UG.$U78PP1Q M+YC"CV 9Y+ MOK/%@[8P=G8^_\]$HW>9W,&APVF//I4%]DM BOWGB;Q9C:@VX:R\F.*T!5B. M,TXT[S"LF)^)Q>>46<'.!SM;EQB-ZQ -7V:^6BP_^YW?*XR,IX[,AL; ;Q$7 M)"E<59;J2>IZ5_*!CR-VK.O;%?O=6I1EYTX&-2,C)SP&:(#.:3EML:/RUUNC#C*F M,5I,'V4,QS)&S@CX*D[&7#N!FU?$B&I;1@F#6LQZ"3-_" <.SA)%*D3#F8VXE M1NS(V&$)=9AU$N9^0ERBC7WB-D+.%%R(L7QQ5$0EQIZ<$WPC)TQSE*JN_=$_.R/C:0Y#] MM W3TRG&B''UK,-7APQQ^;6K08\W[_::X*&W?$NY9BA6/T*I)CQJ5L#BN\>! M'{@$52T>)=D&52NCA,(NR46);,HI@_H=L=/IN&$Q_;>E M^&B$:$%=*I14&65-<..)%'I\68*HM+$KP'[<>Q8>KW*>6J&'#MD MX<;JI5JNRHT].7<@JQJI-H=9W]*.BMA6!WSYV@1$E+B(OF>&;^.%D,2V/T= <7W2E+ST''\T#6-C$CQN]T'7P MZ#K0BD[PSBR@Y163NE T43TD(KS60!NFU:-L5F>/<@)^,(5OL0MX@A/XGJ_9 M!JM^Y{@"T?0)%Y!DAB!>?L&=P CDF;BZ"?]*W2NWBCI#*K%58A:"=H!=[\N:S4)QLQ2-,K&A&PR"+)0UB]6:R!((&=#+S&4C#S^G/ MY]^.#JOJ5"&@Hf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}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|\1SL]1G^W(0PX&D MPX%P(!P(!*!:C80=SK$:H+<85>DVM+14G_U_/55G$BV!G'H*.^2QDP+W? W7 MI@GPU2A-E5?R>\R%D^?_7)NV9NNF9GU)^D^%48XK862O0AQ3DG=7?W/]>&-2 M4SMO'F];E-0U*>T5/O[R08C SPE\]4+@YRUITJ-M+M? 4K$74(^HWH[Z3@GJE M)M--^#NV4@UU@ M@P(KBYU!+=173E")3%#E0;5,V'4CV,R SH6;'PQ@#L#KH$':C]//TZ%>Y>E M_3;N,*VFBJO2SJ&X_KS[Y "O;/K&0H\(6HYA^$#@%\1#JPXW_J30^*1'&CK M-8\4'&FX2EK$Q28-E\L=(TO_[5#]=S!84VL/^<'}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{^!!.I'+8K=U2+WQIKI M"H_4^4B#@5>Z](O-N;8A"]JG]#*P(:420)- !Q*%T0L#-05(H%GPS'SZVQ>1 MQ=3";|*06N]50.U;&CG[OGZALW.B>I?)XER\7,[7X%NT!!]A?3/"9A4,F\50 MK0).?GIX\H-1LXBB,E&$0;.HB5,XA&? P&+N!N,'8#00S@AF%(.(&A6#E8,8 MMLE[H2M7&<_6N<-,XKTO!QT<2#4<"_?"@7-@'*AF W&G+S2@01",^Y?I3TO;_MD(07IHKF-B' _BH"&W!59UU<=H@74YQICB(OO-OE?P$41I2?ECMAMUZ*=-6*> M3\QG=$L^_.:HI<\,Z_QX;U===2A+Q7F>|YZZ(6IF,EP9BKX>!FHCYW)C/;&O, MH8P'O"MRQ=6TL0$,Q|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|&T)P!T=M[]NC \T(%,S^E:9/WN52EP,?R=2[P9@=$? MB?5R*KS"F 6O28$@&^R<.KCE$_D*K_(^$:7=S@FPP\N9R#W^407['[" M/R%95_(G+B'L](4/B #@$AF#UXSDFS:89#T4E=.M.99K\ U'7GP6;@MXG_ M6M[""F9#8D7+CMNU[*OM6G9MD+0L??,"NRRJO0R9NG+?DOS8>./=E!M7YC>N M5'[C@@>[+;A*L)B>Z"D+H H+&)6I)=G\- GFOT]V#:82>B4 S.&Q+1[V2* M1M93B,|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|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`9E2'\4H]7R-SH7X!EE8R';X97%<-[]EI&R)WBN]L';$G[6,PAV9+4RZ" [(3XH<46-K M"VLG7#K3F6;_""YY-,D3,03ZIJZY[@L04WBDJ>P](&U_$"RZ<_H1<*KRK2OUTB/-'_RQ33*S%V:R&?)277$^:+ M,N]$8+:.7!&;+(SH5FD^P#7G$7I67MO-*7*:O!=SW@^92T28LK#'#L/K!FR^F M/!%\@6X2I@LKKPE_!P #TP$$1%FQ*6S),.I\-EY@HW"%04G M< 5-UYV BK0'(*X/,X7?P (&EB'0OP%5EO4BZ!-8!'",76=*KV0Z!KUL])L>_0ZTQ9.PYA#/?''NI?\-CH5",1RKX\=6#Y 0?CP =9(L!\8"<3HW$\ M6 =!-UT]F'JP^C]5_Y2I='%FP'BXC&:Q9=/|$!?. ^%3X,H:;\0/X) 000,G-M% ZVXX?2 2;FF1Z]+DS4GX3KXGG!=$8?D,?&3A9'| QF!ZD6A:&4*&\ A>=:MP"#0Q@=:B*!;<.M_QGSX=`U_>Q)/ M9%%9TF'*Q/T@Q+MYN_U[XO5>O.)DW'*=I[E#?.4SG< B_/AT_-;YBCIWNI8 M!)S7!=VMX?7]U^U[0 MK"?MQ8MU3^I#M\G2 GT0)H3JF.!%F>HGT?G!;VWV3]K10O31R;O41_/Y8_JC MH0I/,0_F_OOE5]/^E8QBF-[,TE[H*EJF35HCNO.O*]%L\,4'H D3EPK8WWQ' M/UF"]%.T&"8(9,>-H1/F7YC]$")M4HH@;D;8$-W0^U&%W\4RVU<)B_34QX0K?M5^@ M%=@FR/"OYB,5^W"CYV,FTEVF41G$UTP+_N/IKCF*-*

f'1=6+SFY,'RQI6;!? MT3<2+8R=_E4NP^%,&P)692&G?TTG/D^JLS8L2SGB5Y^[X*(;^?,7"G M3X@16.3[.-:*TC7_?]KF#^8?6\A0,C)EBO0TD$N&#\/%FU M'IDXS=X6=I *BRP!4_%Y+L'.%@W"|*AY/K7/1*,WD$SNT*?/ASY7WN!C.OQ ML.\!"".P_3^3-ZD"U86OE'<&G+<#RL?P7>P:./GP4GL3S,[$[XCZ:^J;\BH,& ME""H:PKJS\Z4Z&"[\89IJK%\=KP9X!IAC;#>%3Y#T ^9KQ'!@^#9%3PL_HXW MX' 7BUEF1FOL9NG*OU<8E_E_-#O0W!=!"DW9A@9D\A@QDGV:/,@]! <#BQZD3 MX2+P3)MXWEWH4_#8(7"B\|_L0F?-U)#5#O8#)1GQOU63G8V:B/ MC8*A;40Z>'FPEWH=L=NM.+H0@;\K\ ^H0J8%#R69- 0@*CD'!DS3,2&T_L#SK MB_*@6P=YQIV)T8!TK^3?0>BWB(_@FF%<8/8]2*;!5D%4)1@Jf.S9)<;'@$:X M_F !1WFEGJA4+?,PW1W3W9>I-FBWBZ!: (=;1+EP!W@4S%)IB5:%"8900_5I M5:9+1<:@HP;$]2G8D/JIK^(EFV$'8OKR:[F65GN@^0/LPI]3KBI+2XTOJ8780 M4FN%6FF5 4]T_>I\,H;LPMQ]/FP_1! f*]16YGE8U8B?[+V^?V-Y [TJ;A15 M5G&&E?H(QY^N_V53XIP7)S7':?3SS+8S_S-8F+:6YJ9MBDQK8R;.F#]VGR] MOM+E6]U]P1+-4M/;^H.C26N+\MF]S6/;UI=RZ)\TC$1/[_ULCD3/R*U-U.I2G55 M^]$E7=0QK98& X"1:Q-BE+4Q:1 "O.U%;>V?\^Y%B\O^?7P#B\X+*5F @]I= MT]&(O[B&I]FGMF #3UM35N;E4;&A]\A;,E#5V38GYU]-, Y9^E7N;=!,)G!@@=/K@DK$+-$>YE49;6(1]W ?!)5;. 3TJNK":U MQT8NJ;?.ZD> [I^34O)6J, +P?[U>]EQ;3"X+R/:TI[5:G^F490@.QWUX3ZLW?`MF?_Q[($'HDC= E^_(E)&&UGV0M9^,,Z<-^6>Y>U!7]Y M\QW\5WJ5YO1PED?: K9KV1(5(&\)[#:$65(+7'VB>43XX3H/KC85FM6:)4S\ M8M#/:F9AVB1RU6ZW M>]Q36/[%$[MMF4K;5^MW*I0';64/;*^],D:HRB2/1]DOM#OT&/-U! f="D2VE M9<,6NGS5(%L6,_UUP+X'F$5KR#I6C0,&6=8_2=>\B0!K-*%]":V7?4.G?8XL M*])67.('KATVF*'0]6!M O8\M,"?."[L,(8P"GRZ!IX7$,- TBZYQ1Z'CS!O0 M?1]3B(;2I]%%OPT[,)M^%F[58,]VHL9W&.1)!H"/-;FC5UOX MYH6E)5.[TR>.!=.=_? 19GS3'(-9I^'S7SYY)6G@S6\:NT1[4%>WABPW7)HFD M_>KH;! F8>\|T"QX+\?[2'H@'\|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~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`P9/IM>Z_7;TC<2 M'NKF/PG;:DJO1_JJ/!$W_,N>N%/Y9%E: M]9>81G7[]T;@OH#9"?;-:7LUD(#3O%B@F;D>AS$!,V1MC^W5"5)5+HRKWGY M/)BQ S1?-V@VRG;E(TN2LG+=S5=5.NVA^;HS"+>K 'GT{"S(?!WT3MO5)$XW M1',NIB30H17L?72+3+;*E1O#NU.TYL;P0#[E)(:9]4/>5XTS_FSM^4:V=LT MYG6MO=TYE:]PMX^TDEH91OBZK)ET!B75G_A,)SEPV,|V5KBRZ1"YC("D,H*0 M%DRI#545PZFE%%4L>BZK*6@);$O""$=+D8&*X])2_7DS)5'IA!#6L M0[0I/ET- U:#0L4S/=^CR;G^A "K+,MYHA6]WYR9YP:\TER/QEV#H D!P> MH//\[?O2E[# 5%Z&<=!ERFRX]HEU^M92=EVB6'Z MPAC,3@NV9, [&"%21GK'QN+?=;BLGY_]# M'S@\.%'HG?9_7SSV+6D1-SA-.7N4C8%/1IG%MCR8'P,C2BJX\W]M QEN4A= MT'0SXE"I@_2+[?ENP(K,TB"S<)NYCG:9M C2K!.%Y%Q6V?IDF2,6[F?5:Y P5WZO%JAMYA;=.J5.*OQ/,$/7!=$%|"S'&IS"C' M;G:*26O&:N-C+7.1CF5_S9$@P9."N:7\WV0JHKG;1"XJF)>A MM, ^C9W9/SE6QRYV6N<8)]Q99L3,K*J<-VIKCL06;G79,EV]U>FR]XZO68)% M0]B2H"W491NH]!S? 0/A8CVC7WKL%&, ^:,8Y68*#92KE;@2UJMC>.K>^EW$K* MH'KU-D=L/K(E/UNJGRBW*N\.R%M2>>,DD;@U%1^I(F7E7Z2D$WRWLW(QA&'P M) <1+#[C2BP_99F&- L)LU^$=BY)C%HO((C;,* LKHJ]ME1%QJ-+C?:\|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}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bS$@/0#,ZB[JH_AN:=5YK068L<>^(78)<7&LS&W+DL.)0=+@ MQ?8:Q1Q.,*# >Z)3 K8UTQGPIS0FRX,/$FOK(\0N2%&4U/!T MT>N2OT%T3FJ19)*I.6(:UE\BJWU!"RX]HT0_N0$#KGN$7$$<$$6[!0L"HE_>P%+9H4?+NBF>Z"#>P+TD%E)T,? R#8KY"/3T?00!D+H0U"><@BGQ!+ Y"/+E^!L(;M#]RR BGM,Y0:< KG)PW1_N8);QH(L$NG B+&5&I()AUP_]: MB4!@"QPS$5S QK$I*1\E-U0.2NBJ\ (K/GV;&'NA;*=7H84$M]<3W\WG2[*- MG<]0/NN$4A=435B'PL43>#4"P?A;&GNXQ7C&J^4AWUH3+T+Y.\9R>(<=\"/6 M? 5\X1+X6#X<_,MTLTT7IH3^SZ*CR"-*\@H:.$]I0:&]> @GR_|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`^^.,48,%1Y%-#IUBB>(,L^!PV9/QC0_CKN0Q_'9_^[_&&YYK-X8"C M*<RJ+);.015CV,N'@@Z2QHWK;R"RQ$%6QJ,U\@ 2 MM"E3,F"XSFHL,#EE<]N+_Z2!L-IM\AXV&WS]XL%=1@M@SR>?"CD$L,8I\?WF MH3\Y<%!*AAJM?&A0$*8P"$NNKSZZ$+SI-)8S! !)QYIR7@!H/_6PY%UA>-;'> M1 W ??!?!\;V9V$2.?86]"JX"'*_/9Z^.)P;B!)VE%]'$OJ*Y!H(.A9_&)3F M7WW4QK"W0B[5;G27&>3\\;JL.AQGEASS!B# (WZCDAA;;U!?FG"=VEP#RTG7 M725=W#%E<2+_?':DR9<3.TR)^PW #ZMSE&O&'0E(#UR0VQH?)KM/#3YAMUEI MUS+]9!H)D7NY8 .YVFNV- O8GS;#LN@QN $=`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}8D:!N,X.PR]PN+@B/Z^=&,1C MD!^=0,59+%(:;1_? P'3^3@%\K%(**%[/%HYR=H)Y24%Q3!_#. 5"D'[Y&!-/ MLO5AH.^S$||NT0*%$6@^N7$\"5VE1^=N/ 0[]]@,#0T\"^,%OI:9>FH]\@R_ MH<6)LE\(0:U1IG*PV ='V3342\A"*" M/WF38GZ)S)}]?99($*0HLLWD>'??%#\Y6R9WLY*)88%H2^U\^Y?FA61\,3H!- MN$\DMD"IR6!CGT*'0K]JZAX%(_/@@N0&L%@^A%<8P[2+]G=B&.JZ4SD8!LO& MHCCW:9I@3FX>&U#6/H=*BPM#]]45:A[P;_G"6Q8(4+F;F6-KBM$7&RU2V%'* MXN(L)/@IAEE.O5G$=/0_G+!K3NZ+)6^(>5T?=^54M>5#?6TDG"1:WZK]76Z MO8WUJ59V;$ES6U;U<4Y:1+N?W&Y5/@U1]7 3>-8I;>=_'MIZH9(SYSE MH<.\<$#E%A2*%!5+%!4+%.V(,79V^FT?CGH71I@ H"(PV[^8]8J_]8M_A"&Y M(_+R/#/IFUZH,BH.)+/,!2 .32QRG) '9\.O4B M;L 6EFM*5D/.PU3=A&E5\I

6J/\.LV^I!@-YP_'_M]N MKTLYEL4=E_4-,!9SG3FD:6%UH??S;E MM XE5J@X$SV6H[HM8AX)$IF8>D'!)1YYEVB@%=@C3W. I> T M= (&QQ"VT>4DTL+XG*Y5R&H'11/#AZQG;G^UHI02V<9<1,D)MHK2M>:XTXQ M9% M99(E74DFZU4]P Q5T(RH"V(A= [WTFGKP(@JO,)RR0,SA_2)67?,'<3I1 MZ-.(I12Y_!J.3%\KO"1-4GJ?A UI]R75.U/52R^*'X"-A.=/U3 DEO&^KD6A M/G'AN=;"=V3^H.J,6JEZ" (P8L7DKIDD_I)S+:;$D\D=9<\L MBQKLQXHU;9/5GY@$5KY&VR*8K#ZM[A L_X"+R[_.4-+OYI7@9.[0R MQ[/;*.,PYQ3/&V7*^EG)HY'R$L+_LJ@(([[LAPD,21[MO0FA7.0LNY-D4]09 MSR%UN2@);3F0LK_E'?9+G.R:%AV 0REK!]VDS+6W1J#\8O7@8UER@- "5*P@[1 M-XM%?_'Z2:&%?3'!1Z:&9W<.*=.$]I)-+I&LV$23777ZK]K#A2P5NG[*HT1PSTD0UMR-Z0_7V1O;)0LSOY9$8M9\BIC.RT?%.LRM1EVSB/ M#7&0-@[]- MD8QD(9*3W^G7KL M2%75:/B!:HF=48W(MY4S^]GLU..XVPI'?1)RC"%\I OYWZ;$;DC!WDQRK4C/_ M@YOR&O./>\U[_9=IK[? <\''^?]/JPOZ4$G.6]Y9

*#%C1) *KTTUDOK!WZ;A4 T8E5-M4R".@ MTDE(3;F)S.J_2]JHPU!BF"?HTV!1RB.FMAAE$> M.*/(TC:R\$@D%FGBJ.2*+#FWD(0K"^P4*@EE:0NRL@!5\]J;*

Copyright © 2026 Google LLC. All rights reserved.

[SS+UEQ)*?^[`M)62MD#BE>"X73`JNE\@>+RE(]A\'PG%GQJUI6."9K;DM#]'D1KZTM;>,H^^^=:0@C#)2X;D74KR`M7.`\B<5#5<6)C&E16Q*
*M,D\:*WWY7329+,1W\PK7RBJBW%E@D'1#]2+=DI-6%/PXQYMO5+OC&N_D3-'' MHLI17XFQ%6/M43QNKZX:P'TKTN5B6-58U]V*
*M\I#7X#FO6BG0*JU*9ES3-;SLQ=64+UP>)E-E+:_" .\&DD"R4E5Y0RVF4)Z- M!U2*PR2D43!5#^8 PV"B&65^1KERP=$B[/$F@ "\N4I]:5@?IYQ5/,UV-[9"*
*M%UZPEZJ]Y;25Y>-85)2F*M747:[@!]!EF7#\1/D05,4\X#EB%0I.)4LBA^-B MD2P2@;.(9T[$E:ZHU9P<7E988@*_!A3B5OF8^8;7N^A&)]=!N.,ZV0I/#>L]*
M6.%!":\KZ$JN'BYZP(M]H J37.Q0)7M2V_?F$)WY?F^3.$^D;B*.$'-07:R<@JV!@%,XM2.4!'^0*9>WNGWRY1(3 MD\55S6Z W'2U0-VV_OSA5 EY>>M87<-*
*F*95=Q:82:,Y0W,<\"*#BR7.NWI_K?Z@>K>]!W!JZ<@'ZF#".U:$Z.9 MPO84>]B@#"L+G5JH1M%]JY:LU#TUA5&%P66]?EXV2C>DK"5L!TX!KL5?:-MB3*
M$8M97AME3X0N93?G'4U58>(PA7]D\8!2I9N'*C]_5EB>2J!:%:XZ0^N;*E+P MR0N\>3K'C0(>YKZRT+C+#$BIVID%GB5\>428(W@Z@/ ,M,
*MV)B2U(!=M]0*0'}(SLA39&FNL=QVA-U!=(<@N.$!=%)G4I$FH&([#'SX>]95 M.E%KFZ=45Y&O6CI)DR<#$;C9Z/0L?QZ%E"7\PCE#015+^Y8@]^YSA-*
..I=J.[M,@"_Y.'@)DNF2 6H">,]$O(AAO.Q;%.(;Q<6;3TY^VSG)RC7L'2SC6$OIOSQ M,G25QD&_4H7E? I/=6'#X.LODG!9FGB?M(",/K \0?*5+[.*
*[X]N1,I#E=2W M%C>27*D.:H%F13!SJ(2_).UK2BR,8YE+GG,9'X?%KW"ON6=38)U]MM"LA1.T MW97T[2!1VU2]A\"/^,V5$-\S@FQWGPUR.N=X#^D'R^X?*
$&Y)F^9G?>P$3D74WX(EKY]&Q%<&5S 5[I$,23#K0AOG2Z)8;@IB#/CD MXH*DB3>79?&9Y?&.ZS1RYEF%H#62.LX.'28@A<(B(64-B"Y$Y]W5I6 H):QF*
M?C M@Z+6RE\W]+Y'(M'P9Z^#QV9K!@2V0 M.%"$;ZE&H9;L$;K!Q%=Z QOX1RX\/AXW.8V[?$;%6 =^T'F=#*
MQ4Y>]6A;LQ@AH>E7MCOY*/D"LB!HHU8X=:H6&&O'>H6[JY33[B]->] 8WCCM M'=.N225=ETHZ-*FD)I7T*
::2[NTT>I.2%B\;E60%/@L.3;JBC5&X)&>8H&1 M8)"B6$.(CB\OJZ0!.J\7$2:R^U/%U(2|*I"#EV'QJDFIAB#^3&I2XGS'API=`MS|*
D7!!8I_+6=#!B(2%96X6OV,K+5Y3,PS49BM!Q\&8PD?Z.277%Z=/51&X^ M0K5(\!\FORDD@QNPZC:'B-G6N=D+.%'HP.PAT;D:N=/PLG&MJ/U30Q$&W*
MGUB8OB$[7B%#X,>8!\ER/-0UG?QN3KDR8-9ZK]3GR[_FHOVTR"P(C+8(*Q$] M\6_F+:3W73G-U0KM?-)Y6B L5T;4V%\-@#P>L/]H
X(18S$V.L1X(;H=F:? M"15.O&23@NJHY/%9+#(%ISCG (HZ10OK#>+;QRDLB@[+K'G#/;@]V0A="_6 M24,F3PL6'4+//([MBWP%A"]+0-U2^W/&F0G?*
*B%K)DR+\!>4&8%%,B@YA'0J- MMO*_(@UAV#B*E8]W21^<8T(!.(V>ZCM^TR0NB'TQ_V]EV"P$CQX@?BER@@NJ*
*M6X6;#KQS):B7]$Q%1!8!=HU*_(MAE(N0*H\]*3PQ%JH, 8K$IZO=%EF=L; X M,U:#+A15/G95-X3,I:E(@2+Q-R2BCGM*QRE1>K.DSV M7-*
*/?,^%>SV/AAU=63&8] ,$9@@C^5297*_ND5--+Y3IDE,7/.#&>K>]!W!JZ<@'ZF#"\U.

*+/I<11>Y0[_^2=7^+[U!?WG/S]MA%&MCBOL+VTG[_#LJQ.6X%!'G SO&6?·MBQ}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{3%Q_%JZ@-Q#^C?N6IH MT*\3^H?=IMWO[++(V-/4T7;IP#SP5 ,#QH Q8 P8 T97,)]=O0?O'P&XIV&<MQ!9>1Q(_%B*(34]X 6/ &# &C %CM(ZIA:!)\(M^TACLSM#HIYEK 7$?FCEP?WNG^<D[BMA0%%,YUY"#O_#WUAM+2]:6D#NSLP=K,6$/<1TNB9VF9:0-P'Z]OMCFZ'M!:X MJ 7V04=K]W5SEVNFH]7-8?81]}.+^/"=9C4IRM'N[}(&-S5?:D9>IF25(2Y# M7(:X'AYQ/9"#43-UN#XN2UF]BAHV6>[*[4RC'Q^&&.@/P0CN{3*AUYPT-2,Q MH++!.SQ0.-A1V;Q36[=C-UB[S;R%U8S"ALV.W6_MTE=!*!JS*1QFP!@P!HP! M8\ :H'YSL!NMG1+IM9,+3OXG#J ^SD, MCO,6-QXI:48;VQ=7FE:]6D TF-<##[7 ?*MMMW8:L3#H-^A_6(I8'?QC?P:1 M@&W]1TRL"\<+8BL\(GO(G'&OK#$WZF77 ,$-XV\Q#.)?8<2L3,):PX:X#'$9 MXGIXQ-6V1]T'T4;9$)@AL'LE,,W499/*9< 8, :, 6/'#P8S<[>.KBJ.)7+ M&HMI& D9,[02YT<=G%(W:K,=T&8G88H^NR5U]I'F>OCZF>||26Q9$^_4U]2K M)<'M/"W-$%R]"6Y@MPR]&7K;V_;<""6YC$3O*@V(E-: M(;\TZ;\J T7^=/2L:@,^O#FKW #((']NA^+6,$T;} 8 YY@X/K 3WDN:%O4G"5G5*R&SY--7 6HE"(I_PJF ME$81GQSTKCQT_YIY<#I\<;Y;BS!*IL#B88-W(/D:HVP/KZ2>Q8(I M0%*5P@*$$\EVV,=,SL,6SF/KR23T?2>*F5+#- 8, AY!T@.)H*+"PM("&>H\ M?;[CC>6S@TW*5T?-(PMM,ND;R/Z.D8O5WVS%P1%&]DRU^;,9'KZ%%57$")CJ M/Y3!]S)W/'"4+Y_6!^\@Y+.)W7?@[X#3:=P041^\.NIO=(7LSG^V-C-L=Y'/MJ@TH1T//Z53XQ(?!6SP,.]JSPR+9].F".V].1M;Q,F&MA\<;7]&/<>0]NU) M>SDKQ9Q7]\G3;[OI.[NK,JIZ[4?[_$NSV>1]!L\3I)$WCCE$%$26I\=F93RM(0_7GH;10F9KU?"NCWX9QT>ONVUI,!QI5C_*T,}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|*=V'+0BX "T;D@N@X 4%@HWI@A0V.*=S$<$B95M@ MG S!3X!A>;8!8-2:PWI,8DO 9";6-[$ X&,161TXA=O-=I<>A ^=QL/'K3QV%MRH0_?OVUM)W82#FONG$FM_/EL_&NB9NIBD^;5T?-(PM%ME12LK]C+.RA_F;A M/O4"DGG5I__F$_06DK;(%2#,?]A#X66N ;'#,9_6!^'@Y+.)W;6Y1X+|<1:%Y%L;>+ LEK8D*& MHAX<17W&([1$4$0^^DSP/RE,4"^]7HY(F0/B/MFY;=AY>VY!C5/7K>:S<:>R\H\ MU@T-!O$&\0>->(-V@_:]HETSK>S@[T "W-,P3ECQ4F4H3']%\:,6 ,& /& MJ%>LP76O[^M(4WBF^/#TSCDE7.!_Z!V.!:!F']*5*U-TV!WV[HHJHM!"U34 M_F=ABE5I 7$?2"_U3+W;6 N!^QKQOR-5/0#MY-LZR@?4EF(LKC9T8EVQ=O MMKOF5-8#XCZ0WVN8QGA:0-P/\O?HC-7./_9& M+"+A>@Y5<O_H2^,_< MUD@T-SIR6Z:G]2.O'9I-!CR,N1ER,N05\W(2S.=N#X. M2U6+-TPL8(,_1UK_)KGUUS#'T=.GWU M=NHF/A0]^>:|Qˆ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|<>5,GNCXA M@O\&'/`G+&D3P@PPG0XR1U]5LM3 4'/*Z$(%+F$RX,ITF\(QDTZS734>(IGE@H<1)!/UO89K,K%,G@IT)M'!K@,VQ4_I6<]C9D|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}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{O/^CB_]A%_-XXPFW=:{ UO5+BF+E4BXX45 WNY'{O; M[1%CI7Z=:1;>.+//[P6PCH3:.3A&7P*^/<2ZPF&U]K-%V_/*-#6;KUX]ORO M<'#C*21B])E[\8QS.@CVR=G;,|.)RT%&I ";*@";"7]AC5-@=$$E:2*D&^)- M+Z*\;^!XF=7M7(8>DMMU.)T"Q>8; RYAY9L 78>XEO*'OP[!11-/0S.8G8GS8:3QF$M<1I1W#7+]ER@AH(@)-2X M816P%@LD_*7:0W@^^SZQA*?RLDKX8&%-<*Y$A((YC]?*1>'6%W +?UW 01\% MR$%K=X\]=-8!68.4LR9ZS?;?K^YRRBA.C<&/1OD0G9PC.CF*$;HAH.A/>ST M"Y=OALV.W>J PJ&LXP[LYR_2ZA6-H5(BR.[R(MT[6[O?8="3%S&:=&UN'6EW':]J"[FG%HKN.8ZSB[NHZSE43#VSB=KMT>=;>^ MC=/9UVT>95=?\E0'|%JO&A%+KDO< MV%@$J#I7)*-S;A$%8RB8Y,IX PV?C]\|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`)G#C6GGX9/4&=6T'|-%(H3P>.EVRSL8-<>_LR1LVX#/P;6?YP@Q5YL MJP'W0102;"C$'}]IJ/K?^&'B#X$K"<@L-KP(1Q3-OP7WR8/ZX-,>:P=',#0 O M1.!>RX5S:VA<|)J-?-2V6TP84NI9[VY%U?83S#@EG_DS^03&T<>VAT^ZZF_ M8'D9MC7'V4FF!]D.FQ(R)2==01DY20)$I=HBA8R;O(";[[7@#]N@@" M$<=="R(D?NM!^EV5&EH7V :]|6]6Z*FDT%|\R[?!?:8N_*!T;B"-<[K93PAUM:LT()$X-.N6;N;0LB%&&C$*]N.*"L'!%>_.!"]M')3-2P^!_8$E'U/I1,1-U M_X0%>4G>S!,;@2Y@Z!_>')0PX$60?+17+(+?@&R%*>*;R8!H3E"Q#\5C@&FG+X0%RU'H;]@F#O_P&U\OU M\FF=]47-9@Q; G0U1Q45%<\92'J0YP5E8V#WI%4B)P[&W5<)7-$&B=E0Z9O M]]K-;0R9%6YKK=1/_"QK#']D,YK! M0'&)C%:Q2"_/L-=L+G/MM@%=]:[U'J+X+H(VKT<*Z76[+.]7MVQ==41)^N=LZ M?*5:KY;&>W=>W>I==9WY]\W>O([__.>GFUO[K,2>E7MR&:]'KQF6976&"NQ- M_=2ME[.L(>#KR?NWQ[^=O3WY_?CDW?G;L^>6XU\YU[%RLF*P&SN.E[9W)IO* MMS%:(\/\OS3IOZH, /G3T;.]+?_PIGK+]<7\'6SX^9?3/|S@>P9CXL4+W[G& M+O?82_UX{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{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

MFU9_FINNJ'2Q64>*Z.1#PQY&4-&?M;H2TM5EZ"W9N.RJ16T)!J!#>_(SBJXQ M6):R.+Z18.JKH1_+$DKV?
LI\D0D]*R=]:X;/ES!]OV1.>.]T%#_@IK_"NK#O,;LZ=@8LMFWW!@#WH]=JY\80T.OVP,LYRIU6&R0]R6 M6FNF#<(:/G_XF'EA5L%U!HT6DY ^FL:UH>"
[>2SM=U\ M? .VI/XL[3:ZUJDL(^4]Q 4KOV)UX(,6J:[;YVI-Q3VO88ZGM712&*V PYDS MH;NVJY?TZ?[-J#'*!\
[HHO@UW_XOOVSC5;UVHY,]XY4,PTIBV;469F+"/Q$3 M[I9BPMVJF'#W8<6$4=^(0I_-XZ]9E K7I# !WUNX5ATX(5!RL1Y"MUQ9P +/ MYW=6XQ2^O?
1B56.$C#(Z)!WD#&_A](($?=B\^CBLM9$S[_+SH65Y\]ESV?GD:! "XQ>C*I,!&;O M\/FA+D:LF_XD2S'@U%5%=GEPM)'[@"ERF^^H?=L->?
N%%_KNBTVF-9>#H5%_M;F[6%>H^V29@XE(E*1C'<9%;@";(+T9>BHO4FY CGYP76<3NV]M31@R&@&)0 MEV*.SLDP8,!Z"^+$PLRR@CH3"=3!*%-
\2BJ&R\Y&NG6.:>DJ]5@%"T,Y&1@%V/]E(-&"O;R"CB06%Y%O*&@B-*=KT2^B'"U0@G-'\MJ ME*==R::H;FS#>NM+G,C$%IA*J_Z+]-
&@O#W^Q6K2I42*=A>;$/([2HY0"ZT M!"B04[^=C-E@=,1&QC3DW]_.[MI@PHM)"#%TI50EQ&^[GIF=F7WFF@"@]Q+
(B7BG(96!80;*=]B&1I\&K7%P%=%(K"V_9V?R'26!NP4+ M)5 ++.[C,,H]\3WJ2$$R]S_"<5HO3KC8[:DSL>5P#-Z?2-VN'ZMZQV%]5J-$;LWE;;J-
:X;;OK&ZMV8BC 1G:93:TL_,0SN'X#4>_OHSN M\%%=W4RH.9 D(^)O9[?'LB;Z(&P8N4"VC";>4S3R42L3^. +DH7T78VSY=!
MC1POB0X%Q(CSN8G:BGE5@R-2=.4+-.:D/A-"4,.G*QXNQCQMH3N< &49%3)- M@!M^R*30AUB.S6;"7K(3]DI#867(4BR/A^V2W,35A+^]14A8
2%?"W1A$'2(M9/WFR"/R.%FFP)N[;['7*9Q?!A@0U9S=Z4U>]!]P=1H[FN>]Q_,1HJ?CC5VBPS)\>"RHW:6R. MP4W))\W/LB?*Y":?(>.38GSW7D &0--
H54GXCL66[V=A;U,NNK><_A61*@] MS==VAX9Z&@N5H5++CT'+|;26GT+Y884\V--1.$'WP"LA\CQS[9::G$:3/:F_ M1Z&_1E)_3V&K^
YR[QW[@=!%>:%:6.KMJU=@@.VQZ1(%,$DLWQSI\UXZ*-1O MJ^(=A<:928TS5VG<%_IOX7D!RDD#MB%=FZA=IWJ+6'4CM,J)W";*?
W(0XN>$LYP[(])@K!^-2J:!I9BG=<04MY7$X MY7'Y:#T71$(K_QNG0OA*C/ZA,/]&)C'Z$]-_A!C|S;Z&]/*W)_X+20>CL,K!
M*&3(I5\>3'7F#GO#D#OL"]*12;?]B 0R3?/1?"%9=C=J[S[-UIE]_BIY/-@# MUD7U.!'RF5VA/!SPI/KSMG9=ZZ):HU+]>400DATFA@L>4]1%1Y()8L*/C$1S
ME>:N$.ADUUT&/41X/(M=IR4E!QWGCZ(KQ<_K3?+^7[.PQUS<#W3/AO\"U;\X M=TMSP^=03(^FE#YOLW8[SGWB^@;>]_PG1EXA$R<8,L*?
#09FC4QMDYF-D[+V MY#0SNO;D:+I>G/WVT1Q,&G4%*W@'>=SSU!VP<#4*;MPP'%^IZM/3DS(ACC+P M?ZE6X+C#7V2BDO[
#M2^'=HJUHRBKILJ*$W)U+!AY$K%G(;U0D%7PED8VUN6 M6Z W!QKP*[& C$!#!VP1YQQNN8Y<[A "D0!.IN?P6'Z ;2;)0+)) P7HJ\O M0C2TV?XM8+=C-
$(@OF(79.37'!,O8 F=G(',;H#+B=HDI.MZ3B_B2_,<<:!X MTPE]!DZX0+A4*BKGX&)+QLY4W/!Q M1^6UJ-
KT>3]1KFMO5&X^]6DUW(SN*F#NHV>!+E_$%_U #\-1HE!%!T@1EFJ; M-;4UWM/[.ZQW]YZJRS]B'=9?4U<]U^D] P>Z_P'HF8X/IBIYZT=U5)>_L9W3)
]R'U,5/Z:$CO=^=%U,CA-)K' M](#EZEF[U0YK)M.PXRY6RL7O>-7,JR=AI8E!M42!)D,$@N(660- L(C+!Y M@=47R&X#]4CX! 60C=NRVFQ=H+K24H#
(YO2>BB,GU6QXV/\ET/7=L!Q'L6O6,7R!]M]"V^OC5!W0!8@('8@%$/+QU" MX\]?/N][P@Y$]Z]%*FP>ODW1/,,H*\5V*4LL0+#K>(%NNDMK,@F!\2GM!<@
M8*\S@)>B8/E%@EX:BX_RD$\D(;5Z_26S?XMZZ;)@I/=IU2;L&[GL%FGZO8 M[/-/"_ &G"#C7D(_(53!;@GT2"9O-@IT]O*K8+]@R9&"G27!/@FQ3AU"19)>
MV"V3" (]G@83Z %O@]^1/=*1RDK4(#!_HIU4P,79QV3U ;6**D/&=('K&&E MUNB<@E(DQE5C0$+T\[I=1S4/6D-0+[SB.
[Q!RUG4L(5]W8^^[OOTGAX'WT/E M]V $8KV(;$[C1:,$&[%]]!YQ;""'!UHE=IO0'H@&5X\]TH>0 9ALXFO,GR>Z MG_3CLZ0%G?+M*6C!MJ5A41"
[]HSU']Y.V.X2>29#Y:(B4T0Q);MNI2 M0E'9'CFBJ2P"$#DP44MY$:*\5]HW4EY1A3RPZ@(IKAD7U[IU+<45U>T>&4E)
MS;2DMMI5*:FHQ6EFI2>0=8'=!45TM,):9J2J+>BVL9@O8*F"L[09@:A?+K!# M0_9AOF>(-R4+/KC.15;_KJO^Q=%M9?6OK/X]HNK?PU6N=6I_-
ZSN?;O;^8"R MM0]C.V\M[*TPAD?"N/OCAD6LS<&5/N*2+CI9!7$A!7+M">H# M>H6EI?N<(%; 2NAMH#HZ(_Q@KY90U9Y@?2|>&ECI?2FI\7F?KSZ
M_<_@]T]_QR$=SHD'#. 5:E!7GE'=%CG@;M-;3I:PLNI57L<:#'IGV@6"G_,_ MT2%%=]L@U8F*.B$90^?
T&P7=C.SP1;2<@;>>&5.P;3]E7.XQBEZ'#3RU*IU+4(-MQ/>.[.QD8NM6IYN;IQ+7YE8SES/-[Y@EHQ^_]&S2__BBNN'CZ.O_4$L! A0# M% @
8(=G6;@SYT/>!P R30 T (! &5X7S%\W,SDX-C8N:'1M4$L! A0#% M @ 8(=G6:-+%.D0%P QRL! ! (!VA4 &YH8RTR,#(T M,#DS,"YXA1,.4KO0$?E$@ !, M (
!IY ! &YH8S(P,C0P.3,P7S$P<2YH=&U02P4& H "@!O) @ TX# end XML 95 nhc20240930_10q_htm.xml IDEA: XBRL DOCUMENT 0001047335 2024-
01-01 2024-09-30 0001047335 2024-11-04 0001047335 2024-07-01 2024-09-30 0001047335 2023-07-01 2023-09-30 0001047335 2023-01-01 2023-
09-30 0001047335 2024-09-30 0001047335 2023-12-31 0001047335 nhc:WhiteOakSeniorLivingMember 2024-01-01 2024-09-30 0001047335
nhc:WhiteOakSeniorLivingMember 2023-01-01 2023-09-30 0001047335 nhc:OtherBusinessAcquisitionsMember 2024-01-01 2024-09-30 0001047335
nhc:OtherBusinessAcquisitionsMember 2023-01-01 2023-09-30 0001047335 2022-12-31 0001047335 2023-09-30 0001047335 us-
gaap:CommonStockMember 2023-12-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001047335 us-
gaap:RetainedEarningsMember 2023-12-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001047335 us-
gaap:NoncontrollingInterestMember 2023-12-31 0001047335 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001047335 us-
gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001047335 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001047335
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001047335 us-gaap:NoncontrollingInterestMember 2024-01-01
2024-03-31 0001047335 2024-01-01 2024-03-31 0001047335 us-gaap:CommonStockMember 2024-03-31 0001047335 us-
gaap:AdditionalPaidInCapitalMember 2024-03-31 0001047335 us-gaap:RetainedEarningsMember 2024-03-31 0001047335 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001047335 us-gaap:NoncontrollingInterestMember 2024-03-31 0001047335
2024-03-31 0001047335 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-04-01
2024-06-30 0001047335 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001047335 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001047335 us-gaap:NoncontrollingInterestMember 2024-04-01
2024-06-30 0001047335 2024-04-01 2024-06-30 0001047335 us-gaap:CommonStockMember 2024-06-30 0001047335 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001047335 us-gaap:RetainedEarningsMember 2024-06-30 0001047335 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001047335 us-gaap:NoncontrollingInterestMember 2024-06-30 0001047335
2024-06-30 0001047335 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-07-01
2024-09-30 0001047335 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001047335 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001047335 us-gaap:NoncontrollingInterestMember 2024-07-01
2024-09-30 0001047335 us-gaap:CommonStockMember 2024-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001047335
us-gaap:RetainedEarningsMember 2024-09-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001047335 us-
gaap:NoncontrollingInterestMember 2024-09-30 0001047335 us-gaap:CommonStockMember 2022-12-31 0001047335 us-
gaap:AdditionalPaidInCapitalMember 2022-12-31 0001047335 us-gaap:RetainedEarningsMember 2022-12-31 0001047335 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001047335 us-gaap:NoncontrollingInterestMember 2022-12-31 0001047335 us-
gaap:CommonStockMember 2023-01-01 2023-03-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001047335 us-
gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-
31 0001047335 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001047335 2023-01-01 2023-03-31 0001047335 us-
gaap:CommonStockMember 2023-03-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001047335 us-
gaap:RetainedEarningsMember 2023-03-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001047335 us-
gaap:NoncontrollingInterestMember 2023-03-31 0001047335 2023-03-31 0001047335 us-gaap:CommonStockMember 2023-04-01 2023-06-30
0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001047335 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-
30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001047335 us-
gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001047335 2023-04-01 2023-06-30 0001047335 us-gaap:CommonStockMember 2023-
06-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001047335 us-gaap:RetainedEarningsMember 2023-06-30 0001047335 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001047335 us-gaap:NoncontrollingInterestMember 2023-06-30 0001047335
2023-06-30 0001047335 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-07-01
2023-09-30 0001047335 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001047335 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001047335 us-gaap:NoncontrollingInterestMember 2023-07-01
2023-09-30 0001047335 us-gaap:CommonStockMember 2023-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001047335
us-gaap:RetainedEarningsMember 2023-09-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001047335 us-
gaap:NoncontrollingInterestMember 2023-09-30 0001047335 srt:MinimumMember 2024-09-30 0001047335 srt:MaximumMember 2024-09-30
0001047335 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-09-30 0001047335 srt:MaximumMember us-
gaap:BuildingAndBuildingImprovementsMember 2024-09-30 0001047335 srt:MinimumMember nhc:EquipmentAndFurnitureMember 2024-09-30
0001047335 srt:MaximumMember nhc:EquipmentAndFurnitureMember 2024-09-30 0001047335 nhc:RefundableAdvanceFeesMember 2024-01-01
2024-09-30 0001047335 nhc:OriginalEntryFeeMember 2024-01-01 2024-09-30 0001047335 nhc:AppreciationMember 2024-01-01 2024-09-30
0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-08-01 2024-08-01 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-08-
01 0001047335 stpr:SC nhc:WhiteOakSeniorLivingPortfolioMember 2024-08-01 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-07-01
2024-09-30 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-01-01 2024-09-30 0001047335
nhc:WhiteOakSeniorLivingPortfolioMember 2023-07-01 2023-09-30 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2023-01-01 2023-09-30
0001047335 nhc:InpatientServicesMember 2024-07-01 2024-09-30 0001047335 nhc:InpatientServicesMember 2023-07-01 2023-09-30 0001047335
nhc:InpatientServicesMember 2024-01-01 2024-09-30 0001047335 nhc:InpatientServicesMember 2023-01-01 2023-09-30 0001047335
nhc:HomecareAndHospiceMember 2024-07-01 2024-09-30 0001047335 nhc:HomecareAndHospiceMember 2023-07-01 2023-09-30 0001047335
nhc:HomecareAndHospiceMember 2024-01-01 2024-09-30 0001047335 nhc:HomecareAndHospiceMember 2023-01-01 2023-09-30 0001047335
nhc:MedicareMember 2024-07-01 2024-09-30 0001047335 nhc:MedicareMember 2023-07-01 2023-09-30 0001047335 nhc:MedicareMember 2024-
01-01 2024-09-30 0001047335 nhc:MedicareMember 2023-01-01 2023-09-30 0001047335 nhc:ManagedCareMember 2024-07-01 2024-09-30
0001047335 nhc:ManagedCareMember 2023-07-01 2023-09-30 0001047335 nhc:ManagedCareMember 2024-01-01 2024-09-30 0001047335
nhc:ManagedCareMember 2023-01-01 2023-09-30 0001047335 nhc:MedicaidMember 2024-07-01 2024-09-30 0001047335 nhc:MedicaidMember
2023-07-01 2023-09-30 0001047335 nhc:MedicaidMember 2024-01-01 2024-09-30 0001047335 nhc:MedicaidMember 2023-01-01 2023-09-30
0001047335 nhc:PrivatePayAndOtherMember 2024-07-01 2024-09-30 0001047335 nhc:PrivatePayAndOtherMember 2023-07-01 2023-09-30
0001047335 nhc:PrivatePayAndOtherMember 2024-01-01 2024-09-30 0001047335 nhc:PrivatePayAndOtherMember 2023-01-01 2023-09-30
0001047335 nhc:MedicaidMember 2024-07-01 2024-09-30 0001047335 nhc:MedicaidMember 2023-07-01 2023-09-30 0001047335
nhc:MedicaidMember 2024-01-01 2024-09-30 0001047335 nhc:MedicaidMember 2023-01-01 2023-09-30 0001047335
nhc:MedicareAndMedicaidMember 2024-09-30 0001047335 nhc:MedicareAndMedicaidMember 2023-12-31 0001047335 stpr:FL 2024-09-30
0001047335 nhc:NationalMember 2024-09-30 0001047335 nhc:NationalMember 2024-07-01 2024-09-30 0001047335 nhc:NationalMember 2023-07-
01 2023-09-30 0001047335 nhc:NationalMember 2024-01-01 2024-09-30 0001047335 nhc:NationalMember 2023-01-01 2023-09-30 0001047335

nhc:WorkersCompensationRevenueMember 2024-07-01 2024-09-30 0001047335 nhc:WorkersCompensationRevenueMember 2023-07-01 2023-09-30 0001047335 nhc:WorkersCompensationRevenueMember 2024-01-01 2024-09-30 0001047335 nhc:WorkersCompensationRevenueMember 2023-01-01 2023-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2024-07-01 2024-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2023-07-01 2023-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2024-01-01 2024-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2023-01-01 2023-09-30 0001047335 nhc:HomecareAgencyInNashvilleTennesseeMember 2023-12-31 0001047335 2024-01-01 2024-01-31 0001047335 nhc:InpatientServicesSegmentMember 2024-07-01 2024-09-30 0001047335 nhc:HomecareServicesSegmentMember 2024-07-01 2024-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2024-07-01 2024-09-30 0001047335 nhc:InpatientServicesSegmentMember 2023-07-01 2023-09-30 0001047335 nhc:HomecareServicesSegmentMember 2023-07-01 2023-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0001047335 nhc:InpatientServicesSegmentMember 2024-01-01 2024-09-30 0001047335 nhc:HomecareServicesSegmentMember 2024-01-01 2024-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-09-30 0001047335 nhc:InpatientServicesSegmentMember 2023-01-01 2023-09-30 0001047335 nhc:HomecareServicesSegmentMember 2023-01-01 2023-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0001047335 nhc:TwoLeasesWithNHIMember 2024-09-30 0001047335 nhc:LeaseOneWithNhiMember 2024-09-30 0001047335 nhc:NHILeaseAgreementMember 2024-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2024-07-01 2024-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2023-07-01 2023-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2024-01-01 2024-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2023-01-01 2023-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001047335 us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001047335 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001047335 us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 nhc:NHICommonStockMember 2024-09-30 0001047335 nhc:NHICommonStockMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 nhc:InpatientServicesSegmentMember 2023-12-31 0001047335 nhc:HomecareAndHospiceSegmentMember 2023-12-31 0001047335 nhc:HomecareAndHospiceSegmentMember 2024-01-01 2024-09-30 0001047335 nhc:InpatientServicesSegmentMember 2024-09-30 0001047335 nhc:HomecareAndHospiceSegmentMember 2024-09-30 0001047335 us-gaap:TradeNamesMember 2024-09-30 0001047335 us-gaap:TradeNamesMember 2023-12-31 0001047335 nhc:CertificatesOfNeedMember 2024-09-30 0001047335 nhc:CertificatesOfNeedMember 2023-12-31 0001047335 us-gaap:LicensingAgreementsMember 2024-09-30 0001047335 us-gaap:LicensingAgreementsMember 2023-12-31 0001047335 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001047335 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2024-07-01 2024-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2023-07-01 2023-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2024-01-01 2024-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2023-01-01 2023-09-30 0001047335 2023-01-01 2023-12-31 0001047335 nhc:ExercisePriceRange1Member 2024-09-30 0001047335 nhc:ExercisePriceRange1Member 2024-01-01 2024-09-30 0001047335 nhc:ExercisePriceRange2Member 2024-09-30 0001047335 nhc:ExercisePriceRange2Member 2024-01-01 2024-09-30 0001047335 nhc:CreditFacilityMember 2024-09-30 0001047335 nhc:CreditFacilityMember 2024-08-01 0001047335 nhc:CreditFacilityMember 2024-08-01 2024-08-01 0001047335 nhc:TermFacilityMember nhc:CreditFacilityMember 2024-08-01 0001047335 us-gaap:RevolvingCreditFacilityMember nhc:CreditFacilityMember 2024-08-01 0001047335 srt:MinimumMember nhc:CreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-08-01 2024-08-01 0001047335 srt:MaximumMember nhc:CreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-08-01 2024-08-01 0001047335 srt:MinimumMember nhc:CreditFacilityMember us-gaap:BaseRateMember 2024-08-01 2024-08-01 0001047335 srt:MaximumMember nhc:CreditFacilityMember us-gaap:BaseRateMember 2024-08-01 2024-08-01 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y 0001047335 NATIONAL HEALTHCARE CORP false --12-31 Q3 2024 0.01 0.01 45000000 45000000 15440970 15440970 15350661 15350661 0.59 0.61 0.61 0.57 0.59 0.59 P2Y P15Y 1606000 1 1928 48 37305000 1557000 -62000 2 0 0 637409 P2Y 331037 311352 642389 0.068 P5Y 0.003 0.0065 0.21 false false false false 10-Q true 2024-09-30 false 001-13489 DE 52-2057472 100 E. Vine Street Murfreesboro TN 37130 615 890-2020 Common, $0.01 par value NHC NYSE Yes Yes Large Accelerated Filer false false false 15441070 328674000 277005000 894415000 804617000 11524000 11480000 34172000 36013000 0 0 9445000 0 340198000 288485000 938032000 840630000 213395000 182664000 576609000 525782000 82509000 72490000 238092000 217213000 10886000 10094000 31804000

30087000 10619000 10135000 30543000 30266000 1742000 77000 1788000 268000 319151000 275460000 878836000 803616000 21047000 13025000 59196000 37014000 4224000 4097000 14865000 12116000 32767000 -3093000 56290000 2943000 58038000 14029000 130351000 52073000 15338000 3908000 34294000 14750000 42700000 10121000 96057000 37323000 -89000 -267000 211000 -1069000 42789000 10388000 95846000 38392000 2.78 0.68 6.23 2.51 2.73 0.68 6.15 2.5 15411680 15299913 15384758 15311453 15667321 15324511 15576294 15334269 0.61 0.59 1.81 1.75 42700000 10121000 96057000 37323000 3516000 -1185000 3074000 -605000 -0 -0 -1388000 -20000 460000 -124000 711000 -3000 3056000 -1061000 3751000 -582000 -89000 -267000 211000 -1069000 45845000 9327000 99597000 37810000 84807000 107076000 29032000 17725000 164754000 111117000 0 5427000 23001000 26779000 2045000 12822000 128782000 108545000 7840000 7386000 4887000 8855000 578000 503000 445726000 406235000 1283184000 1101681000 596759000 608352000 686425000 493329000 1235000 1167000 121866000 109478000 10084000 14786000 85926000 94201000 169690000 168295000 19805000 7038000 21950000 16267000 430556000 411232000 156270700 1310796000 22724000 19194000 0 860000 31366000 29352000 89757000 84110000 18815000 18369000 31076000 30549000 37289000 22991000 9419000 9051000 7500000 0 247946000 214476000 139500000 0 53079000 63175000 79128000 72710000 6063000 6376000 30842000 17200000 19353000 26379000 575911000 400316000 154000 153000 230635000 227604000 755532000 687599000 -2853000 -6604000 983468000 908752000 3328000 1728000 986796000 910480000 1562707000 1310796000 96057000 37323000 30543000 30266000 589000 1941000 512000 470000 56290000 2943000 331000 -603000 1024000 -0 -15559000 1059000 3062000 2119000 19898000 2617000 -598000 285000 -8809000 -2444000 193000 -936000 3530000 -487000 1989000 -2791000 446000 -1043000 6945000 5656000 12434000 14035000 -8031000 6669000 94514000 85483000 19444000 19300000 215896000 -0 -2097000 2700000 2100000 0 75000 197000 8370000 -0 24736000 21763000 39776000 36578000 -225048000 -7382000 150000000 0 3000000 -0 860000 3711000 27545000 26520000 1389000 0 13471000 260000 13502000 2482000 -313000 -258000 119640000 -32711000 -10894000 45390000 125968000 74865000 115074000 120255000 84807000 100308000 30267000 19947000 115074000 120255000 15350661 153000 227604000 687599000 -6604000 1728000 910480000 0 0 26213000 0 38000 26251000 0 0 0 -437000 0 -437000 0 793000 0 0 0 793000 150194 1000 8412000 0 0 0 8413000 101131 -0 9900000 -0 -0 -0 9900000 -0 -0 9086000 -0 -0 9086000 15399724 154000 226909000 704726000 -7041000 1766000 926514000 0 0 26844000 0 262000 27106000 0 0 0 1132000 0 1132000 0 1176000 0 0 0 1176000 38849 0 2827000 0 0 0 2827000 15636 -0 1502000 -0 -0 -0 1502000 -0 -0 -0 9408000 -0 -0 9408000 15422937 154000 229410000 722162000 -5909000 2028000 947845000 0 0 42789000 0 -89000 42700000 1389000 1389000 0 0 0 3056000 0 3056000 0 1093000 0 0 0 1093000 34417 2232000 0 0 0 2232000 16384 -0 2100000 -0 -0 -0 2100000 -0 -0 -0 9419000 -0 -0 9419000 15440970 154000 230635000 755532000 -2853000 3328000 986796000 15357746 153000 226991000 656664000 -9532000 3238000 877514000 0 0 0 11723000 0 -438000 11285000 0 0 0 1679000 0 1679000 0 639000 0 0 0 639000 7046 0 0 0 0 0 0 44349 -0 2482000 -0 -0 -0 2482000 -0 -0 -0 8733000 -0 -0 8733000 15320443 153000 225148000 659654000 -7853000 2800000 879902000 0 0 16281000 0 -364000 15917000 0 0 0 -1200000 0 -1200000 0 772000 0 0 0 772000 100 0 6000 0 0 0 6000 -0 -0 9039000 -0 -0 9039000 15320543 153000 225926000 666896000 -9053000 2436000 886358000 0 0 10388000 0 -267000 10121000 0 0 0 -1061000 0 -1061000 0 708000 0 0 0 708000 4017 0 254000 0 0 0 254000 -0 -0 9040000 -0 -0 9040000 15324560 153000 226888000 668244000 -10114000 2169000 887340000 Note 1 - Description of Business   National HealthCare Corporation (“NHC” or the “Company”) is a leading provider of senior health care services. As of September 30, 2024, we operate or manage, through certain affiliates, 80 skilled nursing facilities with a total of 10,349 licensed beds, 26 assisted living facilities with 1,413 units, nine independent living facilities, three behavioral health hospitals, 34 homecare agencies, and 32 hospice agencies. We operate specialized care units within certain of our healthcare centers such as Alzheimer's disease care units and sub-acute nursing units. In addition, we provide insurance services, management and accounting services, and we lease properties to operators of skilled nursing and assisted living facilities. We operate in 9 states and are located primarily in the southeastern United States. 80 10349 26 9 3 34 32 9 Note 2 - Summary of Significant Accounting Policies   The listing below is not intended to be a comprehensive list of all our significant accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by U.S. generally accepted accounting principles (“GAAP”), with limited need for management’s judgment in their application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result. See our audited December 31, 2023 consolidated financial statements and notes thereto which contain accounting policies and other disclosures required by U.S. GAAP. Our audited December 31, 2023 consolidated financial statements are available at our web site: www.nhccare.com.   Basis of Presentation   The unaudited interim condensed consolidated financial statements to which these notes are attached include all normal, recurring adjustments which are necessary to fairly present the financial position, results of operations and cash flows of NHC. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by NHC. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to NHC and the noncontrolling interest in its consolidated statements of operations.   We assume that users of these interim financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate the disclosure contained in our most recent annual report to stockholders have been omitted. This interim financial information is not necessarily indicative of the results that may be expected for a full year for a variety of reasons.   Estimates and Assumptions   The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.   Net Patient Revenues and Accounts Receivable   Net patient revenues are derived from services rendered to patients for skilled and intermediate nursing, rehabilitation therapy, assisted living and independent living, home health care services, hospice services, and behavioral health services. Net patient revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient services. These amounts are due from patients, governmental programs, and other third-party payors, and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations.   The Company recognizes revenue as its performance obligations are completed. Routine services are treated as a single performance obligation satisfied over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered. Contract liabilities are recorded for payments the Company receives in which performance obligations have not been completed.   The Company determines the transaction price based on established billing rates reduced by explicit price concessions provided to third party payors. Explicit price concessions are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,574,000 and $7,098,000 for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $1,668,000 and $5,331,000, respectively. As of September 30, 2024 and December 31, 2023, the Company has recorded allowance for doubtful accounts of $10,859,000 and $8,054,000, respectively, as our best estimate of expected losses inherent in the accounts receivable balance. <p style="font-family:'Times New

Roman';font-size:10pt;font-variant:normal;margin:0pt;">   Other Revenues   Other revenues include revenues from the provision of insurance services to other healthcare providers, management and accounting services to other healthcare providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements.   We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned.   Government Grants   We account for government grants in accordance with International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, and as such, we recognize grant income on a systematic basis in line with the recognition of specific expenses and lost revenues for which the grants are intended to compensate.   For the nine months ended September 30, 2024, all conditions related to the Employee Retention Credit ("ERC") were met and the credit was recognized as government stimulus income. The ERC was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The qualified wages and health insurance benefits paid by the Company were related to the second, third and fourth quarters of 2020.   Segment Reporting   In accordance with the provisions of Accounting Standards Codification ("ASC") 280, Segment Reporting, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an "all other" category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 7 for further disclosure of the Company's operating segments.   Other Operating Expenses   Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance.   General and Administrative Costs   With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation and incentive compensation, which were $6,288,000 and $19,678,000 for the three and nine months ended September 30, 2024, respectively. General and administrative costs were $5,661,000 and $16,309,000 for the three and nine months ended September 30, 2023, respectively. The increased general and administrative costs incurred during 2024 are due to acquisition-related expenses for the White Oak Senior Living portfolio. See Note 3 - Acquisition of White Oak Senior Living for additional detail regarding the acquisition.   Long-Term Leases   The Company's lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, regional offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain.   The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recorded and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases.   Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuate with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred.   Property and Equipment   Property and equipment are recorded at cost or fair value, if acquired. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method.   Business Combinations   We account for transactions that represent business combinations using the acquisition method of accounting in accordance with FASB ASC Topic 805, Business Combinations (Topic 805). Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts during the measurement period. The measurement period is defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date.   <p style="font-family:Times New Roman;font-size:10pt;font-

variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Goodwill generated from business combinations is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates   Goodwill and Other Intangible Assets   Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter. Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.   The Company's indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the fair value of the intangible asset is below its carrying amount.   Accrued Risk Reserves   We are self-insured for risks related to workers' compensation and general and professional liability insurance. We have two wholly-owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis.   Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period.   We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverage includes both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us.   Continuing Care Contracts   We have continuing care retirement centers ("CCRC") within our operations. Residents at these retirement centers may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original resident's entry fee.   Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarially determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrent liabilities in our consolidated balance sheets.   We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recorded with a corresponding charge to income. As of September 30, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.   Other Noncurrent Liabilities   Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation ("National") and the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents.   Noncontrolling Interest   The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Company's earnings per share is calculated based on net income attributable to NHC's stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions.   Variable Interest Entities   We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity ("VIE") and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.   The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as "investments in unconsolidated companies" in the interim condensed consolidated balance sheets.   Recently Issued Accounting Guidance   In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, "Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures." The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024, and

interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact this standard will have on our disclosures.   Basis of Presentation   The unaudited interim condensed consolidated financial statements to which these notes are attached include all normal, recurring adjustments which are necessary to fairly present the financial position, results of operations and cash flows of NHC. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by NHC. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to NHC and the noncontrolling interest in its consolidated statements of operations.   We assume that users of these interim financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate the disclosure contained in our most recent annual report to stockholders have been omitted. This interim financial information is not necessarily indicative of the results that may be expected for a full year for a variety of reasons.   Estimates and Assumptions   The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.   Net Patient Revenues and Accounts Receivable   Net patient revenues are derived from services rendered to patients for skilled and intermediate nursing, rehabilitation therapy, assisted living and independent living, home health care services, hospice services, and behavioral health services. Net patient revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient services. These amounts are due from patients, governmental programs, and other third-party payors, and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations.   The Company recognizes revenue as its performance obligations are completed. Routine services are treated as a single performance obligation satisfied over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered. Contract liabilities are recorded for payments the Company receives in which performance obligations have not been completed.   The Company determines the transaction price based on established billing rates reduced by explicit price concessions provided to third party payors. Explicit price concessions are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,574,000 and $7,098,000 for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $1,668,000 and $5,331,000, respectively. As of September 30, 2024 and December 31, 2023, the Company has recorded allowance for doubtful accounts of $10,859,000 and $8,054,000, respectively, as our best estimate of expected losses inherent in the accounts receivable balance.   2574000 7098000 1668000 5331000 10859000 8054000 Other Revenues   Other revenues include revenues from the provision of insurance services to other healthcare providers, management and accounting services to other healthcare providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements.   We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned.   Government Grants   We account for government grants in accordance with International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, and as such, we recognize grant income on a systematic basis in line with the recognition of specific expenses and lost revenues for which the grants are intended to compensate.   For the nine months ended September 30, 2024, all conditions related to the Employee Retention Credit ("ERC") were met and the credit was recognized as government stimulus income. The ERC was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The qualified wages and health insurance benefits paid by the Company were related to the second, third and fourth quarters of 2020.   Segment Reporting   In accordance with the provisions of Accounting Standards Codification ("ASC") 280, Segment Reporting, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 7 for further disclosure of the Company’s operating segments.   2 Other Operating Expenses   Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance.   General and Administrative Costs   With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation and incentive compensation, which were $6,288,000 and $19,678,000 for the three and nine months ended September 30, 2024, respectively. General and administrative costs were $5,661,000 and $16,309,000 for the three and nine months ended September 30, 2023, respectively. The increased general and administrative costs incurred during 2024 are due to acquisition-related expenses for the White Oak Senior Living portfolio. See Note 3 - Acquisition of White

*Oak Senior Living for additional detail regarding the acquisition.   6288000 19678000 5661000 16309000 Long-Term Leases   The Company's lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, regional offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain.   The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recorded and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases.   Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuate with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred.   Property and Equipment   Property and equipment are recorded at cost or fair value, if acquired. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method.   P20Y P40Y P3Y P15Y Business Combinations   We account for transactions that represent business combinations using the acquisition method of accounting in accordance with FASB ASC Topic 805, Business Combinations (Topic 805). Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts during the measurement period. The measurement period is defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date.   Goodwill generated from business combinations is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates   Goodwill and Other Intangible Assets   Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter. Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.   The Company's indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the fair value of the intangible asset is below its carrying amount.   Accrued Risk Reserves   We are self-insured for risks related to workers' compensation and general and professional liability insurance. We have two wholly-owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis.   Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period.   We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverage includes both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us.   Continuing Care Contracts   We have continuing care retirement centers ("CCRC") within our operations. Residents at these retirement centers may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original resident's entry fee.   Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarially determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrent liabilities in our consolidated balance sheets.   We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recorded with a corresponding charge to income. As of September 30, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.   0.10 0.90 0.40 1606000 Other Noncurrent Liabilities   Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation ("National") and the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents.   *

Noncontrolling Interest   The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Company's earnings per share is calculated based on net income attributable to NHC's stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions.   Variable Interest Entities   We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity ("VIE") and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.   The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as "investments in unconsolidated companies" in the interim condensed consolidated balance sheets.   Recently Issued Accounting Guidance   In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, "Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures." The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact this standard will have on our disclosures.   Note 3 - Acquisition of White Oak Senior Living   On August 1, 2024, the Company purchased certain assets and assumed certain liabilities of the White Oak Senior Living ("White Oak") portfolio for a purchase price of $221,400,000. The White Oak portfolio consists of 22 healthcare operations, which includes 15 skilled nursing facilities, <em style="font: inherit;">two assisted living facilities, four independent living facilities, and a long-term care pharmacy. The operations have <em style="font: inherit;">1,928 licensed skilled nursing beds, <em style="font: inherit;">48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina (2,278 total beds/units). The acquisition represents both an expansion of NHC's operations into a new state (North Carolina) and a strategic advancement of its growth in its existing operational footprint. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:29pt;">The Company utilized widely accepted income-based, market-based, and cost-based valuation approaches to perform the preliminary purchase price allocation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has performed a preliminary valuation analysis of the fair market value of White Oak's assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was <em style="font: inherit,">not complete as of <em style="font: inherit;"> September 30, 2024, but will be finalized within the allowable measurement period. The following table summarizes the allocation of the preliminary purchase price as of the transaction's closing date (<i>in thousands</i>):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inventories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,054</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prepaid expenses and other assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Property and equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">203,695</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Deferred tax asset </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,499</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">Operating lease right-of-use assets</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,380</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Intangible assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,765</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left:

0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81.8%;"> Total assets acquired </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">231,539</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">Operating lease liabilities, current portion</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">424</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Accrued payroll </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,559</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other current liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,085</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">Operating lease liabilities, less current portion</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,956</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other noncurrent liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,005</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total liabilities assumed </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,029</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Net identifiable assets acquired </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">214,510</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Goodwill </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,395</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Total estimated fair value of the acquisition </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">215,905</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   The indefinite-lived intangible assets acquired include the trade name of White Oak and the skilled nursing certificates of need and licenses. The goodwill is recorded in the inpatient services segment and is attributed to the workforce acquired and reputation of the business as part of the transaction. We expect the goodwill to be deductible for income tax purposes.   For the three and nine months ended September 30, 2024, White Oak contributed net operating revenues of $37,305,000 and income before income taxes of $1,557,000 that are included in the Company's interim condensed consolidated statements of operations. The Company recognized $637,000 and $2,831,000 in acquisition-related expenses for the three and nine months ended September 30, 2024, respectively, in connection with the White Oak acquisition. These costs related to legal and other professional fees, which were included as a component of other operating expenses in the interim condensed consolidated statements of operations.   The following table contains unaudited pro forma interim condensed consolidated statements of operations information for the three months and nine months ended September 30, 2024 and 2023, assuming that the White Oak acquisition closed on January 1, 2023. The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed (in thousands).   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align:

center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net operating revenues and grant income </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">358,334</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">337,817</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,065,418</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">987,186</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income before income taxes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">58,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,087</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">134,777</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to NHC </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">43,413</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,431</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99,121</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,064</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   221400000 22 15 4 302 2278 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Cash and cash equivalents </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Inventories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,054</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Prepaid expenses and other assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Property and equipment </td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">203,695</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Deferred tax asset </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,499</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">Operating lease right-of-use assets</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,380</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Intangible assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,765</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81.8%;"> Total assets acquired </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">231,539</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">Operating lease liabilities, current portion</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">424</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Accrued payroll </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,559</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other current liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,085</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">Operating lease liabilities, less current portion</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,956</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Other noncurrent liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,005</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total liabilities assumed </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,029</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Net identifiable assets acquired </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">214,510</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Goodwill </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,395</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Total estimated fair value of the acquisition </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">215,905</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 9000 1054000 137000 203695000 2499000 11380000 12765000 231539000 424000 3559000 1085000 10956000 1005000 17029000 214510000 1395000 215905000 3 9 37305000 1557000 637000 2831000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin:

0pt;">Three Months Ended September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net operating revenues and grant income </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">358,334</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">337,817</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,065,418</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">987,186</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income before income taxes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">58,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,087</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">134,777</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to NHC </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">43,413</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,431</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99,121</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,064</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 358334000 337817000 1065418000 987186000 58881000 14087000 134777000 49113000 43413000 10431000 99121000 34064000 Note 4 - Net Patient Revenues   The Company disaggregates revenue from contracts with customers by service type and by payor.   Revenue by Service Type   The Company's net patient services can generally be classified into the following two categories: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services (in thousands).   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center;

margin: 0pt;">2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Net patient revenues: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%; border-bottom: 1px solid rgb(0, 0, 0);"> Source </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medicare </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">30%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">33%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">32%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">35%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Managed Care </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">9%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medicaid </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">33%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">32%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">30%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">30%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Private Pay and Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">28%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">25%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">28%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">25%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; text-align: center;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; text-align: center;"> </td> </tr> </tbody> </table>   Medicare covers skilled nursing services for beneficiaries who require nursing care and/or rehabilitation services following a hospitalization of at least three consecutive days. For each eligible day a Medicare beneficiary is in a skilled nursing facility, Medicare pays the facility a daily payment, subject to adjustment for certain factors such as a wage index in the geographic area. The payment covers all services provided by the skilled nursing facility for the beneficiary that day, including room and board, nursing, therapy and drugs, as well as an estimate of capital-related costs to deliver those services.   For homecare services, Medicare pays based on the acuity level of the patient and based on periods of care. A period of care is defined as a length of care up to 30 days with multiple continuous periods allowed. The services covered by the payment include all disciplines of care, in addition to medical supplies, within the scope of the home health benefit.   For hospice services, Medicare pays a daily rate to cover the hospice's costs for providing services included in the patient care plan. Medicare makes daily payments based on 1 of 4 levels of hospice care. All hospice care and services offered to patients and their families must follow an individualized written plan of care that meets the patient's needs.   Our hospice service revenue is subject to certain limitations on payments from Medicare. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded. If applicable, we record these cap adjustments as a reduction to revenue.   Medicaid is operated by individual states with the financial participation of the federal government. The states in which we operate currently use prospective cost-based reimbursement systems. Under cost-based reimbursement systems, the skilled nursing facility is reimbursed for the reasonable direct and indirect allowable costs it incurred in a base year in providing routine resident care services as defined by the program.   Private pay, managed care, and other payment sources include commercial insurance, individual patient funds, managed care plans and the Veterans Administration. Private paying patients, private insurance carriers and the Veterans Administration generally pay based on the healthcare center's charges or specifically negotiated contracts. For private pay patients in skilled nursing, assisted living and independent living facilities, the Company bills for room and board charges, with the remittance being due on receipt of the statement and generally by the 10th day of the month the services are performed.   Certain managed care payors for homecare services pay on a per-visit basis. This revenue is recorded on an accrual basis based upon the date of services at amounts equal to its established or estimated per-visit rates.   State Relief Supplemental Funding   The Company received supplemental Medicaid payments from various states, including healthcare relief funding under the American Rescue Plan Act ("ARPA") and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses or various patient care related expenses. We have recorded $5,267,000 and $4,232,000 in net patient revenues for these supplemental Medicaid payments for the three months ended September 30, 2024 and 2023, respectively. We have recorded $11,314,000 and $15,362,000 in net patient revenues for these supplemental Medicaid payments for the nine months ended September 30, 2024 and 2023, respectively.   Third Party Payors   Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Noncompliance with such laws and regulations can be subject to regulatory actions including fines, penalties, and exclusion from the Medicare and Medicaid programs. We believe that we are following all applicable laws and regulations.   Medicare and Medicaid program revenues, as well as certain Managed Care program revenues, are subject to audit and retroactive adjustment by government representatives or their agents. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. We believe that any differences between the net revenues recorded, and final determination will not materially affect the consolidated financial statements. We have made provisions of approximately $18,815,000 and $18,369,000 as of September 30, 2024 and December 31, 2023, respectively, for various Medicare, Medicaid, and Managed Care claims reviews and current and prior year cost reports. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;

*border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Net patient revenues: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

text-align: center; margin: 0pt;">2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Medicare </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">30%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">33%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">32%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">35%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Managed Care </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">9%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Medicaid </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">33%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">32%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">30%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">30%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Private Pay and Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">28%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">25%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">28%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">25%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; text-align: center;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">100%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; text-align: center;"> </td> </tr> </tbody> </table> 293026000 243865000 790664000 706795000 35648000 33140000 103751000 97822000 328674000 277005000 894415000 804617000 0.30 0.33 0.32 0.35 0.09 0.10 0.10 0.10 0.33 0.32 0.30 0.30 0.28 0.25 0.28 0.25 1 1 1 1 5267000 4232000 11314000 15362000 18815000 18369000 Note 5 - Other Revenues   Other revenues are outlined in the table below. Revenues from rental income include health care real estate properties owned by us and leased to third party operators. Revenues from management and accounting services include fees provided to manage and provide accounting services to other healthcare operators. Revenues from insurance services include premiums for workers' compensation and professional liability insurance policies that our wholly owned insurance subsidiaries have written for certain healthcare operators to which we provide management or accounting services. "Other" revenues include miscellaneous health care related

earnings (in thousands).   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Rental income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,028</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,958</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,015</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,966</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Management and accounting services fees </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,226</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,185</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,744</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,045</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Insurance services </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">818</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">989</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,506</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,920</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">452</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">348</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">907</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,082</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total other revenues </td> <td style="width:

1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,524</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,480</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,172</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,013</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   Rental Income   The Company leases real estate assets consisting of skilled nursing facilities and assisted living facilities to third party operators. Additionally, we sublease four Florida skilled nursing facilities included in our lease from National Health Investors ("NHI") as noted in Note 8 – Long Term Leases.   Management Fees from National Health Corporation   We manage five skilled nursing facilities owned by National Health Corporation ("National"). We recognized management fees and interest on management fees from these facilities of $1,348,000 and $1,243,000 for the three months ended September 30, 2024 and 2023, respectively. We recognized management fees and interest on management fees of $4,014,000 and $3,968,000 from these facilities for the nine months ended September 30, 2024 and 2023, respectively.   Insurance Services   For workers' compensation insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended September 30, 2024 and 2023 were $529,000 and $678,000, respectively. The premium revenues reflected in the interim condensed consolidated statements of operations for the nine months ended September 30, 2024 and 2023 were $1,638,000 and $1,985,000, respectively. Associated losses and expenses including those for self-insurance are included in the interim condensed consolidated statements of operations as "Salaries, wages and benefits."   For professional liability insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended September 30, 2024 and 2023 were $289,000 and $312,000, respectively. The premium revenues reflected in the interim condensed consolidated statements of operations for the nine months ended September 30, 2024 and 2023 were $868,000 and $935,000, respectively. Associated losses and expenses including those for self-insurance are included in the interim condensed consolidated statements of operations as "Other operating costs and expenses".</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Rental income</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,028</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,958</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,015</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,966</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Management and accounting services fees </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,226</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times

New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,185</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,744</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,045</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Insurance services </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">818</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">989</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,506</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,920</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">452</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">348</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">907</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,082</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total other revenues </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,524</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,480</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,172</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,013</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 6028000 5958000 18015000 17966000 4226000 4185000 12744000 14045000 818000 989000 2506000 2920000 452000 348000 907000 1082000 11524000 11480000 34172000 36013000 4 5 1348000 1243000 4014000 3968000 529000 678000 1638000 1985000 289000 312000 868000 935000 Note 6 - Non- Operating Income   Non-operating income is comprised of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <p style="font-

family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividends and net realized gains and losses on sales of securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,690</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,462</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,604</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,603</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,222</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,571</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Equity in earnings of unconsolidated investments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(62</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">185</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">589</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,941</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gain on sale of unconsolidated company </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,024</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total non-operating income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,097</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,865</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,116</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   Gain on sale of unconsolidated company   In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency located in Nashville, Tennessee. The total consideration paid to the Company was $2,100,000, which resulted in a gain of $1,024,000. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;

border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Dividends and net realized gains and losses on sales of securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,690</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,462</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,604</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,603</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,222</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,571</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Equity in earnings of unconsolidated investments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(62</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">185</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">589</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,941</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gain on sale of unconsolidated company </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,024</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total non-operating income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,097</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times,

serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,865</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,116</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 1683000 1690000 5462000 4604000 2603000 2222000 7790000 5571000 185000 589000 1941000 0 0 1024000 0 4224000 4097000 14865000 12116000 0.50 2100000 1024000 Note 7 - Business Segments   The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals; and (2) homecare and hospice services. These reportable operating segments are consistent with information used by the Company's Chief Executive Officer, as chief operating decision maker ("CODM"), to assess performance and allocate resources. The Company also reports an "all other" category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office.   The Company's CODM evaluates performance and allocates capital resources to each segment based on an operating model that is designed to improve the quality of patient care and profitability of the Company while enhancing long-term shareholder value. The CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below.   The following table sets forth the Company's unaudited interim condensed consolidated statements of operations by business segment (in thousands):   <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 0pt; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Inpatient
 Services </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Homecare and Hospice </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> All Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Revenues: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

*style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net operating revenues</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">293,396</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,648</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,154</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">340,198</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,619</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,742</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">267,421</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,842</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,888</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">319,151</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,767</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,183</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,480</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net operating revenues </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">244,162</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33,140</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,183</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">288,485</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

*Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,203</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">185</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">747</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,135</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">77</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">77</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">233,606</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,657</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,197</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,460</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

font-variant: normal; margin: 0pt;">Unrealized losses on marketable equity securities</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,093</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,093</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">894,415</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other revenues </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">710</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33,462</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,172</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Government stimulus income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,445</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,445</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net operating revenues and grant income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">791,374</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">103,751</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42,907</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">938,032</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">207,883</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,977</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,232</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">238,092</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,795</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,736</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,273</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,804</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27,646</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">545</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,352</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,543</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,788</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,788</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">736,302</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85,019</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">57,515</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">878,836</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

*Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,732</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(14,608</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">59,196</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-operating income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,865</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,865</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unrealized gains on marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,290</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,290</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Revenues: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,804</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">29,461</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">525,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other operating </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">192,473</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,356</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,384</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">217,213</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,520</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,639</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,928</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,087</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27,474</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">555</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,237</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,266</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">268</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">268</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">680,252</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80,354</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43,010</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">803,616</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-

serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Inpatient
 Services </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Homecare and Hospice </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> All Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Revenues: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

"Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Salaries, wages, and benefits </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">175,241</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,456</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">213,395</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other operating </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">72,384</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,612</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,513</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">82,509</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,422</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">602</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,862</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,886</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,632</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">172</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">815</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,619</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,742</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,742</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">267,421</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,842</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,888</td> <td

<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">319,151</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

</tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Inpatient
 Services </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Homecare and Hospice </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> All Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Revenues: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Costs and expenses: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Salaries, wages, and benefits </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">151,912</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,066</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,686</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">182,664</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other operating </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">64,228</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,868</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,394</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">72,490</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,186</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">538</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,370</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,094</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,203</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">185</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">747</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,135</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">77</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">233,606</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,657</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,197</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,460</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,483</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,010</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,029</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Inpatient
 Services </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Homecare and Hospice </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> All Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Revenues: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net operating revenues and grant income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">791,374</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">103,751</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42,907</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">938,032</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

*New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,352</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,543</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,788</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,788</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">736,302</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85,019</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">57,515</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">878,036</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,290</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,290</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,119</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,013</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net operating revenues </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">707,689</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">97,822</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,119</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">840,630</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27,474</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">555</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,237</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,266</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">268</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">268</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total costs and expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">680,252</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80,354</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43,010</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">803,616</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unrealized gains on marketable equity securities</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,943</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,943</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,471</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,702</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2029 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,424</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,768</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total minimum lease payments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">96,406</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: amounts representing interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,961</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Present value of future minimum lease payments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84,445</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,366</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Noncurrent lease liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,079</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 28 5 3 4 32625000 32225000 31975000 10085000 9300000 29371000 27719000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 0pt; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Operating</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Leases</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 84%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,858</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,183</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,471</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,702</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2029 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,424</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td> <td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,768</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total minimum lease payments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">96,406</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: amounts representing interest </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,961</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Present value of future minimum lease payments </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84,445</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,366</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Noncurrent lease liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,079</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 35858000 35183000 10471000 1702000 1424000 11768000 96406000 11961000 84445000 31366000 53079000 Note 9 - Earnings per Share   Basic net income per share is computed based on the weighted average number of common shares outstanding for each period presented. Diluted net income per share reflects the potential dilution that would have occurred if securities to issue common stock were exercised, converted, or resulted in the issuance of common stock that would have then shared in our earnings.   The following table summarizes the earnings and the weighted average number of common shares used in the calculation of basic and diluted earnings per share (in thousands, except for share and per share amounts):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended
 September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended
 September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Basic: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,411,680</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,299,913</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td

style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,384,758</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,311,453</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to National HealthCare Corporation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,388</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,846</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,392</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Earnings per common share, basic </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.78</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.68</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,816</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,667,321</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,324,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,576,294</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,334,269</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to National HealthCare Corporation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,388</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,846</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,392</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Earnings per common share, diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.73</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.68</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   For the three and nine months ending September 30, 2024, we did not exclude any stock options from the calculation of diluted weighted average shares of common stock outstanding. For the three and nine months ending September 30, 2023, 637,409 of stock options have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended
 September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended
 September 30 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin:

0pt;">2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Basic: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,411,680</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,299,913</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,384,758</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,311,453</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Effects of dilutive instruments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">255,641</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,598</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">191,536</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,816</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,667,321</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,324,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,576,294</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,334,269</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to National HealthCare Corporation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,388</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,846</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,392</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Earnings per common share, diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.73</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.68</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;

font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 15411680 15299913 15384758 15311453 42789000 10388000 95846000 38392000 2.78 0.68 6.23 2.51 15411680 15299913 15384758 15311453 255641 24598 191536 22816 15667321 15324511 15576294 15334269 42789000 10388000 95846000 38392000 2.73 0.68 6.15 2.5 637409 Note 10 - Investments in Marketable Securities   Our investments in marketable equity securities are carried at fair value with the changes in unrealized gains and losses recognized in our results of operations at each measurement date. Our investments in marketable debt securities are classified as available for sale securities and carried at fair value with the unrealized gains and losses recognized through accumulated other comprehensive income at each measurement date. Any credit-related decline in fair market values below the amortized cost of our available for sale debt securities are recorded in our results of operations through an allowance for credit losses. Realized gains and losses from securities sales are recognized in results of operations upon disposition of the securities using the specific identification method on a trade date basis. Refer to Note 11 for a description of the Company's methodology for determining the fair value of marketable securities.   Marketable securities consist of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortized Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortized Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Investments available for sale: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,990</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,986</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted investments available for sale: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,702</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23,001</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,779</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate debt securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">59,267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">58,812</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">59,586</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">57,731</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Asset-based securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,756</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,646</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,388</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,659</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46,224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">44,671</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46,771</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42,863</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> State and municipal securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,813</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif;

font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,106</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">174,938</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">311,666</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">189,648</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">265,623</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Included in the marketable equity securities are the following <i>(in thousands, except share amounts):</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Shares</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Cost</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Value</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Shares</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Cost</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Value</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NHI Common Stock</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,630,642</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,734</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137,072</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,630,642</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,734</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91,071</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table>   The amortized cost and estimated fair value of debt securities classified as available for sale, by contractual maturity, are as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Maturities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">642</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">479</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,060</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">123,911</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">135,338</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,727</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   Gross unrealized gains related to marketable equity securities are $140,177,000 and $84,514,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to marketable equity securities are $300,000 and $928,000 as of September 30, 2024 and December 31, 2023, respectively. For the three months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $32,767,000 and net unrealized losses of $3,093,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations. For the nine months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $56,290,000 and 2,943,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations.   Gross unrealized gains related to available for sale marketable debt securities are $1,104,000 and $326,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to available for sale marketable debt securities are $4,253,000 and $7,937,000 as of September 30, 2024 and December 31, 2023, respectively.   The Company's unrealized losses in our available for sale marketable debt securities were determined to be non-credit related. The Company has not recognized any credit related impairments for the nine months ended September 30, 2024 and 2023.   For the marketable debt securities in gross unrealized loss positions, (a) it is more likely than not that the Company will not be required to sell the investment securities before recovery of the unrealized losses, and (b) the Company expects that the contractual principal and interest will be received on the investment securities.   Proceeds from the sale of available for sale marketable securities during the nine months ended September 30, 2024 and 2023 were $39,776,000 and $36,578,000, respectively. Investment gains of $331,000 and investment losses of $603,000 were realized on these sales during the nine months ended September 30, 2024 and 2023, respectively. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortized Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortized Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Investments available for sale: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

serif; font-size: 10pt;"> Marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,176</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">164,754</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,176</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">111,117</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate debt securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,497</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,441</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,990</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,986</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted investments available for sale: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,702</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23,001</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,779</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate debt securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">59,267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">58,812</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">59,586</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">57,731</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Asset-based securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,756</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,646</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,388</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,659</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46,224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">44,671</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46,771</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42,863</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> State and municipal securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,813</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,106</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">174,938</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">311,666</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">189,648</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">265,623</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 30176000 164754000 30176000 111117000 0 0 2497000 2441000 0 0 2990000 2986000 17702000 23001000 24134000 26779000 59267000 58812000 59586000 57731000 17756000 16646000 19388000 17659000 46224000 44671000 46771000 42863000 3813000 3782000 4106000 4047000 174938000 311666000 189648000 265623000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> NHI Common Stock </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,630,642</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,734</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137,072</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,630,642</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,734</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91,071</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 1630642 24734000 137072000 1630642 24734000 91071000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Maturities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

*"Times New Roman", Times, serif; font-size: 10pt;"> 6 to 10 years </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,197</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,499</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33,515</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,802</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Over 10 years </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">307</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">307</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">642</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">479</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,060</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">123,911</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">135,338</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,727</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 24509000 24023000 19664000 19328000 71047000 69082000 81517000 77118000 31197000 30499000 33515000 30802000 307000 307000 642000 479000 127060000 123911000 135338000 127727000 140177000 84514000 300000 928000 32767000 -3093000 56290000 2943000 1104000 326000 4253000 7937000 39776000 36578000 331000 -603000 Note 11 -Fair Value Measurements   The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs that may be used to measure fair value: Level 1 - The valuation is based on quoted prices in active markets for identical instruments. Level 2 - The valuation is based on observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Level 3 - The valuation is based on unobservable inputs that are supported by minimal or no market activity and that are significant to the fair value of the instrument. Level 3 valuations are typically performed using pricing models, discounted cash flow methodologies, or similar techniques that incorporate management's own estimates of assumptions that market participants would use in pricing the instrument, or valuations that require significant management judgment or estimation.   A financial instrument's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.   The following table summarizes fair value measurements by level at September 30, 2024 and December 31, 2023 for assets and liabilities measured at fair value on a recurring basis (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid black;"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Quoted Prices in Active
 Markets For*

Identical Assets (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Other Observable Inputs (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Unobservable Inputs (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84,807</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84,807</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">187,755</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">187,755</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate debt securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">58,812</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">39,475</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,337</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Asset-backed securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,646</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,186</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">460</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times,

serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">44,671</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">44,671</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> State and municipal securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">3,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total financial assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,740</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">386,975</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,305</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">460</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid black;"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Quoted Prices in Active Markets For Identical Assets (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Other Observable Inputs (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Unobservable Inputs (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">107,076</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td

style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">107,076</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,892</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,892</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137,896</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137,896</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate debt securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,171</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42,860</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,311</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Asset-backed securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,659</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,210</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">449</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,850</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,850</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> State and municipal securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif, font-size: 10pt,"> Total financial assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">391,591</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">352,574</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,568</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">449</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid black;"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Quoted Prices in Active
 Markets For Identical Assets (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Other Observable Inputs (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Unobservable Inputs (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84,807</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84,807</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash and cash equivalents</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,267</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

font-variant: normal; margin: 0pt;">Marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">187,755</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">187,755</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate debt securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">58,812</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">39,475</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,337</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Asset-backed securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,646</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,186</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">460</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">44,671</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">44,671</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> State and municipal securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total financial assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,740</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">386,975</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,305</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">460</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family:

"Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value Measurements Using </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid black;"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Quoted Prices in Active Markets For Identical Assets (Level 1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Other Observable Inputs (Level 2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Unobservable Inputs (Level 3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">107,076</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">107,076</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash and cash equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,892</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,892</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Marketable equity securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137,896</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">137,896</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate debt securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,171</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42,860</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,311</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Asset-backed securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,659</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,210</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">449</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,850</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,850</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> State and municipal securities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,047</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total financial assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">391,591</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">352,574</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,568</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">449</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 84807000 84807000 0 0 30267000 30267000 0 0 187755000 187755000 0 0 58812000 39475000 19337000 0 16646000 0 16186000 460000 44671000 44671000 0 0 3782000 0 3782000 0 426740000 386975000 39305000 460000 107076000 107076000 0 0 18892000 18892000 0 0 137896000 137896000 0 0 60171000 42860000 17311000 0 17659000 0 17210000 449000 45850000 45850000 0 0 4047000 0 4047000 0 391591000 352574000 38568000 449000 Note 12 - Goodwill and Other Intangible Assets   At September 30, 2024, the Company reviewed the carrying value of goodwill for impairment indicators. As a result of the review, there were no impairment indicators regarding the Company's goodwill that required a quantitative test to be performed. However, our accounting estimates could materially change from period to period due to changing market factors. We will continue to monitor future events, changes in circumstances, and the potential impact thereof. If actual results are not consistent with our assumptions and estimates, we may be exposed to future goodwill impairment losses   See Note 3 - Acquisition of White Oak Senior Living for further detail describing the goodwill and indefinite-lived intangible asset additions in 2024. At September 30, 2024, the following table represents the activity related to our goodwill by segment (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Inpatient Services </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Homecare <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center;

margin: 0pt;">and Hospice </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> All Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> January 1, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,741</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">164,554</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">168,295</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Additions </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,395</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,395</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,136</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">164,554</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">169,690</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   Indefinite-lived intangible assets consist of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Trade names </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,836</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,340</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Certificates of need </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,757</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">532</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Licenses</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,212</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,166</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238,

255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19,805</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,038</td></tr> </tbody></table> 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Inpatient Services </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Homecare and Hospice </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> All Other </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> January 1, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,741</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">164,554</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">--</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">168,295</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Additions </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,395</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">--</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">--</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,395</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,136</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">164,554</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">169,690</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 3741000 164554000 168295000 1395000 0 1395000 5136000 164554000 169690000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Trade names </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,836</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times

New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,340</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of need</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,757</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">532</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Licenses</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,212</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,166</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19,805</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,038</td></tr> </tbody></table> 15836000 4340000 1757000 532000 2212000 2166000 19805000 7038000 Note 13 - Stock Repurchase Program   During the nine months ended September 30, 2024, the Company repurchased 133,151 shares of its common stock for a total cost of $13,502,000. During the nine months ended September 30, 2023, the Company repurchased 44,349 shares of its common stock for a total cost of $2,482,000. The shares were funded from cash on hand and were cancelled and returned to the status of authorized but unissued. 133151 13502000 44349 2482000 Note 14 - Stock-Based Compensation   NHC recognizes stock-based compensation expense for all stock options granted over the requisite service period using the fair value at the date of grant using the Black-Scholes pricing model. Stock-based compensation totaled $1,093,000 and $708,000 for the three months ended September 30, 2024 and 2023, respectively. Stock-based compensation totaled $3,062,000 and $2,119,000 for the nine months ended September 30, 2024 and 2023, respectively. Stock-based compensation is included in “Salaries, wages and benefits” in the interim condensed consolidated statements of operations.   At September 30, 2024, the Company had $5,752,000 of unrecognized compensation cost related to unvested stock-based compensation awards. This unrecognized compensation cost will be amortized over an approximate two-year period.   Stock Options   The following table summarizes the significant assumptions used to value the options granted for the nine months ended September 30, 2024 and for the year ended December 31, 2023.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31,
 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free interest rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.40%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.52%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">24.1%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">29.3%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected life, in years </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.63%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.41%</td> <td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table>   The following table summarizes our outstanding stock options for the nine months ended September 30, 2024 and for the year ended December 31, 2023.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Options outstanding at January 1, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">445,144</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">66.62</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">299,278</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">54.44</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(103,481</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">64.72</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(52,407</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt, border-bottom: 1px solid rgb(0, 0, 0);">60.58</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt, text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding at December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">588,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61.30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">298,097</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94.42</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(211,040</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">63.75</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(33,202</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79.34</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding at September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">642,389</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">74.93</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,658,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Options exercisable at September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">153,439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">63.87</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,498,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 22%;"> Options Outstanding September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> Exercise Prices </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Remaining Contractual Life in Years </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 22%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;">331,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><span style="-sec-

*ix-hidden:c119961624"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53.94</td><td style="width: 2%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">69.19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">58.88</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 22%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">311,352</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">71.64</td><td style="width: 2%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">96.03</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">92.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">4.1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 22%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">642,389</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">74.93</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">3.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   1093000 708000 3062000 2119000 5752000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31,
 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk-free interest rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.40%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.52%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">24.1%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">29.3%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected life, in years </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.9</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.63%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.41%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 0.044 0.0452 0.241 0.293 P2Y10M24D P2Y10M24D 0.0263 0.0441 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p*

style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number of Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Options outstanding at January 1, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">445,144</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">66.62</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">299,278</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">54.44</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(103,481</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">64.72</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(52,407</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60.58</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding at December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">588,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61.30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">298,097</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94.42</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(211,040</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">63.75</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(33,202</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79.34</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding at September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">642,389</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">74.93</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,658,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Options exercisable at September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">153,439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">63.87</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); width: 13%;">9,498,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr></tbody></table> 445144 66.62 299278 54.44 103481 64.72 52407 60.58 588534 61.3 298097 94.42 211040 63.75 33202 79.34 642389 74.93 32658000 153439 63.87 9498000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 22%;"> Options Outstanding September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> Exercise Prices </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Weighted Average Remaining Contractual Life in Years </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 22%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;">331,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53.94</td><td style="width: 2%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">69.19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">58.88</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 23%; font-family: "Times

New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 22%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">311,352</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">71.64</td><td style="width: 2%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">96.03</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">92.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">4.1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 22%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">642,389</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">74.93</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 23%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;">3.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 53.94 69.19 58.88 P3Y 71.64 96.03 92 P4Y1M6D 74.93 P3Y6M Note 15 - Long-Term Debt   Long-term debt consists of the following (dollars in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Interest rate at September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Maturity </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Credit facility, interest payable monthly </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">Variable, 6.8%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2029</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">147,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less current portion </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total long-term debt </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-

size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   On August 1, 2024, the Company entered into a $200,000,000 senior credit facility with a five-year term consisting of a $150,000,000 term facility and a $50,000,000 revolving line of credit (the “Credit Facility”). The Credit Facility is for general corporate purposes, including working capital and acquisitions. The loans bear interest at either (i) Term Secured Overnight Financing Rate (“SOFR”) for interest periods of one, <em style="font: inherit;">three or <em style="font: inherit;">six months, plus the applicable margin or, at NHC’s option, (ii) the Base Rate plus the applicable margin. The applicable margin is an interest rate per annum between 1.30% and 1.65% for Term SOFR loans and between .30% and .65% for Base Rate loans, depending upon the Company meeting certain conditions. The revolving line of credit contains a commitment fee equal to 0.25% of the unused borrowing capacity. There are no amounts outstanding on the revolving line of credit at <em style="font: inherit;"> September 30, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">NHC’s obligations under the Credit Facility are unsecured. The Credit Facility contains customary representations and warranties, financial covenants, and other customary affirmative and negative covenants. The Credit Facility also contains customary events of default. As of <em style="font: inherit;"> September 30, 2024, the Company is compliant with all financial covenants. Based on level <em style="font: inherit;">2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt based upon the interest rates that the Company believes it can currently obtain for similar debt.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">The aggregate maturities of long-term debt for the <em style="font: inherit;">five years subsequent to <em style="font: inherit;"> September 30, 2024 are as follows <i>(in thousands)</i>:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Long-Term Debt</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2029 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Interest rate at September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Maturity </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-

align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Credit facility, interest payable monthly </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">Variable, 6.8%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2029</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">147,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less current portion </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total long-term debt </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 147000000 7500000 139500000 200000000 150000000 50000000 0.013 0.0165 0.0025 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Long-Term Debt </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 7500000 7500000 7500000 7500000 117000000 147000000 Note 16 – Income Taxes   The Company's income tax provision as a percentage of our income before income taxes was 26.4% and 27.9% for the <em style="font:

inherit;">three months ended September 30, 2024 and 2023, respectively.   The Company's income tax provision as a percentage of our income before income taxes was 26.3% and 28.3% for the nine months ended September 30, 2024 and 2023, respectively.   Typically, these percentages vary from the U.S. federal statutory income tax rate of 21% primarily due to state income taxes, excess tax benefits from stock-based compensation, benefits resulting from the lapsing of statute of limitations of items in our tax contingency reserve, and non-deductible expenses. For the three months and nine months ended September 30, 2024, the accrual of state income tax was the most significant reconciling item. For the three and nine months ended September 30, 2023, the accrual of state income tax was the only significant reconciling items.   Our quarterly income tax provision, and our estimate of our annual effective income tax rate, is subject to variation due to several factors, including volatility based on the amount of pre-tax income or loss.   The Company is no longer subject to U.S. federal and state examinations by tax authorities for years before 2020 (with certain state exceptions). 0.264 0.279 0.263 0.283 0.21 Note 17 - Contingencies and Commitments   Accrued Risk Reserves   We have wholly-owned limited purpose insurance companies that insure risks related to workers' compensation and general and professional liability insurance claims both for our owned and leased entities and certain of the entities to which we provide management or accounting services. The liability we have recognized for reported claims and estimates for incurred but unreported claims totals $110,204,000 and $103,259,000 at September 30, 2024 and December 31, 2023, respectively. The liability is included in accrued risk reserves in the interim condensed consolidated balance sheets and is subject to adjustment for actual claims incurred. It is possible that these claims plus unasserted claims could exceed our insurance coverages and our reserves, which could have a material adverse effect on our consolidated financial position, results of operations and cash flows.   As a result of the terms of our insurance policies and our use of wholly owned limited purpose insurance companies, we have retained significant insurance risk with respect to workers' compensation and general and professional liability. We consider the professional services of independent actuaries to assist us in estimating our exposures for claims obligations (for both asserted and unasserted claims) related to deductibles and exposures in excess of coverage limits, and we maintain reserves for these obligations. Such estimates are based on many variables including historical and statistical information and other factors.   Workers' Compensation   For workers' compensation, we utilize a wholly-owned Tennessee domiciled property/casualty insurance company to write coverage for NHC affiliates and for third-party customers. Policies are written for a duration of twelve months and cover only risks related to workers' compensation losses. All customers are companies which operate in the senior care industry. Business is written on a direct basis.   General and Professional Liability Insurance and Lawsuits   The senior care industry has experienced significant increases in both the number of personal injury/wrongful death claims and in the severity of awards based upon alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. Additional insurance is purchased through third party providers that serve to supplement the coverage provided through our wholly owned captive insurance company.   There is certain additional litigation incidental to our business, none of which, based upon information available to date, would be material to our financial position, results of operations, or cash flows. In addition, the long-term care industry is continuously subject to scrutiny by governmental regulators, which could result in litigation or claims related to regulatory compliance matters.   Qui Tam Litigation   United States of America, ex rel. Jennifer Cook and Sally Gaither v. Integrated Behavioral Health, Inc., NHC HealthCare/Moulton, LLC, et al., Case No. 2:20-CV-00877-AMM (N.D. Ala.) This is a qui tam case originally filed under seal on June 22, 2020. The United States declined intervention on March 1, 2021. Thereafter, the Plaintiffs filed an amended Complaint against Dr. Sanja Malhotra, Integrated Behavioral Health, Inc. and other entities that Dr. Malhotra was alleged to own or in which he allegedly had a financial interest. The Complaint also named multiple skilled nursing facilities as Defendants, including NHC Healthcare/Moulton, LLC, an affiliate of National HealthCare Corporation. The Complaint alleged that nurse practitioners affiliated with Dr. Malhotra provided free services to the facilities in exchange for referrals to entities owned by or in which Dr. Malhotra had a financial interest in violation of the False Claims Act and Anti-Kickback Statute. NHC Healthcare/Moulton, LLC denied the allegations and filed a motion to dismiss on November 4, 2021. On January 28, 2022, the district court stayed this matter and administratively terminated the motion to dismiss pending the U.S. Supreme Court's review of a petition for certiorari filed in an unrelated matter but involving one of the legal arguments raised in the motion to dismiss. Thereafter, the U.S. Supreme Court denied the petition for certiorari in the unrelated matter. As a result, NHC Healthcare/Moulton, LLC renewed its motion to dismiss. The District Court granted NHC Healthcare/Moulton's Motion to Dismiss, along with other pending Motions to Dismiss, and entered an Order of Dismissal on March 23, 2023 and an Amended Order of Dismissal on April 4, 2023, which dismissed the case in its entirety with prejudice with respect to the claims asserted by the Plaintiffs. The Plaintiffs filed a Notice of Appeal on April 20, 2023 to appeal the dismissal to the United States Court of Appeals for the Eleventh Circuit. On December 21, 2023, the Eleventh Circuit entered an Order affirming the District Court's dismissal of the claims. The time period for the Plaintiffs to file a Petition for a Writ of Certiorari with the United States Supreme Court has expired making the Order affirming dismissal issued by the Eleventh Circuit final.   Civil Investigative Demand   On or about May 21, 2024, Caris Healthcare, L.P. ("Caris") received a Civil Investigative Demand ("CID") from the U.S. Attorney's Office for the Eastern District of Tennessee. The CID requests the production of certain medical records for patients at Caris' Nashville office and other documents related to the billing for hospice services for the period of January 1, 2019, through the date of the CID. The Company is cooperating with respect to the requests and remains in the process of responding to the CID.   Governmental Regulations   Laws and regulations governing Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid and other federal healthcare programs. 110204000 103259000

1;"@:!%)GD5@$Z.UF5R8&BT3-MVZ#(S0E-N*J\=(KQ,9XS01*YM"8+&FTKWK#&C-MLUM/=NT0S6E?
F\UL_1KV=*]DYWG2ZL=:KO0X.4*NY"'&HEV1%L8+5?'PY"F<(GJ/K^4"/IE,-M<*AS5/5#A%,^*^WM!H>Y]C9^0"16HE-**+7;KS&*5393<8II^&0WB&.<?H@KB^&
^[7,YKBVG"V6V[1DP&BBKX]HRKNZYH\GY{^/:/0-MA-/!B&KZ]XU.W6S:O? $1U?=WP=TI=<4S0!6#M$SQOS.=B$&3.I6-ANL9]PW-M.)Z<4;%(_8+21L-
<&Z8VZ^P4UQ><**ORBC.ECD>?GK*)2(S6:,WB0L_*;! M!>_8"Y[+R=(-AF.I[M0+CEN6WSHK[JIA\9GK;65H-U^PR-TAUXSRP^5WZ\QQ-M:8?H%^.%XM]PHBRJE>
<""JZJ;[^H3&L$,G5%\V:*.)ZR.,([P5#[-7K#IYSL'EW&SBE;SWKQ63O@/LY1K,5XX(%&:'=G&))-^HG-MJ5RFD6IIKE9%>JH;-TJ_[*[ZB(6)P-HU\BWR,H?##JW+T2(O-
%#_]%?Z"O!9Y^"#.;#-M3_[SP2;=U:)0J7/X51']=?O6/!@V!.]5#?KF=XN&X,RR9T+]O;-!^+,@\&TN-M:UDXMWQ[],WC_!;^KP$RH22)P\+[-1C@+:,_3JD<-_&)0#S8*Y%GJ

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}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{S9A,*(7JS[!4;&T-M-'0!D;.WQ-=J&QZ%C,/N+_(>R;73[-M_O(2>T0+&3QERQ6C2ER!8T@:C!6P-M5.SPB'>/G7Z/[331'M%D"S>S!]>.XPLY02@)R#L@9-MA)R?IXL?Q#B=/&Y^A&/G1J,%]!S0-M8;Z,TJ+.1B/T7#>*^*P,HR,@Y\

0BSU!M"0C!5\$@&C^2Q>R2[//IQ'-MZKOL\EP^$B|GAWK?4;I &^MY(_,1.K-MC=2EVI,M:63>U![4_Y&Z8[O4_$?F-MI'4.:+^.=G[9MP(S.=
[OY7OWO'@DLO_G_4$L#!!0 (&"'9UE57<6W;G< M "ND!@ 4 ;FAC+3(P,C0P.3,P7VQA8BYX;6SLO?MSY#:2,/C[1=S_@,]S
ML=N.*+G=GJ=G=O<+M;IEZTXMZ21Y_.TY+B:H(JJ*:Q910[+4K?GK#PD^]XH@ M@<2+FKV(W;%: I&)1")?2&3^V__\LDW),\V+A&7__M6[;[!]BM!LR>
(D6__[M5S\]G)T_7%Q=?46*,LKB*&49_?>O,O;5__R/__U_^[?_<7;V \UH'I4T)D\O MY'&SSV*:?V!;2O[7^_MK[;[WYW]N[=V;=_/#O[
MCW]+D^S7/\/_/$4%)1R)K!#__/>O-F6Y^_/;MY_?_[FRU.>?L/R]=OOOOWV-MMV^;T5_5P^&O<=E^T!_\^[?5']NA)U-__JT8^^[!!]_*_[:#BV2H8%\TG=O
M_]>GZX?EAFZCLR0#BBP!ER+Y??Y MVW???"GBKSC5":E(E[.4WM,5@?_^=\'EA?G]6QCO-J-KV*;KZ(FF'&/<'P.,W0[.5+SO.&T6RW:7TJ?>&F-
]1/&'QQ\PRRL/3 M.L']H8SRT@7VIQ-;QO^1E5%]%_/3*6WCS$48M8SSR926<;ZAEOGC>$)[^"(0 M+4^15,0NA5'7_*=Z($PX(E0%O%J$]R:F7TK*]5$M-
=NYV?)@$=EF>0::Z=OO M?_MMA>5F^:;W: M@_7J37N6]BFI1*!3TN>T8/M\62E4#AE4/LW.?GKXZC\:V(0#)Q5TT@/_;V\[M9$^7"_+\[64;1[":SSEJ9ET?
Q&,)1@IOH7?WO81#E]SS5Z?,&V.YH5 IGS M/.I]?K2,Y8XF+F9@M4)<2@ MX7?#2OK(+I.,^_9)E')/JQ1"[,M.8;%([*\XJI_UK@4?
V*ZLK_#@T0"$8R.FSEA<*:"UT4%T;1A MSAZ;!=\8Z?&B$>-GO9\2CO8J64;\YVBY9'N.?+8^V[$T67(LVQ\&M+N-Z1 Z MWP2LZT/XT.%!SEL\R%T-
WKOVM|)%S#;=_068EAL:[U-ZNQIVR,5OB_;]N6$Y MG-V?X*;NH63+7V^%ZWW'-[=X__+Q"\V724'O\F1)[\&%!P/H/4?W5XEYX \P M-L3D'$'G1PTP/!.
(DSJ"0GH!E@6I$%V0!D[_&R8X MY8]/6+C-MZZT,NZ>G/V62QRN6(M$1+#9ZNSS)N&_9M&O9P7-$I.?I!%;D66,U"T1EMY8C2 M,]^?V<5K?
T]*39+=9A1B2.=;EI=P[B]841K&;*?Z9 ',?_G-G[Y[]^XO*PZ:)#5L DFUKS^) M8'3+72413.^C&^7R^S,&$4T3M3(QA4V%(@'E197\GJL2$?
V=H1*9VH(I]:%$ MUWE[1;;R6,8G]>D-S3:+91A+;UZ0WRR6(P_HE62Q3'"QJ0_D(HM%*IS^P/^3 ML1T\V8&
39(MV98B])3*/#:5U1@\+QKK#^#\0/2KP8%<"1SFH]>4MF1*>;G3 M>78:3*2&\3/UN,G9?KVY3)ZI_91,E?E!9&>.X3$W%3>)L/.<3;O40BB^=Z1D
MW.A]A=F;2@R/3>14WQLM90=?P>XS/-CV+34THA^9%#_Z1Z\$F M)X@\U C,1PDJ[,64"E0E\#P5(!RD^DPY>9.@,K\/!3B&QRP5X!C"SA6@76HA M%. ?0
&^SO<+2AR/U8#J&^-&_[I+&?9FB.R/4MI5*!BEE-SV-1^,EA>=-^? MN.Z[9I#GP.&3:P%_/JIOW.C4*A%8X%"3*8B+N@V;R=L)VTE[1/EL\I>QW
R:F:K;*V%@1\>_X[S>//.6WA% M5?Y?K[A! -/ M3)I*H1]E88>!+(SSGDO'NR[$U@S,.M:G+R5-.S@3=X/S'KIX6F+%A+I78Z3J$&(MK%A."H[2@H
E&3PK7'M[F"G- Q<+C-*T;E@'HW9\&S?0S_WH^OJ@;?K%6S5"?";PIHIY) M.Q[3DP]$*I?3"7WY3*>0,6ZC#?Q+22O#D46([H=MU#'MD BBZ4:X@JF3*D!I
MZ^[UU.T*(FR/--^"ZA45CM4+5>M-8UQV6@V<\R+2-3Z@&SJ,X%\B5OG8Q"KG M5R]:<[L&JS[:B"P>;,+V9EH6WBV:IK3G"6]1H8N+31-V$&,-
$4GW>6, M7 *:O2Y*O0Z5K]I4TV4<:]8:BAL"J#"$NG*HFL*JH7FJ&UW5$D:-2*K4UC^< MQ4D1K=:K"AY V6, M_)XRCWM[?-'M8<-\E@+NB8FA/R-TF
TX[DL}]^$3M-3PH78;'#%#'6=E^W%E MBS%[ZJ^](Z2IO8^6O]*X2QSX1+=/-)M4Z1EFO3R5P>Y)SR' M ^I/+]R%$.]GN$BM/\/8!\Z NZZZ;(1DN&+-AV;$\
W4TPOWFVO,FP_G:%RX MXQU,E6B+#.&KVNNVNA87.(M?G?4D)N8T&X)P6RM6"95@I63YK^HL!7$RQ2]) M3R',\0":;K=^35K$'H9\CG;!7?
LD%IX'RQ[S*"M6E.OU6!:=PDQA[_&8%%3 MAU%2G"R]&K.X9D1A]%8]!S!:D .<2 ^IN;SQFN;)\:=;BD3W6&RZI[S;OT)Y MGL\T66\@P7X;S0]AP6&
[#,]Z$=W_X=ZJ\7%. G%<4(#>" C#N M0E"@FJ$@/Q7B<0ZYZ"@ @]X#!<1,'RH*#(&?H34R6S91MG=RNG(YE>\=_BVL
M(^\>6@T/0@A;_UB%*!MLCOV\2@X+9VKH]R#5>B\3AP?-4+8%8$-;58]M\U98 MZ=.^7X5TXS-
XO]H?"%7)N'/]1^08HA)"SB!1GIUP.3]XQ0R/?/M#/XIU_)-(M%%,NLR5&K+".MUC03P\/L,SB/(OO&$2GN/'UL'^*D^>D@'R/T:M>O8^1\1\U
M(*Y/WD\/I$)#:.86$=+'I'HH,)?;8ULE*T'R4I7L MU"4P:3YJL0G$^!F,#61\/IP1^)X)A$F-,1$H+ZKZPZ3&>D%:O$D/\?F]N;'* M#8.O=.QO<6 S=
OWB/\0=9>+4EC3_*-D&X$QW2NOS_U\4:>O_^F@+G5H$K& M-8@AZVA-\[-TFX62"[Y0H:4_-@OM=ZUHWO/U>UBR$Y^S::P:T:V9BM[X4[O
M;67Z&1:2{4\O9RE]IBE*GCF![*EA#0+#X-UMCG*1)(.>7L@UH#U+R>&&90Q: MZ!CS0=A^.]&RY.Y0"9E2J9!6)>L^?'HQR31TC$*
(#CZ:J,ZKU8^HF5'A3^XK M_*%-?/OI^YU+_=IU' M&8@NS'%WBX*G+F8FJ(;O?79HYO<#D2(!B>O\RNJO W'DAVH!LQ0 CMG)H.6. M/1X)>N?
09YQ^>+8Q%='W#+B)+=XMZ"'@_#YAZ ZA>[N^J$_CHK/19WQK@-S; MB9L"DPT+J5";0\[V)?\^B^&YD3/5J0#,OY(<06INZK!1>K<=JJ7\:DP@QT5
MI[S#W@_B$&;W-/W24(2)PW]#Q(7TT;GNLC MT2!$@.U$BR0X MU-/^FNZS&/8#VL%_$2]G#1(E,$(LC])_&#*2I!?% \BS)K M^^!) V[;S@ENE*#&_$[UH
(> 57A0,>.UZ4-=;996R%JIYW1V8%M*AY96SKG MH<%'NZ"!,#T9PM7Q2'RQ:D$?6*QS4 ??.?@K$97H4_@^Y#$7.3DOBN7_IC]
MOP.13>SA[4<#>D:O.R;)S/1IYTC>C)2P5__(JOSQ5#HH(*2HO]Y[N^%^%G"@WE&3M MZHMZ]5F]^E6W^G(3E6(T!#&C[(44-=;%-
_XEC/8Q9$8[X'"B0RY62-")!TD$1YG!I(.F041G56# M6(I:/,=,B.S1*?F!/=,\ Q0N6+YC>=U1)XO/UY1;)UQ(J'HKZ)G0;HPV1__^
M38<3Z2,E^+I!:T:^#W[3F,6=\,;O#784PFB*G*WT#9*'1^=VS:TM\'F56U"C M-T,1T5_#]E[+X8F.[?*1V);MIS.Z9J4N/@TA6!+O*?FE67&>QJF='"V]2-
>D)U!+@?N.FW>H$GX6A^^&EK.H6,\!#*V\9BX4?6YL!(<7;V#*%_=VVIU"Y)Q=YJ?P')* MW@0X:B=LIGC>ADGLMZ'ER?.!TZZ)6(;IM&@"
(%$C(_FCK.=1GG)MM4))M* MSJUGZ":M+MUCZ5QZU%G!M$-G09JJS*2NRMS\E1*1TTK><"LX9FD:Y079\>,I MRBP';)?ID5F.>V?ZY@!O,J"J_ZD84!@?
C#QAPY,Z;P1[4O_2(1BN/.VKI&SNT[_\>&'2E\G!"G'!&66$@G9D4F>\@79,FK3VZT!AVJ]?FH97 M&>=.[AXN17T)6<\U]P!-W"0GB 7QC*+U.A?
Q1"X\:FR(J$H1SOEQN^O'_HZ' MK9Q5;/&.Y@F++S:P1DFJJJWI',8@A\"&BTO6D;L_SS9<-[I+FB&\:=*'M!4;
MI=GKG#Q5EP8YBSV[<0R::Z9N>UWV\%D0CA$1*!UTH)Y)K1GL?HV;6^J;\!JC MUE6:J?OX]"&<\)'H"I\@EE75YT^$EJL?
7WT\^6ASW42.AW;,WXF#RA@;EL8T M+ZKP{]=Z1XJ8=Q5&2;G/=_ZD=UP^C-N^K&48[*1B"%[FFR8V9UZ$(?E01GFIM^#W40KQRM>WUH^99M:.
MTDI=*0Z[XHJYW8178Y3UJE4=!@T<&6>3\ (9:5*\?!EKO2I7LPR#.=USB[:; MXD8&N^>_?+Y)ZGS;\RP&63*;ZZW[N:5< !D83[='O2H^E2%A6,
[(W?)PAJ0] M/K-(B9ADN9$D"35"^RL_5LF+XI&)4$M.=4J.Z7R++3.F L,7DRHA@RHN9GF5 M)HGH=_SWFR9W
E$^S57Q,"UF8T:T]7;Z'KD.+U;JO#&%CIRB)G75:K7^3B]Y'T6\P$B^9'[S#FM:SO!0])I$GBKNS)Z $<+KTQ3 M_S4&F@*\6=&$'CX(%?+-BN?EH
+G9I;+!&I(MU&AG-#4*PDLBV MT>QBO:9&LV5)+74\1ZE2;08G=HGN*//6(3>)\;*[0\!<,^)H7=I"!)YS MJ[]2!UZ?=G27E K53I/>GQ76]NMUT%7O#2W]
FO!R&=VWLVY!@V^0/@:NK'A[F/JRV=> T3^;Q>Z 873L/_=Q ..<6Q*" -NL'(?<97%E.,=<[105Q): MWQO<2BC!\7DQH800-
E;O:+5&UQ,]G!S=4#A:M>DEQ?#SHSJ@HV#(133B$N75,'__:"',DF>'F>--=]_29I<(8G+;6M+Y!ZK'1
MN5W+HA8XP5ETCM2;&KT9BHCSB4BJIW8Z+>$EA1,^,=]O";]>^K)ZZ:[9TL!N MMLR;ZTRU4)F@<_V?"T/J287$D+PV:2N MB2LWD#;
]3R($U<^7S[374'V8#ZSHD:Q6^4!LQ^63";V'LL.EL8Y0DZF3*!"7 MC)8*&1MJA5/\E.XXX96013M&:2KE%Y,B&A:30^_IDJVSY!\TOH+KN625T+A*
M9:U+Z<1<(%XGT1,@G7#Q6!3[+8U%9S)]%:P\9FXVB%,.HR;W.H& M9Y%ZW<.:U&C/:+]O5+C<,9L@ZV&)OA_\N[SH,QL$":=(":?
3HY&_$G\L398O+>-.])29&(TMXS<\J[?"?8)KE\UMN+Z4VTG6@N*QN&KWMW,)UKKA?P MB 8]H9(2D>F2AQOG'&=+*&?4K8^;_/J1EED2PW#-- M8J9--
V_\!%F-JR1+2GH->07'3P'?OWR*_HOE%VE4%".1&^0L2-[3A.:;(SMT MS@0^ T]' X:!L%O#+-%[+IS@AB>JQ=X4$8D*-APUA MF6R;.K=/[T6XFNAW.?
08+U_N^$Y"U7:HZ;[;ROUN_0EL54>7 @I6(EV*D94Z MZ3;6:ZU8^JY&1@3;J-HZ?55+G^; L9+IBF3VJ).6N3#RHO2";;BR%
P?)^F^K+KL=C720I\Q6]Q"YFY? M?_:(6;4/"RH&@A/18VGOL"CF4S.X\?;P5D$N\I*1DI-TD.P620UKOHA>5A-M FDJH&8(^GGCKJ/GPVW-
;G$X>MED$T%G[#1(/M0%YYHY?SY^ [\4(J;)VNFE M,X;I8{]>'F:+YD&;D_V4Y31*X;[P!^Z40*MU"1OK?6RQ,=DI$-9C94B;EXJ5$B'RX)<_O7LYFI!>H0
C,@;P F5=VU]N2:.C=W] M]=B7;>2\371EFZ)U*)--W)!HF6Q#7]@QV?HS^[G&BFH$@K[D5:&OW$Z3$\WC M]5:;S=
(T'QRWR*8_0%]PR29VGA=8@>NG084QIQ1HR_0)YO$2G4;%/G\17:*G MTOS&!Z,OU(/^Y6,-MJ]\PY[29%V]0 @78-/;@.,XFCY5_=E>XC)*
M9F8=_!%K48E)?-W'5- P[@@6SQ+*!N@Y&Z+2)18F$35E7UWN+%LG I6*N&] MI_$QF\G^;%#'#J;Q6:8.X&'KL>%P-2HRYQ]=T^IPJ S.H&D$\<
M'5)NHI)$.=<10JA24=MD&V71&H*+XLX&JIL\12D\#23%AM*2Q'R@__(E@XS. MIDAL=00$T:-46O-M> #F^!U,Y/H -
M#0!=Y,T;52CR>#1)>:08]*O2U(@V$ M/AWF"39-.7_Y*K+;^:E4?]7OL-DI4_.[/AAW_82,%GH8IU^=V Q-06\<=VBS M?_P"KZIEY;9'QR(Y:W!.?
6YZIOD3TI4>VG>E.3*)R1+R>D?A/BRR""NM-,S+3HY>\N<[M+V0NE#S1_YF;CFKO#RY<0[6P#]FG(^U$1(%8'NF<"7U$E:I)>E MQ2W-
!G,B4%\00)7_MB0OW%?JL%V0*J4HS,6G\Y/&O&_XZQ>+53682Y;7OX)Q M[WS+RE$DYB9 !Y%]]5)U<%6S$K66Z!Y6_E:+("N6D]XRR)O_I%$>)O4XT*'V
M(:L5.,8H-B=R6>_I,\WVM)!=*D\/1,3JAB=T?JD'4$D#5N,RV=T"<%&\7O=. MMB),+"NOD?$?
K9O@#J9.L4"QE.OJ4G3)MFKQE('Q5F{JO7D]Q57NQ>,*D@B8 MYJ$*HP7@# HI C,(60SQB31L(:6=Q]XEC52Y7?55TSU-X5H+-%1Q\MI&JC2;^
S=PSU$Z\H18]3-T)Y+QZ;U9:PT:52,=N&$5 M/] .%8P19W]Y.%MN"H]YK W9)Z&W>1?-YHD?E!?HK*6,XMEA6*IZDQXWM*PL MZ)'W@H-CD'+A8"
[G&4>TK!TU$O5>P,/+ZC89Z4<:I>7F K+1+EB^8U71=,RY M,5P:(B'5U?H<'9MA/F)*%/28]W]8\(?C]/'+,MW#H]\?&(L_)VDJ.21H-RN%-I1V^?
LN=M.)$1V0'Z'%-HD($'[I!BV=E M^D-_*_Q?[<-#MZ]RV@5U\GQIA?FQ_,&#N(M2(5,V,*NTU0?NM$<)Z6_!V)9 MF31UK[KZ
96FJ]K50R!Q7\5];EY5]8C9$59'_O, FQ>X*,Y6996]3.KA\1?5D)IR]F4%E6F?*3;!N\ M9FSCX30=9#YPQ++U:+-)E4^0/#-FZ+; <{J;
<7M5%3<3F829T'NBGI-[;G$7\"0R.D&&C0\UWDEW*.\73U& M7PRB,99F17*Y(71?D1I#-#%Q&W^4^>\3Q;"%Z\S1-GD3)>_W19+1HN#8/R69
M\$VZ))ZI_"^]CY&"00V(Z_/?8$%Z:)!>KF[P;"[-O6!F!/:IZK9)*=+$X"J: MB6YM-(-6;>I\BIL$K\@T@#DOTM=A4Z4E]/&9%0,C-XG9H;S/8J3[[5ZD0WZ
M@AW+I#IQ=)=2T4<]B\^W+"^3?XC?Z[9*L3T]OLRI%32\E?6RA"^J,)A_6ID8 M>CUT2=S#5XB7J(=HJ.JR=OF?
N=ZH\&5MN)DJD28JG]@N9L.G]M9<:00'5#LE MJVM"YEG-J6N2"ONHE.U3':R2 MGV08EW9$U>OX32C\<\R:9IX>U,?6J[M8'7I1Y+3-384>K1D_$?[UB29
YY=#\$;U,F6?"P+YJ:1%A72XA*GN M=)"L?KDN4/4?^4?:!/Y:1ZFC',93%*M%YS%\K." M(]3KGTC>_/Z8
=4VTMT]]0XGM$]LGY4GK3%Z*8*1W-.G'\>%5W48=7/?)^'"/#,%TY M!J9S_E+^QRM2 6W:QF%[=%A!'ME^AB^B:4E=+6(KX/MOQC'&$$R54/Y"9$=O
M9B8LO*GAV "89%K7K-_)3N:5ZW,=8LI5-RV86G,/>XPAMWDGC!=0@?COJFL ML\GQEOC/6RY9RX <,A&@PV>-31-YA*%"YX(-=C>X/#S4*Y!],Z3'TX:RE
MO9\Y)$=HFY\.XV[2QADHE-[L.=8K5-SE9VO5DF:1"4M'O9/11(G40Y^>5&P MI?CM>1;_GRS)RK_RX?M"EW?N 894N%!?
JG_:IKP=5J;31@B)9+Z$H%R]!5JX6@ZW&58%HC M'JA!@R93,D/:>U:)C]&7&KGW-*.K1!;NF1AMI/9.9O65E2$!C]=K)BLQT605
M=%)&7R!#_3DI0KT0F6*3$_TT03&/3R$;G<])]U=NQ((;W3P?_LAE5%D?6\GY MT/X>_0!2$8[IMX\]1!:D084TN)
*F05:GSE[":F[455%%!);OH!0I4(.T,VTM!VT]C MB(2R/Q0YB:%IZ]^O%'TJK[*BS(6C]4CSK>3\R =BNS^=3.B+K4XA8TZ)#?P1 M]Q8 EG1P%P0@A^SQ.
<(83)U:8?4'1 B*N^A%U/?)HUAFP>A];%.3G #QIX MK":(4H!6 0RL:14+R[*H6DZPF8]^D3/9E)*9(/%LND=!5:U]GLLKH^A/X*BC M5 ?(-;>J-
)5:D!3*6M48D1W4KP@4F4'LD$;?(AG9_7F^-.,>4 I50N)MDB60 MS 15=^O@DLSK5?L*Z_&.S^Y+G$Z@@7I+;WME"&.KQD&?TU6!)
Q?]',,:"I!]FC<4:@=R7Q.2+NJFRR3F!P@*S -' MD1]=;%&CZ#_;8HISF 8Q X:L1,;'1;73KY/H*4G'7I=]+PJV\M<"6!XREV5:4_M-
:9/VL&W$[ZRMCA;$2P)0C,)8DWQW&@<2XG6H0]D%Z! G\G1*>P>RT%07D]F MUF+@Z'!:6J+5\SF(TYR.Z#@+3H]2!:)[.ZB<*UG.;=A[*HK^C@?]Q@
M?,LY4S8&PYS'<[E_.BH $O&H'3]WE.(TZFG0HU],,UU'0+B M.,,V3XI?25Z!MN2MVEF5+3]U")N9>*BC/#:JFTZ3V()3,6:Z#0Y .O7>C+8: MF]%3$=!:
Z.L747M781R*J2FV0B1C-CR9Y;_RI5Q7^?<5W/WVN5[\LK_X:)U386 %N(M39C2&(;31L;GC M=./$Y(;H>1:+J*;TN$P-11P3V93N>X,
(N&!_BX!A%:7'G@M]S ^#[MZ83N^ ML)PN3]2@4L,*J#$!S7*JI IR$21YB.B0UXOP?V9:")FHNOA_H&D@O97^E\8@S M,#JOZX/0 .^R,FKPZ,-
@>3FX$W&5K5B^K00_M,^)$BA(T]A(TD7[/P]J3,6T M26LW/6GJ:*A]8"-9R>OA&,A9,CT=MA?DXGC(E[T@GS?)<@.OO--]S'\/P^O2
M,GPJMB+%KTF:M.JY*IY8URHIR6+*[9NXNA5_/AP>/E!J M]"CJ[.JRE70Y3=K]OPVIDD5X.(_='$M_H^_G7-X,<"\3*/UT:&4_EWS#)[, MX_K(M<
(0//*!'*:L4E">"RLLMWE=,.] F[95=4);FAYNWJ,ODBBEPI?H(NG M2&?V%=$;00&57&US18A. @?PZUH:NH6S Y6!F68RAJ"S(]%YD90OYSF-+MC) M^V?
9GQ&"LS^-\S<&4'H1@!& YEUN#E*,39'!F]3\J:"WJX]0I :*JHY? @ MI&P\G,QY_Y5'% !LX:Z,UBMG; &WN+F_GB=E]"E:N8HRKA7^DX)(.> MS.?
+/#P!C#$*+6";/;M7^OFIU3MXD6=5&I4#U";.V!.T'@MH+<'3*Y2S-E,GD MT\EK>ABI'EF53_!NGG1]V4QN\Y3BYJ!".O@!^PA#W:[> MTTWTG'#/,/*V\"'5
@1;L:U M5VS>,ACFAZ,<)7DD[IFW@8R65%*\@JFKM]@$WN\PR"J4279*F6? MR1NV+^&'KR'YI&JC%Y//"7<=:'^]<8TM>5.O_&O_#H4"/S$],@'J / M/ZY6=
GU%^\HWS"^FVO9.RO4'%:,Q E8[O/,ZB8O^3SL(E722XTC+7H&? 1X ME]-=E,0?Z(IR1ZLIP-!D')\7!1UK8VDPF;5'@BI PSVO4\'.SK-"RW0PZ1Y6 MH]
(VVNNEWT<**_;VP%"+7TZAI(GS]'20J.VB7+'R+NK]$H3?Y! MXQ^B)((6GB.*27\2 \VD#LQG$$,=*VPHP\FZ3^=RO=YR'/[\MM\7=@ -=(?#@K3B M&]
@;P"1<)VC%#A**HIG('KA^DE-\)Z,-!:[[8R^A:ZX)IR#R#VEZ:# E1 J MH(O=. 5M?V*-.K$CWUISH =@>"]RTT!NWGF4 -N,-VQE4;;" /(S,0#'N.O
M48=WDKZ.)=DXPIR=L8'6<@C0_F\R:+:\LW6+;&.#69,HD<,86X"WNY3%): MY1<-\(-L"((5CJ?R<"D%3YL (*D@>M]_*?68"DF<[OK'+?R\U%
M59!3R@"CH]&\,#BK)[9H8),*.*FA!V*1+!JLN]U![7^!+[<&T:@B^S M50$5C&GN9(5&.>(5)MSGJ$MYUO)4;9&NGN!H!.HHK6LY2O2NRB=
(A3LVM2]-.X8#1L7:71-" MMS8(D X#PE$@2FMRI%&5>(AAB.C8*^E5)KOFDONJI-NQ"X>QX09>R]"TWKR8 M?G&V7P \$?#])GXK$YGI4LX? SU"

}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{2) :@44Y7.,Q!R&\ MQ"8#4EA*.1^6Z1TKRBC]?Y+=!8OE@=NQP:,VZ<&DODW4"CCAT F #VNE#I-W MR% =H9D/IA&7Y[- B$91X9D8?89Y1R M?@)#X\IV>K!Y:,BSRI5F-PP.^5:\8]&AP,I7@6V&8T-V53 JU31-V6?1!)?E M'|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|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|S$"% MJ9PZAMP1*\+DO"B2 LK"J$N2J4\,Q(AL:I\R1(8#]H396Y.1]&C0L"!)^':8G?G.\E%=I'4B/"=.AM\=2WIS]:%'6UQ02/U8R"EW$^V V M]Q6*W"!:G8/4XXIDL,XIVA7/Z:^W.=94NYS.OB"07$T,G=(,JOKC6]!BXOI M%KCBBP3'2\%)RZMLQ?)M^W0:[G[$ZV F[MV[Q:X:],*DN$RQ$=,DJ#=Q.%"; M^_RI$.^3):)1X0NDF!R9V5?NR@@*F+05JRM"UW3DAV6HB'T0]:#"/0Q!0'^) M*DU>PS7TGVGCIC=\Z?L\YW259:NH? H=-69F:W_V+GQH!D@(&_3RI*]549 :M$0(/.ID\QOPH!ZM$':L&W.E.P^3K*#.70]/2R#!|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|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

M29F.&8_'0PP,QV8JUTPH@,"E[KOOWCQ]31KPP:S&$Q(R%;K,7^AS^+:C!P=S M^A;\ -N?Z/^C5]&/6YMGX0]{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{(_1UA@@*7G8G<^]#K: M?_S[/BE?U W0Z6_-+5$Y#*\F:1^-?R45(C,R3A5V8MA*526O-]:\ALL=R-,& M'/91*MKMC*493'^ 9$+YQ*XY3T F/= $8(=-*% @,].G75"V&DE&GAIND:5\ MI"/+&"I<0O(D@2>8:3Z5ZR?4Y<1H.]7J?:G$^KU0K[9&6 TX15QY.?K 6J[A MYI^39BF\PR12 INC.(&ALIH<5XTT34MYA\$E48?IH;=)B0'BKZ_1.]+A2I M*ZL>Q2*'OEI=G!3+E!7[7- S&5>GT64>0M$/9OV+3YT5F1'=_=PO+#8WW*;U= MG3|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|R^!+[GI;\&,.&7/#_Y[;MB+^B^*6!GS(!P:=_,H$* MUCJWOD(C?^2XRD.'#YG;.FUX\ <5&/)NN\M:%7W*N5:M+E**W+_\YD_? MO?OC7PA56*]S!M-2YF'J%#52]M#K]3):B@L2J0DJ'X10E:>3N69PT8NW 8DV M)FW@;6X[PE)6-1;^9?T((S U*LT]2C3H!O9^X^&&;0#:#&[:>K^9>91H"OW0 M-V]&E$2KQEX>2Y-+\)HB0LHGQ=$5G'337J5 &VQO)FHB^L@@F 0^ W$G1])7 M'AJZP.;K(DYXU2!? S:L7D I'S57*@B*+>!.?=|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|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|? &#IWRA;_/#VQQ]_^F%7^OMM_ MO*8Q*BH8M5WX3EI"_"O:%8O$KZ(W;Z.?WOSM,4^^YZA_]UT-':,IOL7S[\1_ MO]Q>/?MFMHQCQ/#?8KKZ0:#^X^__? B#*/@#%[K *YP5448++$9CC@B+-B@M M<;3'*"]9]>><]ZOZS)+A.1_Q91SM&A*"_-_&[11;SY$.X[\MZ.:'!)-* M!O%#A4N%"?_'OS]D!2F>^ I)- M]+D4/./W']|(_U|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|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|@5%:+"^XBG6L!]_B#B2D M4@Z504VWO.;!$CG;&R(W6SM$QT2;50[\%U\F4EN@(+XR M7Z[>M<5(YP7V!1\7P4HC37<7@I4Z!BNU882=AR#]%*&8:QAU;@L1CO-M2?BO M*?H:\>\2RJ*4;(YNV,+"CTQ;=1=ZUZR'9T&I=/&N7[4\R0&? IZ5\V/ZVIZ MW%!6S/E2IM(@%X-:UD,FIO!"0/,1TP5#ZZ6X%!TX[4!E[4N[&\IC&23A)[JR MG5=,7]Q9+:WXZ4A2_]]_WUV\E.GY;QV'GM07Y\X.&USU(\- J=RRXWN"]D3O) M-:4'D?R"KA[X]B1D@5]H,JL\W1";Z?=@H""@X,R?H 41G/G!F1^<^89>)[UN M1XU4UJEC M5U:&O5SA>$])052%_TQ6, F#"M+%9? \%'',P!-S*F# =|QFTQ< M7WQ&+OC^R;H\ M^OY/O;F.[.^?Z?HPP7T9JW+W[%:D>?X>5B=1ONN'R('(&Y MM\C MJF*N9,SY*&X_WWP;#%36*?^U=? WFU8!?4Y0)N:,;@GUN<8S)1ARTYT^GS4W MPO26ZDB-M+:IP|&K#D=-3FQ?D%.SM7HKQ0>B5K>@ M=+;WU#& '<.&7H'VIFBSOT# [R):+#%KZ1F0 MU7;G$U!+$+P!-N/XJU%$J92*;R[@$__>G*133,CM\I>FD=(7['Z/@;*OF GW MY!IG^?%%/_DE!F"5X*,8GX\BW D9YD[(Y? 5+F9[_=KI^B^GW("3N#(D[S=-< MSG&>5XK+-4$/).5ZTU7&IY?(H:#,YVM2-7B>@N*JZ"YREXGGKK?/\O8(C M7*EIWCA"-LAP>|+A|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|FRPT@RE0 AD.PT|DZ.RW+|_1X,>C/O'CV:/(BCKQ+< MO>%66W!)!I=D<$E.TA8:..5\2;*&6MA#\Z'9O$OT:Q93/VVR!^5F|^J|%EYK M1>I'> QM)&!K#HTF(XF"%16L*'!:Y.T,$F]0'<\PN$;?KI'IVEK3[\% UF*P MM":H*P1+*UA:P=(*EE:PM!Q:6EU4JCYLKV=*.(Z3&K*K+"<<[-T;I8P)WWJ# M>=6HRHM6ZC,W3@Y'K;I)3C96VWYT-J.:>\O_|>]7'YN?0?Y&21D3F)$? |9Q3$M*V4{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

~~(Z65]H]M^@;EWZVAR{789,DUT?O?9X#@B_,P@*=]D+BE;-MH:ML+OXC?J4->6_7BMMHC'B)DS+%L_F6W?T+)U<)'RPR)SBI39%*?GYJ<$WR-M2!WB?RM7.*G<>-JP&CM?"7$V'L39@";0",:_A9P^WMBWLK>'Z"!9=)!Z0DW=-MWQ^^(@D)04-@*.D9"A=1$930S7[2-.+.<@()M$FPFBS;3@8JI@EVV4SY7*F#&]>Q9=IH)!+'I0',PV#W![AFGG"=G]^C6:[!X M@L43+)Y@\02+1V[QM-3@G%L[O_#_9'1W83-BU9.HK4P>2$ON[!ZX-,'X&<)A-M!!D?B&T!'V?GL9*[2R){Z>KWAL^?+NAJ33.Q?X(C(ENT%N3MC&%$9YG="FG8-)WXX{6PLJ2["T-MAK"TI*,#L;.@8^SG%6D7;#!)@HVM4;")@DT4;")U7%];3"#F!7B4G7NM=;[P9*HB_3PX32-MZ$.A!.,V\L=]];CU9U:YYX/>1'-$6+1!:8FC%49YR7#[.Y_@YARR/F8B!:)G-M$*(`.D@@;L=LQ)V3)=0+QM\@QE^K$0-9@AWF@G.S\.-64KB1-M)ZTO4-^N^-J9DXP4^)IL<'*UQ{G>2-U-V%:M!6,U&*MCEO/TC-5V6W"P7(/E-M&BS78+D&R]7$VO[PN/-\]"_BPNRT:4CZ[_A-MP?&X04]B69Q]0RPY%EM0S?4!G.?EJOY=:VRZ?R0P*(%!&;.@@$_00)H$-MTB20)H$T":.2)"4/0O_+DRWQJAV(7]?QT[@RX-@3=DUGO#LE<$_Q0M*.PU(TX-M)*X@@@2Z:A"Z2CTT()(*,KK.J8/W7!)#(D!>9;-^;"\^$9S/YM<(I'E4<$E+E!H.RZ;-.C2?VXD6#&]++!O5G/C#W|))D-M*(L)2O<[{/MZ1.Z?#\B1&6U6L;NH!L]G\+,])7O-=BFQ(MKA$\;?9&5I.$-MFBHP!=Q(NG.QKCLP7F$U%GOHK,U9N*7$EL=-M4'.@/@6J.8*:.?8L3=,&HMH8!:06!X?O(*'@.=&HS0SUXA!+88P?B\\PH?G>D*AN47SV!1&M%@5'Z=/"H=-M3$OGY/3;*"]7*\2>!$V;DT5&YB1&_*\HCFG)9({1Y48>K;AZYZ1!HMSM(K2-G'>?/5UB?(-9+.;JXB5'TKW!'EG!#_\IR;J*C\Z2RY)EI"@9ED(,*-V#-M!R/C?RRS1-B-.Q!-H-)K]LFI3L3;LIM3.S"D-ZPNV%F.V-WPG"4;WG7,/Y%+MA0&4[E$BHZD&J=8GGYRSXHB;Y?\Z[.S\'__^A:[)]JEPU(BG]NWVI2*:6]NGO-MUJ6]XND;SJ_&O[F11HI0PU^=T?"CF97I6:T;BS0A,-@H?-M*SR0%Z7\Y)K_5R[XP?9[L>KU9K139USN7%$6M5UVBOQ.-7)2L$;D-MSB%]05>K,JO8CZ.M=/:0DD6E@O-1NBS%67Z'V89;=_G92@R3I^]?V6@&?-1M9]PX2_D@GB4KOA/E!3?5R-9_>!37=6236E-KH+[4#(X8C1E;H(S\5>%]BS"&40YK\23NXPE;9V_WG#_=<*^?I-9G+]G!S>'FW8;D]5'Y4F62=T9;)42TA(B6-M$-$2(EHZ=+[9*J8:\W3]O6YSFM,.1Z8O>!D;$K2[FNX+=O*-*04S-?5H,>7V-MHN-'IYY21-UO.5L[!?&&1P<:&U*^0-/RS&E!2DY[$;5$S,B1Z0M&^@77C@3T-M9=6UT5R,?)2^3*2V0$$\R_9B5:>!D2Z"Q1=\7%R/,-[6'0L$X7J$--+2A.L\-MH1L2W1SN)W1_PMS?=$*W\UIZN$_II]D1[QˆL)7:'IIX&0[M1L5[<)53^B&1=M(-M2S!$OWD!4;_!Y&#P?I\\>(X"VIS?]ODI0C'?;G.R2\ST;4GXKRGZ&O'O$LJBMM+H3V>VF3]>ON+OETXˆ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{J(4H[SK/7EP<^XT54.1@IYJ44\]I\7R\Q]7-MUV(#WBMKGRHSH($+'!#W1[EO?]&*RCR:G/YXTJZ^-4%G=J+E1R[O$E\8=_S$U9Q!]"9F!8@)@5GRYM-F%!$3R-M^'*-$PH*G-[T95<)<7?!W]3K'5\EX79B07?M.>3B{OKQ#O;.]E'C94Q>VSO-M.?\=3GW3CF#HWIT<=!(R#XS8+Z>)6!/9"\;L5V\P-Q&LSD-6?H_X$&5G(ZRGS\U-Z!ZCMC^%T>MH#2CA&DUMSD6^%Y/GS"^*VC\=;;86(Z!,UZXM'SR3P3,9/)/!,]G^L4@'IP5M-MNRO[-C+@%5-7A[8O_@S'\Q9X$/N",O-6!6]1]JQ<|;5AJSFFA-S|&9)]B(N<_M1RO$OG)=2;Q&FN^[U8TIZO@1=^11+X(&/LDBGU3G1CFLMO-9_*1T3S_DC&,-M4O(73CZ^ALB@9H_W$P!?%(DYVLDJ:O9Y]\-'GF[#)1!+]Y(RD?OD/7XHCM2?-M."Y792J2H#1,@W,\IPS?HT<9Y=)'VT/Q="UE%U/.%B[/VAX(E^>RWAZ-6,,R-MA54:J"=-^\?S.:CH$:SR<.]!/LOY=)8EGUA)'V:S3_M#^N#])),&K<3;D@$-M'C+PD(&'G-CC,%G2)3-.C1%R+;V7$PM.;6DWG5!D:CB<8MFK%-M,#S!&-,:.ALL)1K&;V>CN.?BWT8+2Y!M)TPAE242+)681X5_,%D0PSRC/<==|-MN!T_XI"#[T/0P,&'F$XCWN+C=LKQ[?1]/]7.Q$R[6]T184),"9L:]1K8H|\>-M!?8HL$>!/0KLT4!*<)MCRKT]_%.4B["SB.%UR>(ERG&T9G3!T*]C^FO>L$.5-MMZUP0[W^80?O[>X(%R]>%\RDBUN,",TJ4)$Y8C#FQC,\(2(-M^$^4EO*A-K<-Z^.TM/U@!8C$*+R*\^+5_X^Y?'H'39ZZU:!_VGIG,D,GC$8#-M]-Z7R$@G)ZT.,<J8!7LL^%\O@-MXF@5J))4@%4>ZB{([CHW9AL2XV81/]/JVB/?F+\AEN3WM$#I\=|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}&"U73<@-Z8>V=5)-.;_CXW5\B4MU&-MB0KTV/D]6EAC#J-W300*P;NGE7.A^PWV^1S'XIGJ^C[7/7H4!\(%Y>AE)=</~~